20-F

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark One)

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from to

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

Commission file number: 001-39005

SNDL Inc.

(Exact name of Registrant as specified in its charter)

#300, 919 - 11 Avenue SW

Calgary, AB, Canada, T2R 1P3

Tel.: (403) 948-5227

James Keough, Chief Financial Officer

#300, 919 – 11 Avenue SW

Calgary, AB, Canada, T2R 1P3

Tel.: (403) 948-5227

investors@sndl.com

(Name, Telephone, E-mail and/or facsimile number and Address of Company Contact Person)

Securities registered or to be registered, pursuant to Section 12(b) of the Act

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Shares SNDL Nasdaq Capital Market

Securities registered or to be registered pursuant to Section 12(g) of the Act.

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital stock or common stock as of the close of business covered by the annual report. As at December 31, 2022, 235,194,236 common shares were issued and outstanding.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards † provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☐ International Financial Reporting Standards as issued by the International Accounting Standards Board ☒ Other ☐

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

TABLE OF CONTENTS

		Page
Introduction		5
Cautionary Note Regarding Forward-Looking Statements		5
PART I
ITEM 1.	IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS	7
ITEM 2.	OFFER STATISTICS AND EXPECTED TIMETABLE	7
ITEM 3.	KEY INFORMATION	7
	B. Capitalization and indebtedness	7
	C. Reasons for the offer and use of proceeds	7
	D. Risk factors	7
ITEM 4.	INFORMATION ON THE COMPANY	38
	A. History and development of the company	38
	B. Business overview	41
	C. Organizational structure	55
	D. Property, plant and equipment	55
ITEM 4A.	UNRESOLVED STAFF COMMENTS	56
ITEM 5.	OPERATING AND FINANCIAL REVIEW AND PROSPECTS	56
	A. Operating results	56
	B. Liquidity and capital resources	56
	C. Research and development, patents and licences, etc.	56
	D. Trend information	56
	E. Off-balance sheet arrangements	56
ITEM 6.	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES	57
	A. Directors and senior management	57
	B. Compensation	59
	C. Board practices	67
	D. Employees	71
	E. Share ownership	71
ITEM 7.	MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS	72
	A. Major shareholders	72
	B. Related party transactions	72
	C. Interests of experts and counsel	74
ITEM 8.	FINANCIAL INFORMATION	74
	A. Consolidated statements and other financial information	74
	B. Significant Changes	75
ITEM 9.	THE OFFER AND LISTING	75
	A. Offer and listing details	75
	B. Plan of distribution	75
	C. Markets	75
	D. Selling shareholders	76
	E. Dilution	76
	F. Expense of the issue	76
ITEM 10.	ADDITIONAL INFORMATION	76
	A. Share capital	76

3

	B. Memorandum and articles of association	76
	C. Material contracts	76
	D. Exchange controls	76
	E. Taxation	77
	F. Dividends and paying agents	84
	G. Statement by experts	84
	H. Documents on display	84
	I. Subsidiary information	84
	J. Annual Report to Security Holders	84
ITEM 11.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	84
ITEM 12.	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES	85
PART II
ITEM 13.	DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES	86
ITEM 14.	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS	86
	A-D. Material Modifications to the Rights of Security Holders	86
	E. Use of Proceeds	86
ITEM 15.	CONTROLS AND PROCEDURES	86
ITEM 16		86
	A. Audit committee financial expert	86
	B. Code of Ethics	86
	C. Principal Accountant Fees and Services	86
	D. Exemptions from the Listing Standards for Audit Committees	87
	E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers	87
	F. Changes in Registrant’s Certifying Accountant	87
	G. Corporate Governance	88
	H. Mine Safety Disclosure	88
	I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	88
PART III
ITEM 17.	FINANCIAL STATEMENTS	89
ITEM 18.	FINANCIAL STATEMENTS	89
ITEM 19.	EXHIBITS	89

4

INTRODUCTION

Unless otherwise indicated, all references in this annual report on Form 20-F (the “Annual Report”) to “SNDL,” “we,” “our,” “us,” “the Company” or similar terms refer to SNDL Inc. and its consolidated subsidiaries. We publish our consolidated financial statements in Canadian dollars. In this Annual Report, unless otherwise specified, all monetary amounts are in Canadian dollars, all references to “$,” “C$,” “CDN$,” “CAD$,” and “dollars” mean Canadian dollars and all references to “US$” or “USD”, mean United States dollars.

This Annual Report contains our audited consolidated financial statements and related notes for the year ended December 31, 2022, the year ended December 31, 2021, and the year ended December 31, 2020 (“Annual Financial Statements”). Our Annual Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”).

In addition to our financial results presented in accordance with IFRS as issued by the IASB, we believe certain non-IFRS measures provide useful information both to management and investors in measuring the financial performance and financial condition of the Company. These measures do not have a standardized meaning prescribed by IFRS (or U.S. generally accepted accounting principles (“U.S. GAAP”)); and, therefore, they may not be comparable to similarly titled measures presented by other companies, and they should not be construed as an alternative to other financial measures determined in accordance with IFRS.

All references to “shares” or “common shares” in this Annual Report refer to the common shares of SNDL Inc., no par value.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

•the uncertainties associated with global conditions, including a potential economic recession, inflation, rising interest rates, the Russia-Ukraine conflict and the COVID-19 pandemic;

•our ability to raise future capital through debt or equity financing transactions, and our ability to efficiently deploy the capital raised through such transactions, including as part of our investments;

•our ability to successfully implement our cost and asset optimization initiatives;

•the continued development and growth of the demand and markets for medical and adult-use cannabis;

•the competitive conditions of the cannabis and liquor industries and the expected number of customers using our products and purchasing from our retail stores;

•the maintenance of our existing licences and the ability to obtain additional licences as required;

•our ability to establish and market our cannabis and retail brands within our targeted markets and compete successfully;

•our ability to produce and market additional products as regulations permit;

•our growth strategies;

•the timing and the amount of capital expenditures related to the maintenance of our facilities;

•our ability to attract and retain key employees and franchisees;

•our ability to generate and manage growth in our business, including expanding our cultivation operations, retail network and export opportunities;

•our ability to identify and successfully execute and manage strategic partnerships, joint ventures (including SunStream (as defined below)), strategic alliances, debt and equity investments as well as the costs and benefits associated with such initiatives, including the expected return on any investments;

•our ability to find suitable acquisition opportunities, as well as finance and integrate any acquisitions, including the acquisition of The Valens Company Inc. (“Valens”); and

5

•the volatility in the price of our common shares.

Although we base the forward-looking statements contained in this Annual Report on assumptions that we believe are reasonable, we caution you that actual results and developments (including our results of operations, financial condition and liquidity, and the development of the industry in which we operate) may differ materially from those made in or suggested by the forward-looking statements contained in this Annual Report. In addition, even if results and developments are consistent with the forward-looking statements contained in this Annual Report, those results and developments may not be indicative of results or developments in subsequent periods. Certain assumptions made in preparing the forward-looking statements contained in this Annual Report include:

•our ability to implement our operational and liquidity strategies as well as our strategic initiatives;

•our competitive advantages;

•the impact of competition;

•the changes and trends in the cannabis cultivation and retail, and the liquor retail industry;

•changes in laws, rules and regulations;

•our ability to maintain and renew required licences;

•our ability to maintain good business relationships with our customers, distributors and other strategic partners;

•our ability to keep pace with changing consumer preferences;

•our ability to protect our intellectual property;

•our ability to identify, finance and consummate acquisitions on attractive terms, integrate acquired companies (including Valens) and to realize the benefits of such acquisitions, including Valens;

•our ability to retain key personnel;

•our ability to efficiently deploy capital and achieve our expected and desired returns on such investments;

•our ability to open new retail locations and attract a sufficient number of qualified franchisees; and

•the absence of material adverse changes in our industry or the global economy, including as a result of a potential global recession and COVID-19.

These forward-looking statements are based on our current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Item 3D—Risk Factors”, and elsewhere in this Annual Report. Readers of this Annual Report are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the U.S. Securities and Exchange Commission (the “SEC”) after the date of this Annual Report.

This Annual Report contains estimates, projections and other information concerning our industry, our business, and the markets for our products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

In addition, assumptions and estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this Annual Report titled “Item 3D—Risk Factors”. These and other factors could cause our future performance to differ materially from our assumptions and estimates.

6

PART I

Item 1. Identity of Directors, Senior Management and Advisers

Not applicable.

Item 2. Offer Statistics and Expected Timetable

Not applicable.

Item 3. Key Information

B.Capitalization and indebtedness.

Not applicable.

C.Reasons for the offer and use of proceeds.

Not applicable.

D.Risk factors.

Risk Factors Summary

Investing in our common shares involves a high degree of risk. You should carefully consider the risks described in this item, together with all the other information in the Company’s publicly filed documents, before making a decision to invest in our common shares. If any of these risks actually occur, our business, financial condition and financial performance would likely be materially adversely affected. In such case, the trading price of our common shares would likely decline, and you may lose part or all of your investment. Below is a summary of some of the principal risks we face:

•We have a history of net losses, and we may not achieve or maintain profitability in the future.

•The industry in which we operate and the regulations governing it continue to develop, and if they develop or change in ways that differ from our expectations or ways that are adverse to us, our business and results of operations may be adversely impacted.

•We are dependent upon regulatory approvals and licences for our ability to grow, process, package, store and sell cannabis and other products derived therefrom as well as to own and operate cannabis retail stores through which we and our franchisees sell cannabis products, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal.

•Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.

•We are, and may become, subject to litigation, regulatory or agency proceedings, investigations and audits.

•We face competition from the illegal cannabis market.

•We currently sell, and expect to continue to sell, a significant share of our product to provincial governments through supply contracts that may not generate orders as expected or which may not be renewed.

•We experience significant customer concentration, with a limited number of customers accounting for a significant portion of our revenues.

•We face risks associated with our franchise business model.

•Our success in the cannabis retail market is dependent, in part, on our ability to attract and retain an adequate retail consumer base.

•We are dependent upon a limited number of facilities that are integral to our cannabis cultivation and production business.

•We are subject to risks inherent in an agricultural business, including the risk of crop failure.

7

•Our business and financial results could be adversely affected by a number of global conditions which are outside our control, including a potential global economic recession and the COVID-19 pandemic.

•Significant interruptions in our access to certain key inputs such as labour, raw materials, electricity, water and other utilities may impair our growing operations and materially affect our business.

•Failure in our quality control systems may adversely impact our sales volume, market share and profitability.

•We intend to continue to focus primarily on the premium segment of the adult-use cannabis market, which may not be sustainable, or in which we may not be able to develop or maintain a brand that attracts or retains customers.

•The adult-use cannabis market in Canada has experienced, and may in the future experience, supply and demand fluctuations.

•We may be unsuccessful in competing in the overall legal adult-use cannabis market in Canada.

•We may make investments into equity or debt securities of other companies, or provide credit to other companies, and we may not obtain the anticipated level of return on such investments, or any return at all.

•Our joint venture interest in SunStream is subject to certain risks associated with the conduct of joint ventures.

•We may not realize all or any of the anticipated returns on our joint venture interest in SunStream, or any return at all.

•Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis is a significant risk that would likely result in SunStream’s inability to execute its business plan, and may subject us to significant civil or criminal liability and other adverse consequences.

•We are subject to the risk of possibly becoming an investment company under the Investment Company Act of 1940.

•A decline in the consumption of alcoholic beverage products could adversely affect our business, financial condition and results of operations.

•Unfavourable publicity or poor consumer perception of the Company’s liquor retail brands could have an adverse effect on the Company’s business, financial condition and results of operations.

•If a significant number of the Company’s licences were revoked or not renewed, or if the Company failed to secure new licences, there could be a material adverse effect on its business, financial condition, liquidity and results of operations.

•If we are unable to retain the services of senior management upon whose judgement and leadership the Company is dependent, despite employment agreements, this could have a material effect on the Company and our shares could decline.

•We may not be able to successfully identify and execute future acquisitions or dispositions or to successfully manage the impacts of such transactions on our operations.

•We face integration risks in connection with our acquisition strategy.

•The price of our common shares in public markets has experienced and may in the future experience extreme volatility and you may lose some or all of your investment in our common shares as a result.

•We may sell a substantial number of our common shares in the public market at any time. Such sales or the perception that they may occur could cause the market price of our common shares to drop significantly, even if our business is doing well.

•If we fail to meet applicable listing requirements, Nasdaq may delist our common shares from trading, in which case the liquidity and market price of our common shares could decline.

Risks Related to Our Financial Position and Accounting

We have a history of net losses, and we may not achieve or maintain profitability in the future.

We were incorporated in 2006, began cultivating cannabis in 2012, and started selling cannabis in 2018 after the federal legalization of adult-use cannabis in Canada. In 2021, we expanded into corporate-owned and franchised cannabis retail with the acquisition of Inner Spirit Holdings Ltd. (“Inner Spirit”), as well as created a new investments segment focused on our activities in the deployment of capital to strategic initiatives. In 2022, we expanded into liquor retail with the acquisition of Alcanna Inc. (“Alcanna”). We have yet to generate an annual profit. We generated a net loss from continuing operations before income tax of $379.8 million and $234.7 million, for the fiscal years ended December 31, 2022 and 2021, respectively, and had negative operating cash flows for each of these periods. Our accumulated deficit as of December 31, 2022 was $1,092.0 million. Although we have implemented business optimization initiatives, we will continue to expend significant funds to fund capital investments, expand our marketing and sales operations, expand our cannabis and liquor retail networks, fund strategic investments and acquisitions and maintain our growing and production capacity. We also incur

8

significant legal, accounting, reporting and other expenses associated with being a public company. We may not achieve or maintain profitability.

Our efforts to grow our business may be more costly than we expect and we may not generate enough revenue to offset our operating expenses. We have incurred, and may in the future incur, significant losses for a number of reasons, including as a result of unforeseen expenses, difficulties, complications and delays in obtaining governmental licences, failure to secure and profitably operate corporate-owned retail stores, failure to expand our franchised store network, failure to realize expected benefits of strategic investments and acquisitions and the other factors and risks described in this Annual Report. The amount of any future losses will depend, in part, on our ability to generate revenue on the one hand and any increases in our expenses on the other hand. If we continue to incur losses in the future, the net losses and negative cash flows incurred to date, together with any such future losses, will have an adverse effect on our shareholders’ equity and working capital. Because of the numerous risks and uncertainties associated with our business and industry, we are unable to accurately predict when, or if, we will be able to achieve profitability. Even if we achieve profitability at some point in the future, we may not be able to sustain profitability in subsequent periods. If we are unable to achieve and sustain profitability, the market price of our common shares may significantly decrease and our ability to raise capital, expand our business or continue our operations may be impaired. A decline in the value of our common shares may also cause you to lose all or part of your investment.

The Company may require additional financing and unless and until we achieve profitability, we will be required to finance our losses with issuances of equity or debt. Recently, we financed our liquidity needs primarily with issuances of equity and equity-linked securities, but our ability to do so in the future will depend on future market conditions, which are beyond our control and may be adversely affected by factors which include, but are not limited to, macroeconomic conditions (including rising interest rates and inflation), volatility, wars and other armed conflicts, geopolitical tensions, pandemics, and other factors. The inability to additional capital when required and on terms acceptable to us could have a material adverse impact on our business, financial condition and results of operations, including a delay or indefinite postponement of current business objectives or liquidation of the Company. If additional funds are raised through issuances of equity or equity-linked securities, existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences and privileges superior to those of holders of our common shares. In addition, any debt financing secured in the future could significantly adversely impact our liquidity and result in the imposition of restrictive and financial covenants that could limit future financing and other business and financial activities of the Company.

We have in the past, and may in the future, record significant impairments or write-downs of our assets.

Our cannabis inventory in our cannabis operations and cannabis retail segments has a finite shelf life and is subject to obsolescence, expiration, spoilage, shrinkage, unacceptable quality, contamination or other declines in value prior to wholesale or retail sale. We have in the past, and may in the future, be required to record substantial write-downs or impairments related to loss of value in our cannabis inventory.

In addition, our facilities may be subject to obsolescence, damage, loss of fair market value or other declines in value. For example, in the year ended December 31, 2021, we recorded significant write-downs with respect to our facility in Olds, Alberta (the “Olds Facility”) due to curtailment in the utilization of a portion of the capacity to align cannabis production with demand estimates.

Lastly, we have in the past recorded and may in the future record impairments to goodwill related to our acquisitions, intellectual property, investments or similar assets. For example, in the year ended December 31, 2022, we recorded an impairment with respect to the goodwill and intellectual property assets of Inner Spirit due to changes in circumstances since the date of the acquisition, mainly caused by the continued oversaturation of the cannabis retail market.

There can be no assurance that we will not be required to record inventory, facility, goodwill, intellectual property, investment or other write-downs in the future. Such write-downs could be substantial and result in a material adverse effect on our business, financial condition and results of operations.

We have a material weakness in our internal control over financial reporting and our management may not be able to successfully implement adequate internal control over financial reporting or disclosure controls and procedures.

In connection with the audit of our consolidated financial statements for the fiscal period ended December 31, 2022, our management and independent auditors concluded that there was a material weakness in our internal control over financial reporting as at December 31, 2022. A material weakness is a significant deficiency, or a combination of significant deficiencies, in internal control over financial reporting such that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

The material weakness identified was that information technology general controls (“ITGCs”) were not designed and operating effectively to ensure (i) that access to applications and data, and the ability to make program and job changes, were adequately restricted to appropriate personnel and (ii) that the activities of individuals with access to modify data and make program and job changes were appropriately monitored. Business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted.

9

This material weakness did not result in material misstatements of the consolidated financial statements as of and for the year ended December 31, 2022. This material weakness creates a reasonable possibility that a material misstatement to the consolidated financial statements would not be prevented or detected on a timely basis.

Management has implemented and continues to implement measures designed to ensure that control deficiencies are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:

•continuing to strengthen procedures and controls related to the provision of and periodic review of user access to IT systems;

•continuing to strengthen the logging and monitoring of software updates and changes to systems supporting our financial reporting processes;

•enhancing the timeliness of executing user access reviews and the subsequent actions as required; and

•working with our advisors to continue to assist with process improvements and strengthening of controls over financial systems.

The Company is pursuing remediation of the above material weakness during the 2023 fiscal year.

If we fail to establish and maintain adequate internal controls, including by remediating the aforementioned material weaknesses, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. As a result, we may be subject to costly litigation and shareholder actions, our access to the capital markets may be limited or adversely affected, our results of operations may be adversely affected and the trading price of our common shares may decline. Additionally, ineffective internal controls could expose us to an increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchanges on which we list or to other regulatory investigations and civil or criminal sanctions. Furthermore, we may be the subject of negative publicity focusing on the restatement of our previously issued financial results and related matters and may be adversely impacted by negative reactions from our shareholders, creditors, or others with whom we do business. This negative publicity may impact our ability to attract and retain customers, employees and suppliers.

Proper systems of internal control over financial reporting and disclosure controls and procedures are critical to the operation of a public company. However, we do not expect that our internal control over financial reporting or disclosure controls and procedures will prevent all errors and remove all risk of fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

The valuation of our biological assets is subject to certain assumptions and estimates.

Pursuant to IFRS, we measure the value of our biological assets (consisting of plants in various stages of vegetation) at fair value less costs to sell up to the point of harvest. As market prices are generally not available for biological assets while they are growing, we are required to make assumptions and estimates relating to, among other things, expected harvest yields, selling prices and costs to sell. The assumptions and estimates used to determine the fair value of biological assets, and any changes to such prior estimates, directly affect our reported results of operations. If actual yields, prices, costs, market conditions or other results differ from our estimates and assumptions, there could be material adjustments to our results of operations. In addition, the use of these future estimated metrics differs from US GAAP. As a result, our financial statements and reported earnings are not directly comparable to those of similar companies in the United States.

We may be subject to credit risk.

Credit risk is the risk that the counterparty to a financial instrument fails to meet its contractual obligations, resulting in a financial loss to us. We have credit risk exposure based on the balance of our cash, accounts receivable, investments, and taxes recoverable. There are no assurances that our counterparties, including parties to whom we extended credit, or customers will meet their contractual obligations to us.

We have implemented, and continue to implement, business optimization initiatives, which may negatively impact our control environment and distract from our operation of the business and may not be successful.

In response to slower than expected regulatory approvals of new retail stores and delays in some cannabis derivative products, in 2020 and 2021, we implemented several cost savings and business optimization initiatives, including the enhancement of facility workflows and processes, realignment of product lines and product formats to areas of stronger demand, workforce optimization and a heightened discipline in cost management. In February 2023, we further implemented a headcount reduction of approximately 85 employees at the Olds Facility as part of a larger phased cost savings program, expected to deliver close to $9 million in savings across labour and operational costs for the remainder of 2023. The Company continues to pursue additional business optimization initiatives, including optimization of power usage, streamlining the workforce and improving supply chain efficiency. As part of the leadership team’s focus on improved efficiency, cost management and long-term sustainability, the Company continues to monitor operations to ensure it remains responsive in the current environment.

10

A variety of factors could cause us not to realize some or all of the expected cost savings, including, among others, delays in the anticipated timing of activities related to our cost savings programs, lack of sustainability in cost savings over time, unexpected costs associated with operating our business, our ability to reduce headcount and our ability to achieve the efficiencies contemplated by the business optimization initiatives. We may be unable to realize all of these cost savings within the expected timeframe, or at all, and we may incur additional or unexpected costs in order to realize them. The magnitude of expected cost savings is based upon a number of assumptions and estimates that are in turn based on our analysis of the various factors which currently, and could in the future, impact our business. These assumptions and estimates are inherently uncertain and subject to significant business, operational, economic and competitive uncertainties and contingencies. Certain of the assumptions relate to business decisions that are subject to change, including, among others, our anticipated business strategies, our marketing strategies, our product development and licensing strategies and our ability to anticipate and react to business trends. Other assumptions relate to risks and uncertainties beyond our control, including, among others, the economic environment in which we operate, cannabis regulation and licensing and other developments in our industry as well as capital markets conditions from time to time. The actual results of implementing the various cost savings initiatives may differ materially from our estimates if any of these assumptions prove incorrect. Moreover, our continued efforts to implement these cost savings may divert management attention from the rest of our business and may preclude us from seeking attractive new products and other opportunities. Additionally, former employees may file lawsuits against us, which may be expensive to defend and could potentially result in adverse judgements against us. Any of the foregoing may materially and adversely affect our business, results of operations and liquidity.

Fluctuations in the exchange rate of the Canadian dollar against the U.S. dollar could harm our results of operations.

We may be exposed to fluctuations of the Canadian dollar against the U.S. dollar because we publish our financial statements in Canadian dollars, while a portion of our assets, liabilities, revenues and costs, including, in particular, assets, liabilities, revenues and costs recorded in connection with our joint venture with SunStream Bancorp Inc. (“SunStream”), are denominated in U.S. dollars. Fluctuations in the exchange rate of the Canadian dollar against the U.S. dollar may have a material adverse effect on our earnings or assets when translating U.S. dollars into Canadian dollars.

Risks Related to Cannabis Regulation and Legal Proceedings

The cannabis industry and the regulations governing it continue to develop, and if they develop or change in ways that differ from our expectations or ways that are adverse to us, our business and results of operations may be adversely impacted.

Regulations are continuing to be developed for different aspects of the adult-use cannabis industry in Canada. The regulations and market for adult-use cannabis, various cannabis formats and cannabis retail may not develop as we expect or on the timeline that we expect, which could have a material adverse effect on our business and results of operations.

Any adverse changes in regulations, government or judicial interpretation of regulations, or more vigorous enforcement thereof or other unanticipated events could require extensive changes to our operations, increase compliance costs or give rise to material liabilities or a revocation of our licences and other permits and authorizations. Furthermore, governmental authorities may change their administration, application or enforcement procedures at any time, which may adversely impact our ongoing regulatory compliance costs. There is no assurance that we will be able to comply or continue to comply with applicable regulations.

We are dependent upon regulatory approvals and licences for our ability to grow, process, package, store and sell cannabis and other products derived therefrom as well as to own and operate cannabis retail stores through which we and our franchisees sell cannabis products, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal.

Our Canadian business operations are dependent on licences issued by Health Canada as well as those issued by the various provincial regulators having jurisdiction over the provinces in which we operate licensed cannabis retail stores. Our federal licence for our Olds Facility expires on February 23, 2027, our licence for our Atholville Facility expires on July 12, 2024 and our licences for the acquired Valens facilities expire between December 30, 2023 and March 8, 2028. A holder of a cannabis licence under the Cannabis Act (Canada) (the “Cannabis Act”) and the Cannabis Regulations (Canada) (the “Cannabis Regulations”) must apply to renew its licence on or before the licence expiry date. Following receipt of the renewal application, Health Canada will (i) confirm the security clearance status of all relevant individuals; (ii) confirm the status of fees paid (if applicable) and (iii) confirm the status of licences issued by the Canada Revenue Agency under the Excise Act, 2001 (if applicable). Health Canada may also conduct an inspection to verify compliance or ask the licence holder to provide additional information. A renewed licence with a new expiry date will be issued once Health Canada confirms that all requirements have been met. Cannabis licence holders can apply to renew their licence up to four months before the licence expires. Failure to comply with the requirements of the licences or any failure to renew the licences would have a material adverse impact on us. There can be no guarantee that Health Canada will renew our licences, or that such renewals will occur in a timely fashion or on terms similar to our existing licences or otherwise acceptable to us. Any new facilities or the expansion of our business at existing facilities requires the approval of Health Canada, and there is no guarantee that Health Canada will grant such approvals. Health Canada requires new applicants for cannabis licences under the Cannabis Act to have a fully built site that meets all the requirements of the Cannabis Regulations at the time of their application, as well as satisfying other application criteria. Further, according to Health

11

Canada, it will not substantively review our licence applications until the facilities associated with such licence applications are fully constructed and meet all the requirements of the Cannabis Regulations. Any delay in renewing or granting a licence, revocation of an existing licence, refusal to grant a licence or change in the terms of licence could materially adversely impact our expected future operations.

Our ability to continue operating our cannabis cultivation and retail cannabis business is dependent on the good standing of various licences, permits and authorizations from time to time possessed by us and adherence to all regulatory requirements related to such activities. We will incur ongoing costs and obligations related to regulatory compliance, and any failure to comply with the terms of such licences, permits or authorizations, or to renew the licences, permits and authorizations after their expiry dates, could have a material adverse effect on our business, financial results and operations. There can be no assurance that applicable regulators will extend or renew the applicable licences, permits and authorizations, or if extended or renewed, that they will be extended or renewed on the same or similar terms. In the event that the applicable regulators do not extend or renew the applicable licences, permits and authorizations, or should they renew the applicable licences, permits or authorizations on different terms, any such event or occurrence could have a material adverse effect on our business, financial results and operations.

In our retail cannabis segment, our retail licences, permits and authorizations are specific to individual cannabis retail store locations. As our retail business continues to grow, any expansion to or update of our currently operating cannabis retail stores, or the introduction of new cannabis retail stores, will require the approval of the applicable cannabis regulator. There can be no guarantee that the applicable regulator will approve any such expansions and/or renovations, which could have a material adverse effect on our business, results of operations and financial results.

Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.

Our business activities are heavily regulated in all jurisdictions where we do business. Our operations are subject to various laws, regulations and guidelines by governmental authorities, including Health Canada, relating to the cultivation, processing, manufacture, marketing, management, distribution, transportation, storage, wholesale and retail sale, packaging, labelling, pricing and disposal of cannabis and cannabis products, as well as the wholesale and retail sale of alcoholic products. In addition, we are subject to laws and regulations relating to employee health and safety, insurance coverage and the environment. Laws and regulations, applied generally, grant government agencies and self-regulatory bodies broad administrative discretion over our activities, including the power to limit or restrict business activities as well as impose additional disclosure requirements on our products and services.

Health Canada inspectors routinely assess our production facilities for compliance with applicable regulatory requirements. In addition, we have in the past, and in the future may, self-report violations of regulatory requirements to Health Canada and other regulators. Any failure by us to comply with the applicable regulatory requirements could:

•require extensive changes to our operations;

•result in regulatory or agency proceedings or investigations;

•result in the revocation of our licences, permits and authorizations and increased compliance costs;

•result in damage awards, civil or criminal fines or penalties;

•result in restrictions on our operations;

•result in Health Canada or other regulators destroying, seizing or placing a hold on our inventory;

•harm our reputation; or

•give rise to material liabilities.

Further, our employees or other agents may, without our knowledge and despite our efforts, policies and procedures, engage in prohibited conduct under applicable regulatory requirements for which we may be held responsible.

There can be no assurance that any future regulatory or agency proceedings, investigations or audits will not result in substantial costs, a diversion of management’s attention and resources or other adverse consequences to our business. The Company cannot predict the impact of changes in compliance measures implemented by Health Canada.

Achievement of our business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all necessary regulatory approvals for the cultivation, processing, production, storage, distribution, transportation, wholesale and retail sale, import and export, as applicable, of our products. Any failure to comply with the regulatory requirements applicable to our operations may lead to possible sanctions, including:

•the revocation or imposition of additional conditions on licences, permits and authorizations to operate our business;

•the suspension or expulsion from a particular market or jurisdiction or of our key personnel;

12

•the imposition of additional or more stringent inspection, testing and reporting requirements;

•product recalls or seizures; and

•the imposition of fines and censures.

Trade of cannabis for non-medical purposes within Canada may be restricted by the Canadian Free Trade Agreement.

We have entered into supply agreements with the Provincial Buyers for the supply of adult-use cannabis and cannabis derivative products. We have also been cleared by the SLGA to supply cannabis to retail and wholesale permit holders in Saskatchewan. The Canadian Free Trade Agreement, which generally reduces or eliminates the barriers to the free movement of persons, goods, services, and investments within Canada, specifically excludes cannabis for non-medical purposes from its scope and instead leaves the intra-Canadian movement of non-medical cannabis to future negotiations among the provinces and territories. There is a risk that the outcome of the negotiations will result in the interprovincial and interterritorial trade of cannabis for non-medical purposes in Canada being entirely restricted or subject to conditions that will negatively impact our ability to sell cannabis in provinces and territories in which we do not have cultivation and production facilities, including those in which we have already executed agreements or been approved to supply cannabis to retailers.

Our business is or may become subject to a variety of laws related to controlled substances and money laundering, the application of which to our business is unsettled and still developing and which could subject us to claims or otherwise harm our business.

In the United States, despite cannabis having been legalized for medical use or adult use in a number of states, cannabis and cannabis products, other than hemp and certain hemp-derived products, such as CBD, continue to be categorized at the federal level as a Schedule I controlled substance under the Controlled Substances Act (“CSA”), and subject to the Controlled Substances Import and Export Act, as amended (“CSIEA”). We are or may become subject to various other U.S. federal laws and regulations, including as result of the listing of our common shares on the Nasdaq Capital Market (“Nasdaq”) and lending and providing other financial services to cannabis companies engaging in the adult-use cannabis business in the United States (whether directly or through SunStream). Violations of any U.S. federal laws or regulations, including the CSA and CSIEA, to which we may be found to be subject, whether intentionally or inadvertently, could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings initiated by either the U.S. federal government or private citizens or criminal charges, including disgorgement of profits, cessation of business activities or divestitures. Further, the status of cannabis as a Schedule I controlled substance may cause us, and our business, to be negatively perceived by prospective U.S. investors or other parties, or who may have reputational or other concerns about dealings with a cannabis grower even if it is not distributing any products in the United States, which may limit our ability to access capital in private or public capital markets. For further information about the risks related to U.S. federal laws and regulations with respect to SunStream’s operations, see “—Risks related to our investments—Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis is a significant risk that would likely result in SunStream’s inability to execute its business plan and may subject us to significant civil or criminal liability and other adverse consequences.”

We also are, or may become, subject to a variety of laws and regulations in Canada, the United States and elsewhere that prohibit money laundering, including the Proceeds of Crime and Terrorist Financing Act (Canada), the U.S. Money Laundering Control Act, as amended, and the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by governmental authorities in Canada, the United States or any other jurisdiction in which we may in the future have business operations or to which we export or may export in the future. Although we believe that none of our activities implicate any applicable money laundering statutes, in the event that any of our business activities, any dividends or distributions therefrom, or any profits or revenue accruing thereby are found to be proceeds of crime under one or more of the statutes described above or any other applicable legislation, any persons, including investors, found to be aiding and abetting us in such violations could be subject to criminal or civil liability. Any violations of these laws, or allegations of such violations, could disrupt our operations, significantly distract management and involve significant costs and expenses, including legal fees. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.

If we are not able to comply with all safety, health and environmental regulations applicable to our operations and the industries in which we operate, we may be held liable for any breaches of those regulations.

Safety, health and environmental laws and regulations affect nearly all aspects of our operations, including product development, working conditions, waste disposal, emission controls, the maintenance of air and water quality standards and land reclamation, and, with respect to environmental laws and regulations, impose limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Compliance with safety, health and environmental laws and regulations can require significant expenditures, and failure to comply with such safety, health and environmental laws and regulations may result in the imposition of fines and penalties, the temporary or permanent suspension of operations, the imposition of clean-up costs resulting from contaminated properties, the imposition of damages and the loss of or refusal of governmental authorities to issue permits or licences to us. Exposure to these liabilities may arise in connection with our existing operations, our historical operations and operations that may in the future be closed or sold to third parties. We could also be held liable for worker exposure to hazardous substances and for accidents causing injury or death. There

13

can be no assurance that we will at all times be in compliance with all safety, health and environmental laws and regulations notwithstanding our attempts to comply with such laws and regulations.

Changes in applicable safety, health and environmental standards may impose stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. We are not able to determine the specific impact that future changes in safety, health and environmental laws and regulations may have on our industry, operations or activities and our resulting financial position; however, we anticipate that capital expenditures and operating expenses will increase in the future as a result of the implementation of new and increasingly stringent safety, health and environmental laws and regulations. Further changes in safety, health and environmental laws and regulations, new information on existing safety, health and environmental conditions or other events, including legal proceedings based upon such conditions or an inability to obtain necessary permits in relation thereto, may require increased compliance expenditures by us.

We are, and may become, subject to litigation, regulatory or agency proceedings, investigations and audits.

We are, and may in the future become, subject to litigation, regulatory or agency proceedings, investigations and audits from time to time, some of which may adversely affect our business. Should any litigation, regulatory or agency proceeding, investigation or audit in which we become involved be determined against us, such a decision could, among other impacts, adversely affect our ability to continue operating without more onerous restrictions or at all, adversely affect our financial condition and results of operations, harm our reputation, or reduce the value or market price for the common shares. Even if we are involved in litigation, regulatory or agency proceedings, investigations and audits and are ultimately successful, they can require the redirection of significant resources and may also create a negative perception of our brand.

For example, in connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several actions that alleged violations of securities laws. For further detail in respect of ongoing legal proceedings, please see the section of this Annual Report entitled “Legal Proceedings.”

While we intend to defend ourselves vigorously in all pending and future legal proceedings, we may settle certain matters for strategic reasons, as a part of a resolution of other matters or in order to avoid potentially worse consequences arising from inherently uncertain judicial or administrative processes. Moreover, regardless of the merits of our defenses, if we are unable to resolve certain legal proceedings or regulatory actions, indirect consequences arising from unproven allegations or appealable regulatory findings may have adverse consequences to us. The outcome of any litigation, regulatory or agency proceedings investigations and audits is inherently uncertain. Unfavorable rulings, judgements or settlement terms could have a material adverse impact on our business, liquidity and results of operations.

The Company faces cyber-security and similar risks, which could result in the disclosure, theft, or loss of confidential or other proprietary information, including intellectual property, damage to the Company’s brand and reputation, legal exposure and financial losses. The Company must also comply with a variety of data privacy regulations and failure to comply with such regulations may affect the Company’s financial performance.

We collect, process, maintain and use data, including sensitive personal information on individuals, available to us through online activities and other customer interactions with our business. Our current and future marketing programs may depend on our ability to collect, maintain and use this information, and our ability to do so is subject to evolving laws and enforcement trends in Canada and other jurisdictions. There are a number of laws protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure of that protected information. In particular, the privacy rules under the Personal Information Protection and Electronic Documents Act (Canada) (“PIPEDA”), and similar laws in other jurisdictions, protect medical records and other personal health information by limiting their use and the disclosure of health information to the minimum level reasonably necessary to accomplish the intended purpose. We collect and store personal information about our patients and are responsible for protecting that information from privacy breaches. A privacy breach may occur through a procedural or process failure, an IT malfunction or deliberate unauthorized intrusions. Theft of data for competitive purposes, particularly patient lists and preferences, is an ongoing risk whether perpetrated through employee collusion or negligence or through deliberate cyberattack. Moreover, if we are found to be in violation of the privacy or security rules under PIPEDA or other laws protecting the confidentiality of patient health information, including as a result of data theft and privacy breaches, we could be subject to sanctions and civil or criminal penalties, which could increase our liabilities and harm our reputation.

Certain of our marketing practices rely upon e-mail, social media and other means of digital communication to communicate with consumers on our behalf. We may face risk if our use of e-mail, social media or other means of digital communication is found to violate applicable laws. We post our privacy policy and practices concerning the use and disclosure of user data on our website. Any failure by us to comply with our posted privacy policy, anti-spam legislation or other privacy-related laws and regulations could result in proceedings which could potentially harm our business. In addition, as data privacy and marketing laws change, we may incur additional costs to ensure we remain in compliance. If applicable data privacy and marketing laws become more restrictive at the international, federal, provincial or state levels, our compliance costs may increase, our ability to effectively engage customers via personalized

14

marketing may decrease, our investment in our e-commerce platform may not be fully realized, our opportunities for growth may be curtailed by our compliance burden and our potential reputational harm or liability for security breaches may increase.

Information security risks have increased in recent years because of the proliferation of new technologies and the increased sophistication and activities of perpetrators of cyber-attacks. The Company’s information technology infrastructure may be vulnerable to such attacks, including through the use of malware, software bugs, computer viruses, ransomware, social engineering, and denial of service. It is possible that such attacks could compromise the Company’s security measures or the security measures of parties with whom the Company does business. Although the Company maintains procedures, internal policies and technological security measures to safeguard such content and information, as well as a cyber-security insurance policy, the Company’s information technology systems, and the information technology systems of our current or future third-party vendors, collaborators, consultants and service providers, could be penetrated by internal or external parties intent on extracting information, corrupting information, stealing intellectual property or trade secrets, or disrupting business processes, and any such policies, measures or insurance may be insufficient to guard prevent or mitigate the impact of cybersecurity incidents. In addition, because the techniques that may be used to circumvent the Company’s safeguards change frequently and may be difficult to detect, the Company may be unable to anticipate any new techniques or implement sufficient preventive security measures. The Company seeks to monitor such attempts and incidents and to prevent their recurrence through modifications to the Company’s internal procedures and information technology infrastructure and provides information security training and compliance programs to its employees on an annual basis, but in some cases preventive action might not be successful. Moreover, the development and maintenance of these security measures may be costly and will require ongoing updates as technologies evolve and techniques to overcome the Company’s security measures become more sophisticated. Any such attack or unauthorized access could result in a disruption of the Company’s operations, the theft, unauthorized use or publication of confidential or proprietary information of the Company or its customers, employees, suppliers, business partners or other third parties, a reduction of the revenues the Company is able to generate from its operations, damage to the Company’s brand and reputation, a loss of confidence in the security of the Company’s business, and significant legal and financial exposure, each of which could potentially have an adverse effect on the Company’s business.

The Canadian excise duty framework may affect profitability.

The federal and provincial or territorial legislation and regulatory regimes for cannabis products include excise duties payable by licensed cannabis producers on adult-use cannabis products, in addition to goods and services tax or harmonized sales tax in certain provinces and territories. We currently hold licences issued by the Canada Revenue Agency (“CRA”) required to comply with this excise framework. The rate of the excise duties for cannabis products varies by province and territory. Any significant increase in the rate of excise duties on cannabis products in the future and any restrictive interpretations by the CRA or the courts of the regulatory-like restrictions contained in the Excise Act, 2001 (Canada) (which may be different than those contained in the Cannabis Act) could reduce consumer demands for cannabis products and adversely impact the adult-use cannabis industry and market in general. In addition, any increase in the rate of excise duties on cannabis products in the future could reduce our margins and profitability in the event that we could not or chose not to pass along such increases to consumers.

We are constrained by law in our ability to market our cannabis products in Canada.

The development of our business and operating results may be hindered by applicable restrictions on production, sales and marketing activities imposed on us and other licensed producers and cannabis retailers. All products we distribute into the Canadian adult-use market are subject to restrictions with respect to product formats, product packaging and labelling. In addition, the Cannabis Act regulates our marketing activities, including prohibitions on testimonials and endorsements, lifestyle branding, and promotion that is appealing to young persons. Each Canadian province and territory has also enacted regulatory regimes for the distribution and sale of cannabis for adult-use purposes within its jurisdiction. As such, our portfolio of brands, products and services must be specifically tailored, and our marketing activities carefully structured, to comply with individual provincial and territorial rules and regulations. These restrictions may preclude us from establishing our branding, achieving pricing differentiation, effectively marketing our cannabis products or competing for market share, and may impose costs on us that cannot be absorbed through increased selling prices for our cannabis products.

Risks Related to Cannabis Operations Segment

We face competition from the illegal cannabis market.

We face competition from the illegal dispensaries that are unlicensed and unregulated, and otherwise from illegal market participants, who sell cannabis and cannabis products, including products with higher concentrations of active ingredients, use flavors or other additives that we are prohibited from using, or engage in distribution, advertising and promotion activities in which we are not permitted to engage, use delivery methods that we are prohibited from offering to individuals in Canada, sell products at lower prices, brand products more explicitly, or sell at lower prices. As these illegal market participants do not comply with the regulations governing the cannabis industry, their operations may also have significantly lower costs. The perpetuation of the illegal market for cannabis may have a material adverse effect on our business, results of operations, as well as the perception of cannabis use.

15

We currently sell, and expect to continue to sell, a significant share of our product to provincial governments through supply contracts that may not generate orders as expected or which may not be renewed.

Under the terms of our production licences issued pursuant to the Cannabis Act, we are restricted as to whom we can sell our cannabis products. We currently derive, and expect to continue to derive a significant portion of our revenues from supply agreements with Canadian provincial and territorial governments, including the Alberta Gaming, Liquor and Cannabis Commission (the “AGLC”), the Ontario Cannabis Store (the “OCS”), the BC Liquor Distribution Branch (the “BCLDB”), Manitoba Liquor and Lotteries (the “MLL”), Saskatchewan Liquor and Gaming Authority (the “SLGA”), New Brunswick Liquor Corporation (the “ANBL”), Nova Scotia Liquor Corporation (the “NSLC”), PEI Cannabis Management Corporation (the “PEICMC”), Quebec SQDC (the “SQDC”) and Newfoundland Labrador Liquor Corporation (the “NLC”).

Our provincial or territorial supply agreements do not contain purchase commitments or otherwise obligate the purchaser to buy a minimum or fixed volume of products from us and allow the purchaser broad latitude to return product to us. As a result, the amount of cannabis that the AGLC, the OCS, the BCLDB, MLL, SLGA, ANBL, NSLC, PEICMC, SQDC, or NLC (collectively, the “Provincial Buyers”) may purchase under our supply agreements, or its price, may deviate significantly from our expectations. In addition, our results of operations could fluctuate materially in the future and could be materially and disproportionately impacted by the purchasing decisions of the Provincial Buyers and any other future government purchasers as well as the return of unsold products. If any of the Provincial Buyers decides to purchase lower volumes of products from us (or return more products) than we expect, charges “slotting fees” in connection with carrying our products, charges additional taxes, insists on a price that is lower than we expect, alters its purchasing patterns at any time with no or limited notice, decides not to continue or begin to purchase our cannabis products at all or does not renew its agreement with us on similar terms or other terms acceptable to us, our results of operations could be materially adversely affected. We have in the past, and may in the future, offer price discounts and other promotions to the Provincial Buyers to promote the movement of slower selling products or as the result of price compression in the market. We also record return provisions in our financial statements based on the estimated likelihood of having additional slow-moving and aged product returned. If we underestimate the magnitude of such return provisions, our results of operation would be negatively affected. In addition, if the legal distributions channels in Canada for cannabis do not continue to develop in accordance with our expectations, either because of delays in the opening of dispensaries or otherwise, our results of operations would be materially adversely affected.

We experience significant customer concentration, with a limited number of customers accounting for a significant portion of our revenues.

Our top five customers in the cannabis operations segment accounted for 87% for the year ended December 31, 2022. Of these customers, four customers have each accounted for more than 10% of our revenues for such period. Inherent risks exist when a large percentage of total revenues is concentrated with a limited number of customers.

It is not possible for us to predict the future level of demand for our products that will be generated by these customers or the future demand for the products of these customers in the consumer marketplace. In addition, revenues from these large customers may fluctuate from time to time based on market demand for our products among consumers, the level which may be affected by market conditions or other factors, some of which may be outside of our control. Further, our contracts with these large customers do not contain purchase commitments or otherwise obligate the purchasers to buy a minimum or fixed volume of products from us (and allow these customers to return products to us for a variety of reasons). If any of our major customers experience declining or delayed sales of our products to consumers due to market, economic or competitive conditions, we could be pressured to reduce the prices we charge for our products, reduce the volume of products we supply to such customers, we could lose the customer or have a substantial amount of product returned to us. Additionally, if any of our large customers were to suffer financial instability, they could refuse or delay payment of outstanding receivables. Any such development may have a material adverse effect on our business, results of operations and financial condition.

Any failure on our or our retail store suppliers’ part to comply with supplier standards established by provincial or territorial distributors could prevent us from accessing certain markets in Canada.

Government-run provincial and territorial distributors in Canada require suppliers to meet certain service and business standards, and routinely assess their suppliers for compliance with these standards. For example, our current supply agreement with the AGLC permits the AGLC to inspect and test our products for compliance with a rigorous set of criteria, including packaging, labelling, timing and stated quality test results. We use third parties to extract delta-9-tetrahydrocannabinol (“THC”) and hemp-derived cannabidiol (“CBD”) for use in various product offerings, including for use in our vape products. Any failure by us or our third-party suppliers to comply with such standards could result in our being disqualified as a supplier and could lead to the termination or cessation of orders under existing or future supply contracts. If any of the foregoing events were to occur, our business, financial condition and results of operations could be materially adversely impacted.

We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception.

We believe that the cannabis industry is highly dependent upon positive consumer and investor perception regarding the benefits, safety, efficacy and quality of cannabis and cannabis products. Such categories of products have previously been commonly associated with

16

various other narcotics, violence and criminal activities, and there is a risk that our business might attract negative publicity. Perception of the cannabis industry and cannabis products, currently and in the future, may be significantly influenced by scientific research or findings, regulatory investigations or proceedings, litigation, political statements, media attention and other publicity (whether or not accurate or with merit) both in Canada and in other countries relating to the benefits and risks of consuming cannabis or cannabis products, including unexpected safety or efficacy concerns or the activities of industry participants. There can be no assurance that future scientific research, findings, regulatory investigations or proceedings, litigation, political statements, media attention or other research findings or publicity will be favorable to cannabis or cannabis products. Adverse future scientific research reports, findings, regulatory investigations or proceedings, and political statements, that are, or litigation, media attention or other publicity that is, perceived as less favorable than, or that questions, earlier research reports, findings or publicity (whether or not accurate or with merit) could result in a significant reduction in the demand for cannabis or cannabis products. Further, adverse publicity reports or other media attention regarding consumption of cannabis being associated with physical or mental illness or other negative effects or events, the safety, efficacy and quality of cannabis or cannabis products generally, as well as our current or future products and facilities, specifically could adversely affect us. Adverse publicity could arise even if the adverse effects associated with cannabis use resulted from consumers’ failure to use such products legally, appropriately or as directed.

There is also a risk that the actions of other companies and service providers in the cannabis industry may negatively affect the reputation of the industry as a whole and, thereby, negatively impact our reputation. The increased usage of social media and other web-based tools used to generate, publish and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share negative opinions and views in Canada and elsewhere in regard to our activities and the cannabis industry in general, whether true or not. The legal restrictions with respect to labelling and marketing cannabis may exacerbate these risks by increasing the influence of social media users and prohibiting us from effectively responding to negative publicity.

We do not ultimately have direct control over how we or the cannabis industry is perceived by others. Reputational issues may result in decreased investor confidence, declines in our stock price, litigation, difficulty in obtaining financing, increased challenges in developing and maintaining community relations and may otherwise present an impediment to our overall ability to advance our business strategy and grow our business.

We may be subject to additional risks if we expand our cannabis operations internationally.

In 2022, in partnership with IM Cannabis Corp., we began exporting dried cannabis flower to Israel. In addition, following our business combination with Valens in January 2023, we have begun exporting medical cannabis products to Australia through Valens’ subsidiary, Valens Australia Pty Ltd. (“Valens Australia”). We may in the future further expand our cannabis operations internationally, including to the United States, by importing or exporting cannabis products, and establishing cultivation operations in other jurisdictions or otherwise. Pursuant to the Cannabis Act, only industrial hemp or cannabis used for medical or scientific purposes may currently be imported into or exported from Canada. Any such import or export requires a permit. In the future, we may seek additional permits to import or export cannabis and cannabis products. If we do not receive the required permits or receive licences with limitations that we do not expect, or are unable to renew any required permits or licenses, our ability to import and export cannabis and cannabis products could be materially adversely affected.

Our continued ability to operate and/or sell in foreign jurisdictions will be dependent on our ability to obtain and comply with the necessary regulatory licences and requirements. Additional government licences may be required in the future in connection with our operations, in addition to other known and unknown permits and approvals which may be required, including with respect to our Canadian and other foreign operations. To the extent such permits and approvals are required and not obtained, we may be prevented from operating or expanding our business.

As a result of any continued international expansion, we may become exposed to various levels of political, economic, legal, regulatory and other risks and uncertainties associated with operating in or exporting to foreign jurisdictions. These risks and uncertainties include changes in the laws, regulations and policies governing the production, sale, branding, marketing, and use of cannabis and cannabis-based products; political instability; currency controls; fluctuations in currency exchange rates and rates of inflation; price, export and import controls; land and water restrictions; government policies awarding contracts to local competitors or requiring domestic producers or vendors to purchase supplies from a particular jurisdiction; changes in taxation laws, regulations and policies; restrictions on foreign exchange and repatriation; changing political conditions and governmental regulations relating to foreign investment and the cannabis business more generally.

Failure to comply strictly with applicable laws, regulations and local practices could result in additional taxes, costs, civil or criminal fines or penalties or other expenses being levied on our international operations, as well as other potential adverse consequences such as the loss of necessary permits or governmental approvals or the inability to grow our business in these jurisdictions. Complying with the varying laws of the jurisdictions in which we may choose to expand can be time-consuming, expensive and divert management attention from the rest of our business.

17

Risks Related to Cannabis Retail Operations Segment and Franchise Operations

We face risks associated with our franchise business model.

We receive a significant portion of our cannabis retail revenue in the form of franchise royalty payments. Failure to collect payments due to us from our franchisees, due to their inability to make timely payments, dispute with us or otherwise, could have a material adverse effect on our results of operations and financial condition. Our franchisees operate franchised retail locations independently, and as such are subject to many factors beyond our control, all of which could adversely affect such franchisees’ ability to make timely royalty payments to us.

As a result, the success of our retail business and results of operations is significantly dependent upon the success of our franchisees’ retail cannabis stores and their cooperation with us. Our franchisees' stores may be adversely affected by: declining economic conditions; increased competition in the retail cannabis market; changes in consumer preferences; demographic trends; changes in consumer sentiments towards the use of cannabis products; decreases in consumers’ discretionary income; consumers' willingness to accept product price increases; adverse weather conditions; our reputation, the strength of the Spiritleaf brand and consumer perception of our market position and offerings in terms of quality, price, value and service; consumers' experiences in our retail cannabis stores; and other risk factors related to the operation of cannabis retail stores discussed in this Annual Report, to the extent they apply to such franchisees.

Our franchisees may also be susceptible to increases in certain key operating expenses that are either wholly or partially beyond our control, including: labour costs, including wages, workers' compensation, minimum wage requirements, health care and other benefits expenses; rent expenses and construction, remodeling, maintenance and other costs under leases; compliance costs as a result of changes in legal, regulatory or industry standards; energy, water and other utility costs; insurance costs; information technology and other logistical costs; and expenses associated with legal proceedings, if any.

Our success also relies on the willingness and ability of our independent franchisees to implement major initiatives, which may include financial investment, and to remain aligned with us on operating, value/promotional and capital-intensive reinvestment plans. The ability of franchisees to contribute to the achievement of our plans is dependent in large part on the availability to them of funding at reasonable interest rates and may be negatively impacted by the financial markets in general, by their or our creditworthiness or by banks’ lending practices. If our franchisees are unwilling or unable to invest in major initiatives or are unable to obtain financing at commercially reasonable rates, or at all, our future growth and results of operations could be adversely affected.

In addition, franchise retail cannabis stores are subject to various laws, regulations and guidelines relating to the management, packaging/labelling, advertising, sale, transportation, storage and disposal of cannabis, and our franchisees may not comply with such laws, regulations and guidelines, which may adversely affect the franchisee’s ability to operate profitably, without incrementally onerous restrictions or at all, and which may therefore limit the franchisee’s ability to make timely and full payments to us. In addition, franchisees’ failure to comply, which we may be unable to prevent, may harm our brand, which could have a material adverse effect on the reputation, profitability and operations of our entire corporate-owned and franchised cannabis retail network.

Our ownership mix also affects our results and financial condition. The decision to own or to operate under franchise agreements is driven by many factors whose interrelationship is complex. The benefits of a franchised structure depend on various factors including whether we have effectively selected franchisees, licensees and/or affiliates that meet our rigorous standards, whether we are able to successfully integrate them into our structure and whether their performance and the resulting ownership mix supports our brand and financial objectives.

Our success in the cannabis retail market is dependent, in part, on our ability to attract and retain an adequate retail consumer base.

Our success in the cannabis retail market depends, in part, on our ability to attract and retain consumers and to establish an adequate consumer base. There are many factors which could impact our ability to attract and retain retail consumers, including but not limited to the ability to continually source a sufficient selection of desirable products, the successful implementation of consumer-acquisition plans, the ability to profitably maintain price points attractive to consumers, the ability to secure leases and open retail stores in locations convenient to consumers, the ability to select a sufficient number of qualified franchisees and such franchisees’ ability to effectively manage retail locations, and the continued growth in the aggregate number of consumers. The failure to acquire and retain consumers would have a material adverse effect on our business, operating results and financial condition.

There is no guarantee that our cannabis retail locations will remain successful and attractive to consumers.

The success of our cannabis retail stores is significantly influenced by the location of each store. There can be no assurance that current locations will continue to be attractive, or that additional locations can be identified and secured, especially as cannabis consumption and related consumer behaviour patterns change. It is possible that the current locations of our cannabis retail stores may cease to be competitive and face declining revenues and profitability in the future as a result of various factors, including the opening of stores by competitors, economic conditions and consumption patterns in the neighbourhoods these locations serve and other reasons. There is also no assurance that future store locations will produce the same results as existing locations. To the extent that we enter into long-term

18

leases for our store locations, our ability to respond in a timely manner to changes in the economic, consumer or retail environment at any location may be limited.

We may lease unlicensed premises for potential cannabis retail stores with no guarantee of generating earnings.

We may enter into lease agreements for locations which are not subject to permit or licence to sell cannabis products at the time of entry into the lease. In the event we are unable to obtain applicable licences, permits and authorizations to sell cannabis products at such locations in compliance with applicable law, but are unable to terminate the lease or sub-lease the premises, we will be liable for payments on the lease, but may have no or limited revenues from which to make such payments, which could have a material adverse effect on our business, financial conditions and operating results.

Our retail business is dependent on the supply of cannabis products from third-party licensed producers.

Cannabis retailers are dependent on the supply of cannabis products from licensed producers. There can be no assurance that there will be a sufficient supply of cannabis of acceptable quality and at an acceptable price available to us to purchase in order to operate our cannabis retail business or satisfy all of the consumers’ demands. Licensed producers’ growing operations are dependent on a number of key inputs and their related costs, including raw materials and supplies. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact licensed producers and, in turn, could have a material adverse effect on our business, results of operations and financial results. Any inability of licensed producers to provide us with sufficient supply of cannabis at acceptable prices as a result of factors that include, but are not limited to, the risks described in this Annual Report that are applicable to our cannabis operations, could have a material adverse effect on our business, financial condition and results of operations.

We may not be able to find additional franchisees who meet our desired criteria, and even if we do, they may ultimately be unable to open franchise locations.

The opening of additional franchise retail cannabis stores depends, in part, upon the availability of prospective franchisees who meet our desired criteria. We may not be able to identify, recruit or contract with suitable franchisees in our target markets on a timely basis or at all. In addition, our potential franchisees may not ultimately be able to access or effectively utilize the financial or management resources that they need to open the stores contemplated by their agreements with us, they may elect to cease store development for personal or other reasons beyond our control, or they may ultimately not be permitted to open a store due to limits on the number of licences available for retail locations in a particular province or municipality or other regulatory or business reasons. If we are unable to recruit suitable franchisees or if franchisees are unable or unwilling to open new stores as planned, our growth may be slower than anticipated, or cease, which could materially adversely affect our ability to increase our revenue and materially adversely affect our business, financial condition and results of operations.

We face risks imposed by franchise regulation.

Our cannabis retail franchise business is subject, in part, to provincial franchise requirements, provincial laws regulating the offer and sale of franchises in Canada through the provision of franchise disclosure documents to potential franchisees containing certain mandatory disclosures, and various provincial laws regulating the franchise relationship. There can be no assurance that we will maintain compliance with such laws at all times, and non-compliance could adversely impact our fundraising activities and thereby reduce anticipated royalty income, which in turn could materially adversely affect our business, financial condition and results of operations.

Certain provinces of Canada in which we have granted or may grant franchises have franchise statutes and regulations. These franchise laws require a disclosure document or statement of a material change to be issued to prospective franchisees containing prescribed information. Failure to comply with these statutes can result in a prospective franchisee having the right to rescind the associated franchise agreement, without penalty or obligation, for up to 60 days after receipt of the disclosure document, if the franchisor failed to provide the disclosure document or statement of material change within the time period prescribed or if the contents did not meet the requirements set out in the relevant legislation, or for a period of up to two years after entering into the associated franchise agreement if the franchisor failed to provide the disclosure document. In addition, if a franchisee suffers a loss because of a misrepresentation contained in the disclosure document or in a statement of a material change or as a result of the franchisor failing to comply with the disclosure requirements, a franchisee has a right of action for damages. These rights are in addition to any other rights a franchisee may have at law.

Risks Related to Our Cannabis Cultivation Operations

We are dependent upon a limited number of facilities that are integral to our cannabis cultivation and production business.

As of the date of this Annual Report, all our cultivation and production activities are conducted at our Olds Facility, Atholville Facility, and Valens facilities, and our licences issued under the Cannabis Act are specific to those facilities. Disruptions at, or adverse changes or developments affecting, our facilities, including municipal rezoning, facility design errors, environmental pollution, equipment or process failures, production errors, disease or infestation of our crops, fires, breakdowns of our sewage system, explosions, power failures, natural disasters or security failures, have had and could in the future have negative impacts on our production, the quality of

19

our products, our reputation in the market and our financial results – any one of which could materially adversely impact our business. For example, a fire at our Olds Facility in December 2018 damaged a portion of our crops and caused some delays in our production cycle. In addition, any failure to comply with regulatory requirements under the Cannabis Act could result in the suspension or termination of our Health Canada licences and could have an adverse impact on our ability to renew such licences.

We are subject to risks inherent in an agricultural business, including the risk of crop failure.

The cultivation of cannabis is an agricultural process. As such, our business is subject to the risks inherent in the agricultural business, including risks of crop failure presented by weather, insects, fire, plant diseases and similar agricultural risks. Although we currently grow our products indoors under climate-controlled conditions, there can be no assurance that natural elements, such as extreme weather, insects and plant diseases, will not partially or completely disrupt our production activities or have an adverse effect on our business. Cannabis plants can be vulnerable to various pathogens including bacteria, fungi, viruses and other miscellaneous pathogens. We have had to dispose of crops in the past due to pathogens. Such instances often lead to reduced crop quality, stunted growth or death of the plant. Moreover, cannabis, including hemp, is “phytoremediative”, meaning that it may extract toxins or other undesirable chemicals or compounds from the ground in which it is planted. Various regulatory agencies have established maximum limits for pathogens, toxins, chemicals and other compounds that may be present in agricultural materials. In addition, we have experienced, and may in the future experience, production issues at our facilities, including poor crop yields, harvests of products with THC concentration that is too low to meet product specifications, fires, floods and contamination of our product by foreign objects. As a result of the foregoing, our products may not be suitable for commercial sale or may be returned to us by our customers, and we may have to destroy the affected portions of our crops.

Significant interruptions in our access to certain key inputs such as labour, raw materials, electricity, water and other utilities may impair our growing operations and materially affect our business.

Our production business is dependent on a number of key inputs and their related costs, including raw materials, supplies and equipment related to our operations, as well as electricity, water and other utilities. Any significant interruption, price increase or negative change in the availability or economics of the supply chain for key inputs and, in particular, rising or volatile energy costs could curtail or preclude our ability to continue production and may have a material adverse impact on our business and results of operations. While we believe we have met all milestones and have made applications for all subsidies, there is no assurance that subsidies will continue or that our outstanding applications will be approved. In addition, our operations could be significantly affected by a prolonged power outage. Furthermore, our cultivation operations require a significant amount of electricity as a result it may be difficult for us to locate areas to construct additional cultivation operations as we grow.

Our ability to compete and grow cannabis is dependent on us having access, at a reasonable cost and in a timely manner, to skilled labour, equipment, parts and components. No assurances can be given that we will be successful in maintaining our required supply of labour, equipment, parts and components.

Our headquarters and our Olds Facility, are in Alberta, a province whose economy has historically relied heavily on the oil and gas industry. During periods of strong oil and gas industry conditions, we may face increased competition for employees, which could harm our ability to attract and retain employees or increase our compensation costs.

Failure in our quality control systems may adversely impact our sales volume, market share and profitability.

The quality and safety of our products are critical to the success of our business and operations. As such, it is imperative that our (and our service providers’) quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality training program, and adherence by employees to quality control guidelines, among other factors. Although we strive to ensure that we and all of our service providers have implemented and adhere to high caliber quality control systems, we or our service providers could experience a significant failure or deterioration of such quality control systems. If, as a result of a failure in our (or our service providers’) quality control systems, contamination of, or damage to, our inventory or packaged products occurs, we may incur significant costs in replacing, destroying or repurposing such inventory, providing replacement products to our customers or recalling such products. We may be unable to meet customer demand and may lose customers who have to purchase alternative brands or products. In addition, consumers may lose confidence in our products whether affected or not and our brand may be materially damaged. A loss of sales volume from a contamination event may occur, and such a loss may affect our ability to supply our current customers and to recapture their business in the event they are forced to switch products or brands, even if on a temporary basis. We may also be subject to legal action as a result of a contamination, which could result in negative publicity and negatively impact our results of operations. During this time, our competitors may benefit from an increased market share that could be difficult and costly to regain.

We may not be able to store or transport our cannabis products to customers in a safe, timely and cost-efficient manner, and we may experience breaches of security at our facilities or loss as a result of theft of our products.

Because of the nature of our products and the limited legal channels for distribution, as well as the concentration of inventory in our facilities (including our licensed cannabis retail stores), we are subject to a heightened risk of theft of our product and other security breaches.

20

Canadian adult-use distribution rules take various forms on a jurisdiction-by-jurisdiction basis and often require us to employ third parties to deliver our products to central government sites and from such sites to our cannabis retail stores. Any prolonged disruption of third-party transportation services could have a material adverse effect on our sales volumes or our end users’ satisfaction with our products. Rising costs associated with third-party transportation services used by us to ship our products may also adversely impact our profitability.

The security of our products during transportation to and from our facilities is of the utmost concern. A breach of security at one of our facilities, or during transport or delivery, could result in the significant loss of product as well as customers and reputational damage and may expose us to additional liability, including regulatory fines, litigation or increased expenses relating to the resolution and future prevention of similar events. Any failure to take steps necessary to ensure the safekeeping of our cannabis could also have an impact on our ability to continue operating under our existing licences, to renew or receive amendments to our existing licences or to receive required new licences.

Risks Related to Our Liquor Retail Business

A decline in the consumption of alcoholic beverage products could materially adversely affect our business, financial condition and results of operations.

Our Company relies on consumers’ demand for the alcoholic beverage products it sells in its Alcanna stores. Consumer preferences may shift due to a variety of factors, including changes in demographic or social trends, public health policies, scientific studies and government guidelines about recommended consumption, and changes in leisure, dining and beverage consumption patterns. Even if overall liquor consumption does not decline, shifts in consumer preferences from alcoholic beverage products that are more profitable (for example, high-end wine or the Company’s preferred label products) to those that are less profitable (for example, domestic beer), could materially adversely affect the Company’s business, financial condition, liquidity and results of operations.

A decline in consumption of alcohol generally or of one or more alcoholic beverage product categories could occur in the future due to a variety of factors, including:

•a general decline in economic or geopolitical conditions and/or decline in discretionary consumer income;

•increased public concern about the health consequences of consuming alcoholic beverage products;

•a decline in the consumption of alcoholic beverage products in on-premise establishments, resulting in a decline in alcohol beverage products purchased by such establishments on a “cash and carry” basis;

•consumers favoring alcohol consumption at bars and restaurants instead of purchasing liquor for consumption at home;

•consumer dietary preferences favouring lighter, lower calorie beverages such as diet soft drinks, sports drinks and water products;

•consumer shopping preferences favouring online shopping, resulting in less foot traffic in shopping centres where the Company’s retail liquor stores are located;

•the increased activity of anti-alcohol consumption groups;

•a decline in the consumption of alcoholic beverage products as a result of consumers substituting legalized adult-use cannabis or other similar products in lieu of alcoholic beverage products;

•increased federal, provincial and/or foreign excise or other taxes on alcoholic beverage products that increase product prices for the consumer and possible restrictions on alcoholic beverage advertising and marketing;

•increased regulation placing restrictions on the purchase or consumption of alcoholic beverage products or increasing prices due to the imposition of duties or excise tax or changes to international trade agreements or tariffs;

•inflation; and

•wars, pandemics (including COVID-19), weather and natural or man-made disasters.

Changes in government regulations, in particular changes which decrease the cost of competition, could have a material adverse effect on the Company’s business, financial condition and results of operations.

The Company operates in the highly regulated retail liquor industry in the Provinces of Alberta and British Columbia. The business, operations or licensing of liquor stores may be adversely affected by: (i) new legislation, regulations, rules or bylaws; (ii) changes and court challenges to existing legislation, regulations, rules or bylaws; (iii) new interpretations of existing legislation, regulations, rules or bylaws; or (iv) decisions of the AGLC, the Liquor Control and Licensing Branch of the Province of British Columbia (the “LCRB”), or other governmental authorities (including federal, provincial, municipal, or other local governments or agencies) or applicable courts. Such regulatory changes, interpretations or decisions could increase the cost of operating the Company’s liquor retail business, limit the

21

marketing, sales and other activities in which the Company is permitted to engage, limit the number and types of retail locations the Company can operate, or require the Company to cease operations altogether.

In addition to the foregoing, as a result of the Province of British Columbia’s 2021 renewal of the moratorium on granting new liquor licences for the next ten years, new liquor stores cannot be opened in the province except pursuant to an existing license purchased from another liquor retailer. Growing the Company’s liquor retail network in the Province of British Columbia would, accordingly, require the purchase of existing licenses from other retailers, which may not be available on acceptable terms or at all, which may limit the Company’s ability to profitably expand in this market, resulting a material adverse effect on the Company’s business, financial condition, liquidity, results of operations and prospects.

The private retail distribution of alcoholic beverages in the Provinces of Alberta and British Columbia is both competitive and fragmented. Competition exists mainly on a local basis with the main competitive factors being location, convenience, price and service. Changes in the regulatory regime in a particular jurisdiction, for example to allow the licensing of more retail locations or reduce costs for new entrants in the industry, may increase competition that could materially adversely affect the Company’s business, financial condition, liquidity and results of operations.

In the Province of Alberta, the Company competes with local single store operators, other local and regional chain operators, and liquor stores associated with national and regional grocery store chains. The current regulatory regime in Alberta limits certain of the potential competitive advantages of large-scale retailers by, among other things, requiring liquor stores to be operated as a separate business, prohibiting the sale of liquor in stores selling other goods and by requiring all retailers to pay the same wholesale price and a uniform “postage stamp” delivery charge. Some municipalities have enacted zoning restrictions that limit the number of liquor store locations by establishing minimum distances of liquor stores to schools, religious establishments, playgrounds, and other areas. The Cities of Edmonton and Calgary have also enacted a “mature neighborhood overlay”, requiring a minimum distance separation between two liquor stores of 500 meters (subject to certain “grandfathering” exceptions) in certain areas of the city. These zoning requirements limit the amount of competitors and competition in general in these municipalities and if they were to be relaxed or eliminated, this could adversely affect the Company’s business, financial condition, liquidity and results of operations.

In the Province of British Columbia, the Company competes with government owned and operated liquor stores, local independent stores and wine stores. A retail liquor store is not permitted to be relocated anywhere within 1.0 kilometers of an existing retail liquor store, or the site of an application to licence a new retail liquor store (subject to certain “grandfathering” exceptions). This arrangement limits the number of competitors who are able to enter into the market. Wine is permitted to be sold inside retail grocery stores in British Columbia as long as the grocery store obtains or owns a licence and complies with the current licensing requirements (including the 1.0 kilometer separation requirements to another liquor store). Prior to July 8, 2019, only BC VQA wines were permitted to be sold in grocery stores; however, in order to comply with the United-States-Mexico-Canada Agreement, the Province of British Columbia now allows imported wine to be sold on grocery store shelves.

In addition, competition with new entrants in the liquor retail industry in the Province of British Columbia is reduced as a result of the above-described moratorium on granting new liquor retail licenses. Should such moratorium be lifted, competition in the British Columbian liquor retail industry could increase. If the moratorium remains and the Company’s competitors are able to purchase existing liquor retail licenses on acceptable terms while the Company is not able to do so, the Company may face increased competition, lower market share or similar adverse competitive consequences, all of which could result in a material adverse effect on its business, financial condition, liquidity, results of operations and prospects.

Any future changes to the British Columbia or Alberta regulatory regimes may have a significant impact on the level of competition and the value of licences in such provinces, and therefore could materially adversely affect business, financial condition, liquidity and results of operations.

Unfavourable publicity or poor consumer perception of the Company’s liquor retail brands could have a material adverse effect on the Company’s business, financial condition and results of operations.

Success in the highly competitive retail liquor industry is dependent upon consumer perception of a number of factors, including the accessibility, affordability and safety of a company's retail liquor stores. The Company’s reputation, and consequently its brands, may be negatively affected by various factors, several of which may be outside of the Company's control, including, but not limited to, the Company’s ability to maintain prices for its products despite any increases in costs, the quality and safety of alcohol products supplied to the Company and the success of the Company’s branding, marketing and advertising efforts. In addition, thefts and robberies of retail liquor stores in Alberta have become a publicized issue that may deter customers from shopping at the Company’s stores. There can be no assurance that the Company’s efforts to maintain the physical security and safety of its retail locations will be successful, or that future media attention or publicity regarding this issue, and other consumer perceptions, will be favourable to the Company’s retail liquor business. Any unfavourable publicity or consumer perceptions could materially adversely affect the Company’s business, financial condition, liquidity and results of operations.

22

If a significant number of the Company’s retail liquor licences were revoked or not renewed, or if the Company failed to secure new retail liquor licences, there could be a material adverse effect on its business, financial condition, liquidity and results of operations.

All of the Company’s Alberta liquor retail stores are operated pursuant to licences issued by the AGLC, which must be renewed annually. Similar to the process in Alberta, the Company’s liquor retail store in British Columbia is operated pursuant to a licence issued by the LCRB, which must be renewed annually. The AGLC and the LCRB have discretion in the granting or revocation of a licence to operate a liquor store. If a significant number of the Company's licences were revoked or not reissued, if their terms were modified in a manner materially adverse to the Company, or if new licences for any network expansion are not granted in a timely manner, on favorable terms or at all, it could materially adversely affect the Company's business, financial condition, liquidity and results of operations.

Delays or interruptions in the supply of liquor to the Company’s retail locations, or spoilage or shrinkage of the Company’s inventory, could have a material adverse effect on the Company’s business, financial condition and results of operations.

The Company is dependent upon a limited number of distributors for a substantial majority of its products. Specifically, liquor store operators in Alberta are dependent on the Connect Logistics Service warehouse and Brewers Distributor Ltd. for the substantial majority of their products. In British Columbia, liquor store operators are dependent on the BCLDB for the majority of their products. Any significant disruptions in the operations of these distributors, as a result of, for example, a labour disturbance, lack of product supply, pandemics or epidemics (including COVID-19), natural disasters or severe weather events, road or other transportation link closures, acts of crime, war or terrorism, or for any other reason, and a resulting interruption, delay or reduction in supply could materially adversely affect the Company’s business, financial condition, liquidity and results of operations.

In addition, once the Company’s supply enters its inventory, it may be subject to spoilage, breakage or shrinkage. Spoilage, breakage or shrinkage of inventory at levels materially greater than what the Company’s plans or budgets for could have a material adverse effect on the Company’s business, financial condition, liquidity and results of operations.

There is no guarantee that our liquor retail locations will remain successful and attractive to consumers.

The success of our liquor retail stores is significantly influenced by the location of each store. There can be no assurance that current locations will continue to be attractive, or that additional locations can be located and secured, as demographic patterns change. It is possible that the current locations or economic conditions where our liquor retail stores are located could deteriorate in the future as a result of various factors, including the opening of stores by competitors, and that this could result in reduced sales in those locations. There is also no assurance that future store locations will produce the same results as existing locations. To the extent that we enter into long-term leases for our store locations, our ability to respond in a timely manner to changes in the demographic or retail environment at any location may be limited.

Risks Related to our Markets and Industries

We intend to continue to focus primarily on the premium segment of the adult-use cannabis market, which may not be sustainable, or in which we may not be able to develop or maintain a brand that attracts or retains customers.

We focus primarily on users of cannabis in the Canadian adult-use cannabis market who are looking for premium products; however, such a market may not be sustainable. We may not be able to achieve or maintain attractive margins and our ability to achieve our near term or long-term business objectives would be materially adversely affected. Further, we may not be successful in creating and maintaining consumer perceptions of the value of our premium products. The promotion of cannabis is strictly regulated in Canada. For example, promotion is largely restricted to the place of sale and subject to prescribed conditions set out in the Cannabis Act and the Cannabis Regulations. Among other restrictions, the Cannabis Act prohibits testimonials and endorsements, lifestyle branding and promotion that is appealing to minors. Such restrictions on advertising, marketing and the use of logos and brand names, and other restrictions on advertising imposed by Canadian federal or provincial laws or regulations, or similar regulations imposed in other jurisdictions, may prevent us from creating and maintaining consumer perceptions in the value of our premium products and establishing ourselves as premium producers. If we cannot successfully enter into or compete in the premium market, we may face significant challenges in gaining or maintaining a market share in Canada or in other cannabis markets in which we intend to operate, or we may be forced to sell our products at a lower price, which may materially adversely affect our results of operations.

Our success depends, in part, on our ability to attract and retain customers who in turn sell to ultimate consumers of cannabis and cannabis-related products. To do this, we are dependent upon, among other things, continually producing desirable and effective products and the continued growth in the aggregate number of adult-use cannabis consumers. We have made significant investments in enhancing our brand to attract consumers. Subject to the applicable legal restrictions, we expect to continue to make significant investments to promote our current products to new consumers and new products to current and new consumers. Such campaigns can be expensive and may not result in increased sales. If we are unable to attract new consumers or retain existing consumers and customers, we may not be able to increase our sales or sustain our business.

Our business model, including our ability to successfully target the premium segment of the adult-use cannabis market and maintain our brand, is also dependent on being able to grow at scale different strains of cannabis with consistent yields and THC-levels by strain. To

23

the extent we are unable to do so, or we are unable to achieve desired THC-levels, our ability to achieve our near term or long-term business objectives would be materially adversely affected.

The legal cannabis market is a relatively new industry. As a result, the size of our target market is difficult to quantify, and investors will be reliant on their own estimates on the accuracy of market data.

Because the cannabis industry is in a nascent stage, there is a continuing lack of information about the total addressable market as well as comparable companies available for potential investors to review in deciding whether to invest in us. In addition, the development of the legal cannabis market is dependent on Health Canada and other regulators approving licences for retail stores and other distribution channels in a timely fashion. Any delays in such approvals or other regulatory developments may impact our market and price estimates, which may make it difficult to develop reliable expectations and assumptions. Accordingly, investors should rely on their own estimates regarding the potential size, economics and risks of the cannabis market in deciding whether to invest in our common shares. We have not generated net earnings since our inception and there can be no assurance that we will do so in the future. There can be no assurance that our growth estimates are accurate or that the cannabis market will be large enough for our business to be profitable or to grow as projected.

Although we are committed to researching and developing new markets and products and improving existing products, there can be no assurances that such research and market development activities will prove profitable or that the resulting markets or products, if any, will be commercially viable or successfully produced and marketed. We must rely largely on our own market research to forecast sales and design products as detailed forecasts and consumer research are not generally obtainable from reliable third-party sources in Canada and in other international jurisdictions.

In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in the manner consistent with management’s expectations and assumptions. We could also be subject to other events or circumstances that adversely affect the cannabis industry, such as the imposition of further restrictions on sales and marketing or further restrictions on sales in certain areas and markets.

The adult-use cannabis market in Canada has experienced, and may in the future experience, supply and demand fluctuations.

Following legalization, there was a shortfall in supply in the Canadian adult-use cannabis market leading to increased prices, increases in out-of-stocks and consumers opting to buy cannabis on the illicit market. We and other licensed producers responded by increasing capacity. The increase in production combined with slower than expected retail store growth has resulted in over-supply in 2020, a trend that has continued into 2021. As inventory levels become greater than consumer demand, we have had to, and may in the future have to, engage in sale of excess inventory at discounted prices or offer promotional pricing to move older product, which could significantly impair operating results and our brand image. Conversely, if we underestimate demand for our products, we may experience inventory shortages, which might delay shipments to customers, reduce revenue, negatively impact customer relationships and diminish brand loyalty. For example, we have experienced shortages and out-of-stocks in our vape products due to supply constraints. In addition, demand for cannabis and cannabis products is dependent on a number of social, political and economic factors that are beyond our control, including the novelty of legalization, which may wear off. A material decline in the economic conditions affecting consumers can cause a reduction in disposable income for the average consumer (as a result of the continuing impact of the COVID-19 pandemic or otherwise), change consumption patterns and result in a reduction in spending on cannabis products or a switch to other products obtained through illicit channels. There can be no assurance that market demand for cannabis will continue to be sufficient to support our current or future production levels or that we will be able to generate sufficient revenue to be profitable.

We may be unsuccessful in competing in the overall legal adult-use cannabis market in Canada.

Our Canadian adult-use business faces enhanced competition from others who are licensed under the Cannabis Act and the various provincial and territorial regulatory regimes to participate in the adult-use cannabis industry. The Cannabis Act and the various provincial and territorial legislation have established licensing regimes for the cultivation, production, processing, testing, packaging, labelling, delivery, transportation, distribution, sale, possession and disposal of cannabis for adult use.

Subject to certain restrictions set out in the Cannabis Act, adults are permitted to cultivate, propagate, harvest and distribute up to four cannabis plants per household. If a significant number of individuals take advantage of the ability to cultivate and use their own cannabis, our success in the adult-use business may be limited and may not fulfill our expectations.

As of March 1, 2023, there were approximately 956 active holders of federal commercial licences issued under the Cannabis Act by Health Canada. Certain of these competitors have longer operating histories and significantly greater financial, production, marketing, research and development and technical and human resources than we do. Some of these competitors have become public companies in the United States or Canada, giving them the ability to raise significant amounts of capital quickly or use their publicly traded equity securities to conduct acquisitions. In addition, like us, many other competitors have established retail locations. As a result, our competitors may be able to bring more and better products to market more quickly than us. Our commercial opportunity in the adult-use market could be reduced or eliminated if our competitors produce and commercialize products for the adult-use market that, among other things, are safer, more effective, more convenient, better quality or less expensive than the products that we produce, have greater sales, marketing and distribution support than our products, enjoy enhanced timing of market introduction and perceived effectiveness

24

advantages over our products and receive more favorable publicity than our products. If our adult-use cannabis products do not achieve an adequate level of acceptance by the adult-use cannabis market, or if our retail stores do not achieve and sustain adequate customer bases, we may not generate sufficient revenue from these operations, and our adult-use cannabis business may not become profitable. We expect that competition in the adult-use cannabis market will become more intense as current and future competitors begin to offer an increasing number of diversified products. As competition increases, we may experience additional downward price pressure on our cannabis products, loss of market share and increased marketing costs. To remain competitive, we will require a continued high level of investment in marketing, sales and client support, and we may not have sufficient resources to maintain such efforts.

We also face competition from the illicit cannabis market. Illegal dispensaries and ‘black market’ operations and participants, despite not having a valid licence under the Cannabis Regulations, command a significant percentage of the total market for cannabis and cannabis products in Canada and may be able to (i) offer products with higher concentrations of active ingredients, including THC, than permitted by the Cannabis Act and Cannabis Regulations or offered in the legal market, (ii) use delivery methods, that licensed producers are prohibited from offering to individuals in Canada, (iii) brand products more explicitly, (iv) sell products at lower prices and (v) market and distribute products in ways not permissible by law. As these illicit market participants do not comply with the regulations governing the cannabis industry in Canada, their operations may also have significantly lower costs.

In addition, the legal landscape for medical and adult-use cannabis is changing internationally. An increasing number of jurisdictions globally are passing laws that allow for the production and distribution of medical or adult-use cannabis. Increased international competition, including competition from suppliers in other countries who may be able to produce at lower cost, and limitations placed on us by Canadian or other regulations, might lower the demand for our products on a global scale.

Consumer preferences may change, and we may be unsuccessful in acquiring or retaining consumers and keeping pace with changing market developments.

As a result of changing consumer preferences, many consumer products attain financial success for a limited period of time. Even if our products find success at retail, there can be no assurance that such products will continue to be profitable. Our success will be significantly dependent upon our ability to develop and carry new and improved product lines and adapt to consumer preferences. Even if we are successful in introducing new products or developing our current product offerings, a failure to gain consumer acceptance or to update products and our product offerings could cause a decline in our products’ or our retail stores’ popularity and impair our brand. In addition, we may be required to invest significant capital in the creation of new product lines, strains, brands, marketing campaigns, packaging and other product features, none of which are guaranteed to be successful. Failure to introduce new features and product lines and to achieve and sustain market acceptance could result in us being unable to satisfy consumer preferences and generate revenue.

The legal cannabis industry is in its early stages of development, and it is likely that we, and our competitors, will seek to introduce new products in the future. In attempting to keep pace with any new market developments, we may need to spend significant amounts of capital in order to successfully develop and generate revenues from the new products we introduce. As well, we may be required to obtain additional regulatory approvals from Health Canada and any other applicable regulatory authorities, which may take significant amounts of time. We may not be successful in developing effective and safe new products, anticipating shifts in social trends and consumer demands, bringing such products to market in time to be effectively commercialized, or obtaining any required regulatory approvals, which, together with any capital expenditures made in the course of such product development and regulatory approval processes, may have a material adverse effect on our business and results of operations.

In addition, the patterns of cannabis consumption in Canada may shift over time due to a variety of factors, including changes in demographics, social trends, public health policies and other leisure or consumption behaviors. If consumer preferences for our products or cannabis products move away from our products or cannabis products in general, or if we are unable to anticipate and respond effectively to shifts in consumer behaviors, we may be adversely affected.

We may not be successful in maintaining consumers’ brand recognition and loyalty to our products or retail stores.

Our continued success depends in part on our ability and our ability to continue to differentiate our brand names and maintain similarly high levels of recognition with target consumers.

Our ability to build and maintain brand recognition and loyalty is limited by current and potential future regulations that restrict our packaging, advertising and other branding efforts, making it more difficult to appeal to consumers or to leverage our brands. For example, the Canadian federal regulatory regime requires plain packaging on cannabis products and prohibits testimonials, lifestyle branding and packaging that is appealing to youth. These and similar limitations could have a material adverse impact on our business, financial condition and results of operations, as they make it more difficult to establish and retain brand recognition and customer loyalty.

Furthermore, even if we are able to continue to distinguish our products and retail stores, there can be no assurance that the sales, marketing, retail and distribution efforts of our competitors will not be successful in persuading consumers of our products and retail stores to switch to their products or retail stores. Some of our competitors have greater access to resources than we do, which better positions them to conduct market research in relation to branding strategies or costly marketing campaigns. Any loss of consumer brand recognition or loyalty to our products and offerings or our inability to effectively brand our products and offerings in a recognizable

25

way, whether as a result of regulation or otherwise, will have a material effect on our ability to continue to sell products and maintain our market share, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.

The vape market is a new market that is still evolving and is subject to significant uncertainty, including as a result of negative press and regulatory scrutiny of vape products in the United States.

We sell vape products in Canada. In Canada, vape products are regulated under the Cannabis Act and associated regulations, and such regulations were drafted prior to reports of vaping-related deaths and illnesses in the United States. As a result, Health Canada or the individual provinces may amend or further review the rules governing vape products and restrict or prohibit sales of such products. For example, the AGLC delayed the legalization of vaping products in Alberta and, currently, vaping products are illegal in Quebec. There can be no assurance that we will be able to meet any additional compliance requirements or regulatory restrictions or remain competitive in the face of unexpected changes in market conditions.

There is a limited history and volume of research on the health effects of vaping, electronic cigarettes and other similar products. If the medical community were to determine that vaping or the use of any of the related products caused or posed a risk of long-term health risks, market demand for these products and their use could materially decline. Such a determination could expose us to litigation and result in increased regulation. Furthermore, vaping products sold on the illicit market that contain harmful chemicals or other ingredients may adversely impact the demand for such products in the legal market and create the perception that such products were dangerous. In addition, regulators may prohibit the sale of vaping products all together or severely restrict their use. A decline in the market demand for our vaping products, product liability claims, and increased regulation could have a material adverse effect on our business.

Risks Related to Our Products

There has been limited study on the health effects of cannabis and cannabis products, including vaping products, and future clinical research studies may lead to conclusions that dispute or conflict with our understanding and belief regarding the benefits, viability, safety, efficacy, dosing and social acceptance of such products.

Research in Canada, the United States and internationally regarding the benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids, such as CBD and THC, remains in relatively early stages. Few clinical trials on the benefits and risks of cannabis or isolated cannabinoids have been conducted.

Future research and clinical trials may draw opposing conclusions to statements contained in the articles, reports and studies currently favored, or could reach different or negative conclusions regarding the benefits, viability, safety, efficacy, dosing or other facts and perceptions related to medical or adult-use cannabis, which could adversely affect social acceptance of cannabis and the demand for our cannabis products.

Our products may be subject to recalls or returns for a variety of reasons, which could require us to expend significant management and capital resources.

Manufacturers and distributors of consumer goods products are sometimes subject to the recall or return of their products for a variety of reasons, including public health and public safety risks, product defects, such as contamination, adulteration, unintended harmful side effects or interactions with other substances, packaging safety, inadequate or inaccurate labelling disclosure or expiry. Although we have detailed procedures in place for testing our finished products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid product returns, recalls, regulatory action or lawsuits, whether frivolous or otherwise. While we have not been subject to a recall to date, if any of the products produced by us are recalled in the future due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. In addition, from time to time, we have had customers return our products alleging, among other things, contamination and failure to meet designated specifications as well as a result of the age of slow-moving products. As a result of any such recall or return, we may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall or return may require significant management attention, expose us to liabilities or damage our reputation and goodwill or that of our products or brands.

Additionally, product recalls and returns may lead to increased scrutiny of our operations by Health Canada or other regulatory agencies, requiring further management attention, increased compliance costs and potential legal fees, fines, penalties and other expenses. Any product recall affecting the cannabis industry more broadly, whether or not involving us, could also lead consumers to lose confidence in the safety and security of such products, including products sold by us.

We may be subject to product liability claims or regulatory action if our products are alleged to have caused significant loss, injury or death, which is exacerbated by the fact that cannabis use may increase the risk of certain serious health conditions.

As a manufacturer and distributor of products which are ingested or otherwise consumed by humans, we face the risk of exposure to product liability claims, regulatory action and litigation if our products are alleged to have caused loss, injury or death. We may be subject to these types of claims due to allegations that our products or the products we have sold caused or contributed to injury, illness or death, made false, misleading or impermissible claims, failed to include adequate labelling and instructions for use or failed to include

26

adequate warnings concerning possible side effects or interactions with other substances. This risk is exacerbated by the fact that cannabis use may increase the risk of developing schizophrenia and other psychoses, symptoms for individuals with bipolar disorder, and other side effects. Previously unknown adverse reactions resulting from human consumption of cannabis products alone or in combination with other medications or substances could also occur. In addition, the manufacture, sale and distribution of cannabis products, like the manufacture, sale and distribution of any ingested or consumable product, involves a risk of injury to consumers due to tampering by unauthorized third parties or product contamination. We may in the future have to recall certain of our cannabis products as a result of potential contamination and quality assurance concerns. A product liability claim or regulatory action against us could result in increased costs and could adversely affect our reputation and goodwill with our consumers. There can be no assurance that we will be able to maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could result in us becoming subject to significant liabilities that are uninsured and also could adversely affect our commercial arrangements with third parties.

Risks Related to Our Employees, Partners and Third Parties

We may seek to enter into extraction agreements, co-packing agreements, joint ventures, licensing arrangements or other relationships, or expand the scope of currently existing relationships, with third parties that we believe will have a beneficial impact on us, and there are risks that such strategic alliances or expansions of our currently existing relationships may not enhance our business in the desired manner.

We currently have, and may expand the scope of, and may in the future enter into, extraction agreements, co-packing agreements, tolling services, joint ventures, licensing arrangements or other relationships with third parties that we believe will complement or augment our existing business and create additional revenue streams, including leasing any unused or excess facility space to other licensed producers. Our ability to complete additional arrangements is dependent upon, and may be limited by, among other things, the availability of suitable candidates and capital. In addition, such third-party arrangements could present unforeseen integration obstacles or costs, may not enhance our business and may involve risks that could adversely affect us, including the investment of significant amounts of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such relationships. Future third-party arrangements could result in the incurrence of debt, costs and contingent liabilities, cross-contamination, damage to our products or facilities and harm to our brand, and there can be no assurance that such future arrangements will achieve, or that our existing arrangements will continue to achieve, the expected benefits to our business or that we will be able to consummate future arrangements on satisfactory terms, or at all.

Our contracts with other licensed producers may expose us to additional costs and negatively impact our results of operations.

We derive a portion of our revenue from sales of cannabis flower and trim to other licensed producers in Canada. Our supply contracts with these other licensed producers contain provisions governing, among other things, the quality and THC-content of the cannabis supplied and the manner, time and place of such delivery. We have in the past experienced issues with such supply agreements, including a legal dispute with one of our customers resulting from our failure to timely deliver the product and the provision of additional product at no cost to another customer due to a disagreement over the THC content of the product supplied. Issues with our contracts, including disagreements with our counterparties and any resulting publicity, and failure to comply with such agreements may have a material adverse impact on our results of operation and business. In addition, we are exposed to the credit risk of the licensed producers to which we sell. If any of our licensed producer-customers were to suffer financial difficulty, including bankruptcy, our business and liquidity may be materially adversely affected.

Our success is dependent on our ability to attract or retain key personnel.

Our success is largely dependent on the performance of our management team and certain key employees, in particular our Chief Executive Officer, Zachary George and other members of our senior management team, as well as our ability to continue to attract, develop, motivate and retain highly qualified and skilled employees. Consequently, the loss of any of those individuals may have a substantial effect on our future success or failure. We do not currently maintain key-person insurance on the lives of any of our key employees. Experienced personnel in the cannabis industry, or personnel with other industry experience transferrable to the cannabis industry, are in high demand and competition for their talents is intense. As a result, we have incurred, and may incur in the future, significant costs to attract and retain employees. Although we have entered into employment agreements with all members of our senior management team, certain terms of those agreements may not be enforceable and, in any event, these agreements do not ensure the continued service of these individuals.

Directors and certain key employees of a licensed producer must obtain and maintain a security clearance from Health Canada. There is no assurance that any of our existing directors or employees who presently or may in the future require a security clearance will be able to obtain or renew such clearances in a timely manner or at all, or that new personnel who require a security clearance will be able to obtain one.

Each director and certain key employees of a company that holds a licence for cultivation, processing or sale under the Cannabis Regulations is subject to the requirement to obtain and maintain a security clearance from Health Canada. Certain additional key

27

personnel are also required to obtain and maintain a security clearance. Under the Cannabis Regulations, a security clearance cannot be valid for more than five years and must be renewed before the expiry of a current security clearance. As at December 31, 2022, all of our directors and executive officers have obtained security clearance from Health Canada. There is no assurance that any of our existing personnel who presently or may in the future require a security clearance will be able to obtain or renew such clearances in a timely manner or at all, or that new personnel who require a security clearance will be able to obtain one. A failure by an individual in a key operational position to maintain or renew his or her security clearance could result in a reduction or complete suspension of our operations or loss of our licences. In addition, if an individual in a key operational position leaves us, and we are unable to find a suitable replacement who is able to obtain a security clearance required by the Cannabis Act in a timely manner, or at all, we may not be able to conduct our operations at planned production volume levels or at all. Furthermore, the Cannabis Regulations require us to designate a qualified individual in charge who is responsible for supervising transactions with cannabis, which individual must meet certain educational and security clearance requirements. Moreover, depending on the activity, under current regulations, a qualified person in charge or an individual with security clearance must be physically present in a space where other individuals are conducting activities with cannabis. If our current designated qualified person in charge fails to maintain his security clearance, or if our current designated qualified person in charge leaves us and we are unable to find a suitable replacement who meets these requirements, we may no longer be able to conduct activities with respect to the cultivation, production or sale of cannabis.

We rely on third-party distributors to distribute our products, and those distributors may not perform their obligations.

We rely on third-party distributors, including provincial regulatory boards and private retailers to distribute our products, other than through our retail stores, and may in the future rely on other third parties, to distribute and sell our products to consumers. If these distributors do not successfully carry out their contractual duties, if there is a delay or interruption in the distribution of our products or if these third parties damage our products, it could negatively impact our revenue from product sales. Furthermore, any damage to our products, such as product spoilage, could expose us to potential product liability, damage our reputation and the reputation of our brands or otherwise harm our business and results of operations.

Third parties with whom we do business may perceive themselves as being exposed to reputational risk as a result of their relationship with us.

The parties with whom we do business, or would like to do business, may perceive that they are exposed to reputational risk as a result of our business activities relating to cannabis, which could hinder our ability to establish or maintain business relationships or raise capital. These perceptions relating to the cannabis industry may interfere with our relationship with service providers in Canada and other countries.

Risks Related to Our Investments

We may make investments into equity or debt securities of other companies, or provide credit to other companies, and we may not obtain the anticipated level of return on such investments, or any return at all.

We have made in the past, and intend in the future, to make investments into the equity or debt securities of other companies, including by subscribing to such companies’ common shares, preferred shares, convertible debt or other securities. We may also provide revolving or non-revolving credit facilities or other types of loans to other companies.

Any such investment will be subject to liquidity, market value, credit, interest rate, reinvestment and certain other risks, which will be increased if we invest in securities or instruments which are not investment grade assets. The companies that we invested into in the past have had, and companies we may invest into in the future may have, poor financial performance, liquidity and results of operations and high levels of leverage. These risks may be further increased to the extent that we invest into companies that are distressed or bankrupt, or into new, small companies with limited operating histories. Liquidity risks will be especially high if we invest in companies that are not publicly traded, the shares of which would be subject to legal and other restrictions on resale and which would otherwise be less liquid than publicly traded securities.

Non-investment grade assets are considered speculative in nature and, if such assets represent debt securities or credit instruments, they may become a defaulted obligation for a variety of reasons. If such debt securities or credit instruments become subject to either substantial workout negotiations or restructuring, this may entail, among other things, a substantial reduction in the interest rate, a substantial write-down of principal, and a substantial change in the terms, conditions and covenants of such instruments. Such negotiations or restructuring may be quite extensive and protracted over time, which may detract the attention of our management from other matters and result in substantial uncertainty with respect to the ultimate recovery on the instrument. In the event of default, the liquidity of our investments may be limited, and to the extent that they are sold, it is highly unlikely that the proceeds from such sale will be equal to the amount of unpaid principal and interest thereon.

The fact that any debt securities or credit instruments may be secured does not guarantee that we will receive principal and interest payments according to their terms, or that we will be able to collect on such securities or instruments should we be forced to enforce our remedies. There is also a risk that the assets securing the securities or instruments may decrease in value over time, carry liabilities for which we may be responsible should we take possession of collateral, be impossible to transfer to us as a result of applicable laws and

28

regulations (particularly in the case of cannabis-related assets), be difficult to appraise or liquidate and may fluctuate in value based upon the success of the borrowers’ business and market conditions, including as a result of the inability of such borrowers to raise additional capital or otherwise as a result of deterioration of its financial condition and prospects.

Credit we extend to other companies may contain provisions that allow loans we have made to be prepaid. In some cases, the prepayment of a loan may reduce our achievable yield if the capital returned cannot be invested in transactions with equal or greater expected yields, which could have a material adverse effect on our business, financial condition and results of operations.

If we invest in equity securities of other companies, such companies may never declare dividends, or may declare dividends in amounts insufficient to generate a return on our investment. As such, our only means to earn a return on our investment may be to sell the securities for a greater price than we paid for them, and there can be no assurance that we would be able to do so. The price of such securities may be volatile, and will be dependent on the business, financial position, results of operations and prospects of the company in which we invested, which would be beyond our control as we do not anticipate becoming a controlling shareholder in any such company, as well as factors beyond our control or the control of the company in which we invested, including, but not limited to, performance of the financial markets generally, investor perception of the company and its industry, and speculation about such company in the media, investor community or on the internet. The price of such securities will in all cases be subject to the risks similar to those facing our common shares and risks applicable to the business and securities of the company in which we may invest. Recent developments and volatility throughout the North American cannabis industry, including declines in prices of shares of cannabis companies, challenging access to capital, and mergers and acquisitions activity has in the past, and may in the future, adversely impact the value of our direct cannabis-related investments, as well as SunStream’s credit portfolio. In the event of liquidation of a company in which we invested, any interest we have in the company’s equity will be subordinate to the interests of holders of debt and preferred shares of the company, if any, and as a result, we may lose our entire investment in the event of liquidation. If the company in whose equity securities we invest is private or ceases to trade on a stock exchange by virtue of de-listing following inability to comply with requirements of such stock exchange or otherwise, the liquidity of our investment in equity securities may become limited or cease to exist, causing the value of our investment to decline or be eliminated. All the foregoing could cause us to fail to realize the expected or any return on our investment in equity securities of another company.

If any of our investments provide for the payment of a royalty to us, then part of the value of our investment will be dependent on the ability of the company in which we invested to effectively maintain and grow sales of the products subject to such royalty. Such company’s ability to do so will be subject to the risks applicable to its business and there can be no assurance that such company will achieve the revenue targets required to trigger royalty payments in the near-term or at all. Should the company be unable to maintain or grow sales of its products, we may not be able to realize all or any anticipated revenues from any royalty arrangements.

Any investment we make will be subject to the risks applicable to the business, securities and operations of the company in which we invested, which, if such company is public, will be disclosed in the company’s filings with securities regulators in the applicable jurisdiction. You should read the disclosure of any such risks in the company’s filings to assess the risk profile to which our investments may be subject.

In some circumstances, particularly in connection with an investment in distressed or bankrupt companies, we may be required to bear certain extraordinary expenses, including legal, accounting, valuation and transaction expenses, in order to protect or recover our investments.

Any of the foregoing could cause us not to realize all or any of the anticipated benefits of our investments and may result in our taking an impairment charge related to such investments, which may materially adversely affect our financial position, results of operations and prospects. All of our investment decisions will be subject to our discretion, and you will not be able to influence investment decisions with which you might disagree.

Our joint venture interest in SunStream is subject to certain risks associated with the conduct of joint ventures.

Our joint venture interest in SunStream is subject to the risks normally associated with the conduct of joint ventures, including: (i) disagreement with SAF Group about the strategy, financing or operations of SunStream; (ii) that SAF Group may not comply with the underlying agreements governing the joint venture and may fail to meet its obligations thereunder; (iii) that SAF Group may at any time have economic or business interests or goals that are, or become, inconsistent with our interests or goals; (iv) the possibility that SAF Group may become insolvent; and (v) the possibility of litigation with SAF Group.

We may not realize all or any of the anticipated returns on our joint venture interest in SunStream, or any return at all.

SunStream is intended to leverage our strategic, financial and operational partnership with SAF Group to target asymmetrically enhanced risk-return opportunities in the cannabis industry to provide exposure to a portfolio of financial services and instruments. The profitability of SunStream, and, therefore, the return we realize on our investment in it, is dependent on SunStream’s ability to effectively execute its business strategy, which is subject to risks affecting its planned business, which include, but are not limited to: economic recessions or downturns and global economic, political and market conditions (including as a result of the COVID-19 pandemic and the Russia-Ukraine conflict); volatility, disruption and instability of the capital markets generally and the cannabis industry in particular; changes in interest rates; competition for business opportunities; the qualities of SunStream’s investment advisor’s investment expertise

29

and the ability of such advisor to deploy its expertise in the financial services process and maintain referral and other relationships that generate business opportunities; regulations applicable to SunStream (and any adverse changes therein) and the regulations applicable to SunStream’s portfolio; and the ability of SunStream to generate returns on its business ventures, which include, but are not limited to, such other risks as are described under this section entitled “Item 3D—Risk Factors”.

Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis is a significant risk that would likely result in SunStream’s inability to execute its business plan, and may subject us to significant civil or criminal liability and other adverse consequences.

In the United States, despite cannabis having been legalized for medical use or adult use in a number of states, cannabis and cannabis products, other than hemp and certain hemp-derived products, such as CBD, continue to be categorized at the federal level as a Schedule I controlled substance under the CSA. The U.S. Supreme Court has ruled that the federal government has the authority to regulate and criminalize the sale, possession and use of cannabis, even for individual medical purposes, regardless of whether it is legal under state law. The U.S. government has not enforced the CSA or related federal laws related to cannabis against companies complying with state cannabis law and their vendors for over seven years, but there can be no assurance that this will continue. Accordingly, there can be no assurance that the portfolio companies to which SunStream provided financial services will not be prosecuted under the CSA or other federal laws for their cannabis-related activities. If SunStream’s portfolio companies were so prosecuted, it would have a material adverse effect on our business, financial condition and operations as a result of our interest in SunStream. There is also no assurance that third party service providers with whom we work could suspend or withdraw services due to SunStream’s involvement in the U.S. cannabis industry, which could have a material adverse effect on our business, financial condition and operations.

Moreover, individuals and entities may violate federal law if they aid and abet another in violating the CSA, or conspire with another to violate the law, and violating the CSA is a predicate for certain other crimes, including money laundering laws and the Racketeer Influenced and Corrupt Organizations Act. To the extent that any of SunStream’s portfolio companies are found to violate the CSA, there can be no assurance that SunStream and/or SNDL would not be found to be in violation of the CSA, money laundering, racketeering or similar laws for financing such companies. If SunStream and/or SNDL are found to violate such laws, it could lead to arrests, criminal charges, forfeiture of property, significant fines and penalties, disgorgement of profits, administrative sanctions, criminal convictions and cessation of business activities, as well as civil liabilities arising from proceedings initiated by either the U.S. government or private citizens, all of which would materially adversely affect our business, financial condition, results of operations and reputation.

We are subject to the risk of possibly becoming an investment company under the Investment Company Act of 1940.

To the extent we hold or acquire equity or debt securities of other companies, or were to be viewed as holding ourselves out or conducting our affairs so as to become an investment company, we run the risk of inadvertently becoming an “investment company” under the Investment Company Act of 1940, as amended (the “Investment Company Act”), which may require us to register as an investment company under the Investment Company Act. Registered investment companies are subject to extensive, restrictive and potentially adverse regulations relating to, among other things, operating methods, management, capital structure, dividends and transactions with affiliates. Registered investment companies are not permitted to operate their business in the manner in which we operate our business, nor are registered investment companies permitted to have many of the relationships that we have with our affiliated companies.

As a company primarily engaged in the businesses of (i) retailing wines, beers and spirits; (ii) operating and supporting corporate owned and franchised retail cannabis stores in Canadian jurisdictions where the private sale of adult-use cannabis is permitted; (iii) producing, distributing, and selling cannabis in Canada; (iv) deploying capital to direct and indirect financing opportunities and partnerships throughout the global cannabis industry; and (v) deploying capital to opportunities in the global cannabis industry, we believe that we are not an investment company under the Investment Company Act. Since we do not believe that we can operate our businesses if we were required to register as an investment company under the Investment Company Act, we may structure our transactions accordingly, Specifically, we may avoid otherwise attractive opportunities which may be available to us, or we may avoid otherwise economically desirable transactions. We may also be compelled to dispose of assets at a time and on a basis that may not be advantageous to us.

In addition, adverse developments with respect to our ownership of certain of current or future assets, including significant appreciation or depreciation in the market value of certain publicly traded holdings, could result in our inadvertently becoming an investment company. If we were to become an investment company without registering, there would be a risk, among other material adverse consequences, that we could become subject to monetary penalties or injunctive relief, or both, in an action brought by the SEC, that we would be unable to enforce contracts with third parties or that third parties could seek to obtain rescission of transactions with us undertaken during the period it was established that we were an unregistered investment company.

Risks Related to our Acquisitions

We may not be able to successfully identify and execute future acquisitions or dispositions or to successfully manage the impacts of such transactions on our operations.

We have in the past, and may in the future, seek strategic acquisitions. Our ability to identify and consummate any future potential acquisitions on terms that are favorable to us may be limited by the number of attractive acquisition targets, internal demands on our

30

resources and, to the extent necessary, our ability to obtain financing on satisfactory terms, if at all. Any such activities may require, among other things, various regulatory approvals, licences and permits and there is no guarantee that all required approvals, licences and permits will be obtained in a timely fashion or at all. Acquisitions, including our recent acquisition of Valens, may expose us to additional risks including: difficulties in integrating administrative, financial reporting, operational and information systems; difficulties in managing newly acquired operations and improving their operating efficiency; difficulties in maintaining uniform standards, controls, procedures and policies through all our operations; difficulties entering into markets in which we have little or no direct experience; difficulties in retaining key employees of the acquired operations; and disruptions to our ongoing business. In addition, future acquisitions could result in the incurrence of additional debt, costs, and contingent liabilities. In the past, we have incurred substantial goodwill impairments related to prior acquisitions. We may also incur costs for and divert management attention to potential acquisitions that are never consummated. For acquisitions that are consummated, expected synergies may not materialize.

We face integration and liability risks in connection with our acquisition strategy, some of which may be unforeseen by us.

Our acquisitions are completed with the expectation that the successful completion of such acquisition will result in increased earnings and cost savings by taking advantage of operating and other synergies to be realized from the integration of the acquired entity. These anticipated benefits will depend in part on whether the acquired entity’s operations can be integrated in an efficient and effective manner. Management may face challenges incorporating the systems and personnel of an acquired entity, such as Valens, including possible unanticipated liabilities, unanticipated costs, the loss of key employees and commercial relationships, the need to revisit assumptions about future revenues, capital expenditures and operating costs, including synergies, and the need to address unanticipated liabilities. As a result of these factors, it is possible that the synergies expected from the combination of our business and that of an acquired entity will not be realized. In addition, integration efforts require substantial management attention and could detract attention from our day-to-day business.

Despite any diligence we may perform on an acquisition target, we may not fully appreciate, understand or fully anticipate the extent of the risks associated with a target business and the acquisition and integration. Even if we have the benefit of indemnification provisions, escrow funds and/or insurance policies in connection with an acquisition agreement, our exercise of due diligence and risk mitigation strategies may not anticipate or mitigate the full risks of the acquisition and the associated costs. As a result of an acquisition, we will incur the liabilities of the target, including, but not limited to, matters related to litigation, regulation, the environment or otherwise, some or all of which may be unforeseen by us. We may not be able to contain or control the costs associated with unanticipated risks or liabilities, which could materially and adversely affect our business, liquidity, capital resources or results of operations.

The foregoing risks could be exacerbated, and new risks to our company, some or all of which we may be unable to foresee, may arise, if we acquire businesses engaged in other business lines, such as alcohol retail, even if the new business lines are ancillary or related to our current business.

Our inability to manage growth effectively could have an adverse effect on our business and financial results.

We recently experienced significant growth in our operations and employee base as a result of several acquisitions, and we may experience acquisition-related and organic growth in the future. We will need to continue to improve our internal systems to address recent and anticipated growth of our business, which we may not be able to do effectively or on a timely basis in order to meet our current growth targets. Our inability to execute our growth strategy, to ensure the continued adequacy of our current systems or to manage our expansion, workforce capital and other resources effectively could have a material adverse effect on our business, financial performance, financial condition and cash flows.

Risks Related to Our Jurisdiction of Incorporation

We are incorporated in the Province of Alberta and enforcement of actions may be difficult.

We are incorporated under the laws of the Province of Alberta and our head office is located in the Province of Alberta. All of our directors and officers and some of the experts named in this Annual Report are residents of Canada or otherwise reside outside of the United States, and a substantial portion of their assets and our assets are located outside the United States. Consequently, it may be difficult for investors in the United States to bring an action against such directors, officers or experts or to enforce against those persons or us a judgement obtained in a United States court predicated upon the civil liability provisions of U.S. federal securities laws or other laws of the United States.

We are a foreign private issuer and intend to take advantage of less frequent and detailed reporting obligations.

We are a “foreign private issuer”, as such term is defined in Rule 405 under the Securities Act, and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the U.S. Exchange Act of 1934, as amended (the “Exchange Act”), we are subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. As a result, we are not required to file the same reports that a U.S. domestic issuer would file with the SEC, although we are required to file or furnish to the SEC the continuous disclosure documents that we are required to file in Canada under Canadian securities laws. In addition, our officers, directors, and principal shareholders are exempt from the reporting and “short swing” profit recovery provisions of Section 16 of the Exchange Act. Therefore, our shareholders may not know on as timely a basis

31

when our officers, directors and principal shareholders purchase or sell shares, as the reporting deadlines under the corresponding Canadian insider reporting requirements are longer.

As a foreign private issuer, we are exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements. We are exempt from Regulation FD, which prohibits issuers from making selective disclosures of material non-public information. While we will comply with the corresponding requirements relating to proxy statements and disclosure of material non-public information under Canadian securities laws, these requirements differ from those under the Exchange Act and Regulation FD and shareholders should not expect to receive the same information at the same time as such information is provided by U.S. domestic companies. In addition, we will have more time than U.S. domestic companies after the end of each fiscal year to file our annual report with the SEC and will not be required under the Exchange Act to file quarterly reports with the SEC.

In addition, as a foreign private issuer, we have the option to follow certain Canadian corporate governance practices, except to the extent that such laws would be contrary to U.S. securities laws, and provided that we disclose the requirements we are not following and describe the Canadian practices we follow instead. We have elected to follow Canadian practices with regard to certain corporate governance matters. As a result, our shareholders may not have the same protections afforded to shareholders of U.S. domestic companies that are subject to all corporate governance requirements.

We may in the future lose our foreign private issuer status.

We may in the future lose our foreign private issuer status if a majority of our shares are held in the United States and if: (i) a majority of either our directors or executive officers, considered as separate groups, are either U.S. citizens or residents; (ii) a majority of our assets are located in the United States; or (iii) our business is administered principally in the United States. Although we have elected to comply with certain U.S. regulatory provisions, our loss of foreign private issuer status would make such provisions mandatory. If we are not a foreign private issuer, we would not be eligible to use foreign issuer forms and would be required to file periodic and current reports and registration statements on U.S. domestic issuer forms with the SEC, which are generally more detailed and extensive than the forms available to a foreign private issuer. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on the Nasdaq that are available to foreign private issuers. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer will be significantly more than the costs incurred as a Canadian foreign private issuer.

General Risks

Our business and financial results could be adversely affected by a number of global conditions which are outside our control.

Certain global conditions which are outside our control, such as economic and geopolitical conditions, acts of violence or war, natural disasters or extreme weather events and the COVID-19 pandemic, could have an adverse effect on our business. For example, as a result of the COVID-19 pandemic, we had been required to extend paid sick leave we offer employees, implement enhanced safety protocols, staffing changes and remote work procedures, all of which had increased our expenses, and we have also experienced delays in shipment of vape cartridge hardware for our products from China. There can be no certainty as to the future impact of the COVID-19 pandemic on the economies and industries in which we operate or on our business and we may again experience such impacts in the future, and may also experience, among other things, short- or long-term facility, retail store and other operational disruptions and closures, production delays and reductions, inability to timely obtain and renew any necessary regulatory permits or licenses, and adverse impacts on consumer demand for our products, any of which could materially adversely affect our business, financial condition and results of operations.

In addition, economic conditions have created, and may continue to create, volatility, uncertainty and economic disruption. The global economy has entered into a period of inflation, higher interest rates and slower economic growth and some regions may experience a recessionary period and we cannot predict how long such conditions may last or what their ultimate impact may be on our business. Global economic conditions may adversely affect our liquidity and financial condition, increase the cost of borrowing and cause credit to become more limited and less available, limit our ability to access financing or increase our cost of financing to meet liquidity needs, all of which could have a material adverse effect on our business, financial condition, financial performance and cash flows. Changes in the general level of economic activity, such as decreases in consumer spending, could result in pricing pressure on our products and a decrease in demand for our services, which would reduce our revenue. Acts of violence or war, including the Russia-Ukraine conflict, may adversely affect worldwide financial markets and could potentially lead to, or exacerbate, an economic recession, which could adversely affect our business, financial performance, financial condition and cash flows.

Further, the risk of cybersecurity incidents has increased in connection with the ongoing Russia-Ukraine conflict. It is possible that these attacks could have collateral effects on critical communications infrastructure and financial institutions globally, which could adversely affect our operations and could increase the frequency and severity of cyber-based attacks against our information technology systems. The proliferation of malware from the conflict into systems unrelated to the conflict, or cyberattacks against companies based in countries that have instituted sanctions against Russia and Belarus, such as Canada, could also adversely affect our results of operations. To the extent the current conflict between Russia and Ukraine adversely affects our business, it may also have the effect of heightening many other risks disclosed in this Annual Report.

32

We may not be able to obtain adequate insurance coverage in respect of the risks we and our business face, the premiums for such insurance may not continue to be commercially justifiable or there may be coverage limitations and other exclusions which may result in such insurance not being sufficient to cover potential liabilities that we face.

We currently have insurance coverage, including product liability, business interruption and property insurance, protecting many, but not all, of our assets and operations. Our insurance coverage is subject to coverage limits and exclusions and may not be available for the risks and hazards to which we are exposed. In addition, no assurance can be given that such insurance will be adequate to cover our liabilities, including potential litigation and product liability claims, or will be generally available in the future or, if available, that premiums will be commercially justifiable. If we were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, we may be exposed to material uninsured liabilities that could impede our liquidity, profitability or solvency.

We may be subject to risks related to the protection and enforcement of our intellectual property rights, or intellectual property we licence from others, and may become subject to allegations that we or our licensors are in violation of intellectual property rights of third parties.

The ownership, licensing and protection of trademarks and other intellectual property rights are significant aspects of our future success.

It is possible that we will not be able to make non-provisional applications, register, maintain registration for or enforce all of our intellectual property, including trademarks, in all key jurisdictions. The intellectual property registration process can be expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable intellectual property applications at a reasonable cost or in a timely manner or may obtain intellectual property registrations which are invalid. Further, changes in either intellectual property laws or interpretation of intellectual property laws in Canada, and other countries may diminish the value of our intellectual property rights or narrow the scope of our intellectual property protection. As a result, our current or future intellectual property portfolio may not provide us with sufficient rights to protect our business, including our products, processes and brands.

Termination or limitation of the scope of any intellectual property licence may restrict or delay or eliminate our ability to develop and commercialize our products, which could adversely affect our business. We cannot guarantee that any third-party technology we licence will not be unenforceable or licensed to our competitors or used by others. In the future, we may need to obtain licences, renew existing licence agreements in place at such time or otherwise replace existing technology. We are unable to predict whether these licence agreements can be obtained or renewed, or the technology can be replaced on acceptable terms, or at all.

Unauthorized parties may attempt to replicate or otherwise obtain and use our products, brands and technology. Policing the unauthorized use of our current or future trademarks, patents or other intellectual property rights could be difficult, expensive, time consuming and unpredictable, as may be enforcing these rights against unauthorized use by others. Identifying the unauthorized use of intellectual property rights is difficult as we may be unable to effectively monitor and evaluate the products being distributed by our competitors, including parties such as unlicensed dispensaries and black-market participants, and the processes used to produce such products. In addition, in any infringement proceeding, some or all of our trademarks or other intellectual property rights or other proprietary know-how, or those we licence from others, or arrangements or agreements seeking to protect the same for our benefit, may be found invalid, unenforceable, anti-competitive or not infringed; may be interpreted narrowly; or could put existing intellectual property applications at risk of not being issued.

In addition, other parties may claim that our products, or those we licence from others, infringe on their intellectual property, including their proprietary or patent protected rights. Such claims, whether or not meritorious, may result in the expenditure of significant financial and managerial resources and legal fees, result in injunctions or temporary restraining orders or require the payment of damages. As well, we may need to obtain licences from third parties who allege that we have infringed on their lawful rights. Such licences may not be available on terms acceptable to us, or at all. In addition, we may not be able to obtain or utilize on terms that are favorable to us, or at all, licences or other rights with respect to intellectual property that we do not own. In the event that we licence our intellectual property to a third party, including a third-party manufacturer, such third party could misappropriate our intellectual property or otherwise violate the terms of our licence. If any of the foregoing events were to occur, it could have a material adverse effect on our business, results of operations and financial condition.

We also rely on certain trade secrets, technical know-how and proprietary information that are not protected by patents to maintain our competitive position. Our trade secrets, technical know-how and proprietary information, which are not protected by patents, may become known to or be independently developed by competitors.

We may be subject to risks related to our information technology systems, including the risk that we may be the subject of a cyberattack.

We have entered into agreements with third parties for hardware, software, telecommunications and other information technology (“IT”), services in connection with our operations. Our operations depend, in part, on how well we and our vendors protect networks, equipment, IT systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism or theft. Our operations also depend on the timely maintenance, upgrade and replacement of networks, equipment and IT systems and software, as well as

33

preemptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays or increases in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact us.

We may be subject to cyber security risks or other breaches of IT security intended to obtain unauthorized access to our proprietary information or the information of our customers and consumers, destroy data or disable, degrade, hold for ransom, or sabotage these systems through the introduction of computer viruses, fraudulent emails, cyber-attacks and other means, and such breaches could originate from a variety of sources including our own employees or unknown third parties. There can be no assurance that measures implemented to protect the integrity of these systems will provide adequate protection, and any such breach of our IT could go undetected for an extended period of time. A breach of our cyber security measures or the failure or malfunction of any of our computerized business systems, associated backup or data storage systems could cause us to suffer a disruption in one or more parts of our business and experience, including the shutdown of certain of our facilities or retail stores among other things, financial loss, a loss of business opportunities, misappropriation or unauthorized release of confidential or personal information, damage to our systems and those with whom we do business, violations of privacy and other laws, litigation, regulatory enforcement actions and penalties, indemnity obligations, remediation and restoration costs, increased costs to maintain our systems and other possible liabilities. Cyber-security breaches, ransomware attacks, or failures of our information technology systems could have a material adverse effect on our business operations, financial reporting, financial condition and results of operations, and result in reputational damage.

Risks Related to Our Common Shares

The price of our common shares in public markets has experienced and may in the future experience extreme volatility and you may lose some or all of your investment in our common shares as a result.

The price of our common shares has experienced significant volatility since the time of our listing on the Nasdaq Global Select Market, sometimes in the absence of a recent change in our financial condition or results of operations, such as our earnings, revenues, or other measure of company value, such that increases in our share price have at times been significantly inconsistent with improvement in the actual or expected indicators of the value of the Company.

The market price for our common shares has been and may in the future continue to be extremely volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond our control, including the following: (i) actual or anticipated fluctuations in our quarterly results of operations; (ii) recommendations by securities research analysts; (iii) changes in the economic performance or market valuations of other issuers that investors deem comparable to us; (iv) the addition or departure of our executive officers and other key personnel; (v) the release or expiration of lock-up or other transfer restrictions on our common shares; (vi) sales or perceived sales, or expectation of future sales, of our common shares or instruments convertible or exercisable for our common shares; (vii) significant dispositions, acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by or involving us or our competitors; (viii) news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in our industry or target markets; (ix) trading activity by investors which is not motivated by or commensurate with changes in the actual or expected indicators of the value of our Company; (x) speculation in the press, in the investment community, or on the internet, including on online forums and social media, about our Company, our industry or our securities; (xi) anticipated or pending investigations, proceedings, or litigation that involve or affect us, other companies in our industry, or other companies that investors deem comparable to us; and (xii) the occurrence of any other risk identified in the risk factors included in our filings with the Securities and Exchange Commission or the Canadian securities regulators.

Financial markets have experienced significant price and volume fluctuations which have affected the market prices of equity securities of public entities. Companies in the cannabis sector have also experienced extreme volatility in their trading prices. In many cases, these fluctuations, and the effect that they have on market prices, have been unrelated to the operating performance, underlying asset values or prospects of such entities. For example, certain companies, including ours, have recently experienced extreme volatility and increases in share price due to trading activity by retail investors which was motivated primarily by a desire to influence the financial performance of hedge funds, rather than changes in actual or expected value of the companies subject to trading activity. Accordingly, the market price of our common shares may decline rapidly and substantially even if our operating results or prospects have not changed.

Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed not to be temporary, which may result in impairment losses to us. Furthermore, certain investors may base their investment decisions on considerations of our environmental, governance and social practices of our industry as a whole, and our performance in these areas against such institutions’ respective investment guidelines and criteria. The failure to satisfy such criteria may result in limited or no investment in our common shares by those institutions, which could materially adversely affect the trading price of our common shares. There can be no assurance that continuing fluctuations in the price and volume of equity securities will not occur and affect the trading price of our common shares.

Since we have never paid, and, for the foreseeable future, do not anticipate paying, dividends to holders of our common shares, other than the anticipated distribution of Nova shares held by SNDL to reduce the Company’s equity interest in Nova to approximately 19.9%, pursuant to the Nova Transaction (see “—Interests of Management and Others in Material Transactions—Nova Strategic Partnership”,

34

your only means of receiving any return on an investment in our common shares may be to sell our shares for a price greater than that which you paid for them. Any of the foregoing risks may prevent you from doing so in the foreseeable future or at all, and you may lose some or all of your investment. In addition, while the daily trading volume in our common shares has recently been significant, there can be no assurance that such volume will not decline, perhaps rapidly and substantially, limiting your ability to sell our common shares and make a return on your investment on your desired timeline or at all.

The risk that you fail to resell our common shares at a price greater than you paid for them and lose some or all of your investment as a result will be further exacerbated if our shares experience a “short squeeze” and you purchase shares during a short squeeze.

Investors may purchase our common shares to hedge existing exposure in our common shares or to speculate on the price of our common shares. Speculation on the price of our common shares may involve long and short exposures. To the extent aggregate short exposure exceeds the number of our common shares available for purchase in the open market, investors with short exposure may have to pay a premium to repurchase our common shares for delivery to lenders of such common shares. Those repurchases may, in turn, dramatically increase the price of our common shares until investors with short exposure are able to purchase additional common shares to cover their short position. This phenomenon is often referred to as a “short squeeze”. A short squeeze could lead to or exacerbate volatile price movements in our common shares that are not directly correlated to the performance or prospects of our Company. Once investors purchase the shares necessary to cover their short position, our share price will likely decline rapidly and substantially relative to its levels during the short squeeze, and may not return to levels at or above those during the short squeeze for a long time or at all. As a result, if you purchase our shares during a short squeeze, you will be at an increased risk of failing to sell our shares at a price greater than what you paid for them and losing some or all of your investment. While we currently have no reason to believe our shares would be the target of a short squeeze, there can be no assurance that we will not in the future be a target of a short squeeze, and you may lose a significant portion or all of your investment if you purchase our shares at a price that is significantly disconnected from the underlying value of our Company.

We may sell a substantial number of our common shares in the public market at any time. Such sales or the perception that they may occur could cause the market price of our common shares to drop significantly, even if our business is doing well.

We have in the past, and may in the future, sell a substantial number of our common shares, or securities convertible or exercisable into our common shares, in the public market at any time, without approval of existing shareholders, which we are not required to obtain under our articles. Such sales, or the perception in the market that they may occur, could reduce the market price of our common shares rapidly and substantially. Accordingly, you may become unable to resell our shares at a price greater than you paid for them for a long time or at all, and may lose some or all of your investment. The foregoing could also impair our ability to raise capital through the sale of additional equity securities.

Holders of our common shares may be subject to dilution resulting from future offerings of securities, the conversion or exercise, as applicable, of our outstanding warrants and the issuance of equity-based compensation by us.

We may raise additional funds in the future pursuant to a registration statement or otherwise, by issuing common shares, or securities exercisable or convertible into common shares, including preferred shares, warrants, rights or units comprising two or more of the foregoing securities. Holders of our common shares do not have preemptive rights in connection with such further issuances. Our board of directors has the discretion to determine if an issuance of securities is warranted, the price at which such issuance is effected and the other terms of any such future issuance. In addition, additional common shares may be issued by us in connection with the exercise of options and exchange of restricted share units (“RSUs”) and deferred share units (“DSUs”) granted by us or as part of an employee compensation plan or agreement, as well as in connection with warrants we previously issued to certain investors, which are subject to customary anti-dilution protections and certain other adjustments contained in such instruments. Such additional equity issuances have in the past, and could in the future, depending on the price at which such securities are issued, substantially dilute the interests of the holders of our common shares.

If we fail to meet applicable listing requirements, Nasdaq may delist our common shares from trading, in which case the liquidity and market price of our common shares could decline.

Our common shares are listed on the Nasdaq. In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, a requirement that our closing bid price be at least US$1.00 per share. We were first notified by the Listing Qualifications Department of the Nasdaq that the closing bid price of our common shares did not meet the minimum bid price of US$1.00 per share on May 12, 2020. Subsequent to this notification, we transferred our listing from the Nasdaq Global Select Market to the Nasdaq Capital Market in order to take advantage of an additional period of time to comply with the minimum bid price requirement, and regained compliance with the requirement on February 12, 2021.

On August 9, 2021, we were again notified by the Listing Qualifications Department of the Nasdaq that the closing bid price of our common shares for the last 30 consecutive business days from June 25, 2021 to August 6, 2021 did not meet the minimum bid price of US$1.00 per share as set forth in the minimum bid requirement. At that time, we had until February 7, 2022, to regain compliance with the minimum bid requirement. On February 8, 2022, we received a 180-day extension to regain compliance with the minimum bid requirement. As a result, we had until August 8, 2022 to regain compliance with the minimum bid requirement. On July 25, 2022,

35

immediately following the shareholder approval, the board of directors determined to affect a share consolidation on the basis of one post-consolidation common share for every ten pre-consolidation common shares. The share consolidation took effect on July 25, 2022, and the common shares began trading on Nasdaq on a post-consolidation basis beginning on July 26, 2022.

On August 9, 2022, we were notified by Nasdaq that we had regained compliance with the minimum bid requirement as the bid price for our common shares closed at or above US$1.00 per share for the 10 consecutive business days between July 26, 2022 and August 8, 2022.

If we fail to maintain compliance with the minimum bid price rule or fail to maintain compliance with any other applicable Nasdaq continued listing requirements, Nasdaq may determine to delist our common stock, at which time our common stock would be quoted on the over-the-counter markets. If we fail to comply with the applicable listing standards and Nasdaq delists our common shares, we and our shareholders could face significant material adverse consequences, including:

•a limited availability of market quotations for our common shares;

•reduced liquidity for our common shares;

•a determination that our common shares are “penny stock”, which would require brokers trading in our common shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common shares;

•a limited amount of news about us and analyst coverage of us; and

•a decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.

We cannot assure you that we will be able to maintain compliance with the continued listing standards of Nasdaq in the future.

Any equity securities we issue will be subordinate to our future indebtedness, if any, and any common shares we issue will be subordinate to any preferred shares we issue.

Common shares are equity interests in our Company and do not constitute indebtedness. As such, our common shares will rank junior to our future indebtedness, if any, and other non-equity claims on our Company with respect to assets available to satisfy claims on our Company, including in a liquidation of our Company. Additionally, our board of directors is authorized to issue series of preferred shares without any action on the part of shareholders of our common shares. Holders of our common shares are subject to the prior dividend, liquidation preferences, terms of redemption, conversion rights and voting rights, if any, of any holders of our preferred shares or depositary shares representing such preferred shares then outstanding.

Ownership of our common shares may be considered unlawful in some jurisdictions and holders of our common shares may consequently be subject to liability in such jurisdictions.

Cannabis-related financial transactions, including investment in the securities of cannabis companies and receipt of any associated benefits, such as dividends, are currently subject to anti-money laundering and a variety of other laws that vary by jurisdiction, many of which are unsettled and still developing. While the interpretations of these laws are unclear, in some jurisdictions, financial benefit directly or indirectly arising from conduct that would be considered unlawful in such jurisdiction may be viewed to be within the purview of these laws, and persons receiving any such benefit, including investors in an applicable jurisdiction, may be subject to liability under such laws. Each prospective investor should therefore contact his, her or its own legal advisor regarding the ownership of our common shares and any related potential liability.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our share price and trading volume could decline.

The trading market for our common shares depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our shares or publish inaccurate or unfavorable research about our business, our share price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our shares could decrease, which might cause our share price and trading volume to decline.

Our articles permit us to issue an unlimited number of common shares without additional shareholder approval.

Our articles permit the issuance of an unlimited number of common shares, and shareholders will have no pre-emptive rights in connection with such further issuance. Additional issuances of our securities may involve the issuance of a significant number of common shares at prices less than the current market price for the common shares. Issuances of substantial numbers of common shares, or the perception that such issuances could occur, may adversely affect prevailing market prices of our common shares. Any transaction involving the issuance of previously authorized but unissued common shares, or securities convertible into common shares, would result in dilution, possibly substantial, to security holders.

36

It is not anticipated that any regular dividends will be paid to holders of our common shares for the foreseeable future.

No dividends on our common shares have been paid to date. We anticipate that, for the foreseeable future, we will retain future earnings and other cash resources for the operation and development of our business, other than the anticipated distribution of Nova shares held by SNDL to reduce the Company’s equity interest in Nova to approximately 19.9%, pursuant to the Nova Transaction (see “—Interests of Management and Others in Material Transactions—Nova Strategic Partnership”. Payment of any future dividends will be at the discretion of our board of directors after taking into account many factors, including our earnings, operating results, financial condition and current and anticipated cash needs. In addition, our ability to pay cash dividends on our common shares is limited by the terms of our financing arrangements. As a result, investors may not receive any return on an investment in our common shares unless they are able to sell their shares for a price greater than that which such investors paid for them.

Our by-laws, and certain Canadian legislation, contain provisions that may have the effect of delaying or preventing a change in control.

Certain provisions of our by-laws, together or separately, could discourage potential acquisition proposals, delay or prevent a change in control and limit the price that certain investors may be willing to pay for our common shares. For instance, our by-laws contain provisions that establish certain advance notice procedures for nomination of candidates for election as directors at shareholders’ meetings. A non-Canadian must file an application for review with the minister responsible for the Investment Canada Act (Canada) and obtain approval of the minister prior to acquiring control of a “Canadian business” within the meaning of the Investment Canada Act (Canada), where prescribed financial thresholds are exceeded. Furthermore, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. Otherwise, there are no limitations either under the laws of Canada or Alberta, or in our articles on the rights of non-Canadians to hold or vote our common shares. Any of these provisions may discourage a potential acquirer from proposing or completing a transaction that may have otherwise presented a premium to our shareholders.

Our by-laws provide that any derivative actions, actions relating to breach of fiduciary duties and other matters relating to our internal affairs will be required to be litigated in Canada, which could limit investors’ ability to obtain a favorable judicial forum for disputes with us.

We have adopted a forum selection by-law that provides that, unless we consent in writing to the selection of an alternative forum, the Alberta Court of Queen’s Bench of the Province of Alberta, Canada and appellate Courts therefrom (or, failing such Court, any other “court” as defined in the ABCA, having jurisdiction, and the appellate Courts therefrom), will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf; (2) any action or proceeding asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us; (3) any action or proceeding asserting a claim arising pursuant to any provision of the ABCA or our restated articles or by-laws; or (4) any action or proceeding asserting a claim otherwise related to our “affairs” (as defined in the ABCA), provided that the by-law does not apply to any action brought to enforce any liability or duty created by the Exchange Act or the Securities Act, including the respective rules and regulations promulgated thereunder, or any other claim under U.S. securities law for which the United States federal or state courts have exclusive jurisdiction. Our forum selection by-law also provides that our securityholders are deemed to have consented to personal jurisdiction in the Province of Alberta and to service of process on their counsel in any foreign action initiated in violation of our by-law. Therefore, it may not be possible for securityholders to litigate any action relating to the foregoing matters outside of the Province of Alberta.

Our forum selection by-law seeks to reduce litigation costs and increase outcome predictability by requiring derivative actions and other matters relating to our affairs to be litigated in a single forum. While forum selection clauses in corporate charters and by-laws are becoming more commonplace for public companies in the United States and have been upheld by courts in certain states, they are untested in Canada. It is possible that the validity of our forum selection by-law could be challenged and that a court could rule that such by-law is inapplicable or unenforceable. If a court were to find our forum selection by-law inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions and we may not obtain the benefits of limiting jurisdiction to the courts selected.

The regulated nature of our business may impede or discourage a takeover, which could reduce the market price of our common shares.

We require and hold various government licences to operate our business, which would not necessarily continue to apply to an acquiror of our business following a change of control. In addition, our directors, officers and certain other personnel are required to obtain, and maintain, security clearances from Health Canada. These licensing and security clearance requirements could impede a merger, amalgamation, takeover or other business combination involving us or discourage a potential acquiror from making a tender offer for our common shares, which, under certain circumstances, could reduce the market price of our common shares.

37

There is a significant risk that we may be treated as a passive foreign investment company, which could result in adverse U.S. federal income tax consequences to U.S. investors.

Based on the past and projected composition of our income and assets, and the valuation of our assets, including goodwill, there is a significant risk that we may be treated as a passive foreign investment company (“PFIC”), for the taxable year ending December 31, 2022, and we can make no assurances in this regard with respect to the current taxable year or any future taxable years. The determination of whether or not we are a PFIC is made on an annual basis and will depend on the composition of our income and assets, from time to time. Specifically, for any taxable year, we will be classified as a PFIC for U.S. federal income tax purposes if either: (i) 75% or more of our gross income in that taxable year is passive income, or (ii) the average percentage of our assets by value in that taxable year which produce or are held for the production of passive income is at least 50%. The calculation of the value of our assets is expected to be based, in part, on the quarterly market value of our shares, which is subject to change.

If we are or were to become a PFIC, such characterization could result in adverse U.S. federal income tax consequences to U.S. investors. For example, if we are a PFIC, U.S. investors may become subject to increased tax liabilities under U.S. federal income tax laws and regulations and will become subject to burdensome reporting requirements. U.S. Holders should consult their tax advisor concerning the U.S. federal income tax consequences of holding and disposing shares of a PFIC, including the possibility of making any election that may be available under the PFIC rules (including a mark-to-market election) which may mitigate the adverse U.S. federal income tax consequences of holding shares of a PFIC. See “Item 10E—Taxation—Certain U.S. Federal Income Tax Considerations for U.S. Persons” for more information.

The New Warrants, the 2020 Series A Warrants and the New Investor Warrants have certain terms which may impede a takeover or similar transaction, which, under certain circumstances, could reduce the market price of our common shares.

The outstanding warrants issued pursuant to a securities purchase agreement, dated June 5, 2020 (the “New Investor Warrants”), the Series A warrants issued in connection with a unit offering on August 18, 2020 (the “2020 Series A Warrants”) and the warrants issued pursuant to the warrant exercise agreement dated February 19, 2021 (the “New Warrants”) prohibit us from engaging in Fundamental Transactions (as defined in such instruments), including specified transactions related to Change of Control (as defined in such instruments), unless the successor entity assumes all of our obligations under such instruments under a written agreement in form and substance satisfactory to, and approved by, the holder thereof. These restrictions could impede a merger, amalgamation, takeover or other business combination involving us or discourage a potential acquiror from making a tender offer for our common shares, which, under certain circumstances, could reduce the market price of our common shares.

Item 4. Information on the Company

A.History and development of the company.

SNDL was incorporated under the Business Corporations Act (Alberta) (the “ABCA”) on August 19, 2006. On July 22, 2019, we filed articles of amendment to effect a 1 to 1.6 share split. On August 1, 2019, our common shares commenced trading on the Nasdaq under the symbol “SNDL”. On July 25, 2022, our shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from “Sundial Growers Inc.” to “SNDL Inc.” and to complete the consolidation of the issued and outstanding common shares on a basis to be determined by our board of directors, subject to certain conditions. On July 26, 2022, our board of directors approved the consolidation of the issued and outstanding common shares on a 10:1 basis, which became effective on the same day. On January 1, 2023, SNDL amalgamated with our wholly-owned subsidiary, Alcanna, under the ABCA to form the currently existing corporation. We have twenty-five direct and indirect subsidiaries.

Our headquarters and principal executive offices are located at #300, 919 – 11 Avenue SW, Calgary, Alberta, Canada, T2R 1P3 and our registered office is located at 4000 – 421 7 Avenue SW, Calgary, Alberta, Canada, T2P 4K9. Our phone number is +1 (403) 948-5227. Our website is www.sndlgroup.com. The information on or accessible through our website is not part of and is not incorporated by reference into this Annual Report, and the inclusion of our website address in this Annual Report is only for reference.

We are subject to the informational requirements of the Exchange Act and are required to file reports and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding registrants that make electronic filings with the SEC using its EDGAR system.

Over the three most recently completed fiscal years and for the current fiscal year, we have undertaken and/or completed a business disposition, several business acquisitions and capital expenditures, including, among others, the following:

38

Business dispositions

Bridge Farm

On February 22, 2019, the Company, through its wholly-owned subsidiary, Sundial UK Limited, signed a Sale and Purchase Agreement to acquire all the issued and outstanding shares of Project Seed Topco (together with its subsidiaries, “Bridge Farm”). The acquisition closed on July 2, 2019. Bridge Farm was acquired to expand the Company’s business to CBD extraction and production, subject to certain regulatory, licensing and other restrictions, to launch CBD sales in the United Kingdom. At December 31, 2019, the Company recorded a goodwill impairment based on significant delays and uncertainties in the licensing and regulatory framework in the United Kingdom. As part of the negotiations with the Company’s senior lenders regarding a December 31, 2019 covenant breach and restructuring of its credit agreements, the Company was required to enter into a definitive sale and purchase agreement related to the sale of Bridge Farm.

On May 15, 2020, the Company entered into an agreement to sell all of the outstanding shares of Bridge Farm to a company affiliated with the former management sellers that were parties to the original acquisition (the “Bridge Farm Purchaser”) in exchange for (i) the assumption by the Bridge Farm Purchaser of $45 million of the total $115 million principal amount outstanding under the secured credit agreement (thereby reducing the Company’s obligations thereunder to $70 million), (ii) the assumption by the Bridge Farm Purchaser of contingent consideration liabilities related to the additional share obligation and remaining earn out obligation under the original Bridge Farm acquisition agreement dated July 2, 2019, and (iii) the cancellation of approximately 2.7 million SNDL common shares (value of $3.0 million), representing all of the shares currently held by the management sellers of Bridge Farm issued in connection with the original acquisition of Bridge Farm by the Company in 2019 (collectively, the “Bridge Farm Disposition”). The sale of Bridge Farm closed on June 5, 2020.

The Bridge Farm operations comprised the Company’s entire Ornamental Flower segment located in the United Kingdom. The Ornamental Flower segment was not previously classified as held-for-sale or as a discontinued operation as it was not highly probable that the carrying amount of the disposal group would be recovered through a sale transaction rather than through continuing use. The comparative statement of loss and comprehensive loss and statement of cash flows has been re-presented to show the discontinued operation separately from continuing operations. With the disposition of the Ornamental Flower segment, the Company no longer has multiple segments. Accordingly, the Cannabis operations in Canada comprise the entire operations of the Company.

Pathway Rx

On March 23, 2021, the Company’s equity interest in its subsidiary, Pathway Rx Inc. (“Pathway”), decreased from 50% to 25%, resulting in a loss of control. The Company decreased its equity interest in connection with amending the licence agreement that provides for use of Pathway’s intellectual property. The licence agreement was amended to terminate the quarterly fixed payments.

Business acquisitions

Inner Spirit

On May 5, 2021, the Company and Inner Spirit announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021.

The Inner Spirit Transaction consideration was comprised of:

(i)an aggregate $92.6 million cash ($0.30 in cash for each Inner Spirit common share);

(ii)an aggregate 2.4 million SNDL common shares valued at $26.2 million based on the fair value of each common share of the Company on the closing date (0.00835 of a SNDL common share for each Inner Spirit common share); and

(iii)contingent consideration valued at $1.2 million representing the fair value of Inner Spirit warrants.

The acquisition of Inner Spirit has led to the establishment of a retail operations segment that comprises the sale of adult-use cannabis through wholly owned and franchise retail cannabis stores. Inner Spirit is a retailer and franchisor of Spiritleaf adult-use cannabis stores across Canada, with a network that includes more than 100 franchised and corporate-owned locations.

Alcanna

On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna pursuant to which the Company would acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022, and the Alcanna Transaction closed on March 31, 2022. Alcanna holds an approximate 63% equity interest in Nova Cannabis Inc. (“Nova”), a Canadian cannabis retailer. The Company is deemed to control Nova for accounting purposes due to the level of its equity ownership interest and, consequently, Nova’s results are included in the financial statements of the Company with the interests not owned by the Company shown as non-controlling interest through equity.

39

The Alcanna Transaction consideration was comprised of:

(i)an aggregate $54.3 million cash ($1.50 in cash for each Alcanna common share), and

(ii)an aggregate 32.1 million SNDL common shares valued at $287.1 million based on the fair value of each common share of the Company on the closing date (0.885 of a SNDL common share for each Alcanna common share).

The Alcanna Transaction constituted a “significant acquisition” within the meaning of Canadian securities laws and the Company filed a business acquisition report under the Company’s profile on SEDAR in respect of the Alcanna Transaction on June 14, 2022.

Zenabis

On November 1, 2022, the Company announced that, in the context of proceedings pursuant to the Zenabis Group’s (as defined below) filing under the Companies’ Creditors Arrangement Act (“CCAA”), it had successfully acquired all of the assets of the business of the Zenabis Group, subject to certain exclusions, (the “Zenabis Business”), pursuant to an approval order of the Québec Superior Court (the “Quebec Court”).

The order of the Quebec Court approved the acquisition by a wholly owned subsidiary of SNDL of all issued and outstanding shares of Zenabis Ltd., a corporation resulting from the amalgamation of select Zenabis entities (collectively, the “Zenabis Group”), as part of the consideration for the senior secured debt of the Zenabis Group due to the SNDL subsidiary. Zenabis Ltd. owns all of the Zenabis Business, free and clear of any encumbrances except certain permitted encumbrances (namely the security of the wholly owned subsidiary of SNDL, which was preserved).

Valens

On August 22, 2022, the Company and Valens announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) pursuant to which the Company would acquire, subject to Valens’ shareholder approval and customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). Concurrently with the execution of the Valens Arrangement Agreement, the Company assumed Valens’ non-revolving term loan facility from its then-existing lender, and amended and restated the related credit agreement to provide for a $60.0 million non-revolving term loan facility with a maturity date of December 15, 2023 and an interest rate of 10% per annum (the “Valens Facility”). As Valens is now a wholly-owned subsidiary of the Company, the Valens Facility became inter-company debt following closing of the Valens Transaction. The Valens Transaction closed on January 17, 2023.

The Valens Transaction consideration was comprised of (i) the assumption of Valens’ $60 million non-revolving term loan facility from its then-existing lender as described above, and (ii) an aggregate 27.6 million SNDL common shares valued at $84.0 million based on the fair value of each common share of the Company on the closing date (0.3334 of a SNDL common share for each Valens common share).

Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and adult-use consumer segments. Valens also distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. Additionally, Valens manufactured, distributed and sold a wide range of CBD products in the United States through its subsidiary, Green Roads, Inc. (“Green Roads”), prior to the Valens Transaction. Green Roads filed for bankruptcy in the United States on March 6, 2023.

Superette

On February 7, 2023, the Company announced that, in the context of the Superette Group’s (as defined below) proceedings under the CCAA, it had successfully closed the Superette Transaction (as defined below) contemplated by the agreement of purchase and sale dated August 29, 2022 (as amended and restated on December 12, 2022) (the “APS”) and the approval and vesting order issued by the Ontario Superior Court of Justice (Commercial List) on December 20, 2022.

The Superette Group sells cannabis and non-cannabis branded merchandise and has furthered its market exposure and brand awareness through private-label cannabis offerings. Pursuant to the APS, certain of the Superette entities, including Superette Inc. and Superette Ontario Inc. (“Superette Ontario”) (collectively, the “Superette Group”), have sold their right, title and interest in (i) the five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand (the “Superette IP”); and (iii) the shares of Superette Ontario (collectively, the “Superette Transaction”).

Pursuant to applicable laws and regulatory considerations, SNDL directed that the shares of Superette Ontario be transferred to Spirit Leaf Ontario Inc. (“SLO”). SNDL has entered into an option agreement with SLO to purchase all of the issued and outstanding shares of Superette Ontario if certain conditions are met, including compliance with regulatory considerations. The retail locations and intellectual property rights were transferred to Superette Ontario to assist in operating the retail locations and the Superette IP was transferred to SNDL directly. Certain of the Superette IP is being licensed by SNDL to SLO to allow it to use the Superette brand in the retail locations.

40

Capital expenditures

Olds Facility

Capital expenditures in 2022 totaled $3.5. million and mainly related to machinery and equipment.

Capital expenditures in 2021 totaled $1.4 million and mainly related to infrastructure.

Capital expenditures in 2020 totaled $2.3 million and mainly related to buildings and infrastructure. The Olds Facility is complete and fully licensed for cannabis cultivation, processing and sale by Health Canada. In addition, the Company completed and operates a 20,000 square foot processing facility.

Merritt Facility

Our facility in Merritt, British Columbia (the “Merritt Facility”), which was intended to serve as the primary production facility of the Company’s BC Weed Co. brand, was sold in April 2022 for proceeds of $3.5 million.

There were no capital expenditures with respect to the Merritt Facility in 2022 or 2021.

Capital expenditures in 2020 were a recovery of $1.2 million relating to refunds of provincial hydro and utility deposits.

Clay Lake Facilities

Capital expenditures in 2020 totaled $4.4 million mainly related to the construction and development of the second phase of the facility in Clay Lake, prior to disposition of the entire facility as part of the Bridge Farm Disposition (see “Business dispositions—Bridge Farm” above).

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed herewith as Exhibit 15.1 for information about significant financing transactions.

B.Business overview.

Our Company

SNDL is a public company whose shares are traded on the Nasdaq under the symbol “SNDL”.

The principal activities of the Company are (i) the retailing of wines, beers and spirits under the Wine and Beyond, Liquor Depot and Ace Liquor retail banners, (ii) the operation and support of corporate owned and franchised retail cannabis stores in Canadian jurisdictions where the private sale of adult-use cannabis is permitted, under the Value Buds and Spiritleaf retail banners, (iii) the production, distribution and sale of cannabis in Canada pursuant to the Cannabis Act through a cannabis brand portfolio that includes Top Leaf, Sundial Cannabis, Palmetto, Spiritleaf Selects and Grasslands; and (iv) deployment of capital to direct and indirect investments and partnerships throughout the global cannabis industry. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult-use access in Canada.

The Company’s reportable segments are organized by business line and comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers and spirits through wholly owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through wholly owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use market and medical markets in Canada. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as “Corporate”.

Our Industry

Liquor

We are currently serving the liquor industry in Alberta and British Columbia, as a retailer of wines, beers and spirits. The supply and distribution of alcoholic beverages in Canada is regulated primarily by provincial legislation and is subject to policy changes that may positively or negatively impact our business, operations, financial condition, liquidity or results of operations. Regulations generally require, among other things, the licensing of retail store outlets, the separation of liquor from other types of products and a prohibition on sales to minors or intoxicated persons.

In Alberta, liquor retail sales are conducted by private industry only. In British Columbia, liquor retail sales are conducted by both private industry and provincial government-owned stores.

41

Adult-use Cannabis

We are currently serving the adult-use cannabis industry in Canada and abroad, as a cannabis producer, retailer, exporter and investor in other businesses in the global cannabis industry (directly or through our SunStream joint venture). In October 2018, Canada became the first major industrialized nation to legalize adult-use cannabis at the federal level. On October 17, 2019, the Canadian government has amended the Cannabis Regulations and Schedules to the Cannabis Act, to permit the production and sale of cannabis edibles, extracts and topicals by holders of federal licences specific for these product classes. Products in the new classes were made available for sale to provincially or territorially authorized distributors beginning in December 2019.

In 2022, we have also begun exporting dried cannabis flower products to Israel, in partnership with IM Cannabis Corp., and, following our business combination with Valens in January 2023, we have begun exporting medical cannabis products to Australia through Valens’ subsidiary, Valens Australia. We expect that additional countries will also legalize adult-use cannabis, creating the opportunity for us to serve the adult-use market in those other countries in the future, although we cannot predict whether or when this will occur.

CBD

In Canada, the updated Industrial Hemp Regulations (Canada) (the “IHR”) under the Cannabis Act replaced the previous form of the Industrial Hemp Regulations (Canada) under the Controlled Drugs and Substances Act (Canada) on October 17, 2018. The regulatory scheme for industrial hemp largely remains the same; however, the IHR permits the sale of hemp to federally licensed cannabis processors under certain circumstances, and licensing requirements were softened in accordance with the perceived lower risk posed by industrial hemp. The IHR defines industrial hemp as a cannabis plant, or any part of that plant, in which the concentration of THC is 0.3% by weight or less in the flowering heads and leaves. In Canada, cannabis products containing CBD are subject to the Cannabis Act and the Cannabis Regulations. Not every activity involving industrial hemp falls within the scope of the IHR. For example, the extraction of CBD or another phytocannabinoid from the flowering heads, leaves and branches of the plant falls under the Cannabis Regulations and requires a cannabis processing licence.

Furthermore, although we do not currently have plans to address the U.S. CBD market in the near term, U.S. federal legislation has legalized hemp-derived CBD products, subject to certain conditions, including compliance with state and federal regulations.

Our Liquor Retail Operations

Liquor retail operations are comprised of convenience-focused liquor stores and destination/large-format stores. Product selection throughout the various brands is tailored to each location. The Company operates its convenience format liquor stores in Alberta primarily under the brand names Liquor Depot and Ace Liquor. The Company operates its destination/large-format stores in Alberta and British Columbia under the brand name Wine and Beyond with a significantly expanded product selection compared to the convenience format stores.

Production and Services

The Company’s stores offer a large selection of wine, spirits, coolers, liqueurs, beer and specialty products. Product selection is individually tailored to store banners, neighbourhoods and formats. In convenience-focused stores, product selection varies between 1,000 and 4,000 wine, spirit, cooler and beer items, which management believes is a larger product selection and inventory than the industry average. The Wine and Beyond large-format “destination” stores offer over 10,000 items. New and preferred label varieties and products arrive at the Company’s stores throughout the year.

Specialized Skill and Knowledge

The Company strives to provide high-quality customer service through its employees who are highly knowledgeable in each liquor category to best serve the Company’s customers. Staff are trained to have strong product knowledge that is shared with customers. The Company endeavours to maintain product knowledgeable managers, assistant managers and line staff through frequent seminars and training.

Competitive Conditions

In all jurisdictions in which the Company operates, the liquor retail market is competitive and ownership of private liquor retail stores is fragmented. Grocery chains such as Real Canadian Superstore, Sobeys, Costco and Safeway Canada also compete in the Alberta liquor retail market.

Strategic markets

Management’s primary strategy is to focus on urban centres including the Calgary and Edmonton metropolitan areas. The Company believes that urban centres provide the best opportunities for larger per-store revenues and likelihood of population increases. While the Company’s focus is primarily on urban centres, it also has many stores in smaller urban centres where demographic and economic

42

conditions warrant. This includes communities with resource-based economies such as Fort McMurray, Alberta and Grand Prairie, Alberta.

Store locations

Our liquor retail business model is based on highly visible and accessible store locations. The Company endeavours to locate its liquor retail stores in areas where access to customers is maximized, such as near grocery stores or on main arteries in or near residential areas.

Store design and format

The Company generally designs its stores to optimize traffic flow and present its products in a welcoming environment.

Economies of scale

The Company’s leading market position and large-scale operations (relative to most other industry participants) provide it with a number of competitive advantages, including: the benefit of operating efficiencies relative to non-liquor expenses (including finance, marketing, human resources and corporate), and greater access to capital.

Cycles

The liquor retail industry is subject to seasonal variations and timing of holidays, relative to the Company’s interim periods. Historically, the Company’s sales have been lowest in the first quarter and increase each quarter thereafter, with the last quarter typically generating the highest sales due to the holiday season.

Economic Dependence

The Company is not substantially dependent on any individual retail liquor store, licence, or lease.

Our Cannabis Retail Operations

Retail operations comprise the private sale of adult-use cannabis through corporate-owned and franchised retail cannabis stores under the “Spiritleaf” retail banner. Spiritleaf aims to be the most knowledgeable and trusted source of adult-use cannabis by offering a premium consumer experience and quality curated cannabis products.

Since the legalization of adult-use cannabis on October 17, 2018, Inner Spirit has built a strategic portfolio of 105 corporate-owned and franchised Spiritleaf retail cannabis stores in five provinces across Canada. SNDL acquired Inner Spirit on July 20, 2021.

Spirit Leaf Corporate

The Company, through Spirit Leaf Corporate Inc. (“Spirit Leaf Corporate”), opens and operates corporate-owned Spiritleaf retail cannabis stores in strategic locations across Canada in jurisdictions where permitted.

The Company intends to continue to seek and secure leases of real estate locations for potential corporate Spiritleaf retail cannabis stores in jurisdictions where permitted.

Spirit Leaf operations

The Company, through Spirit Leaf Inc. (“Spirit Leaf”), supports a chain of franchised Spiritleaf branded retail cannabis stores in jurisdictions where permitted. In addition, Spiritleaf operates an online business through which it sells non-cannabis products (cannabis accessories and apparel) and allows consumers to arrange for pick-up of their orders in-store and through which it plans to, in the future, sell cannabis products, where permitted. A franchise partner of Spiritleaf operates an online store in the province of Saskatchewan, through which it sells cannabis products and accessories.

Production and Services

As a retailer, the Company, through Spirit Leaf Corporate, sells cannabis products, cannabis accessories and other products permitted to be sold in accordance with applicable regulatory frameworks. As a franchisor, the Company, through Spirit Leaf, sells fixtures to franchise partners prior to them opening their Spiritleaf retail cannabis stores, and once such stores open, its sells Spiritleaf cannabis accessories to them.

In general, the Company is only authorized to sell cannabis products purchased from an authorized provincial distributor and cannabis accessories and other items prescribed by the applicable provincial regulator.

43

Specialized Skill and Knowledge

All aspects of the Company’s retail operations, whether it is the operation of retail cannabis stores, the sale of cannabis and cannabis accessories, the sale of franchises, the ongoing support of franchisees or otherwise, require specialized skills and knowledge. Such skills and knowledge include, among other things, knowledge on franchising, cannabis, cannabis products and accessories, retail, real estate, consumer goods, customer service and the sale of adult-use cannabis in Canada.

Competitive Conditions

The private retail cannabis industry in Canada is very competitive, and the Company anticipates increased levels of competition in the industry as new participants enter the market and established retails consolidate. In anticipation of the Cannabis Act coming into effect on October 17, 2018, numerous parties sought and applied for licences to operate retail cannabis stores in jurisdictions where the private retail of cannabis was permitted. As certain jurisdictions moved to a private or semi-private market system for the retail of cannabis, and as regulators increased the aggregate number of licences available for issuance to private cannabis retailers and the pace at which such licences are issued, competition in the private retail cannabis industry continued to increase.

The principal aspects of competition include, among other things, obtaining retail cannabis store licences and regulatory approvals, the availability of cannabis products and cannabis accessories, securing optimal real estate locations and the ability to attract and retain key personnel and customers. The Company believes that its significant competitors are other entities seeking multiple retail cannabis store licences in multiple jurisdictions. It is also important to note that competition between retail cannabis stores is significantly geographical in nature, and the main competition Spiritleaf retail cannabis faces is from other retail cannabis outlets that are located in the same local geographical area and that serve the same consumer demographic.

The Company also faces competition from vertically integrated cannabis companies, existing retailers, government retailers, and the illegal market. The recent consolidation of retail companies in the market is also anticipated to increase competition in the industry, as larger consolidated companies generally have better access to capital and other necessary resources. Increased competition by numerous independent retail cannabis stores and larger competitors could materially and adversely affect the business, financial condition, and results of the Company.

In light of the strong competition in the industry, cannabis retailers are attempting to differentiate themselves from their competitors through retail cannabis store locations, their brands and their product offerings (through perceived quality, product variety and price). Retailers are using a variety of communication strategies to draw attention to these differentiators, including through social media, experiential marketing and traditional print and digital advertising, to the extent possible under the applicable regulatory frameworks.

To remain competitive, the Company and its subsidiaries will require a continued high level of investment in marketing, sales and client support. The Company believes that its product knowledge, experience operating retail outlets, and strategic partnerships with established companies in the cannabis industry, will allow it to offset some of the risks associated with any increased competition in the retail cannabis market.

The Company believes that the experience of management in both the retail and cannabis spaces has and will continue to be a competitive advantage in navigating the highly regulated marketplace.

Vertically integrated competitors

Certain competitors in the retail cannabis industry are also licensed producers that are able to produce the products sold at retail stores. Such companies are generally well capitalized and have an established operating history in Canada and may have significant scale and international operations. At the time of this Annual Report, vertically integrated companies are able to compete directly with the Company and its franchise partners in the Alberta and Saskatchewan markets. However, they are subject to regulatory operating restrictions in the major markets of British Columbia and Ontario that are likely to significantly limit their ability to compete directly with the Company and its franchise partners in those jurisdictions.

Existing retailers

These competitors generally have an existing business with some kind of retail footprint (in liquor sales, cannabis accessories sales, or otherwise) and have already entered or are potentially entering the private retail cannabis market as a growth opportunity. These competitors may also be well capitalized with established retail operations in Canada.

Government retailers

The Company and its franchise partners also face competition from government wholesalers that sell directly to consumers online such as the Ontario Cannabis Store in Ontario. In British Columbia, the Company’s franchise partners face additional direct competition from the government in the form of government-owned retail stores.

44

Illegal market

The Company and its franchise partners face significant competition from persons continuing to operate in the illegal cannabis market in Canada. Management believes that until there is sufficient private retail coverage, methods of engaging potential customers and types of products legally available to consumers, competition from the illicit market will remain significant.

Market Consolidation

It is anticipated that as the retail cannabis industry matures, competitors in the market will consolidate or acquire smaller operators to capitalize on cost synergies and increase their market share. To date, several of the Company’s competitors have increased their retail cannabis store counts and market share through consolidations or acquisitions, or are in the process of consolidating or making acquisitions.

Intangible Properties

The Company aims to be the most knowledgeable and trusted source of adult-use cannabis by offering a premium consumer experience and quality curated cannabis products. To achieve that, the Company focuses on associating its brand with high quality product selections and a customer-first experiences. The Company recognizes the importance of its retail brand on its success and its competitiveness in the retail cannabis industry, and the need to protect and enhance its value. In an effort to protect and expand its brand, the Company has applied for, or has received, Canadian trademark protections for certain of its marks. The Company has also applied for United States trademark protections for certain of its marks.

Seasonality

To date, the Spiritleaf retail cannabis store network has experienced marginal seasonality, with sales increasing in the summer months from May to August, as well as during the month of December.

Economic Dependence

The Company is not substantially dependent on any individual retail cannabis store, licence, or lease, but the maintenance of our licences and authorizations issued by provincial regulators, generally, is critical to the success of our retail business.

Our Cannabis Operations

SNDL currently produces and markets cannabis products for the Canadian adult-use market. The Cannabis Act provides provincial, territorial and municipal governments with the authority to prescribe regulations regarding retail and distribution of adult-use cannabis. As such, the distribution model for adult-use cannabis differs from province to province. Some provinces have government-run retailers, while others have government-licensed private retailers, and some have a combination of the two. All of the Company’s sales are conducted according to the applicable provincial and territorial legislation and through applicable local agencies. The Company has established supply agreements with ten Canadian provinces and has a distribution network that covers 98% of the national adult-use cannabis industry.

The Company’s primary focus in the cannabis operations segment has been on producing and distributing premium inhalable products and brands (flower, pre-rolls and vapes). Upon receiving a licence from Health Canada to sell cannabis oil products, the Company began the sale and distribution of cannabis vape products in December 2019.

The Company is currently marketing its adult-use products under its Top Leaf (Premium), Sundial Cannabis (Premium Core), Palmetto (Core) and Grasslands (Value) brands and intends to introduce new products under these brands as it expands its brand portfolio.

SNDL’s operations cultivate cannabis using an individualized “room” approach, in approximately 448,000 square feet of total available space in Olds and approximately 380,000 square feet of total space in Atholville. SNDL is headquartered in Calgary, Alberta, with operations in Olds, Alberta, and Atholville, New Brunswick.

Production and Services

Our purpose-built indoor modular grow rooms enable us to produce large volumes of cannabis in small batches. Our individual room-based cultivation format affords us several advantages compared to other growing methods, including optimized and customizable environments for each one of our strains, efficient scaling of our production capacity, higher and more predictable yields and real-time collection of cultivation data and multiple harvests per day. Different strains may have different harvest cycles and different harvest yields. Our modular cultivation rooms have been designed with the objective of improving our ability to learn, experiment and improve our cultivation process and end products. This approach also helps mitigate the risk of crop loss.

45

Specialized Skill and Knowledge

All aspects of the Company’s business require specialized skills and knowledge. The Company’s management is comprised of individuals with extensive experience and expertise in areas including, but not limited to, cultivation of cannabis, consumer packaged goods, product development, strategy, analytical testing and legal and regulatory compliance.

Specialized skills and knowledge are important to the Company’s success as it continues to evolve with the industry and grow its brands, and we continue to build on the skills and knowledge required within our organization to meet our goals.

Competitive conditions

The Company’s cannabis operations face enhanced competition from others who are licensed under the Cannabis Act and the various provincial and territorial regulatory regimes to participate in the adult-use cannabis industry. The Cannabis Act and the various provincial and territorial legislation have established licensing regimes for the cultivation, production, processing, testing, packaging, labelling, delivery, transportation, distribution, sale, possession and disposal of cannabis for adult use.

Pursuant to transitional provisions in the Cannabis Act, existing holders of medical cannabis licences under the Access to Cannabis for Medical Purposes Regulations have, subject to satisfying certain requirements, automatically been deemed licensed under the Cannabis Act for corresponding activities, and other individuals and corporations are now able to apply for such licences.

Subject to certain restrictions set out in the Cannabis Act, adults are permitted to cultivate, propagate, harvest and distribute up to four cannabis plants per household.

We expect that competition in the adult-use cannabis market and other cannabis markets in which we expect to participate will become more intense as current and future competitors begin to offer an increasing number of diversified products. To remain competitive, we will require a continued high level of investment in research and development, marketing, sales and client support.

We also face competition from the illicit cannabis market. Illegal dispensaries and ‘black market’ operations and participants, despite not having a valid licence under the Cannabis Regulations, command a significant percentage of the total market for cannabis and cannabis products in Canada.

In addition, the legal landscape for medical and adult-use cannabis is changing internationally. An increasing number of jurisdictions globally are passing laws that allow for the production and distribution of medical or adult-use cannabis. Increased international competition, including competition from suppliers in other countries who may be able to produce at lower cost, and limitations placed on us by Canadian or other regulations, might lower the demand for our products on a global scale.

Components

In the cultivation process, obtaining seeds for growing cannabis must be done in accordance with the Cannabis Act. Seeds can be obtained from Health Canada, imported from a jurisdiction for medical purposes, or acquired from another licence holder. An authorization from Health Canada may be required to conduct such a transaction depending on its nature.

Intangible Properties

The ownership, licensing and protection of trademarks and other intellectual property rights are significant aspects of our future success. Currently we rely on trade secrets, technical know-how and proprietary information. We protect our intellectual property by seeking and obtaining registered protection where possible, developing and implementing standard operating procedures to protect trade secrets, technical know-how and proprietary information and entering into agreements with parties that have access to our inventions, trade secrets, technical know-how and proprietary information, such as our partners, collaborators, employees and consultants, to protect confidentiality and ownership. We also seek to preserve the integrity and confidentiality of our inventions, trade secrets, trademarks, technical know-how and proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems.

Economic Dependence

The Company’s supply contracts with the various Canadian provinces are a critical element of the Company’s current revenues. If any larger Canadian provinces change the material terms of such agreement or otherwise alter the supply arrangement with the Company, such a change may have a material adverse effect on the Company’s revenue. See “Risk Factors — Risks Related to Cannabis Operations Segment — We currently sell, and expect to continue to sell, a significant share of our product to provincial governments through supply contracts that may not generate orders as expected or which may not be renewed.”

Our Investment and Financial Services Operations

The Company’s investment and financial services operations include the deployment of capital to investment opportunities targeting the global cannabis industry.

46

The Company invests in cannabis related equity instruments that are traded on public stock exchanges such as the Toronto Stock Exchange or Nasdaq. The Company may also deploy capital to cannabis-related debt and hybrid instruments targeting Canadian cannabis companies. In addition, the SunStream joint venture, in which the Company has an interest, provides financing and other financial services that target the global cannabis industry.

The Company’s investment committee is responsible for evaluating investment opportunities encompassing cannabis-related equity instruments that are traded on public stock exchanges and cannabis-related debt and hybrid instruments targeting the Canadian cannabis industry.

SunStream

On March 15, 2021, the Company and SAF Group announced they had entered into an agreement to form a 50/50 joint venture through a new corporation, SunStream. SunStream is a private company which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities.

On December 2, 2021, SunStream IVXX Investment Corp. (“SunStream IVXX”), an affiliate of SunStream, announced that it had submitted a draft registration statement on a confidential basis to the SEC for a proposed initial public offering of its common stock. SunStream IVXX will be a specialty finance company that operates as a closed-end, non-diversified management investment company that anticipates electing to be regulated as a business development company under the Investment Company Act of 1940.

In the United States, SunStream has provided lending services to cannabis businesses in the form of secured debt and hybrid debt and derivative instruments. SNDL, through its involvement in the SunStream joint venture, is classified as having indirect ancillary involvement in the U.S. marijuana industry as referenced in CSA Staff Notice 51-352, which states that ancillary involvement arises when an issuer provides goods and/or services not limited to financing, branding, recipes, leasing, consulting or administrative services to third parties who are directly involved in the U.S. marijuana industry.

Cannabis (or, as referred to in the United States, marijuana) is illegal under U.S. federal law and the enforcement of relevant U.S. laws poses a significant risk to the results of our operations and financial results. For further information about the risks related to U.S. federal laws and regulations with respect to SunStream’s operations, see “Item 3D. Risk Factors—Risks related to our investments—Cannabis remains illegal under U.S. federal law. Strict enforcement of federal laws regarding cannabis is a significant risk that would likely result in SunStream’s inability to execute its business plan and may subject us to significant civil or criminal liability and other adverse consequences”. The risk of federal enforcement and other risks associated with the Company’s business are described in “Item 3D—Risk Factors”.

The Company’s involvement in SunStream could have an undetermined impact on the Company’s ability to access both public and private capital.

The Company’s balance sheet exposure is limited to its equity-investment in SunStream of $519.3 million at December 31, 2022, and its share of loss of equity-accounted investees of $43.0 million for the year ended December 31, 2022.

Legal advice has been obtained by SunStream and the Company regarding applicable U.S. federal and state law in relation to SunStream’s business.

The Company is not aware of any of the businesses of recipients of SunStream services being in non-compliance with applicable licensing requirements and the regulatory framework enacted by the U.S. states in which they operate.

SunStream’s investment committee, which includes SNDL’s Chief Executive Officer, is responsible for evaluating investment and financing opportunities encompassing secured debt, hybrid securities and distressed debt and equity targeting the global cannabis industry.

Specialized Skill and Knowledge

All aspects of the Company’s investments require specialized skills and knowledge. The Company’s investment committee and SunStream’s investment committee are comprised of individuals with extensive experience and expertise in areas including, but not limited to, deal sourcing, investment management, client management, reporting and operational requirements, and cannabis operations.

Specialized skills and knowledge are important to the Company’s success as it continues to evolve its investments, and we continue to build on the skills and knowledge required within our organization to meet our financial goals.

Competitive Conditions

Since 2019, the equity capital availability to the Canadian cannabis sector has become increasingly selective and largely unobtainable for smaller licensed producers. This provides a significant opportunity to strategically invest in and consolidate smaller licensed producers with premium offerings and/or scalable intellectual property to attractive valuations.

47

Historically, many of the larger licensed producers were able to obtain asset-backed bank credit facilities secured by their cultivation assets. However, the slower than expected ramp up of Canadian national sales caused the banks to significantly reduce their exposure through 2019 and 2020. Bank appetite remains tepid at best for the largest licensed producers and current outstanding credit facilities generally have burdensome covenant packages despite many borrowers having net-cash positions.

The global legal cannabis market is expected to grow substantially over the next few years as public sentiment continues to drive legalization worldwide. Market growth will require an immense amount of capital at a time when regulatory hurdles have sidelined many traditional sources of capital, such as banks and private equity. This has created opportunities to generate attractive risk adjusted returns for investors in Canada, the United States and internationally.

Foreign Operations

The investments segment is dependent upon foreign operations as the majority of the investments through the SunStream joint venture are outside of Canada.

Investing

Policy and Objectives

General – The overall objective of the Company’s investment policy is to protect or enhance funds flow and shareholder value consistent with the Company’s business plan. The policy applies to the investment of all cash, short-term and long-term financial assets of the Company.

Return on Investment – The Company’s investment activities shall be constructed with the objective of attaining a rate of return while meeting the above objectives.

Capital Preservation – Preservation of capital is a primary objective of the Company’s investment activities. Investments shall be undertaken in a manner that seeks to ensure the preservation of capital, while managing market risk, credit risk and interest rate risk.

Liquidity – Investments shall remain sufficiently liquid in order to meet all reasonably anticipated operating capital requirements.

Standard of Care – Investments shall be made with judgement and care, under circumstances then prevailing, which persons of prudence, discretion and intelligence would exercise.

Ethics and Conflicts of Interest – Officers and employees involved with the investment process shall refrain from personal business activity that could conflict with proper execution and management of the investment program or impair their ability to make impartial investment decisions. Any such personal business activity shall require proper disclosures to the chief executive officer and chief financial officer and to the audit committee in case of a material investment.

Permitted Investment Activities

The following types of investment activities are expressly permitted subject to board of director approved investment activities and limits under which an investment activity may be conducted:

•Investments in cash

•Equity investments

•Debt investments

•Investments in shares, warrants or other equities, convertible debt securities, derivatives, swaps, options or futures

•Other investments, subject to board approval

Regulatory Framework in Canada

Alberta Liquor Industry

The Alberta Liquor Retail Regulatory Environment

Alberta is the only Canadian province with a fully privatized liquor retail industry.

The AGLC regulates the liquor retail business pursuant to the Gaming, Liquor and Cannabis Act (Alberta) (“GLCA”) and the Gaming, Liquor and Cannabis Regulation (“GLCR”). Licenses to operate liquor retail stores must be renewed annually and are issued by the AGLC. The GLCA does not restrict the total number of outlets or the areas where they may be located. Specific store locations, however, may be subject to regulation through local and municipal by-laws and zoning requirements. AGLC inspectors regularly conduct inspections of liquor stores to ensure operations are in compliance with licensing requirements.

48

Alberta Liquor Store Operations

Liquor store operations in Alberta are free to set their own retail prices, including selling at or below the wholesale cost, and may adjust prices based on the customer, the amount of the sale or any other factor determined relevant by the store operator.

In addition to selling alcoholic beverages, liquor stores may also sell certain related items, such as soft drinks and other drink mixes, ice, de-alcoholized beverages, glassware and other accessories, although the sale of such items may not exceed ten percent (10%) of total sales. Liquor stores may sell liquor to other liquor stores, other licensed premises (e.g., lounges, restaurants, pubs, taverns, etc.) and special event license holders. Liquor stores may also sell special event licenses for private functions and may provide delivery service. A liquor store in Alberta must either be a freestanding building or, if it is in a building in which there are other businesses, it must have its own entrance and exit, its own receiving and storage area, and a wall between the liquor store and any other business. A liquor store cannot be operated within the same commercial development as an existing non-liquor store business owned by the licensee if the existing business is larger than 929 square meters (10,000 square feet) unless certain requirements are met, including a separate building envelope. In that case, the premises for the liquor store must be physically separated and subject to approval by the AGLC.

A person may own more than one liquor store and/or other certain licensed premises, and operate them under the same or different names. While liquor stores must normally store their own liquor products on site, the AGLC may approve a separate warehouse to enable a liquor retail store licensee to serve multiple liquor stores operated by the licensee. Liquor manufacturers or agents for manufacturers may not hold licenses in liquor stores (subject to certain exceptions for off sales).

Alberta Liquor Supply

The AGLC is the sole importer of liquor products into Alberta. Liquor stores must purchase liquor products at wholesale prices through the AGLC warehouse, from a manufacturer authorized by the AGLC to warehouse and distribute liquor products, or from other liquor stores. A number of domestic beers may be purchased from the AGLC by placing orders with the respective brewery. Breweries may set minimum order quantities for delivery service. Liquor stores are required to pay for products ordered before they are released from the warehouse.

The Company obtains wine, spirits and imported beer from Connect Logistics Services Inc. (“CLS”), which operates from its main warehouse in St. Albert, Alberta and carries approximately 19,000 products. We obtain domestic beer from the three other licensed Alberta warehouse companies: (i) Brewers Distributor Ltd., which warehouses and distributes beer products for Molson Canada and Labatt Brewing Company Limited in Edmonton and Calgary; (ii) Big Rock Breweries Inc., which distributes its products from its brewery/warehouse in Calgary; and (iii) Sleeman Breweries Ltd., which warehouses and distributes its products from a warehouse in Calgary.

The AGLC operates a consignment system of inventory management, where the ordering, consolidation, shipment and ownership of inventory are the responsibility of the manufacturers and/or agents representing the manufacturers. In order to import liquor into Alberta, manufacturers must use a liquor agent registered with the AGLC. Manufacturers and/or their agents determine which products will be sold in Alberta and are responsible for promoting and marketing their products to retailers.

Alberta Liquor Wholesale and Delivery Pricing Systems

The AGLC requires that there be one wholesale price quoted for each product and prohibits individual retailers from negotiating discounts with liquor suppliers. Supplier price changes are permitted on a biweekly basis. Approximately every two to four months, licensed manufacturers offer discounts through limited time offers (“LTO”), primarily on spirits and wine. The Company achieves savings and obtains a competitive advantage over competitors by using its cash flow and warehousing capabilities to purchase larger volumes at the discounted LTO prices and managing inventories to maintain stock until the next LTO, a practice known as “bridge buying”.

The AGLC imposes a flat mark-up that is added to the supplier’s quoted price and is levied in dollars per litre and varies by product class. The warehouse storage, handling, order processing and distribution charges are paid to the warehouse operator.

Wholesale prices for products shipped from CLS’ warehouse are available when the order is a minimum of 25 cases. Customers must also pay order processing and distribution charges based on: (i) delivery schedule (urgent or regular); (ii) pickup or delivery; and (iii) the number of cases ordered. Suppliers are charged for warehouse handling and storage. Wholesale prices are also available for beer purchased directly from a number of Alberta breweries that brew, warehouse and distribute their own products to retailers. The individual breweries set minimum order quantities. The AGLC collects the wholesale price from the purchaser and, in turn, remits to the brewer its portion of the wholesale price.

A “postage stamp” delivery system applies for the delivery of liquor products from the warehouse, which means that the delivery charge per case shipped from CLS’ warehouse is the same no matter where in Alberta the receiving store is located. A similar system exists for purchases of beer from certain beer manufacturers that are licensed to operate warehouses in Alberta.

49

Alberta Liquor Advertising and Promotion

Advertising is permitted in any medium, but is subject to restrictions imposed by advertising policy guidelines contained in the terms and conditions of the licenses issued by the AGLC as well as by the Canadian Radio-Television Telecommunications Commission (“CRTC”). The common owner/operator of a liquor store and another non-liquor business may not conduct cross-market or co-operative advertising or promotions between the liquor store and the other business or company but can if not commonly owned. There are further limits on co-operative advertising between a liquor store and affiliated non-liquor business or a liquor store and a manufacturer. The consequence of this rule is that liquor retailers who are owned by grocers cannot cross market. Notwithstanding the foregoing, effective July 15, 2020, the GLCR was amended to allow liquor store operators who own or operate another business to maintain a customer loyalty program that recognizes purchases made in each of the businesses. The practical result is that liquor retailers who are owned by grocers can now offer their customers loyalty rewards, at their grocery stores and their liquor stores, and make them redeemable at both businesses.

Subject to restrictions in the advertising policy guidelines contained in the terms and conditions of the licenses issued by the AGLC, liquor stores are permitted to promote specific brands of liquor within their stores by such means as in-store tastings, displaying brand posters or banners, giving away small value items with brand logos and holding contests.

Generally, a liquor store may give away merchandise it otherwise is not permitted to sell, other than liquor or food, to promote the store, provided the merchandise identifies the store and is not given to the store by suppliers. A liquor store may give away merchandise it is permitted to sell, with or without store identification. Suppliers’ promotional activities must be directed to store customers and may not benefit the store owner directly.

British Columbia Liquor Industry

The British Columbia Liquor Retail Regulatory Environment

The Province of British Columbia regulates the importation, distribution and retailing of liquor through the Liquor Control and Licensing Act (British Columbia) and the Liquor Distribution Act (British Columbia). The Liquor and Cannabis Regulation Branch enforces the Liquor Control and Licensing Act and the BCLDB enforces the Liquor Distribution Act (British Columbia). Liquor store licences may only be issued to residents of British Columbia who normally reside in the province, which includes a corporation whose agent or manager is a resident of, and normally resides in, the province.

In November of 2007, the Province of British Columbia extended indefinitely a moratorium initially imposed in 2002 on new retail liquor store licences. Anyone wishing to enter the market must acquire a licence from an existing private operator. As a result, the number of private industry stores, government-owned stores and independent wine stores has remained relatively stable at approximately 871 stores since then.

British Columbia Liquor Store Operations

In British Columbia, privately-owned retail liquor stores may set their own prices for products, subject to the minimum price for each product established by the BCLDB. All government-owned liquor stores and rural agency stores charge an identical price for the same product throughout the province, and all government-owned, private and rural, liquor stores pay the same wholesale price for alcohol. The wholesale pricing model provides that “licensed retail stores” and government-owned liquor stores purchase product from the government wholesaler at the same price.

In addition to beer, wine, cider, coolers, liqueurs and spirits, a privately-owned retail liquor store may sell liquor-related items such as glasses, bottle openers and corkscrews and, in most cases, other goods such as soft drinks and other drink mixes, tobacco, confectionary goods and British Columbia lottery tickets.

If a privately-owned retail liquor store is located on the same property as a primary liquor establishment, the two establishments may share a common lobby but must have full-height walls between them and separate entrances. If a privately-owned retail liquor store is not located on the same property as the primary establishment, it may not appear to be part of any other business in close proximity to it. Customers must enter the retail liquor store via a public thoroughfare such as a street or mall entrance and not through any other business.

The regulatory regime in British Columbia permits limited alcohol sales from grocery stores; either: (i) with a retail liquor store licence as a “store within a store”; or (ii) the sale of wine on dedicated shelf space within a licensed grocery store.

Licensees are permitted to store liquor in secure, off-site locations, subject to approval of the regulator.

British Columbia Liquor Supply

Licensed liquor retailers purchase most of their products from the BCLDB, the sole importer of liquor products into British Columbia. Private liquor retailers are also able to purchase British Columbia wine directly from the wineries and to purchase domestic beer from Brewers Distributor Ltd. Privately-owned retail liquor stores must purchase all other liquor products directly from the BCLDB. The

50

BCLDB sources and purchases products from suppliers and manufacturers in British Columbia and in other provinces and countries, and distributes sourced products through distribution centers in Vancouver and Kamloops.

British Columbia Liquor Wholesale Pricing

In British Columbia, public and private liquor retailers purchase liquor products from the government wholesaler at the same price. Liquor retailers, including government-owned liquor stores, purchase their product from the BCLDB at a common wholesale price. Previously, different retailers operated with different discounts based off the government-owned liquor stores’ display price.

The BCLDB offers month-long LTOs and three-month long temporary price reductions with a limited time frame to purchase. As in Alberta, the Company strives to achieve savings by purchasing larger volumes at the discounted prices and managing inventories to maintain stock until the next discount.

British Columbia Liquor Advertising and Promotion

Advertising is permitted subject to restrictions imposed by advertising policy guidelines under the Liquor Control and Licensing Act (British Columbia) and the CRTC. Liquor advertising may include the prices and brands of liquor available (including pricing specials) and licensees may enter into agreements with liquor manufacturers to promote and feature their products. Advertisements that encourage intoxication or target minors are prohibited, among other rules.

Canadian Cannabis Industry

Background to the Cannabis Act and Regulations

On December 13, 2016, the Task Force on Cannabis Legalization and Regulation, which was established by the Canadian federal government to seek input on the design of a new system to legalize, regulate and restrict access to cannabis, published its report outlining its recommendations. On April 13, 2017, the Canadian federal government released Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, which proposed the enactment of the Cannabis Act to regulate the production, distribution and sale of cannabis for unqualified adult use.

On October 17, 2018, the Cannabis Act, together with its accompanying regulations, including the Cannabis Regulations and the IHR and, together with the Cannabis Regulations (the “Regulations”) came into force. The Regulations, among other things, outline the rules for the legal cultivation, processing, research, testing, distribution, sale, importation and exportation of cannabis in Canada, including the various classes of licences that can be granted, and set standards for cannabis products.

Pursuant to the regulatory framework, each province and territory in Canada is also permitted to adopt its own laws governing the distribution, sale and consumption of cannabis and cannabis accessory products within the province or territory. See “— Provincial and Territorial Regulatory Framework for Adult-Use Cannabis” below.

Given that the Cannabis Act and the Regulations were only recently enacted and are still developing, the impact of the regulatory framework on our business is uncertain. See “Risk Factors — Risks Related to Cannabis Regulation and Legal Proceedings”. Cannabis for adult use only recently became legal in Canada. As a result, the industry and the regulations governing the industry are rapidly developing, and if they develop in ways that differ from our expectations, our business and results of operations may be adversely impacted.

Adult-Use Cannabis

The Cannabis Act provides a licensing and permitting scheme for the cultivation, processing, research, testing, distribution, sale, importation and exportation of cannabis for non-medicinal use (i.e., adult use), that were implemented by regulations promulgated under the Cannabis Act.

In particular, among other things, the Cannabis Act:

•Restricts the amounts of cannabis that individuals can possess and distribute, public consumption and use, and prohibits the sale of cannabis unless authorized by the Cannabis Act.

•Permits individuals who are 18 years of age or older to cultivate, propagate, and harvest up to and including four cannabis plants in their dwelling-house, propagated from a seed or plant material authorized by the Cannabis Act.

•Restricts (but does not strictly prohibit) the promotion and display of cannabis, cannabis accessories and services related to cannabinoids to consumers, including restrictions on branding and a prohibition on false or misleading promotion and on sponsorships.

•Permits the informational promotion of cannabis by entities licensed to produce, sell or distribute cannabis in specified circumstances to individuals 18 years and older.

•Introduces packaging and labelling requirements for cannabis and cannabis accessories and prohibits the sale of cannabis or cannabis accessories that could be appealing to young persons.

51

•Provides the designated minister with the power to recall any cannabis or class of cannabis on reasonable grounds that such a recall is necessary to protect public health or public safety.

•Permits the establishment of a national cannabis tracking system.

•Provides powers to inspectors for the purpose of administering and enforcing the Cannabis Act and a system for administrative monetary penalties.

Cannabis for Medical Purposes

Effective October 17, 2018, the Cannabis Act and the Cannabis Regulations replaced the CDSA’s Access to Cannabis for Medical Purposes Regulations (Canada) (the “ACMPR”), as the governing regulations in respect of the production, sale and distribution of medical cannabis and related oil products in Canada. Transitional provisions of the Cannabis Act provide that every licence to produce and sell cannabis issued under the ACMPR that was in force immediately before the day on which the Cannabis Act came into force was deemed to be a licence issued under the Cannabis Act, and that such licence will continue in force until it is revoked or expires.

Part 14 of the Cannabis Regulations set out the regime for medical cannabis following legalization, which is substantively the same as the ACMPR with adjustments to create consistency with rules for non-medical use, improve patient access, and reduce the risk of abuse within the medical access system. Patients who have the authorization of their healthcare provider continue to have access to cannabis under the Cannabis Act and Cannabis Regulations, either purchased directly from a federally licensed entity under the Cannabis Act and the Cannabis Regulations, or by registering to produce a limited amount of cannabis for their own medical purposes or designating someone to produce cannabis for them in the manner prescribed.

Licences, Permits and Authorizations

The Cannabis Regulations establish six classes of licences:

•licence for cultivation;

•licence for processing;

•licence for analytical testing;

•licence for sale;

•licence for research; and

•a cannabis drug licence.

The Cannabis Regulations also create sub-classes for cultivation licences (standard cultivation, micro-cultivation and nursery) and processing licences (standard processing and micro-processing). Different licences, and each sub-class therein, carry differing rules and requirements that are intended to be proportional to the public health and safety risks posed by each licence category and each sub-class. Producers holding production and sales licences under the ACMPR were transferred to similar licences under the Cannabis Act. Licences issued under the Cannabis Regulations have associated expiry dates and are subject to renewal requirements.

As of May 8, 2019, Health Canada required that new applicants for cannabis licences under the Cannabis Act have a fully built site that meets all requirements of the Cannabis Regulations at the time of their application.

Security Clearances

Certain people associated with cannabis licensees, including individuals occupying “key positions”, such as directors, officers, individuals who exercise, or are in a position to exercise, direct control over the corporation licensee, and individuals identified by the Canadian Federal Minister of Health (the “Minister of Health”), must hold a valid security clearance issued by the Minister of Health. Under the Cannabis Regulations, the Minister of Health may refuse to grant security clearances to individuals with associations to organized crime or with past convictions for, or an association with, drug trafficking, corruption or violent offences. Individuals who have histories of nonviolent, lower-risk criminal activity (for example, simple possession of cannabis, or small-scale cultivation of cannabis plants) are not precluded from participating in the legal cannabis industry. However, grant of security clearance to such individuals is at the discretion of the Minister of Health and such applications will be reviewed on a case-by-case basis.

As at December 31, 2022, all of our directors and executive officers have obtained security clearance from Health Canada. Failure by an individual in a key operational position to maintain or renew his or her security clearance could result in a reduction or complete suspension of our operations. See “Risk Factors — Risks Related to Our Employees, Partners and Third Parties — Our success is dependent on our ability to attract or retain key personnel”.

Cannabis Tracking System

Under the Cannabis Act, the Minister of Health is authorized to establish and maintain a national cannabis tracking system. The purpose of this system is to track cannabis throughout the supply chain, to help prevent cannabis from being diverted to an illicit market or

52

activity and to help prevent illicit cannabis from being a source of supply of cannabis in the legal market. Pursuant to the Ministry of Health’s Cannabis Tracking System Order, holders of a federal licence for cultivation, a licence for processing or a licence for sale for medical purposes that authorizes the possession of cannabis, must report monthly to the Minister of Health with specific information about their authorized activities with cannabis (e.g. cannabis inventory quantities), in the form and manner specified by the Minister of Health. The order also provides for monthly reporting by provincial bodies and provincially authorized private retailers of certain information in the form and manner specified by the Minister of Health.

Cannabis Products

The Cannabis Regulations set out the requirements for the sale of cannabis products at the retail level, including the THC content and serving size of cannabis products and cannabis products containing CBD. As of October 17, 2019, the Cannabis Act and the Cannabis Regulations permit the sale, subject to certain transitional periods, of only dried cannabis, fresh cannabis, edible cannabis, cannabis extracts, cannabis topicals, cannabis plants and cannabis plant seeds, each as defined in the Cannabis Act.

Prior to the coming-into-effect of the amended forms of the Cannabis Act and Cannabis Regulations, which occurred on October 17, 2019, the Cannabis Act only permitted the sale of dried cannabis, cannabis oil, fresh cannabis, cannabis plants and cannabis plant seeds. The amended forms of the Cannabis Act and Cannabis Regulations (i) remove cannabis oil from the list of permitted classes of cannabis products and (ii) authorize and regulate the production and sale of edible cannabis, cannabis extracts and cannabis topicals.

The amended forms of the Cannabis Act and Cannabis Regulations introduced restrictions on product composition specific to each of edible cannabis, cannabis extracts and cannabis topicals, including specific THC limits. Examples of other class-specific restrictions include:

•Edible cannabis: must be shelf stable; only food and food additives will be allowed to be used as ingredients in edible cannabis and the use of food additives will need to be in accordance with the limits and purposes that are prescribed for foods; must not have caffeine added, however the use of ingredients containing naturally occurring caffeine will be permitted in edible cannabis products provided that the total amount of caffeine in each immediate container does not exceed 30 milligrams; must not contain alcohol in excess of 0.5% w/w; must not contain anything that would cause the sale of the edible cannabis, if it was a food regulated under the Food and Drugs Act (Canada), to be prohibited and must not be fortified with vitamins or mineral nutrients.

•Cannabis extracts: must not contain ingredients that are sugars, sweeteners or sweetening agents, nor any ingredient listed on Column 1 of Schedule 2 to the Tobacco and Vaping Products Act (Canada) (which is a list of ingredients that are prohibited in vaping products) except if those ingredients and their levels are naturally occurring in an ingredient used to produce the extract.

•Cannabis topicals: must not contain anything that may cause injury to the health of the consumer when the product is used as intended or in a reasonably foreseeable way.

As is the case for cannabis oil, a processing licence is required in order to legally produce edible cannabis, cannabis extracts and cannabis topicals. Though a processing licence is required in order to package and label all types of cannabis products for sale to consumers. Holders of processing licences issued prior to October 17, 2019, were required to amend their processing licences before they could begin manufacturing products constituting edible cannabis, cannabis extracts or cannabis topicals. The Cannabis Regulations require the filing of a notice with Health Canada at least 60 days before releasing a new cannabis product to the market. As a result, mid-December 2019, was the earliest date that any products constituting edible cannabis, cannabis extracts or cannabis topicals could be made available for sale to consumers.

In addition, if a holder of a processing licence chooses to process edible cannabis and food products on the same site, then the production, packaging, labelling, and storage of cannabis and the production, packaging, and labelling of food products must be conducted in distinctly separate portions of the holder’s licensed facility. All cannabis production is required to occur in a sufficiently separate area from any food production.

Packaging, Labeling and Advertising

The Cannabis Regulations set out requirements pertaining to the packaging and labelling of cannabis products. These requirements are intended to promote informed consumer choice and allow for the safe handling and transportation of cannabis, while also reducing the appeal of cannabis to youth. The Cannabis Regulations require all cannabis products to be packaged in a manner that is tamper-proof and child resistant.

Limits are also imposed on the use of colors, graphics, and other special characteristics of packaging. For example, all-over packaging wraps must be clear, and the interior surface and exterior surface of any container in which a cannabis product is packaged must be one uniform color. Cannabis package labels must include specific information, such as (i) product source information, including brand name, the class of cannabis and the name, phone number and email of the licensed processor or cultivator, (ii) mandatory warnings, including rotating health warning messages on Health Canada’s list of standard health warnings; (iii) the Health Canada standardized cannabis symbol; and (iv) information specifying THC and CBD content. Amendments to the Cannabis Regulations effective as of October 17, 2019, impose additional packaging and labelling requirements for all classes of cannabis.

53

Promotion of cannabis is strictly regulated in Canada. For example, promotion is largely restricted to be implemented in a limited number of prescribed manners (e.g., at the point of sale) and is subject to prescribed conditions set out in the Cannabis Act and the Cannabis Regulations. Also, among other restrictions, the Cannabis Act prohibits testimonials and endorsements, lifestyle branding, depictions of a person, character or animal, whether real or fictional, and promotion that is appealing to young persons.

Import and Export Permits for Medical or Scientific Purposes

Pursuant to the Cannabis Act, import and export licences and permits will only be issued for medical or scientific purposes, or for industrial hemp. The Cannabis Regulations set out the process by which a licence holder may apply for an import or export permit for medical or scientific purposes. A permit must be obtained for each shipment of cannabis. An application for an import or export permit must contain specific information including the name and address of the holder, licence number and specifics of the particular shipment including the intended use of the cannabis and specific shipment details. The Cannabis Regulations contain reporting requirements in respect of the import and export of cannabis in reliance on a permit issued under the Cannabis Regulations.

Provincial and Territorial Regulatory Framework for Adult-Use Cannabis

Pursuant to the regulatory framework, each province and territory in Canada is also permitted to adopt its own laws governing the distribution, sale and consumption of adult-use cannabis and cannabis accessory products within the province or territory. As a result, provincial and territorial governments may choose to set lower maximum permitted quantities for individuals and higher age requirements. Currently, each of the Canadian provincial and territorial jurisdictions has established a minimum age of 19 years old for the consumption of adult-use cannabis, except for Québec and Alberta, where the minimum age is 21 and 18, respectively.

Retail-distribution models vary nationwide from one province and territory to another. All Canadian provinces and territories have implemented mechanisms for the distribution and sale of cannabis for adult-use purposes within their jurisdictions. Quebec, New Brunswick, Nova Scotia and Prince Edward Island have adopted government-run models for retail and distribution. Ontario, British Columbia, Alberta, Manitoba and Newfoundland have adopted hybrid models, with some aspects, including stores, distribution and /or online retail being government-run, (subject to certain exceptions for private online sales), while allowing for private retail. Saskatchewan has implemented a private retail system. Yukon, Northwest Territories and Nunavut have adopted a model that resembles their government-run liquor distribution model. However, New Brunswick has introduced plans to incorporate privately owned cannabis retail stores into its permitted distribution model. As the laws continue to evolve, and the distribution models mature, there is no assurance that provincial and territorial legislation enacted for the purpose of regulating adult-use cannabis will remain the same or otherwise continue to allow, or be conducive to, our business model. Differences and changes in provincial and territorial regulatory frameworks could result in, among other things, increased compliance and supply costs.

Municipal and regional governments may also choose to impose additional requirements and regulations on the sale of adult-use cannabis, adding further uncertainty and risk to our business. Municipal by-laws may restrict the number of adult-use cannabis retail outlets that are permitted in a certain geographical area, or restrict the geographical locations wherein such retail outlets may be opened. See “Risk Factors — Risks Related to Cannabis Regulation and Legal Proceedings — Any failure on our part to comply with applicable regulations could prevent us from being able to carry on our business, and there may be additional costs associated with any such failure.”

As of the date of this Annual Report, we believe we are in compliance in all material respects with the Cannabis Act and the Regulations, and all other applicable Canadian federal and provincial laws and regulatory requirements relating to cannabis, with the exception of obtaining security clearance from Health Canada for certain of our executive officers and directors, which we are working to obtain. In addition, our directors, officers and certain other key employees are subject to security regulations due to the nature of our industry, which may make it more difficult for us to attract, develop and retain talent. See “Risk Factors — Risks Related to Our Employees, Partners and Third Parties — Our success is dependent on our ability to attract or retain key personnel.”

54

C.Organizational structure.

Below, and attached as Exhibit 8.1 to this Annual Report, is the list of our subsidiaries as at December 31, 2022, each of which is directly or indirectly wholly-owned by SNDL unless otherwise indicated.

Subsidiaries	Principal activity	Jurisdiction of incorporation	Equity ownership			Non-controlling interest ("NCI")
KamCan Products Inc.	Inactive	British Columbia, Canada		100	%		0	%
Sundial Deutschland GmbH	Inactive	Germany		100	%		0	%
2657408 Ontario Inc.	Operations	Ontario, Canada		100	%		0	%
NGBA-BC Holdings Ltd.	Operations	British Columbia, Canada		100	%		0	%
Sundial Insurance (Bermuda) Ltd.	Operations	Bermuda		100	%		0	%
Inner Spirit Holdings Ltd.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Corporate Inc.	Operations	Alberta, Canada		100	%		0	%
Spirit Leaf Ontario Inc. (1)	Operations	Ontario, Canada		0	%		100	%
Zenabis Ltd.	Operations	Alberta, Canada		100	%		0	%
Alcanna Inc.	Operations	Canada		100	%		0	%
Liquor Stores GP Inc.	Operations	Alberta, Canada		100	%		0	%
Liquor Stores Limited Partnership	Operations	Alberta, Canada		100	%		0	%
Canadian Liquor Retailers Alliance GP Inc.	Operations	Alberta, Canada		100	%		0	%
Nova Cannabis Inc.	Operations	Alberta, Canada		63	%		37	%
Nova Cannabis Stores GP Inc.	Operations	Alberta, Canada		63	%		37	%
Nova Cannabis Stores Limited Partnership	Operations	Alberta, Canada		63	%		37	%
Nova Cannabis Analytics GP Inc.	Operations	Alberta, Canada		63	%		37	%
Nova Cannabis Analytics Limited Partnership	Operations	Alberta, Canada		63	%		37	%
Alcanna Cannabis Stores Finance Ltd.	Operations	Alberta, Canada		63	%		37	%
YSS SK Cannabis Inc.	Operations	Alberta, Canada		63	%		37	%
2472573 Alberta Inc.	Operations	Alberta, Canada		63	%		37	%
Sweet Tree Modern Apothecary Ltd.	Operations	Alberta, Canada		63	%		37	%
YSS Cannabis Corp.	Operations	Alberta, Canada		63	%		37	%
2102012 Alberta Ltd.	Operations	Alberta, Canada		63	%		37	%

(1)This entity may be considered to be “controlled” by the Company solely for the purposes of IFRS, but the entity is not controlled by the Company within the meaning of applicable corporate law. For the purposes of IFRS, control of this entity is determined by the Company being exposed to variable returns and having the ability to affect those returns through its power over the entity.

D.Property, plants and equipment.

Information regarding our material tangible fixed assets is as follows:

	Olds, Alberta		Atholville, New Brunswick		Kelowna, British Columbia		Kelowna, British Columbia		Bolton, Ontario
Format	Indoor Modular		Indoor		Indoor		Indoor		Indoor
Primary Purpose	Cultivation and Extraction		Cultivation and Extraction		Extraction and Manufacturing		Manufacturing		Manufacturing
Capital expenditures to December 31, 2022	$186.5 million		$nil		N/A		N/A		N/A
Facility size at December 31, 2022 (Sq. Ft.)		448,000		380,000		74,000		7,800		32,000
Production Capacity at December 31, 2022	71 million grams		46 million grams		18 million units		3 million units		7 million units
Utilized Capacity at December 31, 2022	36 million grams		9 million grams		12 million units		1 million units		1 million units

During the year ended December 31, 2022, the Company disposed of its Rocky View facility for proceeds of $3.9 million.

55

Retail Operations

All of the corporate-owned and franchised Spiritleaf retail cannabis stores are operated from leased premises. The terms of the leases may vary from location to location, but the Company and its franchise partners typically aim for a lease term of five years, with an option for at least one subsequent renewal for a further five years.

The Company has a real estate development team and custom mapping software, along with relationships and leases with most major landlords across Canada. It uses the data from over 70 operating locations to help identify variables that make for an ideal location.

Item 4A. Unresolved Staff Comments

None.

Item 5. Operating and Financial Review and Prospects

A.Operating Results

Refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1 filed herewith for a discussion of our financial condition and results of operations as of and for the year ended December 31, 2022 as compared to the year ended December 31, 2021.

A discussion of our financial condition and results of operations as of and for the year ended December 31, 2021 as compared to the year ended December 31, 2020 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed as Exhibit 15.1 to our annual report on form 20-F for the year ended December 31, 2021, filed with the SEC on April 28, 2022.

B.Liquidity and Capital Resources

For a discussion of liquidity and capital resources as of and for the year ended December 31, 2022 as compared to December 31, 2021, refer to the sections entitled “Cash Flow Summary” and “Liquidity and Capital Resources” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1

A discussion of liquidity and capital resources as of and for the year ended December 31, 2021 as compared to December 31, 2020, can be found in the sections entitled “Cash Flow Summary” and “Liquidity and Capital Resources” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” filed as Exhibit 15.1 to our annual report on form 20-F for the year ended December 31, 2021, filed with the SEC on April 28, 2022.

C.Research and Development, Patents and Licences, etc.

See “Item 4.B—Business Overview” above.

D.Trend Information

See “Item 4.B—Business Overview—Our Industry” and the section entitled “Strategy & Outlook” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

E.Off-Balance Sheet Arrangements

None.

56

Item 6. Directors, Senior Management and Employees

A.Directors and senior management.

The following table sets forth certain information regarding our directors and executive officers as of the date of this Annual Report. The terms of office of each of our directors expires on the date of the next annual meeting of our shareholders. The business address for our directors and executive officers is c/o SNDL Inc., #300, 919 – 11 Avenue SW, Calgary, Alberta, Canada T2R 1P3.

Name, Province or State and Country of Residence	Age	Position/Title
Zachary George	45	Chief Executive Officer and Director
Connecticut, USA
James Keough	59	Chief Financial Officer
Alberta, Canada
Ryan Hellard	34	Chief Strategy Officer
British Columbia, Canada
Tyler Robson	32	President, Cannabis
British Columbia, Canada
Tank Vander	45	President, Liquor Retail
Alberta, Canada
Marcie Kiziak	43	President, Cannabis Retail
Alberta, Canada
Robbie Madan	44	Chief Information Officer and Digital Officer
Alberta, Canada
Deanna Garand	40	Vice President, Human Resources
Alberta, Canada
Greg Mills (1)	60	Non-Executive Chairman and Director
Ontario, Canada
Gregory Turnbull (1)	68	Director
Alberta, Canada
Bryan Pinney (1)	70	Director
Alberta, Canada
Lori Ell (1)	56	Director
Alberta, Canada
Frank Krasovec (1)	78	Director
Texas, USA

(1)Independent director for the purposes of National Instrument 58-101 – Disclosure of Corporate Governance Practices (the “NI 58-101”), of the Canadian Securities Administrators and the Nasdaq Stock Market Rules (the “Nasdaq Rules”). See “—Corporate Governance—Director Independence”.

Biographical Information Regarding Our Directors and Executive Officers

Zachary George – Chief Executive Officer and Director

Mr. George joined SNDL as director in November 2019 and was appointed Chief Executive Officer in January 2020. Mr. George has spent more than 15 years evaluating catalyst-based investment opportunities across the capital structure of North American companies with a focus on real assets. Mr. George has worked in a management capacity, including as a chief executive officer, with numerous corporate boards to turn around operations, affect corporate action and implement governance policies to maximize shareholder value.

57

James Keough – Chief Financial Officer

Mr. Keough joined SNDL as Chief Financial Officer in May 2018. Mr. Keough began his career with KPMG and Ernst & Young in Canada and Europe. Prior to joining SNDL, he was a tax and finance consultant as a Chartered Professional Accountant for two and a half years. Prior to that role, he served for 20 years as Chief Financial Officer of a diversified private company with operations in energy, real estate and hospitality. Mr. Keough holds a Bachelor of Commerce degree from the University of Calgary. He holds CPA, CA and CPA (Illinois, USA) designations.

Ryan Hellard – Chief Strategy Officer

Mr. Hellard joined the Company as the Chief Marketing and Product Officer in March 2018 and was appointed Chief Strategy Officer on June 1, 2021. From 2012 and until joining SNDL, he held increasingly senior roles, including as President, at AppColony, an agency that develops marketing strategies and digital solutions for Canadian companies. Mr. Hellard completed a Bachelor of Commerce degree at the University of Calgary.

Tyler Robson – President, Cannabis

Mr. Robson joined the Company as President, Cannabis in January 2023 subsequent to the Valens acquisition. Mr. Robson was Chief Executive Officer of Valens from May 2017 to January 2023. Prior to being appointed Chief Executive Officer in May 2017, Mr. Robson served as Chief Operating Officer. Mr. Robson attended the University of Saskatchewan, graduating with a Bachelor of Science degree.

Tank Vander – President, Liquor Retail

Mr. Vander joined the Company as President, Liquor Retail in April 2022 subsequent to the Alcanna acquisition. Prior to the acquisition of Alcanna, Mr. Vander was President, Liquor Retail at Alcanna from 2020 to 2022. Mr. Vander was Chief Executive Officer of the Canadian Liquor Retailers Alliance Limited Partnership from 2019 to 2020 and Chief Executive Officer of Ace Liquor Corporation from 2013 to 2018.

Marcie Kiziak – President, Cannabis Retail

Mrs. Kiziak joined the Company as President, Cannabis Retail in April 2022 subsequent to the Alcanna acquisition. Prior to the acquisition of Alcanna, Mrs. Kiziak was President, Nova Cannabis from January 2020 to March 2022. Mrs. Kiziak was Senior Vice President, Human Resources at Alcanna from February 2018 to January 2020. Prior to joining Alcanna, Mrs. Kiziak was a Human Resource Consultant at Compass Management Consulting from July 2017 to February 2018. Mrs. Kiziak holds a Bachelor of Management degree from the University of Lethbridge.

Robbie Madan – Chief Information Officer and Digital Officer

Mr. Madan joined the Company as Chief Information Officer and Digital Officer in March 2022 subsequent to the Alcanna acquisition. Prior to the acquisition of Alcanna, Mr. Madan served as Senior Vice President and Chief Information Officer at Alcanna since 2020. From 2014 until 2020, he held increasingly senior roles, including as Senior Vice President, Business Technology and Director, IT Business Applications at Alcanna. Mr. Madan holds a Bachelor of Science degree from the University of Alberta.

Deanna Garand – Vice President, Human Resources

Mrs. Garand joined the Company as the Vice President of Human Resources in April 2022 subsequent to the Alcanna acquisition. Prior to the acquisition of Alcanna, she spent four years with Alcanna in a role of HR Director and Vice President of Human Resources. Prior to joining Alcanna, Mrs. Garand spent 13 years practicing Human Resources within the Industrial Construction/Oil and Gas industry. Ahead of her career in Human Resources, she spent three years in jewelry retail management aboard cruise ships. Mrs. Garand holds a Bachelor of Commerce degree from St. Mary’s University, in Halifax Nova Scotia.

Greg Mills – Non-Executive Chairman and Director

Mr. Mills joined our board of directors in June 2019. Mr. Mills has 34 years of experience in capital markets, including 20 years with RBC Dominion Securities Inc. Mr. Mills has extensive leadership experience, having served as managing director of RBC Capital Markets’ Global Equities division and on RBC Capital Markets’ Spending and Global Risk committees. Mr. Mills is currently a director of Frontier Lithium Inc. and was previously a director of RBC USA Holdco Corporation. Mr. Mills holds a Bachelor of Science degree in geology from the University of Windsor.

Gregory Turnbull – Director

Mr. Turnbull joined our board of directors in October 2018. Mr. Turnbull is a former partner in the Calgary office of McCarthy Tétrault LLP. He has worked as a lawyer since 1980, having held a variety of roles with firms including Gowlings LLP, Donahue LLP and

58

MacKimmie Matthews. In addition to being a director of the Company, Mr. Turnbull is a director of Sleeping Giant Capital Corporation. Throughout his career, Mr. Turnbull has served as an officer or director of many other public and private companies. He is a member of the Law Society of Alberta, the Canadian Bar Association and the Calgary Bar Association. He holds a Bachelor of Arts degree (with honors) from Queen’s University and a Bachelor of Law degree from the University of Toronto. He was chair of the board of Alberta Health Services and has also previously been chair of the Calgary Zoo.

Bryan D. Pinney – Director

Mr. Pinney joined our board of directors in December 2019. Mr. Pinney was a partner with Deloitte between 2002 and 2015. He served as Calgary Managing Partner from 2002 through 2007, as National Managing Partner of Audit & Assurance from 2007 to 2010, and Vice-Chair until 2015. Prior to joining Deloitte, Mr. Pinney was a partner with Andersen LLP and served as Calgary Managing Partner from 1991 through May of 2002. Mr. Pinney is currently a Board Member with TransAlta Corporation, serving on their Audit and HR Compensation Committees. He is also the lead Board Director for North American Construction Group Ltd., and a director of one private company. Previously, Mr. Pinney served as Chair of the Board of Governors of Mount Royal University and on numerous other non-profit boards. He is a Fellow of the Institute of Chartered Accountants, a Chartered Business Valuator and is a graduate of the Ivey Business School at the University of Western Ontario with an honours degree in Business Administration. He is also a graduate of the Canadian Institute of Corporate Directors.

Lori Ell – Director

Ms. Ell joined our board of directors in July 2021. Ms. Ell has over 25 years of broad-based executive experience working with multi-billion dollar, start up, and midmarket companies in diverse industries including food manufacturing and technology. Her most recent position is President of Growing Ideas, a business consulting practice located in Calgary, Alberta. Ms. Ell sits on the board of directors of the Sawridge Group and Tall Grass Ventures. She is a director on two Canadian Federal Departmental Audit Committees – Crown-Indigenous Relations and Northern Affairs Canada and Indigenous Services Canada. Previously, Ms. Ell served as chair of the board of AgJunction Inc., where she previously held interim president and chief executive officer roles. Ms. Ell has also served on a number of other retail and food processing boards. From 2004 to 2012, Ms. Ell was the President of Agristar Inc., an agri-food manufacturing company. Prior thereto, Ms. Ell was Chief Financial Officer for Quortech Solutions Ltd. a technology company. Ms. Ell is a Certified Public Accountant, holds a Bachelor or Management degree and holds an ICD.D designation from the Institute of Corporate Directors.

Frank Krasovec – Director

Mr. Krasovec joined our board of directors in January 2023. Mr. Krasovec is an experienced entrepreneur who has founded companies in multiple industries, including media/telecommunications, promotional products, energy products and services and real estate development and management. Mr. Krasovec is currently the CEO of Norwood Investments, a position he has held for over forty years, and is also co-founder and chairman of DPC Dash which owns and operates approximately 600 Domino’s Pizza stores in China, since inception in 2011. Mr. Krasovec co-founded TopGolf China and Southeast Asia, a golfing and entertainment complex in 2016, and has been a director and on the executive committee since 2019. Mr. Krasovec is also an advisor to Hidden Star, a professionally managed fund that will invest in minority and woman owned businesses. Mr. Krasovec currently serves on the boards of Southwestern University and the Austin Theater Alliance. Mr. Krasovec received his MBA degree from Ohio University in 1966 and his bachelor’s degree in business from Ohio University in 1965.

B.Compensation.

Overview

In order to succeed in the highly competitive and evolving market in which we operate, we need to attract, retain and motivate a highly talented executive team. Our executive compensation program is designed to achieve the following objectives:

•provide compensation opportunities in order to attract and retain talented, high-performing and experienced executive officers, whose knowledge, skills and performance are critical to our success;

•motivate our executive team to achieve our strategic business and financial objectives;

•align the interests of our executive officers with those of our shareholders by tying a meaningful portion of compensation directly to the long-term value and growth of our business; and

•provide incentives that encourage appropriate levels of risk-taking by our executive team.

We currently offer our executive officers, including our NEOs, cash compensation in the form of base salary and annual short-term incentives that will reward participants for the achievement of pre-established corporate, team and individual goals and objectives. From time to time, our board of directors may also grant discretionary cash bonuses to our executives to reward them for exemplary performance. Long-term annual incentives may consist of stock options, performance share units and/or RSUs.

59

Our compensation philosophy is to motivate our employees to participate directly in the value that their efforts create for shareholders because our employees are also shareholders. We believe that equity-based compensation awards motivate our executive officers to achieve our strategic business and financial objectives, and also align their interests with the long-term interests of our shareholders.

We continue to evaluate our compensation philosophy and compensation program on an ongoing basis to ensure that we are providing competitive compensation opportunities for our executive team as a publicly traded company in this evolving industry. As part of the annual compensation review process, we expect to be guided by the philosophy and objectives outlined above, as well as other factors that may become relevant.

Base Salary

Base salary is provided as a fixed source of compensation for our executive officers. Base salaries are determined on an individual basis, taking into account the scope of the executive officer’s role, responsibilities, expertise and prior experience. Base salaries for our executive officers, including our NEOs, are expected to be reviewed annually by the board of directors and may be adjusted based on the executive officer’s success in meeting or exceeding individual objectives, as well as to maintain market competitiveness. In addition, base salaries can be adjusted by the board of directors throughout the year to reflect promotions or other changes in the scope or breadth of an executive officer’s role or responsibilities.

Short-Term Annual Cash Incentive

Our short-term annual cash incentive plan is designed to reward the achievement of pre-determined corporate, team and personal goals and objectives over the ensuing year, with the intention of aligning compensation with corporate strategies. Annual incentive targets under the plan may be set as a percentage of the relevant executive officer’s base salary and payout of the annual cash incentive (if any) are linked to the achievement of corporate, team and personal performance. In order to further increase alignment with shareholders, executives and employees also have the ability to elect to receive short-term cash incentive payments in the form of RSUs.

Long-Term Equity Incentives

Stock Option Plan and Restricted and Performance Share Unit Plan

The SNDL Inc. Stock Option Plan (the “Option Plan”) and SNDL Inc. Restricted and Performance Share Unit Plan (the “RSU Plan”) each provide eligible participants with compensation opportunities that will support the achievement of the Company’s performance objectives, align the interests of eligible participants with those of the Company’s shareholders, and attract, retain and motivate eligible participants critical to the long-term success of the Company and its subsidiaries.

Benefit Plans

We provide our executive officers, including our NEOs, with life, medical, dental and vision insurance programs on the same basis as other employees, or an allowance to purchase individual benefit and insurance coverage. We offer these benefits consistent with local market practice.

Perquisites

We do not offer significant perquisites as part of our compensation program.

Executive Share Ownership Guidelines

Our executive share ownership guidelines are intended to further align the interests of our executive officers with those of our shareholders. The ownership guidelines establish minimum equity ownership levels for executive officers based on a multiple of their base salary and their level of seniority. Executive officers are expected to meet the prescribed ownership levels within five years of the later of our initial offering and the date of their appointment to an executive position.

The following table shows the expected ownership guideline for the executive officers:

Level	Base Salary Multiple
Chief Executive Officer	3x
Other Executive Officers	2x

60

Summary Compensation Table

Our named executive officers (“NEOs”) for the fiscal year ended December 31, 2022 were our Chief Executive Officer, Zachary George, Chief Financial Officer, James Keough, former President and Chief Operating Officer, Andrew Stordeur, Chief Strategy Officer, Ryan Hellard and Chief Information Officer and Digital Officer, Robbie Madan. For the fiscal year ended December 31, 2022, the aggregate compensation and benefits accrued or paid to our then serving executive officers for services in all capacities was $11,543,130, and the aggregate compensation paid to each of our NEOs is set forth below:

Name and Principal Position	Year	Salary (1)		Share-based Awards (2)		Option-based Awards (3)		Annual Incentive Plans		All Other Compensation (4)		Total Compensation (5)
Zachary George (6)	2022	$	700,000	$	6,303,168	$	—	$	899,675	$	7,404	$	7,910,247
Chief Executive Officer and Director
James Keough	2022	$	450,000	$	679,413	$	—	$	100,000	$	5,432	$	1,234,845
Chief Financial Officer
Andrew Stordeur (7)	2022	$	400,000	$	590,922	$	—	$	80,000	$	6,861	$	1,077,783
Former President and Chief Operating Officer
Ryan Hellard	2022	$	250,000	$	590,922	$	—	$	50,000	$	4,469	$	895,391
Chief Strategy Officer
Robbie Madan (8)	2022	$	191,250	$	105,578	$	—	$	—	$	128,036	$	424,864
Chief Information Officer and Digital Officer

Notes:

(1)Represents the base salary paid in Fiscal 2022.

(2)All share-based awards were granted pursuant to the RSU Plan in the form of RSUs. The fair-value of the share-based awards shown were calculated by multiplying the total number of units granted to each NEO on the grant date by the closing price of the Company’s common shares on the trading day immediately preceding the grant date.

(3)No option-based awards were granted in Fiscal 2022.

(4)None of our NEOs are entitled to perquisites or other personal benefits which, in aggregate, are worth over $50,000 or over 10% of their base salary.

(5)All monetary amounts in this table are in CAD$ unless otherwise specified.

(6)Mr. George’s salary is in USD.

(7)Mr. Stordeur left the Company effective January 13, 2023.

(8)All compensation amounts for Mr. Madan are for the period March 30, 2022 to December 31, 2022.

61

The table below shows the incremental payments that would be made to our NEOs under the terms of their employment agreements upon the occurrence of certain events:

Name and Principal Position	Event	Severance (1)		Option-based Awards (2)		Other Payments (1)		Total Compensation (1)
Zachary George	Termination without cause	$	1,400,000	$	—	$	21,000	$	1,421,000
Chief Executive Officer and Director	Termination and change of control	$	1,400,000	$	—	$	21,000	$	1,421,000
James Keough	Termination without cause	$	900,000	$	—	$	9,750	$	909,750
Chief Financial Officer	Termination and change of control	$	450,000	$	—	$	9,750	$	459,750
Andrew Stordeur	Termination without cause	$	800,000	$	—	$	12,000	$	812,000
Former President and Chief Operating Officer	Termination and change of control	$	800,000	$	—	$	12,000	$	812,000
Ryan Hellard	Termination without cause	$	500,000	$	—	$	7,500	$	507,500
Chief Strategy Officer	Termination and change of control	$	500,000	$	—	$	7,500	$	507,500
Robbie Madan	Termination without cause	$	500,000	$	—	$	7,500	$	507,500
Chief Information Officer and Digital Officer	Termination and change of control	$	—	$	—	$	—	$	—

Notes:

(1)Mr. George’s severance, other payments and total are in USD.

(2)All option-based awards were out-of-the money, based on the December 31, 2022 price of US$2.09 (CAD$2.83) per common share.

62

Outstanding Option-Based Awards and Share-Based Awards

The following table sets out information on the outstanding warrants and other option-based awards held by each of our NEOs as at December 31, 2022:

Name and Principal Position	Number of common shares underlying unexercised option-based awards		Exercise price (USD)		Expiration date		Value of unexercised in-the-money option-based awards (1)
Zachary George		—	$	—		—	$	—
Chief Executive Officer and Director
James Keough		8,000	$	29.69	August 14, 2023		$	—
Chief Financial Officer		10,800		29.69	August 1, 2024			—
		16,000		62.50	April 1, 2027			—
		7,500		8.33	May 27, 2030			—
Andrew Stordeur		3,840	$	6.25	March 1, 2023		$	—
Former President and Chief Operating Officer		3,840		6.25	March 1, 2024			—
		11,520		6.25	August 1, 2024			—
		16,000		62.50	January 11, 2027			—
		10,000		8.33	May 27, 2030			—
		19,200		6.25	5 years from vest date			—
		19,200		31.25	5 years from vest date			—
Ryan Hellard		3,840	$	6.25	March 1, 2023		$	—
Chief Strategy Officer		3,840		6.25	March 1, 2024			—
		11,520		6.25	August 1, 2024			—
		16,000		62.50	January 11, 2027			—
		10,000		8.33	May 27, 2030			—
		19,200		6.25	5 years from vest date			—
		19,200		31.25	5 years from vest date			—
Robbie Madan		—	$	—		—	$	—
Chief Information Officer and Digital Officer

Notes:

(1)All option-based awards were out-of-the money, based on the December 31, 2022 price of US$2.09 (CAD$2.83) per common share.

The following table sets out information on the outstanding share-based awards held by each of our NEOs as at December 31, 2022:

Name and Principal Position	Number of common shares underlying unvested share-based awards		Value of share-based awards that have not vested (2)		Value of vested share-based awards not distributed (3)
Zachary George	RSUs:	733,333	$	5,726,957	$	—
Chief Executive Officer and Director	DSUs:	—	$	—	$	91,153
James Keough	RSUs:	74,453	$	520,789	$	—
Chief Financial Officer
Andrew Stordeur	RSUs:	60,500	$	474,002	$	—
Former President and Chief Operating Officer
Ryan Hellard	RSUs:	58,600	$	459,516	$	—
Chief Strategy Officer
Robbie Madan	RSUs:	16,250	$	52,789	$	—
Chief Information Officer and Digital Officer

63

Notes:

(1)All monetary amounts are in CAD$ unless otherwise specified.

(2)The value of the share-based awards that have not yet vested were calculated by multiplying the total number of units that have not yet vested by the closing price of the Company’s common shares on the trading day immediately preceding the grant date.

(3)The value of the share-based awards that have not been distributed were calculated by multiplying the total number of units that have not been distributed by the closing price of the Company’s common shares on the trading day immediately preceding the grant date.

Incentive Plan Awards – Value Expected to be Vested or Earned During the Year

The following table sets out, for each of our NEOs, the value of the option-based awards and share-based awards that vested in accordance with their terms as of December 31, 2022:

Name and Principal Position	Option-based awards - Value Vested During 2022 (1)		Share-based Awards - Value Vested During 2022 (2)
Zachary George	$	—	$	3,625,891
Chief Executive Officer and Director
James Keough	$	—	$	352,494
Chief Financial Officer
Andrew Stordeur	$	—	$	391,747
Former President and Chief Operating Officer
Ryan Hellard	$	—	$	358,142
Chief Strategy Officer
Robbie Madan	$	—	$	52,789
Chief Information Officer and Digital Officer

Notes:

(1)The option-based awards held by each of our NEOs that vested during 2022, altogether were 57,166 awards, were out-of-the money, based on the December 31, 2022 price of US$2.09 (CAD$2.83) per common share.

(2)The value of the share-based awards that vested during 2022 were calculated by multiplying the total number of units that vested by the closing price of the Company’s common shares on the trading day immediately preceding the grant date.

Employment Agreements

The Company has entered into employment agreements with each of our NEOs. The material terms of the employment agreements are discussed below.

Zachary George, Chief Executive Officer

The Company may terminate Mr. George at any time, without cause, and the Company will be required to provide him with his accrued but unpaid annual base salary, pay for accrued and unused vacation and business expenses up to the termination date (the “Accrued Obligations”), plus (i) termination notice of two years (which may be provided as pay in lieu of notice), (ii) a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary, and (iii) any unvested stock options or RSUs will immediately vest on the termination date. The receipt of the separation package is conditioned on Mr. George’s execution of a release of claims.

Pursuant to Mr. George’s employment agreement, if a change of control occurs, and his employment with the Company is subsequently or contemporaneously terminated by the Company or its successor, Mr. George will be entitled to receive, within thirty (30) days after such termination, a lump sum payment equal to (i) the Accrued Obligations, (ii) two times his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits.

Mr. George’s employment agreement also contains a customary confidentiality covenant and certain covenants that will continue to apply following the termination of his employment, including non-competition and non-solicitation provisions which are in effect during Mr. George’s employment and for the twelve months following the termination of his employment (collectively, the “Restrictive Covenants”).

James Keough, Chief Financial Officer

The Company may terminate Mr. Keough at any time without cause and the Company will be required to provide him with his Accrued Obligations, plus (i) termination notice of two years (which may be provided as pay in the form of base salary in lieu of notice), and (ii)

64

a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary. Additionally, subject to the terms of the applicable equity plan and of any applicable agreement, any issued but unvested stock options, simple warrants and performance warrants previously granted to Mr. Keough will immediately vest on the cessation date. The receipt of the separation package is conditioned on Mr. Keough’s execution of a release of claims.

Pursuant to Mr. Keough’s employment agreement, if a change of control occurs and his employment is subsequently or contemporaneously terminated by the Company or its successor, Mr. Keough will be entitled to receive, within 30 days after such termination, a sum of money equal to (i) the Accrued Obligations, (ii) one year of his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits.

Mr. Keough’s employment agreement also contains the Restrictive Covenants.

Andrew Stordeur, Former President and Chief Operating Officer

Pursuant to Mr. Stordeur’s employment agreement, the Company could terminate Mr. Stordeur at any time without cause and the Company would have been required to provide him with his Accrued Obligations, plus (i) termination notice of two years (which may be provided as pay in the form of base salary in lieu of notice), (ii) a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary, and (iii) all of his outstanding performance warrants immediately vest on the cessation date. Additionally, subject to the terms of the applicable equity plan and of any applicable agreement, any issued but unvested stock options, simple warrants and performance warrants previously granted to Mr. Stordeur immediately vest on the cessation date. The receipt of the separation package is conditioned on Mr. Stordeur’s execution of a release of claims.

Pursuant to Mr. Stordeur’s employment agreement, if a change of control occurs and his employment is subsequently or contemporaneously terminated by the Company or its successor, Mr. Stordeur will be entitled to receive, within 30 days after such termination, a sum of money equal to (i) the Accrued Obligations, (ii) two times his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits, and all of his outstanding performance warrants will immediately vest on the cessation date.

Mr. Stordeur’s employment agreement also contains the Restrictive Covenants.

Mr. Stordeur left the Company effective January 13, 2023.

Ryan Hellard, Chief Strategy Officer

The Company may terminate Mr. Hellard at any time without cause and the Company will be required to provide him with his Accrued Obligations, plus (i) termination notice of two years (which may be provided as pay in the form of base salary in lieu of notice), (ii) a lump sum payment in lieu of benefits equivalent to 3% of his annual base salary, and (iii) all of his outstanding performance warrants will immediately vest on the cessation date. Additionally, subject to the terms of the applicable equity plan and of any applicable agreement, any issued but unvested stock options, simple warrants and performance warrants previously granted to Mr. Hellard will immediately vest on the cessation date. The receipt of the separation package is conditioned on Mr. Hellard’s execution of a release of claims.

Pursuant to Mr. Hellard’s employment agreement, if a change of control occurs and his employment is subsequently or contemporaneously terminated by the Company or its successor, Mr. Hellard will be entitled to receive, within 30 days after such termination, a sum of money equal to (i) the Accrued Obligations, (ii) two times his annual base salary, and (iii) 3% of his annual base salary in lieu of benefits, and all of his outstanding performance warrants will immediately vest on the cessation date.

Mr. Hellard’s employment agreement also contains the Restrictive Covenants.

Robbie Madan – Chief Information Officer and Digital Officer

The Company may terminate Mr. Madan at any time without cause and the Company will be required to provide her with his Accrued Obligations, plus (i) pay in lieu of notice of 24 months, calculated on the basis of annual base salary and target STIP for the applicable of the 24 month period which is being provided as pay in lieu, plus (ii) 3 % of his annual base salary in lieu of benefits, plus (iii) ii) a portion of the Participant’s unvested RSUs and related dividend share units will vest as of the termination date. The percentage which will vest will be determined by a fraction, the numerator of which is the number of days that have elapsed from the grant date up to and including the termination date, and the denominator of which is the number of days from the grant date up to and including the original vesting date and shall be settled as soon as practicable following the termination date.

The receipt of the separation package is conditioned on Mr. Madan's execution of a release of claims and resignation as an officer and director.

Mr. Madan’s employment agreement also contains the Restrictive Covenants.
 

65

Director Compensation

Our board of directors, on the recommendation of our compensation committee, is responsible for reviewing and approving any changes to the directors’ compensation arrangements. The aggregate of compensation and benefits in kind, accrued or paid to our directors in the year ended December 31, 2022 for services in all capacities was $350,000.

In consideration for serving on our board of directors, each director, other than directors who are employees of the Company (the “Excluded Directors”), is paid an annual cash retainer of $75,000.

In addition, to reflect the additional workload required in respect of special projects performed, Mr. George was entitled to receive 50,000 warrants (subsequently amended to an entitlement to 50,000 stock options in accordance with the Option Plan, in equal installments on, March 31, 2020, June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021, December 31, 2021, March 31, 2022 and June 30, 2022). The unvested portion of Mr. George’s compensation as a director in the form of stock options was cancelled for no consideration when he became Chief Executive Officer on January 29, 2020. Since becoming our Chief Executive Officer, Mr. George has not received additional compensation for his director services.

In addition, on May 28, 2020, to reflect the additional workload and responsibilities of our board of directors in recognition for their contributions in the restructuring of the Company, and the closing of the following transactions: (i) the sale of Bridge Farm, (ii) a new Credit Agreement with senior lenders, (iii) the issuance of a new second lien security to SAF, and (iv) a new capital infusion of at least $10 million, Mr. Mills received 60,000 deferred share units with an aggregate value of $710,222, Mr. Turnbull received 20,000 deferred share units with an aggregate value of $236,741, Ms. Cannon received 20,000 deferred share units with an aggregate value of $236,741, and Mr. Pinney received 8,500 deferred share units with an aggregate value of $100,615. With respect to all of these deferred share units, half of each deferred share unit granted were vested as of the time of grant, and the remaining half became vested as of December 31, 2020.

In addition, on May 28, 2020, for the balance of the 2020 calendar year and each successive year until otherwise determined by our board of directors, the independent non-management directors, other than the chair of our board of directors, will receive annual cash compensation of $75,000 payable in quarterly instalments, and will receive $225,000 in compensation to be paid in the form of deferred share units. The chair of our board will receive annual cash compensation of $125,000 payable in quarterly instalments and $575,000 in compensation to be paid in the form of deferred share units. In accordance with the May 28, 2020 board resolution, Messrs. Pinney and Turnbull and Ms. Cannon each received $225,000 in deferred share units in equal instalments on June 15, 2020, September 15, 2020, December 15, 2020, March 15, 2021, and June 15, 2021. Mr. Mills received $575,000 in deferred share units in equal instalments on June 15, 2020, September 15, 2020, December 15, 2020, March 15, 2021, and June 15, 2021.

If a change of control occurs, Mr. Mills will be entitled to receive any unpaid portion of the annual cash retainer for the calendar year in which the change of control occurs and any unpaid portion of the IPO DSUs. In addition, if a change of control occurs, all outstanding warrants held by Mr. Mills and Mr. Turnbull will immediately vest.

In accordance with the May 28, 2020 board resolution, Messrs Pinney and Turnbull each received $225,000 in deferred share units and $75,000 cash compensation for the 2021 calendar year, Ms. Cannon received $225,000 in deferred share units and $75,000 cash compensation prorated for her time served on the board from January 1, 2021 to July 7, 2021, Ms. Ell received $225,000 in deferred share units and $75,000 cash compensation prorated for her time served on the board from July 7, 2021 to December 31, 2021. Mr. Mills received $575,000 in deferred share units and $125,000 cash compensation for the 2021 calendar year.

In addition, on February 16, 2021, a discretionary DSU allocation was granted. Mr. Mills received 50,000 deferred share units with an aggregate value of $1,321,944, Mr. Turnbull, Ms. Cannon, and Mr. Pinney each received 25,000 deferred share units with an aggregate value of $660,972. With respect to all of these deferred share units, half of each deferred share unit granted vested as of June 15, 2021, and the remaining half vested as of December 15, 2021.

In accordance with the May 28, 2020 board resolution, Messrs Pinney and Turnbull and Ms. Ell each received $225,000 in deferred share units and $75,000 cash compensation for the 2022 calendar year. Mr. Mills received $575,000 in deferred share units and $125,000 cash compensation for the 2022 calendar year.

In addition, on December 23, 2022, a discretionary DSU allocation was granted. Mr. Mills received 414,838 deferred share units with an aggregate value of $1,150,000, Mr. Turnbull, Mr. Pinney and Ms. Ell each received 162,328 deferred share units with an aggregate value of $450,000 each. With respect to all of these deferred share units, the full amount of each deferred share unit granted vests as of December 15, 2025.

All directors will be reimbursed for their reasonable out-of-pocket expenses incurred while serving as directors.

66

Director Share Ownership Guidelines

We have director share ownership guidelines for directors (other than Excluded Directors) to further align the interests of such directors with those of our shareholders. The ownership guidelines have established minimum equity ownership levels for each of our directors, other than Excluded Directors, based on a multiple of their annual retainer. Directors subject to the ownership guidelines are expected to meet the prescribed ownership levels within five years of the later of (i) the completion of the IPO and (ii) the date of their appointment to the board of directors. Common shares and other equity-based awards will be included in determining an individual’s equity ownership value. The expected ownership guideline for these directors is three times their annual retainer.

C.Board practices.

Composition of our Board of Directors

Under our amended articles of incorporation, our board of directors consists of a minimum of one and a maximum of 15 directors as determined from time to time by the directors. Our board of directors is currently comprised of five directors, and under the ABCA, as a reporting issuer, we must have no fewer than three directors. Under the ABCA, a director may be removed with or without cause by a resolution passed by a majority of the votes cast by shareholders present in person or by proxy at a meeting and who are entitled to vote. The directors are appointed at the annual general meeting of shareholders and the term of office for each of the directors expires at the time of our next annual shareholders meeting. Our articles of incorporation provide that, between annual general meetings of our shareholders, the directors may appoint one or more additional directors, but the number of additional directors may not at any time exceed one-third of the number of directors who held office at the expiration of the last meeting of our shareholders. Under the ABCA, at least one quarter of our directors must be resident Canadians as defined in the ABCA.

Majority Voting Policy

We have a majority voting policy to the effect that a nominee for election as a director of the Company who does not receive a greater number of votes “for” than votes “withheld” with respect to the election of directors by shareholders will be expected to offer to tender his or her resignation to the chairman of our board of directors promptly following the meeting of shareholders at which the director was elected. The nominating and corporate governance committee will consider such offer and make a recommendation to our board of directors about whether to accept it or not. Our board of directors will promptly accept the resignation unless it determines, in consultation with the nominating and corporate governance committee, that there are exceptional circumstances that should delay the acceptance of the resignation or justify rejecting it. Our board of directors will make its decision and announce it in a press release within 90 days following the meeting of shareholders. A director who tenders a resignation pursuant to our majority voting policy will not participate in any meeting of our board of directors or the nominating and corporate governance committee at which the resignation is considered. Our majority voting policy will not apply for contested meetings at which the number of directors nominated for election is greater than the number of seats available on the board.

Director Term Limits and Other Mechanisms of Board Renewal

Our board of directors has not adopted director term limits or other automatic mechanisms of board renewal. Rather than adopting formal term limits, mandatory age-related retirement policies and other mechanisms of board renewal, the nominating and corporate governance committee of our board of directors is developing a skills and competencies matrix for our board of directors as a whole and for individual directors. The nominating and corporate governance committee also conducts a process for the assessment of our board of directors, each committee and each director regarding his or her effectiveness and contribution and reports evaluation results to our board of directors on a regular basis.

Director Independence

Under the Nasdaq Rules, independent directors must comprise a majority of a listed company’s board of directors. For purposes of the Nasdaq Rules, an independent director means a person other than an executive officer or employee of the company who, in the opinion of the board of directors, has no relationship with the company that would interfere with the exercise of independent judgement in carrying out the responsibilities of a director. Under NI 58-101, a director is considered to be independent if he or she is independent within the meaning of Section 1.4 of National Instrument 52-110—Audit Committees (“NI 52-110”). Section 1.4 of NI 52-110 generally provides that a director is independent if he or she has no direct or indirect relationship with the issuer which could, in the view of the issuer’s board of directors, be reasonably expected to interfere with the exercise of the director’s independent judgement.

Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her background, employment and affiliations, our board of directors has determined that as of December 31, 2022, Messrs. Mills, Turnbull and Pinney, and Ms. Ell, representing four of the five members of our board of directors, are “independent” as that term is defined under the Nasdaq Rules and NI 58-101. In making this determination, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors

67

deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director. As of December 31, 2022, Mr. George was not independent by reason of the fact that Mr. George was our Chief Executive Officer.

Certain members of our board of directors are also members of the boards of other public companies. See “—Biographical Information Regarding Our Directors and Executive Officers”. Our board of directors has not adopted a director interlock policy but is keeping informed of other public directorships held by its members.

Mandate of the Board of Directors

Our board of directors is responsible for supervising the management of our business and affairs, including providing guidance and strategic oversight to management. Our board adopted a formal mandate that includes the following:

•appointing our Chief Executive Officer;

•developing the corporate goals and objectives that our Chief Executive Officer is responsible for meeting and reviewing the performance of our Chief Executive Officer against such corporate goals and objectives;

•taking steps to satisfy itself as to the integrity of our Chief Executive Officer and other executive officers and that our Chief Executive Officer and other executive officers create a culture of integrity throughout the organization;

•reviewing and approving our code of conduct and reviewing and monitoring compliance with the code of conduct and our enterprise risk management processes;

•reviewing and approving management’s strategic and business plans and our financial objectives, plans and actions, including significant capital allocations and expenditures; and

•reviewing and approving material transactions not in the ordinary course of business.

Meetings of Independent Directors

Our board of directors holds regularly scheduled quarterly meetings as well as ad hoc meetings from time to time. The independent members of our board of directors also meet, as required, without the non-independent directors and members of management before or after each regularly scheduled board meeting.

A director who has a material interest in a matter before our board of directors or any committee on which he or she serves is required to disclose such interest as soon as the director becomes aware of it. In situations where a director has a material interest in a matter to be considered by our board of directors or any committee on which he or she serves, such director may be required to absent himself or herself from the meeting while discussions and voting with respect to the matter are taking place. Directors will also be required to comply with the relevant provisions of the ABCA regarding conflicts of interest.

Position Descriptions

Our board of directors has written terms of reference for the chairman which set out his or her key responsibilities, including duties relating to determining the frequency, dates and locations of meetings and setting board of directors meeting agendas, chairing board of directors and shareholder meetings and carrying out any other or special assignments or any functions as may be requested by our board of directors or management, as appropriate.

Our board of directors has written terms of reference for each of the committee chairs which set out each of the committee chair’s key responsibilities, including duties relating to determining the frequency, dates and locations of meetings and setting committee meeting agendas, chairing committee meetings, reporting to our board of directors and carrying out any other special assignments or any functions as may be requested by our board of directors.

In addition, our board of directors, in conjunction with our Chief Executive Officer, has developed and implemented a written position description for the role of our Chief Executive Officer.

Orientation and Continuing Education

We have implemented an orientation program for new directors under which a new director will meet separately with the chairman of our board of directors, members of the senior executive team and the secretary.

The nominating and corporate governance committee is responsible for coordinating orientation and continuing director development programs relating to the committee’s mandate. The chairman of our board of directors is responsible for overseeing director continuing education designed to maintain or enhance the skills and abilities of our directors and to ensure that their knowledge and understanding of our business remains current.

68

Code of Conduct

We have adopted a code of conduct applicable to all of our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer, which is a “code of ethics” as defined in section 406(c) of SOX and which is a “code” under NI 58-101. The code of conduct sets out our fundamental values and standards of behavior that are expected from our directors, officers and employees with respect to all aspects of our business. The objective of the code of conduct is to provide guidelines for maintaining our integrity, reputation and honesty with a goal of honoring others’ trust in us at all times as well as to deter wrongdoing and promote (i) honest and ethical behavior and fair dealing by our directors, officers, employees, consultants and contractors, (ii) full, fair, accurate, timely and understandable disclosure in filings with the SEC and other public communications, (iii) compliance with applicable governmental rules and regulations, and (iv) accountability for adherence to the code of conduct and prompt reporting of its violations.

The full text of the code of conduct has been posted on our website at www.sndlgroup.com. The information on or accessible through our website is not part of and is not incorporated by reference into this Annual Report, and the inclusion of our website address in this Annual Report is only for reference. If we make any amendment to the code of conduct or grant any waiver therefrom, whether explicit or implicit, to a director or executive officer, we will disclose the nature of such amendment or waiver on our website to the extent required by, and in accordance with, the rules and regulations of the SEC and the Canadian securities regulatory authorities.

Monitoring Compliance with the Code of Conduct

Our nominating and corporate governance committee is responsible for reviewing and evaluating the code of conduct at least annually and recommends any necessary or appropriate changes to our board of directors for consideration. The nominating and corporate governance committee assists our board of directors with the monitoring of compliance with the code of conduct and is responsible for considering any waivers therefrom (other than waivers applicable to members of the nominating and corporate governance committee, which are considered by the audit committee, or waivers applicable to our directors or executive officers, which are subject to review by our board of directors as a whole).

Requirement for Directors and Officers to Disclose Interest in a Contract or Transaction

In accordance with the ABCA, each director and officer must disclose the nature and extent of any interest that he or she has in a material contract or material transaction whether made or proposed with us, if the director or officer is a party to the contract or transaction, is a director or an officer or an individual acting in a similar capacity of a party to the contract or transaction or has a material interest in a party to the contract or transaction. Subject to certain limited exceptions under the ABCA, no director may vote on a resolution to approve a material contract or material transaction which is subject to such disclosure requirement.

Benefits upon Termination of Employment

The service contracts with our directors do not provide for any benefits upon termination of employment, other than a “tail” directors and officers insurance policy.

Complaint Reporting

In order to foster a climate of openness and honesty in which any concern or complaint pertaining to a suspected violation of the law, our code of conduct or any of our policies, or any unethical or questionable act or behavior, our code of conduct requires that our employees promptly report the violation or suspected violation. In order to ensure that violations or suspected violations can be reported without fear of retaliation, harassment or an adverse employment consequence, we have adopted a whistleblowing policy which contains procedures that are aimed to facilitate confidential, anonymous submissions of complaints by our directors, officers, employees and others.

Diversity

We believe that having a diverse board of directors can offer a breadth and depth of perspectives that enhance the board’s performance. We value diversity of abilities, experience, perspective, education, gender, background, race and national origin. Recommendations concerning director nominees are based on merit and past performance, as well as expected contribution to the board’s performance and, accordingly, diversity is taken into consideration. As of December 31, 2021, we had one female director, which represents 20% of our board.

We similarly believe that having a diverse and inclusive organization overall is beneficial to our success, and we are committed to diversity and inclusion at all levels of our organization to ensure that we attract, retain and promote the brightest and most talented individuals. We have recruited and selected senior management candidates that represent a diversity of business understanding, personal attributes, abilities and experience.

We do not currently have a formal policy for the representation of women on the board of directors or senior management of the company. We already take gender and other diversity representation into consideration as part of our overall recruitment and selection

69

process. We have not adopted targets for gender or other diversity representation, in part due to the need to consider a balance of criteria for each individual appointment. We do not believe that quotas or strict rules set out in a formal policy would result in improved identification or selection of the best candidates. Quotas based on specific criteria would limit our ability to ensure that the overall composition of the board of directors and senior management meets the needs of our organization and our shareholders.

The composition of the board of directors is shaped by the selection criteria established by the nominating and corporate governance committee. This is achieved through developing an evergreen list of potential candidates for anticipated board vacancies who fit the committee’s list of evolving selection criteria, ensuring that diversity considerations are taken into account in senior management, monitoring the level of female representation on the board and in senior management positions, continuing to broaden recruiting efforts to attract and interview qualified female candidates, and committing to retention and training to ensure that our most talented employees are promoted from within our organization, all as part of our overall recruitment and selection process to fill board or senior management positions as the need arises.

Committees of the Board of Directors

We have an audit committee, a compensation committee, a nominating and corporate governance committee, and an operations and capital committee with each committee having a written charter.

Audit Committee

Our audit committee is comprised of Greg Mills and Lori Ell, and chaired by Bryan Pinney. Our board of directors has determined that each of Greg Mills, Lori Ell and Bryan Pinney is financially literate and meets the independence requirements for directors, including the heightened independence standards for members of the audit committee under Rule 10A-3 under the Exchange Act and NI 52-110. Our board of directors has determined that Bryan Pinney is “financially sophisticated” within the meaning of the Nasdaq Rules, “financially literate” within the meaning of NI 52-110, and a “financial expert” as defined by Rule 10A-3 under the Exchange Act. For a description of the education and experience of each member of the audit committee, see “—Biographical Information Regarding Our Directors and Executive Officers”.

Our board of directors has established a written charter setting forth the purpose, composition, authority and responsibility of the audit committee, consistent with the rules of the Nasdaq, the SEC and NI 52-110 and our audit committee reviews the charter annually. The principal purpose of our audit committee is to oversee the accounting and financial reporting processes and audits of the Company and to assist our board of directors in discharging its oversight of:

•the quality and integrity of our financial statements and related information;

•the independence, qualifications, appointment and performance of our external auditor;

•our disclosure controls and procedures, internal control over financial reporting and management’s responsibility for assessing and reporting on the effectiveness of such controls;

•our compliance with applicable legal and regulatory requirements; and

•our enterprise risk management processes.

Our audit committee is directly responsible for the appointment, retention and compensation of external auditors and for considering their independence and any potential conflicts of interest. Our audit committee has access to all of our books, records, facilities and personnel and is able to request any information about us as it may deem appropriate. It also has the authority in its sole discretion and at our expense, to retain and set the compensation of outside legal, accounting or other advisors as necessary to assist in the performance of its duties and responsibilities.

Our audit committee also reviews our policies and procedures for reviewing and approving or ratifying related-party transactions and is responsible for reviewing and approving or ratifying all related-party transactions.

Compensation Committee

Our compensation committee is comprised of Lori Ell and Bryan Pinney and is chaired by Greg Mills. Under SEC and the Nasdaq Rules, there are heightened independence standards for members of the compensation committee. Our board of directors has determined that each of Lori Ell, Bryan Pinney and Greg Mills meet this heightened standard and are also independent for purposes of NI 58-101. For a description of the background and experience of each member of our compensation committee, see “—Biographical Information Regarding Our Directors and Executive Officers”.

Our board of directors has established a written charter setting forth the purpose, composition, authority and responsibility of the compensation committee consistent with the rules of the Nasdaq, the SEC and the guidance of the Canadian securities regulatory authorities and our compensation committee reviews the charter annually. The compensation committee’s purpose is to assist the board

70

in its oversight of executive compensation, management development and succession, director compensation and executive compensation disclosure. The principal responsibilities and duties of the compensation committee include:

•reviewing at least annually our executive compensation plans;

• in the absence of the Chief Executive Officer, evaluating at least once a year our Chief Executive Officer’s performance in light of the goals and objectives established by our board of directors and based on such evaluation, providing recommendations to our board of directors regarding the Chief Executive Officer’s annual compensation;

•reviewing on an annual basis the evaluation process and compensation structure for our executive officers and, in consultation with our Chief Executive Officer, reviewing the performance of the other executive officers in order to make recommendations to our board of directors with respect to the compensation for such officers; and

•reviewing and, if appropriate, recommending to our board of directors the approval of any adoption, amendment and termination of our incentive and equity-based incentive compensation plans (and the aggregate number of shares to be reserved for issuance thereunder), and overseeing their administration and discharging any duties imposed on the compensation committee by any of those plans.

Further particulars of the process by which compensation for our executive officers is and will be determined are provided under the heading “Compensation”.

Our compensation committee also has the authority in its sole discretion and at our expense, to appoint, compensate and oversee any compensation consultant, legal counsel or other adviser, upon taking into consideration various factors which could impact such consultant’s, counsel’s or adviser’s independence.

Nominating and Corporate Governance Committee

Our nominating and corporate governance committee is comprised of Bryan Pinney and Lori Ell, and chaired by Gregory Turnbull, each of whom is independent for purposes of NI 58-101 and the Nasdaq Rules.

Our board of directors has established a written charter setting forth the purpose, composition, authority and responsibility of our nominating and corporate governance committee. The nominating and corporate governance committee’s purpose is to assist our board of directors in:

•identifying individuals qualified to become members of our board of directors;

•selecting, or recommending that our board of directors select, director nominees for the next annual meeting of shareholders and determining the composition of our board of directors and its committees;

•developing and overseeing a process to assess our board of directors, the chairman of the board of directors, the committees of the board of directors, the chairs of the committees, individual directors and management; and

•developing and implementing our corporate governance guidelines.

In identifying new candidates for our board of directors, the nominating and corporate governance committee considers what competencies and skills our board of directors, as a whole, should possess and assess what competencies and skills each existing director possesses, considering our board of directors as a group, and the personality and other qualities of each director, as these may ultimately determine the boardroom dynamic.

It is the responsibility of the nominating and corporate governance committee to regularly evaluate the overall efficiency of our board of directors and our chairman and all board committees and their chairs. As part of its mandate, the nominating and corporate governance committee conducts the process for the assessment of our board of directors, each committee and each director regarding his, her or its effectiveness and contribution, and report evaluation results to our board of directors on a regular basis.

D.Employees.

As of December 31, 2022, we employed 2,607 total employees, comprised of 1,346 full-time employees and 1,261 hourly employees.

We consider relations with our employees to be good and have never experienced a work stoppage. None of our employees are represented by a labour union or subject to a collective bargaining agreement.

E.Share ownership.

See “Item 7A Major Shareholders and Related Party Transactions—Major Shareholders”.

See “Item 6B Directors, Senior Management and Employees—Compensation” for information regarding option-based awards.

71

Item 7. Major Shareholders and Related Party Transactions

A.Major shareholders.

The following table sets forth information relating to the beneficial ownership of our shares as of March 1, 2023, by:

•each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares;

•each of our current directors;

•each of our current executive officers; and

•all the foregoing directors and executive officers as a group.

Beneficial ownership is determined in accordance with SEC rules. The information is not necessarily indicative of beneficial ownership for any other purpose. In general, under these rules a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares voting power or investment power with respect to such security. In addition, the rules include common shares issuable pursuant to the exercise of stock options, warrants or other convertible securities that are either immediately exercisable or exercisable on or before April 30, 2023, which is 60 days after March 1, 2023. These shares are deemed to be outstanding and beneficially owned by the person holding those options, warrants or other convertible securities for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. The information contained in the following table is not necessarily indicative of beneficial ownership for any other purpose, and the inclusion of any shares in the table does not constitute an admission of beneficial ownership of those shares. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.

The percentage of common shares beneficially owned is based on 260,495,996 common shares outstanding as of March 1, 2023. The address for each of our directors and executive officers listed below is c/o SNDL Inc., #300, 919 – 11 Avenue SW, Calgary, Alberta, Canada T2R 1P3.

	Common Shares Beneficially Owned
Directors and Executive Officers	Number	Percent
Zachary George	*	*
James Keough	*	*
Ryan Hellard	*	*
Tyler Robson	*	*
Tank Vander	*	*
Marcie Kiziak	*	*
Robbie Madan	*	*
Deanna Garand	*	*
Greg Mills	*	*
Gregory Turnbull	*	*
Bryan Pinney	*	*
Lori Ell	*	*
Frank Krasovec
All current directors and executive officers as a group (thirteen persons)	*	*

* Represents beneficial ownership of less than one percent.

As of March 1, 2023, we had 1,122 record holders of our common shares, with 926 record holders in Canada, representing 16% of our outstanding common shares, 160 record holders in the United States, representing 84% of our outstanding common shares and 36 record holders in other foreign jurisdictions, representing less than one percent of our outstanding common shares.

B.Related party transactions.

In addition to the compensation arrangements discussed under “Compensation”, the following is a description of the material terms of those transactions with related parties to which we are party and which we are required to disclose pursuant to the disclosure rules of the SEC.

72

Indemnity Agreements with Directors and Officers

We have entered into indemnity agreements with each of our directors and officers undertaking to indemnify each of them to the fullest extent permitted by law from and against all liabilities, costs, charges and expenses incurred as a result of actions in the exercise of their duties as a director or officer.

Please see “Item 6B Directors, Senior Management and Employees—Compensation” for information regarding details on employment agreements and agreements with directors.

Equity Awards

We describe our equity awards under “Item 6B Directors, Senior Management and Employees—Compensation—Long-Term Equity Incentives”.

Interest of Management and Others in Material Transactions

On July 8, 2019, we entered into a two-year professional services agreement with AppColony Inc., a company controlled by our former Executive Chairman and in which our Chief Strategy Officer was a shareholder, for certain information technology project and development services to be agreed between the parties from time to time pursuant to one or more statements of work, for a total monthly retainer of $0.3 million. We paid AppColony $1.1 million during the year ended December 31, 2020 and had no amounts owing at December 31, 2020. AppColony Inc. ceased to be a related party with the resignation of our former Executive Chairman from our board of directors in April 2020.

During the year ended December 31, 2020, we paid $30,000 for research and development services and for access and licence of certain strains of cannabis for research purposes, and owed nothing for their services as at December 31, 2020, to PlantBiosis Ltd. and Inplanta Biotechnology Inc., in both of which one of our former non-executive employees, Dr. Igor Kovalchuk, maintained influence.

One of our directors, Gregory Turnbull, is a former partner at McCarthy Tétrault LLP, a law firm that provides legal services to the Company. We paid McCarthy Tétrault LLP $2.5 million during the year ended December 31, 2020 and owed a balance of $0.5 million at December 31, 2020, which was fully paid during 2021. McCarthy Tétrault LLP ceased to be a related party with the retirement of Gregory Turnbull from McCarthy Tétrault in December 2020.

A member of key management personnel jointly controls a company that owns property leased to SNDL for one of its retail liquor stores. The lease term is from November 1, 2017 to October 31, 2027 and includes extension terms from November 1, 2027 to October 31, 2032 and November 1, 2032 to October 31, 2037. Monthly rent for the location includes base rent, common area costs and sign rent. The rent amounts are subject to increases in accordance with the executed lease agreement. Subsequent to the Alcanna Transaction and for the period March 31, 2022 to December 31, 2022, the Company paid $117.9 thousand in total rent with respect to this lease.

Nova Strategic Partnership

On December 20, 2022, the Company and Nova announced that they had entered into an implementation agreement pursuant to which the Company and Nova agreed to implement a strategic transaction in the Canadian retail cannabis industry (the “Nova Transaction”). Our Chief Executive Officer, Zachary George, is the Chair of the Board of Directors of Nova.

As part of the Nova Transaction, the Company and Nova agreed to complete the following transactions, subject to certain terms and conditions (including receipt of the requisite regulatory approvals and approval of Nova shareholders under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions): (i) the Company will transfer or cause to be transferred its 26 corporate-owned cannabis retail stores to Nova; (ii) Nova will transfer its intellectual property related to the “Value Buds” retail banner to the Company; (iii) the parties and certain of their subsidiaries will enter into a strategic partnership agreement and store level license agreement with respect to the “Spiritleaf”, “Superette” and “Value Buds” retail banners to implement certain collaborative retail initiatives; (iv) the parties will amend certain existing governance documents (to which Alcanna was a predecessor party), including their investor rights agreement; (v) the Company will reduce its equity ownership interest in Nova to approximately 19.9%; and (vi) the parties will replace Nova’s existing credit facility with SNDL with a $15.0 million credit facility, with a $10.0 million “accordion” feature.

In connection with the Nova Transaction, the Company entered into voting support agreements with the directors and executive officers of Nova. The Nova Transaction is expected to be completed in the first half of 2023.

Except as set out above or described elsewhere in this Annual Report, there are no material interests, direct or indirect, of any of our directors or executive officers, any shareholder that beneficially owns, or controls or directs (directly or indirectly), more than 10% of any class or series of our outstanding voting securities, or any associate or affiliate of any of the foregoing persons, in any transaction within the preceding three fiscal years that has materially affected or is reasonably expected to materially affect us or any of our subsidiaries.

73

Indebtedness of Directors, Executive Officers and Employees

As of the date of this Annual Report, none of our directors, executive officers, employees, former directors, former executive officers or former employees or any of our subsidiaries, and none of their respective associates, is indebted to us or any of our subsidiaries or another entity whose indebtedness is the subject of a guarantee, support agreement, letter of credit or other similar agreement or understanding provided by us or any of our subsidiaries.

For a description of certain other related party transactions, see note 32 to our audited consolidated financial statements for the fiscal periods ended December 31, 2022 and 2021.

C.Interests of experts and counsel.

Not applicable.

Item 8. Financial Information

A.Consolidated Statements and Other Financial Information.

The Company’s Annual Financial Statements are included beginning on page F-1 of this Annual Report.

Legal Proceedings

Securities Class Actions

In connection with our IPO, we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re SNDL Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re SNDL Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions asserted claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally alleged that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also included allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021. On October 5, 2022, the court entered an order and final judgement approving the settlement.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. SNDL Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserted claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act and Section 10(b) the Exchange Act, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleged that the Company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

We can provide no assurance as to the outcome of any litigation matter in which we are a party. In particular, securities class action lawsuits are typically costly to defend, and divert the attention of management and other resources from operations and, accordingly, even if resolved in our favor, could have a material adverse effect on our business, financial condition, results of operations and liquidity and may force us to reduce or cease operations or seek relief under the applicable bankruptcy or insolvency laws.

LP Supply Agreements

We have several supply agreements or arrangements with other licensed cannabis producers (“LP Supply Agreements”), a certain number of which provide obligations for us to deliver bulk cannabis for resale by such other producer under its own brand.

Although we do not have a supply agreement with the province of Quebec, we do have a licence to sell cannabis to licensed producers, including those based in Quebec. We have received notice of a legal proceeding commenced against us in the province of Quebec by another licensed cannabis producer, which is based in Quebec, alleging breach of an LP Supply Agreement and have filed a statement

74

of defence. As of December 31, 2022, we have recorded a reserve in the amount of $2.6 million in respect of this matter. All litigation steps have been completed, including discoveries and our filing of a defence, and the trial has been scheduled for October 2024.

Other Proceedings

Our former Vice President, Processing, has sued us for over $856,000 in respect of unpaid consideration for certain equipment we have purchased from him, unpaid wages and wrongful termination. We believe we have meritorious defenses to this claim and intend to vigorously defend it, but we can provide no assurance as to the outcome of this proceeding. In our view, it is premature to provide an evaluation of the claim; however, we have recorded a reserve in the amount of $560,000 in respect of this matter.

Zenabis filed a petition with the Supreme Court of British Columbia for a determination of the amount required to repay and terminate the royalty. Zenabis sought the court’s determination of the correct calculation of the amount required to exercise an option to buy out the amended royalty, which Zenabis contended was nil and SNDL asserted was $13.7 million. The court subsequently dismissed the petition and did not decide the merits of the case. Zenabis had 30 days from December 17, 2021 to file a notice of appeal in respect of the court’s findings, but they did not do so.

Sundial Growers Inc. was named as a defendant in an action commenced in the Court of King’s Bench of Alberta by a statement of claim filed on June 17, 2021 whereby the plaintiff alleges that he was entitled to 25% ownership of Sundial Growers Inc. and was not paid for his interest prior to its IPO. The action was resolved on a without costs basis, and a discontinuance of claim consented to by all parties was filed on December 8, 2022.

One of our former employees commenced a wrongful dismissal claim against us for $425,000, plus costs and interest. We filed a statement of defence on November 8, 2021. The proceeding’s next stage involves the exchange of Affidavits of Records.

Potential Litigation Proceedings

From time to time, in addition to the litigation proceedings described above, we may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include, among other matters, commercial litigation related to breach of contract claims brought by our customers, suppliers and contractors, as well as litigation related to our securities and litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgements or settlement terms could have a material adverse impact on our business and results of operations.

Dividend Policy

We have never paid dividends on our common shares. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business, other than the anticipated distribution of Nova shares held by SNDL to reduce the Company’s equity interest in Nova to approximately 19.9%, pursuant to the Nova Transaction (see “—Interests of Management and Others in Material Transactions—Nova Strategic Partnership”. As such, we do not intend to declare or pay cash dividends on our common shares in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our earnings, operating results, financial condition and current and anticipated cash needs. Our future ability to pay cash dividends on our common shares may be limited by the terms of any then-outstanding debt or preferred securities.

B.Significant changes.

Not applicable.

Item 9. The Offer and Listing.

A.Offer and listing details.

Not applicable.

B.Plan of distribution.

Not applicable.

C.Markets.

The Company’s common shares were listed on the Nasdaq in the United States for trading in U.S. dollars since August 1, 2019 under the symbol “SNDL”.

75

D.Selling shareholders

Not applicable.

E.Dilution.

Not applicable.

F.Expenses of the issue.

Not applicable.

Item 10. Additional Information.

A.Share capital.

Not applicable.

B.Memorandum and articles of association.

Reference is made to the section entitled “Description of Share Capital—Other Important Provisions of our Amended Articles of Incorporation, By-Laws and the ABCA” and “Description of Share Capital—Comparison of Alberta Corporate Law and Our Articles of Incorporation and Delaware Corporate Law” in the Company’s prospectus, filed with the SEC on July 31, 2019.

C.Material contracts.

We have not entered into any material contracts outside the ordinary course of business other than as described elsewhere in this Annual Report or exhibits hereto.

D.Exchange controls.

There is no limitation imposed by Canadian law or by our amended articles of incorporation on the right of a non-resident to hold or vote our common shares, other than discussed below.

Competition Act

Limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition (the “Commissioner”), to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. This legislation grants the Commissioner jurisdiction, for up to one year after the acquisition has been substantially completed, to challenge this type of acquisition by seeking a remedial order, including an order to prohibit the acquisition or require divestitures, from the Canadian Competition Tribunal, which may be granted where the Competition Tribunal finds that the acquisition substantially prevents or lessens, or is likely to substantially prevent or lessen, competition.

This legislation would also require any person or persons who intend to acquire more than 20% of our voting shares or, if such person or persons already own more than 20% of our voting shares prior to the acquisition, more than 50% of our voting shares, to file a notification with the Canadian Competition Bureau if certain financial thresholds are exceeded. These financial thresholds would be exceeded if: (i) we have assets in Canada or revenues in or from Canada generated from those assets of $93 million or more (this threshold is adjusted annually); and (ii) we and the potential acquirer together have assets in Canada or revenues from sales in, from or into Canada of $400 million or more. Where a notification is required, unless an exemption is available, the legislation prohibits completion of the acquisition until the expiration of the applicable statutory waiting period, unless the Commissioner either waives or terminates such waiting period or issues an advance ruling certificate. The Commissioner’s review of a notifiable transaction for substantive competition law considerations may take longer than the statutory waiting period.

Investment Canada Act

The Investment Canada Act requires each “non-Canadian” (as defined in the Investment Canada Act) who acquires “control” of an existing “Canadian business”, to file a notification in prescribed form with the responsible federal government department or departments not later than 30 days after closing, provided the acquisition of control is not a reviewable transaction under the Investment Canada Act. Subject to certain exemptions, a transaction that is reviewable under the Investment Canada Act may not be implemented until an application for review has been filed and the responsible minister of the federal cabinet has determined that the investment is likely to be of “net benefit to Canada” taking into account certain factors set out in the Investment Canada Act. Under the Investment Canada Act, an investment in our common shares by a non-Canadian would be reviewable only if it were an investment to acquire

76

control of us pursuant to the Investment Canada Act and our enterprise value was equal to or greater than $1.931 billion for non-state owned “trade agreement investors” (which include United States or EU investors, among certain others) and $1.287 billion for other investors from World Trade Organization (“WTO”), member countries. Lower financial thresholds apply to state-owned or influenced enterprises and non-WTO investors. These thresholds are adjusted annually.

Under the national security review regime in the Investment Canada Act, review on a discretionary basis may also be undertaken by the federal government in respect to a much broader range of investments by a non-Canadian to “acquire, in whole or part, or to establish an entity carrying on all or any part of its operations in Canada.” No financial threshold applies to a national security review. The relevant test is whether such investment by a non-Canadian could be “injurious to national security.” The responsible ministers have broad discretion to determine whether an investor is a non-Canadian and therefore subject to national security review. Review on national security grounds is at the discretion of the responsible ministers and may occur on a pre- or post-closing basis.

Other

There is no law, governmental decree or regulation in Canada that restricts the export or import of capital, or which would affect the remittance of dividends or other payments by us to non-resident holders of our common shares, other than withholding tax requirements.

E.Taxation.

Certain U.S. Federal Income Tax Considerations for U.S. Persons

The following is a general discussion of the principal U.S. federal income tax consequences of the acquisition, ownership and disposition of our common shares that are generally applicable to a U.S. Holder, as defined below. This summary assumes that the common shares are held as capital assets (generally, property held for investment), within the meaning of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), in the hands of a U.S. Holder at all relevant times. This discussion is based on the Code, final, temporary and proposed Treasury regulations thereunder (the “Treasury Regulations”) pertinent judicial decisions, interpretive rulings of the U.S. Internal Revenue Service (the “IRS”), and such other authorities as we have considered relevant. Future legislative, judicial, or administrative modifications, revocations, or interpretations, which may or may not be retroactive, may result in U.S. federal income tax consequences significantly different from those discussed herein. This discussion is not binding on the IRS. No ruling has been or will be sought or obtained from the IRS with respect to any of the U.S. federal tax consequences discussed herein. There can be no assurance that the IRS will not challenge any of the conclusions described herein or that a U.S. court will not sustain such a challenge.

This discussion does not address the U.S. federal income tax consequences to U.S. Holders subject to special rules, including U.S. Holders that (i) are banks, financial institutions, or insurance companies, (ii) are regulated investment companies or real estate investment trusts, (iii) are brokers, dealers, or traders in securities or currencies, (iv) are tax-exempt organizations, (v) are governments or agencies or instrumentalities thereof, (vi) elect to mark their securities to market, (vii) hold the common shares as part of hedges, straddles, constructive sales, conversion transactions, or other integrated investments, (viii) acquire the common shares as compensation for services or through the exercise or cancellation of employee stock options or warrants, (ix) have a functional currency other than the U.S. dollar, or (x) own or have owned directly, indirectly, or constructively, shares of the Company representing 10% or more of the voting power or value of the Company.

In addition, this discussion does not address tax considerations relevant to U.S. Holders under any non-U.S., state or local tax laws, the Medicare tax on net investment income, U.S. federal estate, gift tax, or other non-income tax, or the alternative minimum tax. Each U.S. Holder is urged to consult its tax advisors regarding the U.S. federal, state, local, and non-U.S. income and other tax considerations of an investment in the common shares.

As used herein, “U.S. Holder” means a beneficial owner of common shares that is (i) an individual who is a citizen or resident of the United States for U.S. federal income tax purposes, (ii) a corporation (or other entity taxable as a corporation for U.S. federal tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of its source, or (iv) a trust that (a) is subject to the primary supervision of a court within the United States and for which one or more U.S. persons have authority to control all substantial decisions or (b) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

If a pass-through entity, including a partnership or other entity or arrangement taxable as a partnership for U.S. federal income tax purposes, holds common shares, the U.S. federal income tax treatment of an owner or partner generally will depend on the status of such owner or partner and on the activities of the pass-through entity. A U.S. person that is an owner or partner of a pass-through entity holding the common shares is urged to consult its own tax advisor.

PFIC Rules

A non-U.S. corporation, such as the Company, will be classified as a PFIC for U.S. federal income tax purposes for a taxable year, if either (a) 75% or more of the gross income of the Company consists of certain types of passive income (which we refer to as the “income test”) or (b) 50% or more of the value of the Company’s assets either produce passive income or are held for the production of passive

77

income. The value of the Company’s assets for this purpose is expected to be based, in part, on the quarterly average of the fair market value of such assets (which we refer to as the “asset test”). “Gross income” generally includes all sales revenues less the cost of goods sold. “Passive income” generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions, but does not include active business gains arising from the sale of certain commodities.

For purposes of the PFIC income test and asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and asset test described above, and assuming certain other requirements are met, “passive income” does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain “related persons” (as defined in the Code), to the extent such items are properly allocable to the income of such related person that is not passive income.

There is a significant risk that the Company may be classified as a PFIC for the tax year ending December 31, 2022. No opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. This determination will depend on, among other things, the composition of the assets and income of such corporation over the course of each such tax year and, as a result, the Company’s PFIC status for the current year and future years cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any PFIC determination made by the Company. Each U.S. Holder should consult its own tax advisor regarding the Company’s status as a PFIC and the PFIC status of each non-U.S. subsidiary of the Company.

In any tax year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.

If the Company is a PFIC in 2022 or any other tax year in which a U.S. Holder owns common shares, the U.S. federal income tax consequences to a U.S. Holder of the purchase of common shares and the acquisition, ownership, and disposition of common shares will depend on whether such U.S. Holder makes a “qualified electing fund” or “QEF” election under Section 1295 of the Code (a “QEF Election”) or makes a mark-to-market election under Section 1296 of the Code (a “Mark-to-Market Election”) with respect to common shares. A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election (a “Non-Electing U.S. Holder”) will be subject to certain adverse tax treatment described below.

A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code with respect to (a) any gain recognized on the sale or other taxable disposition of common shares and (b) any excess distribution received on the common shares. A distribution generally will be an “excess distribution” to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder’s holding period for the common shares, if shorter).

Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of common shares of a PFIC, and any excess distribution received on such common shares (or a distribution by a subsidiary PFIC to its shareholder that is deemed to be received by a U.S. Holder) must be ratably allocated to each day in a Non-Electing U.S. Holder’s holding period for the common shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferential tax rates, as discussed below). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as “personal interest,” which is not deductible.

If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds common shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. If the Company ceases to be a PFIC, a Non-Electing U.S. Holder may terminate this deemed PFIC status with respect to common shares by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code as discussed above) as if such common shares were sold on the last day of the last tax year for which the Company was a PFIC.

Mark-to-Market Election

A U.S. Holder may make a Mark-to-Market Election with respect to common shares only if the common shares are marketable stock. The common shares generally will be “marketable stock” if the common shares are regularly traded on a national securities exchange that is registered with the SEC (including the Nasdaq). If such stock is traded on such a qualified exchange or market, such stock generally will be considered “regularly traded” for any calendar year during which such stock is traded, other than in de minimis

78

quantities, on at least 15 days during each calendar quarter. Provided that the common shares are “regularly traded” as described in the preceding sentence, the common shares are expected to be marketable stock. We believe that the Company’s common shares were “regularly traded” in each quarter of 2022 and expect that the common shares should continue to be “regularly traded” in 2023. However, there can be no assurance that the common shares will be “regularly traded” in the current or any subsequent calendar quarters. U.S. Holders should consult their own tax advisors regarding the marketable stock rules.

A U.S. Holder that makes a Mark-to-Market Election with respect to its common shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such common shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder’s holding period for the common shares and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the common shares.

A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the common shares, as of the close of such tax year over (b) such U.S. Holder’s tax basis in the common shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (i) such U.S. Holder’s adjusted tax basis in the common shares, over (ii) the fair market value of such common shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).

A U.S. Holder that makes a Mark-to-Market Election generally also will adjust its tax basis in the common shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of common shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years).

A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed U.S. federal income tax return (taking into account any extensions to file such U.S. federal income tax return). A timely Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the common shares cease to be “marketable stock” or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making, a Mark-to-Market Election.

Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the common shares, no such election may be made with respect to the stock of any subsidiary PFIC that a U.S. Holder is treated as owning because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to eliminate the interest charge and other income inclusion rules described above with respect to deemed dispositions of subsidiary PFIC stock or distributions from a subsidiary PFIC to its shareholder.

QEF Election

A U.S. Holder that makes a QEF Election for the first tax year in which the Company is treated as a PFIC generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its common shares. However, a U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such U.S. Holder’s pro rata share of (a) the Company’s net capital gain, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the Company’s ordinary earnings, which will be taxed as ordinary income to such U.S. Holder. Generally, “net capital gain” is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and “ordinary earnings” are the excess of (a) “earnings and profits” over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as “personal interest,” which is not deductible.

A U.S. Holder that makes a timely QEF Election generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents “earnings and profits” that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder’s tax basis in the common shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of common shares.

The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as “timely” for purposes of avoiding the default PFIC rules discussed above if such QEF Election is made for the first year in the U.S. Holder’s holding period for the common shares in which the Company is a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year (taking into account any extensions to file such U.S. federal income tax

79

return). If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the subsidiary PFIC for the QEF rules to apply to both PFICs.

A QEF Election will apply to the tax year for which such QEF Election is made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company was not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.

U.S. Holders should be aware that there can be no assurances that the Company will satisfy the record keeping requirements that apply to a QEF, or that the Company will supply U.S. Holders with a PFIC Annual Information Statement or other information that such U.S. Holders are required to report under the QEF rules, in the event that we are a PFIC. Thus, U.S. Holders may not be able to make a QEF Election with respect to their common shares. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a QEF Election.

A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed U.S. federal income tax return. However, if the Company does not provide the required information, U.S. Holders will not be able to make a QEF Election for the Company and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions.

Distributions on the Common Shares

Subject to the PFIC rules discussed above, the gross amount of any distribution paid by the Company will generally be subject to U.S. federal income tax as foreign source dividend income to the extent paid out of the Company’s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Such amount will be included in gross income by a U.S. Holder as ordinary income on the date that such U.S. Holder actually or constructively receives the distribution in accordance with such holder’s regular method of accounting for U.S. federal income tax purposes. The amount of any distribution made by the Company in property other than cash will be the fair market value (determined in U.S. dollars) of such property on the date of the distribution. Because the Company does not intend to calculate its earnings and profits on the basis of U.S. federal income tax principles, any distribution paid will generally be treated as a dividend for U.S. federal income tax purposes. Dividends paid by the Company will not be eligible for the dividends received deduction allowed to corporations.

To the extent that a distribution exceeds the amount of the Company’s current and accumulated earnings and profits, as determined under U.S. federal income tax principles, such distribution will be treated first as a tax-free return of capital, causing a reduction in a U.S. Holder’s adjusted basis in the common shares held by such U.S. Holder (thereby increasing the amount of gain, or decreasing the amount of loss, to be recognized by such U.S. Holder upon a subsequent disposition of the common shares), with any amount that exceeds such U.S. Holder’s adjusted basis being taxed as a capital gain recognized on a sale or exchange (as discussed below).

So long as the common shares are listed on the Nasdaq or the Company is eligible for benefits under the Income Tax Convention between the U.S. and Canada, dividends that a U.S. Holder receives from the Company will be “qualified dividend income” if certain holding period and other requirements (including a requirement that the Company is not a PFIC in the year of the dividend or the immediately preceding year) are met. Qualified dividend income of an individual or other non-corporate U.S. Holder is subject to a reduced maximum U.S. federal income tax rate. However, if the Company is a PFIC in the year of the dividend or was a PFIC in the immediately preceding year, distributions on the common shares will not constitute “qualified dividend income” eligible for the preferential tax rates described above.

Subject to certain limitations, Canadian tax withheld with respect to distributions made on the common shares may be treated as foreign taxes eligible for credit against a U.S. Holder’s U.S. federal income tax liability. Alternatively, a U.S. Holder may, subject to applicable limitations, elect to deduct the otherwise creditable Canadian withholding taxes for U.S. federal income tax purposes. The rules governing the foreign tax credit, including those introduced under recently issued U.S. Treasury Regulations that apply to foreign income taxes paid or accruable in taxable years beginning on or after December 28, 2021, are complex and involve the application of rules that depend upon a U.S. Holder’s particular circumstances. Accordingly, a U.S. Holder is urged to consult its tax advisor regarding the availability of the foreign tax credit under its particular circumstances.

Sale, Exchange or Other Taxable Disposition of the Common Shares

Subject to the PFIC rules discussed above, a U.S. Holder generally will recognize gain or loss upon the taxable sale, exchange or other disposition of the common shares in an amount equal to the difference between (i) the U.S. dollar value of the amount realized upon the sale, exchange or other taxable disposition and (ii) such U.S. Holder’s adjusted tax basis in the common shares. A U.S. Holder’s adjusted tax basis in such common shares will generally be its U.S. dollar cost. Generally, such gain or loss will be capital gain or loss and will be long-term capital gain or loss if, on the date of the sale, exchange or other taxable disposition, such U.S. Holder has held the common shares for more than one year. If such U.S. Holder is an individual or other non-corporate U.S. Holder, long-term capital gains will be

80

subject to a reduced maximum U.S. federal income tax rate. The deductibility of capital losses is subject to limitations under the Code. Gain or loss, if any, that a U.S. Holder realizes upon a sale, exchange or other taxable disposition of the common shares generally will be treated as having a U.S. source for U.S. foreign tax credit limitation purposes.

Receipt of Foreign Currency

The U.S. dollar value of any cash distribution made in Canadian dollars to a U.S. Holder will be calculated by reference to the exchange rate prevailing on the date of actual or constructive receipt of the distribution, regardless of whether the Canadian dollars are converted into U.S. dollars at that time. For U.S. Holders following the accrual method of accounting, the amount realized on a disposition of the common shares for an amount in Canadian dollars will be the U.S. dollar value of this amount on the date of disposition. On the settlement date, such U.S. Holder will recognize U.S. source foreign currency gain or loss (taxable as ordinary income or loss) equal to the difference (if any) between the U.S. dollar value of the amount received based on the exchange rates in effect on the date of sale or other disposition and the settlement date. However, in the case of shares traded on an established securities market for U.S. federal income tax purposes that are sold by a cash method U.S. Holder (or an accrual method U.S. Holder that so elects), the amount realized will be based on the spot rate in effect on the settlement date for the disposition, and no exchange gain or loss will be recognized at that time. A U.S. Holder will generally have a basis in Canadian dollars equal to their U.S. dollar value on the date of receipt of such distribution, on the date of disposition, or, in the case of cash method U.S. Holders (and accrual method U.S. Holders that so elects), on the date of settlement. Any U.S. Holder that receives payment in Canadian dollars and converts or disposes of the Canadian dollars after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss and that generally will be U.S. source income or loss for foreign tax credit purposes. U.S. Holders are urged to consult their own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of Canadian dollars.

Information with Respect to Foreign Financial Assets

Individuals and certain entities that own “specified foreign financial assets,” generally with an aggregate value in excess of $50,000 are generally required to file an information report on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect to such assets with their tax returns for each year in which they hold common shares. “Specified foreign financial assets” include any financial accounts maintained by certain foreign financial institutions, as well as securities issued by non-U.S. persons if they are not held in accounts maintained by financial institutions. U.S. Holders are urged to consult their tax advisors regarding the application of this reporting requirement to their ownership of the common shares.

Information Reporting and Backup Withholding

In general, information reporting will apply to dividends paid to a U.S. Holder in respect of the common shares and the proceeds received by such U.S. Holder from the sale, exchange or other disposition of the common shares within the United States unless such U.S. Holder is a corporation or other exempt recipient. Backup withholding may apply to such payments if a U.S. Holder fails to provide a taxpayer identification number or certification of exempt status or fails to report dividend and interest income in full. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a refund or credit against a U.S. Holder’s U.S. federal income tax liability, provided that the required information is timely furnished to the IRS.

Disclosure Requirements for Certain U.S. Holders Recognizing Significant Losses

A U.S. Holder that claims significant losses in respect of common shares for U.S. federal income tax purposes (generally (i) $10 million or more in a taxable year or $20 million or more in any combination of taxable years for corporations or partnerships all of whose partners are corporations, (ii) $2 million or more in a taxable year or $4 million or more in any combination of taxable years for all other taxpayers, or (iii) $50,000 or more in a taxable year for individuals or trusts) with respect to a foreign currency transaction, may be required to file Form 8886 for “reportable transactions.” U.S. Holders should consult their own tax advisors concerning any possible disclosure obligation with respect to the common shares.

Certain Canadian Federal Income Tax Considerations

The following is a general summary, as of the date hereof, of the principal Canadian federal income tax considerations under the Income Tax Act (Canada) and the regulations thereunder (collectively, the “Tax Act”) generally applicable to a holder who as beneficial owner acquires, owns, or disposes of common shares of the Company and who, at all relevant times, for purposes of the Tax Act: (a) holds the common shares as capital property; (b) deals at arm’s length with the Company; and (c) is not affiliated with the Company (a “Holder”). Generally, the common shares will be capital property to a Holder unless they are acquired or held in the course of carrying on a business or as part of an adventure or concern in the nature of trade.

This summary does not apply to a Holder: (a) that is a “financial institution”, as defined in the Tax Act for purposes of the mark-to-market rules contained in the Tax Act; (b) an interest in which is a “tax shelter investment”, as defined in the Tax Act; (c) that is a “specified financial institution”, as defined in the Tax Act; (d) that has made an election under the Tax Act to determine its Canadian tax results in a currency other than Canadian currency; (e) that has entered or will enter into a “derivative forward agreement” or a

81

“synthetic disposition arrangement”, each as defined in the Tax Act, with respect to its common shares; (f) that receives dividends on the common shares under or as part of a “dividend rental arrangement”, as defined in the Tax Act; (g) that is exempt from tax under Part I of the Tax Act; or (h) that is a partnership.

Additional considerations, not discussed herein, may apply to a Holder that is a corporation resident in Canada and is, or becomes (or does not deal at arm’s length with a corporation resident in Canada that is or becomes), as part of a transaction or event or series of transactions or events that includes the acquisition of common shares, controlled by a non-resident person (or a group of non-resident persons not dealing with each other at arm’s length) for purposes of the “foreign affiliate dumping” rules, each for purposes of the Tax Act. All such Holders should consult their own tax advisors.

This summary is based on the facts set out in this Annual Report, the current provisions of the Tax Act, all specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (“Canadian Tax Proposals”) and an understanding of the current published administrative policies of the Canada Revenue Agency. This summary assumes that all Canadian Tax Proposals will be enacted in the form proposed, however no assurance can be made that the Canadian Tax Proposals will be enacted in the form proposed or at all. This summary is not exhaustive of all possible Canadian federal income tax considerations and, other than the Canadian Tax Proposals, does not take into account or anticipate any changes in law or in administrative policy, whether by legislative, regulatory, administrative or judicial decision or action, nor does it take into account provincial, territorial or non-Canadian tax legislation or considerations, which may differ significantly from the Canadian federal income tax considerations discussed herein.

This summary is of a general nature only and is not exhaustive of all possible Canadian federal income tax considerations applicable to a Holder. The income and other tax consequences of acquiring, owning or disposing of common shares will vary depending on a Holder’s particular status and circumstances. This summary is not intended to be, nor should it be construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to acquiring, holding or disposing of the common shares having regard to their particular circumstances.

Currency Conversion

Generally, for purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the common shares must be converted into Canadian dollars based on the exchange rates as determined in accordance with the Tax Act. The amount of any dividends required to be included in the income of, and capital gains or capital losses realized by, a Holder may be affected by fluctuations in the Canadian exchange rate.

Canadian Holders

The following summary applies to a Holder who, for purposes of the Tax Act, and at all relevant times, is, or is deemed to be, resident in Canada (a “Canadian Holder”). A Canadian Holder whose common shares do not otherwise qualify as capital property may in certain circumstances make an irrevocable election in accordance with subsection 39(4) of the Tax Act to have their common shares, and every other “Canadian security” (as defined in the Tax Act) owned by such Canadian Holder in the taxation year of the election and in all subsequent taxation years, deemed to be capital property. Canadian Holders whose common shares might not otherwise be considered to be capital property should consult their own tax advisors concerning this election.

Dividends on Common Shares

Dividends received or deemed to be received on the common shares by a Canadian Holder who is an individual (including certain trusts) will be required to be included in computing the Canadian Holder’s income for the taxation year in which such dividends are received and will be subject to the gross-up and dividend tax credit rules of the Tax Act that apply to taxable dividends received from “taxable Canadian corporations” (as defined in the Tax Act), including the enhanced gross-up and dividend tax credit in respect of dividends designated by the Company as “eligible dividends” (as defined in the Tax Act) in accordance with the Tax Act. There may be limitations on the Company’s ability to designate dividends and deemed dividends as eligible dividends.

Dividends received by a Canadian Holder who is an individual (including certain trusts) may result in such Canadian Holder being liable for alternative minimum tax under the Tax Act. Budget 2022 announced an intention to revise the minimum tax rules and the 2022 Fall Economic Statement released by the government of Canada on November 3, 2022 stated that a detailed proposal and path for implementation will be released with the 2023 Federal Budget (Canada). No draft legislation has been released to date. Canadian Holders who are individuals should consult their own tax advisors in this regard.

Dividends received or deemed to be received on the common shares by a Canadian Holder that is a corporation will be included in computing the corporation’s income for the taxation year in which such dividends are received, but such dividends will generally be deductible in computing the corporation’s taxable income for that taxation year, subject to all relevant restrictions under the Tax Act. In certain circumstances, subsection 55(2) of the Tax Act will treat a taxable dividend received by a Canadian Holder that is a corporation as proceeds of disposition or a capital gain, rather than a dividend. Canadian Holders that are corporations should consult their own tax advisors having regard to their own circumstances.

82

A Canadian Holder that is a “private corporation” or a “subject corporation” (each as defined in the Tax Act) will generally be liable under Part IV of the Tax Act to pay an additional tax on dividends received or deemed to be received on common shares to the extent that such dividends are deductible in computing the Canadian Holder’s taxable income. Such additional tax may be refundable in certain circumstances. A Canadian Holder that is, throughout the relevant taxation year, a “Canadian-controlled private corporation” (as defined in the Tax Act) or a “substantive CCPC” (as proposed to be defined in the Tax Act pursuant to the Canadian Tax Proposals released on August 9, 2022), may be liable to pay an additional tax, refundable in certain circumstances, on its “aggregate investment income” which is defined in the Tax Act to include dividends to the extent that such dividends are not deductible in computing the Canadian Holder’s taxable income for the taxation year.

Dispositions of Common Shares

Generally, on the disposition or deemed disposition of common shares by a Canadian Holder, the Canadian Holder will realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition in respect of such common shares, net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base of the common shares to the Canadian Holder immediately before the disposition or deemed disposition. Such capital gain (or capital loss) will be subject to the tax treatment described under “Taxation of Capital Gains and Capital Losses”.

The adjusted cost base to the Canadian Holder of a common share will be determined at any particular time by averaging the cost of such common share with the adjusted cost base of the other common shares owned by the Canadian Holder as capital property at that time and by making certain other adjustments required under the Tax Act.

Taxation of Capital Gains and Capital Losses

Generally, one-half of the amount of any capital gain (a “taxable capital gain” (as defined in the Tax Act)), realized by a Canadian Holder on a disposition of common shares in a taxation year must be included in computing such Canadian Holder’s income for that year, and one-half of any capital loss (an “allowable capital loss” (as defined in the Tax Act)), realized by a Canadian Holder on a disposition of common shares in a taxation year must be deducted from any taxable capital gains realized by the Canadian Holder in the year, subject to and in accordance with the provisions of the Tax Act. Allowable capital losses in excess of taxable capital gains realized in a taxation year may be carried back and deducted in any of the three preceding taxation years or carried forward and deducted in any subsequent taxation year against net taxable capital gains realized in such years, subject to and in accordance with the provisions of the Tax Act.

The amount of any capital loss realized by a Canadian Holder that is a corporation on the disposition or deemed disposition of a common share may be reduced by the amount of any dividends received (or deemed to be received) by the Canadian Holder on such common share to the extent and under the circumstances prescribed by the Tax Act. Similar rules may apply where a common share is owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary. Such Canadian Holders should consult their own tax advisors.

A taxable capital gain realized by a Canadian Holder who is an individual (including certain trusts) may give rise to a liability for alternative minimum tax. Budget 2022 announced an intention to revise the minimum tax rules and the 2022 Fall Economic Statement released by the government of Canada on November 3, 2022 stated that a detailed proposal and path for implementation will be released with the 2023 Federal Budget (Canada). No draft legislation has been released to date.

A Canadian Holder that is throughout the relevant taxation year a “Canadian-controlled private corporation” (as defined in the Tax Act) or a “substantive-CCPC” (as proposed to be defined in the Tax Act as announced in Budget 2022) may be liable to pay an additional tax on certain investment income, including taxable capital gains (but excluding dividends or deemed dividends deductible in computing taxable income). Such additional tax may be refundable in certain circumstances.

Non-Canadian Holders

The following summary applies to a holder who acquires, as beneficial owner, common shares and who, for purposes of the Tax Act and any relevant income tax treaty or convention, at all relevant times, (a) is not (and is not deemed to be) a resident of Canada and (b) will not use or hold (and will not be deemed to use or hold) the common shares in, or in the course of carrying on a business or part of a business in Canada (a “Non-Canadian Holder”). This summary does not apply to a Non-Canadian Holder that carries on an insurance business in Canada and elsewhere or an “authorized foreign bank” (as defined in the Tax Act).

Dividends on Common Shares

Dividends paid or credited or deemed to be paid or credited on the common shares to a Non-Canadian Holder will generally be subject to Canadian withholding tax at the rate of 25% of the gross amount of the dividend, subject to any reduction in the rate of withholding to which the Non-Canadian Holder may be entitled under an applicable income tax convention between Canada and the country in which the Non-Canadian Holder is resident. For example, under the Convention between Canada and the United States of America with Respect to Taxes on Income and on Capital, as amended (the “Canada-U.S. Tax Treaty”), where dividends on the common shares are considered to be paid to or derived by a Non-Canadian Holder that is a beneficial owner of the dividends and is a U.S. resident for the purposes of,

83

and is fully entitled to benefits of, the Canada-U.S. Tax Treaty, the applicable rate of Canadian withholding tax is generally reduced to 15%.

Dispositions of Common Shares

A Non-Canadian Holder will not be subject to tax under the Tax Act on any capital gain realized on a disposition or deemed disposition of common shares, nor will capital losses arising from the disposition, or deemed disposition, of common shares, be recognized under the Tax Act, unless at the time of disposition the common shares are “taxable Canadian property” (as defined in the Tax Act) of the Non-Canadian Holder for purposes of the Tax Act and the Non-Canadian Holder is not entitled to relief under an applicable income tax convention between Canada and the country in which the Non-Canadian Holder is resident.

Generally, the common shares will not constitute “taxable Canadian property” of a Non-Canadian Holder at the time of disposition or deemed disposition of the common shares provided that the common shares are listed at that time on a “designated stock exchange” (as defined in the Tax Act), which includes the Nasdaq, unless at any particular time during the 60-month period immediately preceding the time of disposition or deemed disposition: (i) at least 25% or more of the issued shares of any class or series of the capital stock of the Company was owned by any combination of (A) the Non-Canadian Holder, (B) persons with whom the Non-Canadian Holder does not deal at arm’s length for purposes of the Tax Act, or (C) partnerships in which the Non-Canadian Holder or any person described in (B) holds a membership interest directly or indirectly through one or more partnerships, and (ii) more than 50% of the fair market value of the common shares was derived, directly or indirectly, from one or any combination of: (a) real or immoveable property situated in Canada, (b) “Canadian resource properties” (as defined in the Tax Act), (c) “timber resource properties” (as defined in the Tax Act), or (d) options in respect of, interests in, or for civil law rights in, any such property, whether or not such property exists. Notwithstanding the foregoing, in certain circumstances set out in the Tax Act, common shares could be deemed to be “taxable Canadian property.” Non-Canadian Holders whose common shares may constitute “taxable Canadian property” should consult their own tax advisors.

F.Dividends and paying agents.

Not applicable.

G.Statement by experts.

Not applicable.

H.Documents on display.

We are a “foreign private issuer” as such term is defined in Rule 405 under the Securities Act and Rule 3b-4 under the Exchange Act, and are not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. As a result, we do not file the same reports that a U.S. domestic issuer would file with the SEC, although we are required to file or furnish to the SEC the continuous disclosure documents that we are required to file in Canada under Canadian securities laws.

Copies of our financial statements and other continuous disclosure documents required under Canadian securities laws are available for viewing on SEDAR at www.sedar.com.

We will provide without charge to each person, including any beneficial owner, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this Annual Report (not including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: #300, 919 - 11 Avenue SW Calgary, AB, T2R 1P3 Attention: Sophie Pilon, phone number: +1 587-327-2017.

I.Subsidiary Information.

Not applicable.

J.Annual Report to Security Holders.

Not applicable.

Item 11. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Interest rate risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

84

Credit Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Credit risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Liquidity Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Liquidity risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Foreign Currency Risk

See the section entitled “Liquidity and Capital Resources—Liquidity risks associated with financial instruments—Foreign currency risk” in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Item 12. Description of Securities Other than Equity Securities.

Not applicable.

85

PART II

Item 13. Defaults, Dividend Arrearages and Delinquencies.

None.

Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds.

A. – D. Material Modifications to the Rights of Security Holders

None.

E. Use of Proceeds

Not applicable.

Item 15. Controls and Procedures.

See the section titled “Disclosure Controls and Procedures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1.

Item 16A. Audit Committee Financial Expert.

The Company’s audit committee is comprised of Greg Mills and Lori Ell, and chaired by Bryan Pinney. Our board of directors has determined that each of Greg Mills, Lori Ell and Bryan Pinney is financially literate and meets the independence requirements for directors, including the heightened independence standards for members of the audit committee under Rule 10A-3 under the Exchange Act and NI 52-110. Our board of directors has determined that Bryan Pinney is “financially sophisticated” within the meaning of the Nasdaq Rules, “financially literate” within the meaning of NI 52-110, and a “financial expert” as defined by Rule 10A-3 under the Exchange Act. For information relating to qualifications and experience of each audit committee member, see “Item 6B Directors, Senior Management and Employees—Compensation”.

Item 16B. Code of Ethics.

The Company’s board of directors has adopted a code of conduct applicable to all of our directors and employees, including our Chief Executive Officer and Chief Financial Officer. This code qualifies as a “code of ethics” as defined in section 406(c) of SOX and which is a “code” under NI 58-101. The Company’s code of conduct is available at www.sndlgroup.com. Information contained on, or that can be accessed through, the Company’s website is not incorporated by reference into this Annual Report.

If we make any amendment to the code of conduct or grant any waiver therefrom, whether explicit or implicit, to a director or executive officer, we will disclose the nature of such amendment or waiver on our website to the extent required by, and in accordance with, the rules and regulations of the SEC and the Canadian securities regulatory authorities.

Item 16C. Principal Accountant Fees and Services.

The following table summarizes the fees charged by Marcum LLP (New York, New York, United States; Auditor Firm ID: 688), the Company’s independent auditor, in the fiscal year ended December 31, 2022:

	Fees billed for the fiscal year ended
Services Retained	December 31, 2022
Audit fees (1)	$	2,305,624
Audit-related fees (2)		33,720
Tax fees (3)		—
All other fees		—

(1)“Audit fees” include fees necessary to perform the annual audit or reviews of the consolidated financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings and engagements.

86

(2)“Audit-related fees” include fees for assurance and related services by our independent auditor that are reasonably related to the performance of the audit or review of our financial statements other than those included in “Audit Fees”.

(3)“Tax Fees” include fees for all tax services other than those included in “Audit Fees” and “Audit-Related Fees”. This category includes fees for tax compliance, tax advice and tax planning.

The following table summarizes the fees charged by KPMG (Calgary, Alberta, Canada; Auditor Firm ID: 85), the Company’s independent auditor, for the periods noted until July 21, 2022 when KPMG ceased to be the Company’s auditor:

	Fees billed for the fiscal year ended
Services Retained	December 31, 2022		December 31, 2021
Audit fees (1)	$	55,052	$	2,800,190
Audit-related fees (2)		—		—
Tax fees (3)		—		—
All other fees		—		—

(1)“Audit fees” include fees necessary to perform the annual audit or reviews of the consolidated financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings and engagements.

(2)“Audit-related fees” include fees for assurance and related services by our independent auditor that are reasonably related to the performance of the audit or review of our financial statements other than those included in “Audit Fees”.

(3)“Tax Fees” include fees for all tax services other than those included in “Audit Fees” and “Audit-Related Fees”. This category includes fees for tax compliance, tax advice and tax planning.

The audit committee is responsible for the pre-approval of all non-audit services to be provided by the Company’s auditor.

Item 16D. Exemptions from the Listing Standards for Audit Committees.

Not applicable.

Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers.

Period	Total Number of Shares Purchased		Average Price Paid per Share (US$)		Total Number of Shares Purchased as Part of Publicly Announced Programs		Maximum Number of Shares that May Yet Be Purchased Under the Programs
June 14 - 17, 2022 (1)		528,031		3.00		528,031		9,751,969
August 25 - 26, 2022 (1)		282,312		2.96		282,312		9,469,657
September 2 - 29, 2022 (1)		878,223		2.49		878,223		8,591,434
October 3 - 4, 2022 (1)		200,000		2.21		200,000		8,391,434
December 28 - 30, 2022 (2)		2,363,849		2.05		2,363,849		9,436,151
Total		4,252,415		2.33		4,252,415		9,436,151

(1)On November 11, 2021, the Company announced that the board of directors of SNDL approved a share repurchase program which authorizes the Company to repurchase, from time to time, up to an aggregate of $100 million of its outstanding common shares through open market purchases at prevailing market prices. SNDL could only purchase a maximum of 10.28 million common shares under the share repurchase program, representing approximately 5% of the issued and outstanding common shares as at the date of announcement. The share repurchase program commenced on November 19, 2021 and expired on November 19, 2022.

(2)On November 16, 2022, the Company announced that the board of directors of SNDL approved a renewal of the share repurchase program upon the expiry of its current share repurchase program on November 19, 2022. The renewed share repurchase program authorizes the Company to repurchase up to $100 million of its outstanding common shares through open market purchases at prevailing market prices. SNDL may only purchase a maximum of 11.8 million common shares under the share repurchase program, representing approximately 5% of the issued and outstanding common shares as at the date of announcement. The program will expire on November 30, 2023.

Item 16F. Change in Registrant’s Certifying Accountant.

On April 7, 2022, the Company received notice of the decision of KPMG LLP (“KPMG”) to not stand for reappointment as the Company’s independent auditor for fiscal year 2022 at its upcoming annual general meeting of shareholders. KPMG’s decision not to stand for reappointment as the Company’s independent auditor was considered and approved by the Company’s audit committee and

87

board of directors. The Company’s audit committee selected and engaged Marcum LLP as its new independent registered public accounting firm effective June 20, 2022.

For the years ended December 31, 2021 and December 31, 2020, no report by KPMG on the Company’s consolidated financial statements contained an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope or accounting principles.

For the years ended December 31, 2021 and December 31, 2020 and through the date hereof, (i) there were no disagreements (as that term is used in Item 16F(a)(1)(iv) of Form 20-F and the related instructions) between the Company and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference thereto in its reports upon on the Company’s audited consolidated financial statements for the years ended December 31, 2021 and December 31, 2020, and (ii) there were no “reportable events” as such term is defined in Item 16F(a)(1)(v) of Form 20-F, other than the material weaknesses in the Company’s internal control over financial reporting (i) disclosed in the section titled “Disclosure Controls and Procedures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached to this Annual Report as Exhibit 15.1 and (ii) previously disclosed in the section titled “Disclosure Controls and Procedures” in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” attached as Exhibit 15.1 to the Company’s annual report on Form 20-F for the year ended December 31, 2020, filed with the SEC on March 18, 2021.

Item 16G. Corporate Governance.

The Nasdaq Rules include certain accommodations in the corporate governance requirements that allow foreign private issuers, such as us, to follow “home country” corporate governance practices in lieu of the otherwise applicable corporate governance standards of the Nasdaq. The application of such exceptions requires that we disclose any significant ways in which our corporate governance practices differ from the Nasdaq Rules that we do not follow. Although our shares are listed on the Nasdaq, we continue to follow Canadian corporate governance practices in lieu of the requirement under Rule 5620(c) of the Nasdaq Rules that a company’s bylaws provide for a quorum for any meeting of the holders of the company’s common shares that is not less than 33 1/3% of the outstanding common shares of the company. Our by-laws provide that a quorum of shareholders is constituted by the holders of at least 25% of the shares entitled to vote at the meeting, present in person or represented by proxy, and at least two persons entitled to vote at the meeting, present in person or represented by proxy. In addition, we do not follow Rule 5635 of the Nasdaq Rules that requires that shareholder approval be required for the Company to issue securities in connection with certain events, such as the acquisition of shares or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, rights issues at or below market price, certain private placements, directed issues at or above market price and issuance of convertible notes. Neither Canadian securities laws nor Alberta corporate law require shareholder approval for such transactions, except where such transactions constitute a “related party transaction” or “business combination” under Canadian securities laws or where such transaction is structured in a way that requires shareholder approval under the ABCA, in which case, we intend to follow our home country requirements.

Item 16H. Mine Safety Disclosure

Not applicable.

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

88

PART III

Item 17. Financial Statements.

See Item 18. – “Financial Statements.”

Item 18. Financial Statements.

Our Annual Financial Statements are included at the end of this Annual Report.

Item 19. Exhibits.

List all exhibits filed as part of the registration statement or annual report, including exhibits incorporated by reference.

Exhibit Number	Description	Method of Filing
1.1	Articles of amalgamation of SNDL Inc., as currently in effect	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
1.2	Bylaws of SNDL Inc. as currently in effect	Incorporated by reference to Exhibit 3.2 to the Registrant’s registration statement on Form F-1/A, filed with the SEC on July 30, 2019
2.1	Specimen Share Certificate	Incorporated by reference to Exhibit 3.2 to the Registrant’s registration statement on Form F-1/A, filed with the SEC on July 30, 2019
2.2	Description of Securities of the Registrant Registered under Section 12 of the Exchange Act	Incorporated by reference to Exhibit 2.4 to the Registrant’s annual report on Form 20-F, filed with the SEC on March 31, 2020
2.3	Securities Purchase Agreement dated as of June 5, 2020 by and among SNDL Inc. and each of the investors listed on the Schedule of Buyers attached thereto, including the forms of the related convertible notes, warrants and registration rights agreement	Incorporated by reference to Exhibit 99.5 to the Registrant’s current report on Form 6-K, filed with the SEC on June 8, 2020
2.4	Form of Series A and B Warrants	Incorporated by reference to Exhibit 99.1 to the Registrant’s current report on Form 6-K, filed with the SEC on August 18, 2020
2.5	Form of New Warrant	Incorporated by reference to Exhibit 99.2 to the Registrant’s current report on Form 6-K, filed with the SEC on February 19, 2021
2.6	Amended and Restated Equity Distribution Agreement, by and between SNDL Inc. and A.G.P./Alliance Global Partners	Incorporated by reference to Exhibit 99.1 to the Registrant’s current report on Form 6-K, filed with the SEC on January 21, 2021
4.1†	Implementation Agreement, dated as of December 20, 2022, by and between SNDL Inc. and Nova Cannabis Inc., together with the agreed forms of Strategic Partnership Agreement, Amended and Restated Management and Administrative Services Agreement, Amended and Restated Investor Rights Agreement, Amended and Restated Collaboration and Financial Reporting Agreement and Grid Promissory Note	Incorporated by reference to Exhibit 99.1 to the Registrant’s current report on Form 6-K, filed with the SEC on April 10, 2023

89

4.2	Amendment No. 1 to the Implementation Agreement, dated as of April 3, 2023, by and between SNDL Inc. and Nova Cannabis Inc	Incorporated by reference to Exhibit 99.2 to the Registrant’s current report on Form 6-K, filed with the SEC on April 10, 2023
8.1	List of Subsidiaries	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
12.1	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
12.2	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
13.1	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
13.2	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
15.1	Management’s Discussion and Analysis of Financial Condition and Results of Operations	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
15.2	Consent of Marcum LLP	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
15.3	Consent of KPMG LLP	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2022
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
†	Portions of this exhibit, marked by brackets, have been omitted because they are both (i) not material and (ii) include information of the type that we treat as private or confidential, or because they include information the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

90

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

	SNDL Inc.
Date: April 24, 2023	By:	/s/ Zachary George
		Name: Zachary George
		Title: Chief Executive Officer

91

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of SNDL Inc. (f/k/a Sundial Growers Inc.)

Opinion on the Financial Statements

We have audited the accompanying consolidated statement of financial position of SNDL Inc. (the “Company”) as of December 31, 2022, the related consolidated statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for the year ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with the International Financial Reporting Standards as issued by the International Accounting Standards Boards (“IFRS”).

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) ("PCAOB"), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013 and our report dated April 24, 2023 expressed an adverse opinion on the effectiveness of the Company’s internal control over financial reporting because of the existence of a material weakness.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Emphasis of Matter – Retrospective Adjustment to provisional amounts

The accompanying consolidated financial statements of the Company as of December 31, 2021 and for the year then ended were audited by another auditor. As described in Note 5(b), the Company recorded adjustments to the fair value in the third quarter of 2022 to reflect additional information and greater certainty with respect to management estimates pertaining to facts and circumstances that were either unknown or uncertain at the date of the Inner Spirit acquisition. These adjustments related to changes in preliminary valuation assumptions, including refinement of accounts receivable, inventory, net investment in subleases, lease liabilities and amounts allocated to intangible assets and deferred tax liability. All measurement period adjustments were offset to goodwill. We audited the retrospective adjustments to provisional amounts in the comparative December 31, 2021 period. However, we were not engaged to audit, review, or apply any procedures to the December 31, 2021 consolidated financial statements of the Company other than with respect to such adjustments and, accordingly, we do not express an opinion or any other form of assurance on the December 31, 2021 consolidated financial statements taken as a whole.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

F-1

Business Combinations

The Company acquired Alcanna, Inc. on March 31, 2022. The acquisition was accounted for as a business combination. We identified the evaluation of the acquisition date fair value of the intangible assets as a critical audit matter.

The main consideration for our determination that the evaluation of the acquisition date fair values of the intangible assets acquired was a critical audit matter is the high degree of subjective auditor judgement associated with evaluating management’s determination of the fair values of the intangible assets, which is primarily due to complexity of the valuation models used and the sensitivity of the underlying significant assumptions. The assumptions used within the valuation models included prospective financial information, including future revenue growth and expected profitability, an applied discount rate, a reasonable approximation of a royalty rate and historical data pertaining to replacement costs. Auditing these assumptions involved extensive audit effort, including the need to involve our valuation specialists, due to the complexity of these assumptions and a high degree of auditor judgment when performing audit procedures and evaluating the results of those procedures.

How the Critical Audit Matter was addressed in the Audit

Our audit procedures related to the evaluation of acquisition date fair values of intangibles assets acquired included the following, among other:

•We evaluated the design effectiveness of certain controls over the acquisition date valuation process, including controls over the development of the key assumptions such as revenue growth and expected profitability, royalty rates, replacement costs and the applied discount rate.

•We obtained the purchase price allocation analyses from management and the third-party specialist engaged by management.

oWe assessed the qualifications and competence of management and the third-party specialist; and

oWe evaluated the methodologies used to determine the fair values of the intangible assets.

•We tested the assumptions used within the relief from royalty, cost and market approach models to estimate the fair values of the intangible assets, which included key assumptions such as the future revenue growth and profitability a reasonable approximation of a royalty rate and historical data pertaining to replacement costs and the applied discount rates.

•We assessed the reasonableness of management’s forecast by inquiring with management to understand how the forecast was developed and comparing the projections to historical results.

•We assessed the reasonableness of managements consideration of identifiable intangible assets separable from goodwill.

•We involved an internal valuation specialist who assisted in the evaluation and testing performed of the reasonableness of significant assumptions to the models, including the applied discount rates.

Goodwill Impairment

Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is possibly impaired. Goodwill is tested for impairment at a cash generating unit (“CGU”) level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount.

The main consideration for our determination that the impairment assessment is a critical audit matter is the complexity of auditing management’s impairment assessment due to judgments and assumptions required to evaluate those factors. Auditing these assumptions involved extensive audit effort, including the need to involve our valuation specialists, due to the complexity of these assumptions and a high degree of auditor judgment when performing audit procedures and evaluating the results of those procedures.

How the Critical Audit Matter was addressed in the Audit

Our audit procedures related to accounting for impairment of goodwill and intangible assets to address this critical audit matter included the following, among others:

•We obtained an understanding and evaluated the design of the internal controls over management’s annual impairment assessment, including identification of CGU’s

F-1

•We obtained the goodwill impairment analyses from management and the third-party specialist engaged by management.

oWe assessed the qualifications and competence of management and the third-party specialist; and

oWe evaluated the methodologies used to determine the fair values of the intangible assets.

•We tested the assumptions used within the income approach and/or market approach to estimate the goodwill impairment, which included key assumptions such as future revenue growth, the applied discount rates, selected market multiples and the market capitalization.

•We assessed the reasonableness of management’s forecast by inquiring with management to understand how the forecast was developed and comparing the projections to historical results.

•We involved an internal valuation specialist who assisted in the evaluation and testing performed of the reasonableness of methodologies and significant assumptions to the models, including the applied discount rates.

Valuation of Equity-Accounted Investees

The Company’s underlying investments in its equity-accounted investee is a joint venture through SunStream Bancorp Inc. (the “Joint Venture”). The Company records its interest in the Joint Venture using the equity method. The Joint Venture records its investments at fair value through profit and loss at each reporting period. The valuation of the investments held by the Joint Venture requires estimates, including market values of investment holdings and related underlying assumptions such as volatility and discount rates.

The main consideration for our determination that the fair value of the measurement of the Joint Venture’s investment is a critical audit matter is the high degree of subjectivity and auditor judgement required to evaluate the estimates, including market values of investment holdings and related underlying assumptions such as volatilities and discount rates used to calculate the fair value of its investments. Auditing these assumptions involved extensive audit effort, including the need to involve our valuation specialists, due to the complexity of these assumptions and a high degree of auditor judgment when performing audit procedures and evaluating the results of those procedures.

How the Critical Audit Matter was addressed in the Audit

Our audit procedures related to valuation of equity-accounted investees to address this critical audit matter included the following, among others:

•We obtained the analysis from management and the third-party specialist engaged by management.

oWe assessed the qualifications and competence of management and the third-party specialist; and

oWe evaluated the methodologies used to determine the fair values of the intangible assets.

•We involved an internal valuation specialists who assisted in the evaluation and testing performed of the reasonableness of the methodologies used in estimating the fair value of the investments, estimates of market values, volatilities and discount rates by comparing to publicly available market data for comparable assets.

/s/ Marcum llp

Marcum llp

We have served as the Company’s auditor since 2022.

New York

April 24, 2023

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

ON INTERNAL CONTROL OVER FINANCIAL REPORTING

To the Shareholders and Board of Directors of SNDL Inc. (f/k/a Sundial Growers Inc).

Adverse Opinion on Internal Control over Financial Reporting

We have audited SNDL Inc. and subsidiaries’ (the "Company") internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework (2013)issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, because of the effect of the material weakness described in the following paragraph on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

A material weakness is a control deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness have been identified and included in “Management's Annual Report on Internal Control Over Financial Reporting”:

Information technology general controls (ITGCs) were not designed and operating effectively to ensure (i) that access to applications and data, and the ability to make program and job changes, were adequately restricted to appropriate personnel and (ii) that the activities of individuals with access to modify data and make program and job changes were appropriately monitored. Business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted.

This material weakness was considered in determining the nature, timing and extent of audit tests applied in our audit of the fiscal December 31, 2022 consolidated financial statements, and this report does not affect our report dated April 24, 2023 on those consolidated financial statements.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets as of December 31, 2022, the related consolidated statements of loss and comprehensive loss, changes in shareholders’ equity, and cash flows for the year ended December 31, 2022, and related notes of the Company, and our report dated April 24, 2023 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying "Management Annual Report on Internal Control Over Financial Reporting". Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with International Financial Reporting Standards, as promulgated by the International Accounting Standards Board, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the

F-1

company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree of compliance with the policies or procedures may deteriorate.

/s/ Marcum llp

Marcum llp

We have served as the Company’s auditor since 2022.

New York, NY

April 24, 2023

F-1

 

SNDL Inc.

Consolidated Financial Statements

For the years ended December 31, 2022 and 2021, and 2020

(Expressed in thousands of Canadian dollars)

F-1

SNDL Inc.

Consolidated Statements of Financial Position

(Expressed in thousands of Canadian dollars)

As at	Note	December 31, 2022			December 31, 2021 (1)
Assets
Current assets
Cash and cash equivalents			279,586			558,251
Restricted cash	7		19,338			27,013
Marketable securities	8		21,926			83,724
Accounts receivable	9		22,636			10,865
Biological assets	10		3,477			4,410
Inventory	11		127,782			29,503
Prepaid expenses and deposits			10,110			4,355
Investments	16		6,552			3,065
Assets held for sale	5(c),13		6,375			2,998
Net investment in subleases	14		3,701			3,991
			501,483			728,175
Non-current assets
Long-term deposits			8,584			7,725
Right of use assets	12		134,154			6,717
Property, plant and equipment	13		143,409			56,472
Net investment in subleases	14		19,618			22,571
Intangible assets (1)	15		74,885			50,148
Investments	16		90,702			70,498
Equity-accounted investees	17		519,255			412,858
Goodwill (1)	5		67,260			72,496
Total assets			1,559,350			1,427,660
Liabilities
Current liabilities
Accounts payable and accrued liabilities	18		48,153			38,452
Lease liabilities	20		30,206			5,701
Derivative warrants	19		11,002			21,700
			89,361			65,853
Non-current liabilities
Lease liabilities	20		139,625			27,769
Other liabilities	21		2,709			4,505
Total liabilities			231,695			98,127
Shareholders’ equity
Share capital	23(b)		2,292,810			2,035,704
Warrants	23(c)		2,260			8,092
Contributed surplus			68,961			60,734
Contingent consideration			2,279			2,279
Accumulated deficit (1)			(1,091,999	)		(785,112	)
Accumulated other comprehensive income			32,188			7,607
Total shareholders’ equity			1,306,499			1,329,304
Non-controlling interest	34		21,156			229
Total liabilities and shareholders’ equity			1,559,350			1,427,660

(1)Adjustment to provisional amounts — refer to note 5(b).

Commitments (note 35)

Subsequent events (notes 8, 16, 17, 23(b), 24(c) and 36)

See accompanying notes to the consolidated financial statements.

Approved by the Board:
“Signed” Bryan Pinney	“Signed” Zachary George
Director	Director

F-2

SNDL Inc.

Consolidated Statements of Loss and Comprehensive Loss

(Expressed in thousands of Canadian dollars, except per share amounts)

		Year ended December 31
	Note	2022			2021 (1)			2020
Gross revenue	25		729,694			67,279			73,321
Excise taxes			17,497			11,151			12,403
Net revenue			712,197			56,128			60,918
Cost of sales (1)	11		558,089			50,612			51,740
Inventory impairment and obsolescence	11		7,012			16,978			45,913
Gross margin before fair value adjustments			147,096			(11,462	)		(36,735	)
Change in fair value of biological assets	10		(1,309	)		4,708			5,432
Change in fair value realized through inventory			(5,412	)		(2,247	)		(18,566	)
Gross margin			140,375			(9,001	)		(49,869	)
Interest and fee revenue	26		16,739			13,149			—
Investment loss	26		(65,164	)		(44,501	)		—
Share of profit (loss) of equity-accounted investees	17		(43,002	)		32,913			—
General and administrative (1)	27		140,168			38,043			32,029
Sales and marketing	27		8,417			5,043			5,737
Research and development			2,448			2,446			488
Depreciation and amortization (1)	5(b),12,13,15		40,945			5,287			4,711
Share-based compensation	24		9,671			12,307			8,566
Restructuring costs			(670	)		874			6,470
Asset impairment	13,15		196,033			60,000			79,191
Government subsidies			—			(2,180	)		(4,128	)
Loss (gain) on cancellation of contracts			(290	)		5,116			2,471
Loss from operations			(347,774	)		(134,376	)		(185,404	)
Transaction costs			(1,352	)		(17,566	)		(3,587	)
Finance costs, net	28		(41,314	)		(3,756	)		(3,819	)
Change in estimate of fair value of derivative warrants	19		10,783			(77,834	)		(12,995	)
Foreign exchange gain (loss)			(19	)		531			(1,000	)
Gain (loss) on disposition of assets			(94	)		235			488
Other expenses			—			(1,932	)		—
Loss before income tax			(379,770	)		(234,698	)		(206,317	)
Income tax recovery (1)	22		7,342			7,914			—
Net loss from continuing operations			(372,428	)		(226,784	)		(206,317	)
Net loss from discontinued operations			—			—			(33,627	)
Net loss			(372,428	)		(226,784	)		(239,944	)
Equity-accounted investees - share of other comprehensive income, net of tax	17		24,581			7,607			—
Gain on translation of foreign operations			—			—			600
Comprehensive loss			(347,847	)		(219,177	)		(239,344	)
Net loss from continuing operations attributable to:
Owners of the Company (1)			(335,114	)		(226,984	)		(199,619	)
Non-controlling interest			(37,314	)		200			(6,698	)
			(372,428	)		(226,784	)		(206,317	)
Net income (loss) attributable to:
Owners of the Company (1)			(335,114	)		(226,984	)		(233,246	)
Non-controlling interest			(37,314	)		200			(6,698	)
			(372,428	)		(226,784	)		(239,944	)
Comprehensive income (loss) attributable to:
Owners of the Company (1)			(310,533	)		(219,377	)		(232,646	)
Non-controlling interest			(37,314	)		200			(6,698	)
			(347,847	)		(219,177	)		(239,344	)
Net loss per common share attributable to owners of the Company
Basic and diluted	30	$	(1.46	)	$	(1.22	)	$	(10.67	)

(1)Adjustment to provisional amounts — refer to note 5(b).

See accompanying notes to the consolidated financial statements.

F-3

SNDL Inc.

Consolidated Statements of Changes in Shareholders’ Equity

(Expressed in thousands of Canadian dollars)

	Note	Share capital			Warrants			Contributed surplus			Contingent consideration		Accumulated deficit (1)			Accumulated other comprehensive income			Non- controlling interest			Total equity
Balance at December 31, 2019			509,654			27,831			30,192			2,279		(360,338	)		6,866			4,714			221,198
Net loss			—			—			—			—		(233,246	)		—			(6,698	)		(239,944	)
Other comprehensive income			—			—			—			—		—			600			—			600
Share issuances			176,931			—			—			—		—			—			—			176,931
Share issuance costs			(5,593	)		—			—			—		—			—			—			(5,593	)
Convertible debt - conversions			63,002			—			—			—		—			—			—			63,002
Derivative warrants exercised			55,912			—			—			—		—			—			—			55,912
Warrants issued			—			306			—			—		—			—			—			306
Warrants expired			—			(21,999	)		21,999			—		—			—			—			—
Dispositions			(38,447	)		—			—			—		35,456			(7,466	)		—			(10,457	)
Share-based compensation			52			—			7,688			—		—			—			—			7,740
Employee awards exercised			535			—			(535	)		—		—			—			—			—
Balance at December 31, 2020			762,046			6,138			59,344			2,279		(558,128	)		—			(1,984	)		269,695
Net loss (1)			—			—			—			—		(226,984	)		—			200			(226,784	)
Other comprehensive income			—			—			—			—		—			7,607			—			7,607
Loss of control of subsidiary			—			—			—			—		—			—			2,013			2,013
Share issuances	23(b)		977,425			—			—			—		—			—			—			977,425
Share issuance costs	23(b)		(16,371	)		—			—			—		—			—			—			(16,371	)
Derivative warrants exercised			277,136			—			—			—		—			—			—			277,136
Acquisition	5(b)		26,216			1,771			—			—		—			—			—			27,987
Convertible debenture settlement	5(b)		2,671			—			—			—		—			—			—			2,671
Warrants issued	23(c)		—			361			—			—		—			—			—			361
Warrants exercised	23(c)		178			(178	)		—			—		—			—			—			—
Share-based compensation	24		8			—			12,715			—		—			—			—			12,723
Employee awards exercised			6,395			—			(6,194	)		—		—			—			—			201
Modification of equity-settled plan			—			—			(5,131	)		—		—			—			—			(5,131	)
Balance at December 31, 2021			2,035,704			8,092			60,734			2,279		(785,112	)		7,607			229			1,329,533
Net loss			—			—			—			—		(335,114	)		—			(37,314	)		(372,428	)
Other comprehensive income			—			—			—			—		—			24,581			—			24,581
Share issuances	23(b)		2,870			—			—			—		—			—			—			2,870
Share repurchases	23(b)		(41,617	)		—			—			—		28,227			—			—			(13,390	)
Share issuances by subsidiaries			—			—			72			—		—			—			43			115
Acquisition	5(a)		287,129			—			—			—		—			—			58,222			345,351
Warrants expired	23(c)		—			(5,832	)		5,832			—		—			—			—			—
Share-based compensation	24		—			—			11,047			—		—			—			—			11,047
Employee awards exercised			8,724			—			(8,724	)		—		—			—			—			—
Distribution declared by subsidiaries			—			—			—			—		—			—			(24	)		(24	)
Balance at December 31, 2022			2,292,810			2,260			68,961			2,279		(1,091,999	)		32,188			21,156			1,327,655

(1)Adjustment to provisional amounts — refer to note 5(b).

See accompanying notes to the consolidated financial statements.

F-4

SNDL Inc.

Consolidated Statements of Cash Flows

(Expressed in thousands of Canadian dollars)

		Year ended December 31
	Note	2022			2021 (1)			2020
Cash provided by (used in):
Operating activities
Net loss for the period (1)			(372,428	)		(226,784	)		(206,317	)
Adjustments for:
Income tax recovery (1)	22		(7,342	)		(7,914	)		—
Interest and fee revenue	26		(16,739	)		—			—
Change in fair value of biological assets			1,309			(4,708	)		(5,432	)
Share-based compensation	24		9,671			12,307			8,566
Depreciation and amortization (1)	13,15		47,322			10,164			11,582
Loss (gain) on disposition of assets	13		94			(235	)		(488	)
Inventory obsolescence	11		7,012			16,978			45,913
Finance costs	28		41,314			3,716			(3,734	)
Change in estimate of fair value of derivative warrants	19		(10,783	)		77,834			12,995
Loss on cancellation of contracts			—			2,870			671
Unrealized foreign exchange (gain) loss			(16	)		(63	)		(757	)
Restructuring costs			—			—			448
Warrants issued for services			—			—			306
Asset impairment	5(b),12,13,15		196,033			60,000			79,191
Share of (profit) loss of equity-accounted investees	17		43,002			(32,913	)		—
Other expenses			—			1,864			—
Gain on disposition of marketable securities	8,26		—			(20,213	)		—
Unrealized loss on marketable securities	8,26		65,553			64,714			—
Additions to marketable securities	8		(3,500	)		(158,101	)		—
Proceeds from disposal of marketable securities	8		—			29,876			—
Income distributions from equity-accounted investees			1,661			15,021			—
Interest received			13,403			—			—
Exercise of cash-settled deferred share units			(204	)		(315	)		—
Change in non-cash working capital	29		(22,073	)		150			(5,259	)
Net cash used in operating activities from continuing operations			(6,711	)		(155,752	)		(62,315	)
Net cash provided by operating activities from discontinued operations			—			—			4,820
Net cash used in operating activities			(6,711	)		(155,752	)		(57,495	)
Investing activities
Additions to property, plant and equipment	13		(10,666	)		(3,793	)		(3,024	)
Additions to intangible assets	15		(197	)		—			(150	)
Additions to investments	16		(75,598	)		(24,206	)		(51,876	)
Additions to equity-accounted investees	17		(119,137	)		(395,569	)		—
Capital distributions from equity-accounted investees			—			10,481			—
Proceeds from disposal of property, plant and equipment			4,000			194			2,109
Acquisition, net of cash acquired	5		(28,640	)		(82,775	)		—
Change in non-cash working capital	29		74			(612	)		(11,319	)
Net cash used in investing activities from continuing operations			(230,164	)		(496,280	)		(64,260	)
Net cash used in investing activities from discontinued operations			—			—			(6,617	)
Net cash used in investing activities			(230,164	)		(496,280	)		(70,877	)
Financing activities
Proceeds from convertible notes, net of costs			—			—			18,070
Change in restricted cash	7		7,675			(21,680	)		10,494
Payments on lease liabilities, net			(27,693	)		(1,008	)		(420	)
Repurchase of common shares, net of costs	23(b)		(13,390	)		—			—
Proceeds from issuance of shares and registered offerings, net of costs	23(b)		22			1,062,310			181,841
Distributions declared by subsidiaries			(24	)		—			—
Proceeds from exercise of derivative warrants			—			119,318			20,391
Proceeds from exercise of employee warrants			—			201			—
Repayment of long-term debt	5(a)		(10,000	)		—			(84,493	)
Convertible debenture settlement			—			(9,354	)		—
Payment on exercise of contingent consideration warrants			—			(219	)		—
Change in non-cash working capital	29		1,620			348			(2,498	)
Net cash (used in) provided by financing activities from continuing operations			(41,790	)		1,149,916			143,385
Net cash used in financing activities from discontinued operations			—			—			(639	)
Net cash (used in) provided by financing activities			(41,790	)		1,149,916			142,746
Effect of exchange rate changes on cash held in foreign currency			—			(9	)		665
Change in cash and cash equivalents			(278,665	)		497,875			15,039
Cash and cash equivalents, beginning of year			558,251			60,376			45,337
Cash and cash equivalents, end of year			279,586			558,251			60,376

(1)Adjustment to provisional amounts — refer to note 5(b).

See accompanying notes to the consolidated financial statements.

F-5

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

1.Description of business

SNDL Inc. (“SNDL” or the “Company”) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company’s shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from “Sundial Growers Inc.” to “SNDL Inc.”.

The Company’s head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada.

The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted, the production, distribution and sale of cannabis domestically and for export pursuant to the Cannabis Act (Canada) (the “Cannabis Act”), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company also owns approximately 63% of Nova Cannabis Inc. (“Nova”) (TSX: NOVC), whose principal activities are the retail sale of cannabis.

SNDL and its subsidiaries currently operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. (“SunStream”) (note 17), the Company provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.

The Company’s common shares trade on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “SNDL”.

2.Basis of presentation

a)Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) in effect as of December 31, 2022.

These consolidated financial statements were approved and authorized for issue by the board of directors of SNDL (the “Board”) on April 24, 2023.

b)Basis of measurement

These consolidated financial statements have been prepared on a historical cost basis, except for biological assets, deferred share units (“DSUs”) and certain financial instruments (note 31(a)) which are measured at fair value with changes in fair value recorded in earnings.

c)Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and its Canadian-based subsidiaries. Sundial Deutschland GmbH uses the European Euro as its functional currency. The Company’s equity-accounted joint venture uses the United States dollar as its functional currency. Transactions in currencies other than the functional currency are translated at the rate prevailing at the date of transaction. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rate prevailing at each reporting date. Income and expense amounts are translated at the dates of the transactions.

In preparing the Company’s consolidated financial statements, the financial statements of foreign subsidiaries and the foreign equity-accounted joint venture are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of foreign operations that do not have a functional currency of Canadian dollars, are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of foreign operations are translated into Canadian dollars using foreign exchange rates that approximate those

F-6

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

on the date of the underlying transactions. Foreign exchange differences from the translation of foreign subsidiaries and the foreign equity-accounted joint venture into Canadian dollars are recognized in other comprehensive income (“OCI”). The Company’s consolidated financial statements include its share of the Canadian dollar profit or loss and OCI of the equity-accounted joint venture.

d)Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. All intercompany balances, income and expenses and unrealized gains and losses resulting from intercompany transactions are eliminated upon consolidation.

3.Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.

RESTRICTED CASH

Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading positions, if any, and (ii) minimum funding requirements for two separate captive insurance structures.

BIOLOGICAL ASSETS

The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour-related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with International Accounting Standard 41 – Agriculture (“IAS 41”) and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

F-7

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

INVENTORY

Harvested cannabis

Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour-related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory.

Retail inventory

Retail inventory at Company-owned stores is valued at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined using the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels.

PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized.

Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates.

Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in profit and loss.

PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained, if required for operation. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

•Production facilities — 20 years

•Equipment — 1 to 10 years

•Right of use assets and leasehold improvements — Shorter of estimated useful life or lease term

INTANGIBLE ASSETS

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available

F-8

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with International Accounting Standard 38 – Intangible Assets (“IAS 38”).

The Company’s intangible assets are comprised of the following:

•Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years.

•Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years.

•Intellectual property acquired through the acquisition of Inner Spirit (as defined below) consisting of a trade name with an indefinite life and franchise agreements with useful lives of 8 years.

•Intangible assets acquired through the acquisition of Alcanna consisting of brands, licenses, permits and software.

Joint arrangements

Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets.

For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases.

Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid.

Interests in equity-accounted investees

The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture.

Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities.

Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.

IMPAIRMENT OF ASSETS

Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining and maintaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates.

F-9

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

(i)Financial assets

The Company applies an expected credit loss (“ECL”) model to all financial assets not held at fair value through profit and loss (“FVTPL”) where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under International Financial Reporting Standard 9 – Financial Instruments (“IFRS 9”) and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECLs are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and has calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information.

(ii)Non-financial assets

The carrying amounts of the Company’s PP&E, right of use assets and intangible assets, including goodwill, are assessed for impairment indicators and impairment reversal indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment or impairment reversal. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss or impairment reversal, if any.

An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of asset’s estimated fair value less costs of disposal and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit (“CGU”)).

Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset or CGU is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized previously. A reversal of an impairment loss, net of any depreciation that would have been recorded, is recognized immediately in the statements of loss and comprehensive loss. Impairments of goodwill are not reversed.

FINANCIAL INSTRUMENTS

The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

F-10

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance.

(i)Financial assets

At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or fair value through other comprehensive income (“FVOCI”) depending on the business model and contractual cash flows of the instrument.

Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss.

The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at FVOCI.

(ii)Financial liabilities

Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method.

Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss.

Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt.

The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition.

Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of

F-11

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2022 and 2021.

NON-MONETARY TRANSACTIONS

All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.

COMPOUND FINANCIAL INSTRUMENTS

The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition.

Interest and losses and gains relating to the financial liability are recognized in profit and loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.

REVENUE

Under International Financial Reporting Standard 15 – Revenue from Contracts with Customers (“IFRS 15”), to determine the amount and timing of revenue to be recognized, the Company follows a five-step model:

1.Identifying the contract with a customer

2.Identifying the performance obligations

3.Determining the transaction price

4.Allocating the transaction price to the performance obligations

5.Recognizing revenue when/as performance obligations are satisfied

Cannabis revenue

Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods.

For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory

F-12

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly.

Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing.

Retail revenue

Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives.

It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift card.

The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price.

Franchise revenue

Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits.

Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and stewarding the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they utilize the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements.

Other revenue

Proprietary licensing revenue is generated from proprietary licensing services provided to customers. Revenue is recognized when the services are delivered to the customer at a point in time as outlined by the contract. The Company does not operate or manage these services separately from its primary retail sales or operations.

Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner.

Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped.

F-13

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

RESEARCH AND DEVELOPMENT

Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38. Research and development costs comprise consulting fees, costs to cultivate and test cultivar batches to the point of commercialization and licence acquisition fees. No development costs have been capitalized as at December 31, 2022, or December 31, 2021.

SHARE-BASED COMPENSATION

The Company’s share-based compensation plans include equity-settled awards and cash-settled awards.

The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted.

Equity-settled

Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted from time to time to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital.

Cash-settled

DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment.

Nova DSUs are granted to Nova directors and represent a right for the holder to receive a cash payment equal to the fair value of Nova’s common shares calculated at the date of such payment, or Nova common shares, at the discretion of Nova.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur.

INCOME TAXES

Income taxes are recognized in profit and loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity.

Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and include any adjustment to income tax payable or recoverable in respect of previous periods.

Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable.

Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted at the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income

F-14

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

(loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized.

Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected.

BUSINESS COMBINATIONS

Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net earnings. Transaction costs associated with business combinations are expensed as incurred.

FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED IN A BUSINESS COMBINATION

The fair value of assets acquired and liabilities assumed in a business combination, including contingent consideration and goodwill, is estimated based on information available at the date of acquisition. Various valuation techniques are applied for measuring fair value including market comparables and discounted cash flows which rely on assumptions such as future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in these variables could significantly impact the carrying value of the net assets. Specific judgement is required in the identification of intangible assets.

GOODWILL

Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in profit and loss. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.

NON-CONTROLLING INTERESTS

The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.

F-15

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

Loss of control

When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

LEASES

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost and any direct costs of obtaining the lease, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease liability. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease liability is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payments made. Lease payments are allocated between the liability and accretion expense. Accretion expense is recognized on the lease liability using the effective interest rate method and payments are applied against the lease liability.

The carrying amounts of the right of use assets, lease liability, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgements including economic environment, term, and the underlying risk inherent to the asset.

As a lessor

When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. Under a finance lease, the Company recognizes a receivable at an amount equal to the net investment in the lease which is the present value of the aggregate of lease payments receivable by the lessor. Under an operating lease, the Company recognizes lease payments received as income on a straight-line basis over the lease term. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right of use asset arising from the head lease, not with reference to the underlying asset.

GOVERNMENT GRANTS

Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.

Captive Insurance

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures.

The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate cell account (“Cell Captive”). The Company applies International Financial Reporting Standard 10 – Consolidated Financial Statements (“IFRS 10”) in its assessment of

F-16

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. The Cell Captive funds are held as cash and may be invested according to the Company’s treasury policy. The funds are disclosed as restricted cash as the Cell Captive must be fully funded at all times. The Company will recognize any gains or losses from fair market value adjustments, interest and/or foreign exchange in the statements of income (loss) and comprehensive income (loss).

The second structure is a wholly owned subsidiary, Sundial Insurance (Bermuda) Ltd. (“SIBL”), incorporated to provide separate and additional coverage. The Company applies IFRS 10 in its assessment of control as it relates to SIBL. The Company’s accounting policy is to consolidate SIBL. The funds are disclosed as restricted cash as the funds were required for initial capitalization of the entity and there is a requirement to maintain minimum capital and surplus in accordance with industry regulations.

NEW ACCOUNTING STANDARDS

The following accounting standards were effective for annual periods beginning on or after January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements:

•Onerous Contracts — Cost of Fulfilling a Contract — Amendments to IAS 37

•Property, Plant and Equipment: Proceeds before Intended Use — Amendments to IAS 16

There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2023, that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2022. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include:

•Classification of Liabilities as Current or Non-current — Amendment to IAS 1

•IFRS 17 Insurance Contracts

•Definition of Accounting Estimate — Amendments to IAS 8

•Deferred Tax related to Assets and Liabilities arising from a Single Transaction — Amendments to IAS 12

4.Significant accounting estimates, assumptions and judgements

The preparation of these consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Judgement is used mainly in determining whether a balance or transaction should be recognized in the consolidated financial statements. Estimates and assumptions are mostly used in determining the measurement of recognized transactions and balances. However, judgements and estimates are often interrelated.

Judgements, estimates and assumptions are continually evaluated and are based on factors including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected.

Judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment include the following:

IMPAIRMENTS

CGU’s are defined as the lowest grouping of integrated assets that generate identifiable cash inflows that are largely independent of the cash inflows of other assets or groups of assets. The classification of assets into CGU’s requires significant judgement and interpretations with respect to the integration between assets, the existence of active markets, external users, shared infrastructure and the way in which management monitors the Company’s operations.

F-17

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The recoverable amounts of CGU’s and individual assets have been determined as the higher of the CGU’s or the asset’s fair value less costs of disposal and its value in use. These calculations require the use of estimates and assumptions and are subject to changes as new information becomes available including information on the likelihood of obtaining future licences from Health Canada, total addressable market, market share escalation factor, gross margin escalation factor, terminal multiple and discount rates. Changes in assumptions used in determining the recoverable amount could affect the carrying value of the related assets and CGU’s.

BIOLOGICAL ASSETS AND INVENTORY

Biological assets, comprising cannabis plants and agricultural product consisting of cannabis, are measured at fair value less costs to produce and sell up to the point of harvest.

Determination of the fair values of the biological assets and the agricultural product requires the Company to make assumptions about how market participants assign fair values to these assets. These assumptions primarily relate to the level of effort required to bring the cannabis up to the point of harvest, costs to convert the harvested cannabis to finished goods, sales price, risk of loss, expected future yields from the cannabis plants and estimating values during the growth cycle.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and thus any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. The Company must also determine if the carrying value of any inventory exceeds its net realizable value, such as cases where prices have decreased, or inventory has spoiled or has otherwise been damaged.

Revenue

Government customers typically have a right of product return, and in some cases, the right to pricing adjustments for products that are subsequently discounted or sold for a lower price in another jurisdiction. Licensed Producers can, in some cases, have a right of product return or warranty period. The estimate of potential future returns includes the use of estimates and assumptions and are subject to change as new information becomes available.

CONVERTIBLE INSTRUMENTS

The derivative warrant liabilities are financial liabilities measured at FVTPL. The determination of the fair value of the liabilities are estimated based on various assumptions, including future share price, volatility, discount rate and various probability factors.

ACQUISITIONS

The Company assesses whether an acquisition should be accounted for as an asset acquisition or a business combination under International Financial Reporting Standard 3 – Business Combinations (“IFRS 3”). This assessment requires management to make judgements on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business inputs and processes.

Investments

The Company’s investments at FVTPL are financial assets measured at fair value each reporting period. The determination of the fair value of each investment requires judgement from management and the primary assumption is the discount rate.

F-18

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

equity-accounted investees

The Company’s interest in a joint venture is accounted for using the equity-method. The current investment portfolio of the joint venture is comprised of secured debt and hybrid instruments which include options and warrants. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss.

The determination of the fair value of the underlying investments is based on a discounted cash flow methodology and requires judgement from management. The discounted cash flows are based on various assumptions, including an estimation of market prices, volatility and discount rates.

5.Business acquisitions

a)Alcanna

On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna Inc. (“Alcanna”) pursuant to which the Company would acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022, and the Alcanna Transaction closed on March 31, 2022. Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”. Alcanna holds an approximate 63% equity interest in Nova, a Canadian cannabis retailer operating stores across Alberta, Saskatchewan and Ontario, under its “Value Buds” and “Sweet Tree” retail brands. The Company is deemed to control Nova through its equity interest and Nova’s results are included in the consolidated financial statements of the Company with the minority interest shown as non-controlling interest through equity.

Alcanna was acquired to diversify and stabilize cash flows and advance the Company’s vertical integration strategy.

The Alcanna Transaction consideration was comprised of (i) an aggregate $54.3 million cash ($1.50 in cash for each Alcanna common share), and (ii) an aggregate 32.1 million SNDL common shares valued at $287.1 million based on the fair value of each common share of the Company on the closing date (0.885 of a SNDL common share for each Alcanna common share).

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts, if any.

The fair value of consideration paid was as follows:

	Provisional		Adjustments		Final
Cash		54,339		—		54,339
Issuance of common shares		287,129		—		287,129
		341,468		—		341,468

F-19

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The fair value of the assets and liabilities acquired was as follows:

	Provisional			Adjustments			Final
Cash		23,190			—			23,190
Accounts receivable		1,868			—			1,868
Prepaid expenses and deposits		10,986			—			10,986
Inventory		105,022			—			105,022
Right of use assets		171,866			(31,117	)		140,749
Property, plant and equipment		86,059			24,632			110,691
Intangible assets		—			45,100			45,100
Goodwill		280,243			(129,308	)		150,935
Accounts payable and accrued liabilities		(36,703	)		(44	)		(36,747	)
Long-term debt		(10,000	)		—			(10,000	)
Lease liabilities		(232,755	)		90,736			(142,019	)
Derivative warrants		(58	)		(27	)		(85	)
Non-controlling interest		(58,250	)		28			(58,222	)
		341,468			—			341,468

Non-controlling interest has been measured as the fair value of the non-controlling interest in Nova, which at the time was 37%, and was measured by applying a market approach with reference to Nova’s closing share price on the day of the Alcanna Transaction of $2.66.

On March 31, 2022, the Company repaid in full the acquired long-term debt balance of $10.0 million.

These consolidated financial statements incorporate the operations of Alcanna commencing March 31, 2022. During the period March 31, 2022 to December 31, 2022, the Company recorded revenues of $639.5 million and net loss of $101.0 million from the Alcanna operations. Had the Alcanna Transaction closed on January 1, 2022, management estimates that for the period January 1, 2022, to March 30, 2022, revenue would have increased by $162.5 million and net loss would have increased by $25.5 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2022.

The Company incurred costs related to the Alcanna Transaction of $7.0 million which have been included in transaction costs.

The Company recorded adjustments to the fair value in the fourth quarter of 2022 to reflect additional information and greater certainty with respect to management estimates pertaining to facts and circumstances that were either unknown or uncertain at the date of acquisition. These adjustments related to changes in preliminary valuation assumptions, including refinement of right of use assets, property, plant and equipment, intangible assets, accounts payable and accrued liabilities, lease liabilities, derivative warrants and non-controlling interest. All measurement period adjustments were offset to goodwill.

goodwill impairment

For the purpose of impairment testing at December 31, 2022, intangible assets with indefinite lives were allocated to the Company’s CGUs as follows: i) $2.7 million to the cannabis retail CGU, ii) $18.3 million to the cannabis franchise CGU and iii) $43.1 million to the liquor retail CGU. Goodwill from the Alcanna acquisition was allocated as follows: i) $126.6 million to the cannabis retail CGU and ii) $24.3 million to the liquor retail CGU. The remaining goodwill from the Inner Spirit acquisition of $4.6 million was allocated to the group CGU containing the cannabis retail and cannabis franchise CGUs. The impairment test for the Company’s cannabis retail CGU used its fair value less costs of disposal and the fair value measurement was categorized as a Level 1 fair value based on the inputs in the valuation technique used. The impairment test for the Company’s cannabis franchise and liquor retail CGUs used a value in use approach based on internal cash flow estimates at December 31, 2022, and a discount rate of 12.0%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis and

F-20

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

liquor industry market sizes and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s retail cannabis CGU of $88.0 million as at December 31, 2022 as the estimated recoverable amount for this CGU of $84.8 million was lower than the respective carrying amount. The impairment loss was fully allocated to goodwill and included in asset impairment. The impairment was recognized in the Company’s cannabis retail reportable segment.

b)Inner Spirit

On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021. Inner Spirit is a retailer and franchisor of Spiritleaf adult-use cannabis stores across Canada, with a network that included more than 100 franchised and corporate-owned locations at the acquisition date.

The Inner Spirit Transaction consideration was comprised of (i) an aggregate $92.6 million cash ($0.30 in cash for each Inner Spirit common share), (ii) an aggregate 2.4 million SNDL common shares valued at $26.2 million based on the fair value of each common share of the Company on the closing date (0.00835 of a SNDL common share for each Inner Spirit common share) and (iii) contingent consideration valued at $1.2 million representing the fair value of Inner Spirit warrants.

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts.

The fair value of consideration paid was as follows:

	Provisional		Adjustments		Final
Cash		92,583		—		92,583
Issuance of common shares		26,216		—		26,216
Contingent consideration		1,150		—		1,150
		119,949		—		119,949

The fair value of the assets and liabilities acquired was as follows:

	Provisional			Adjustments			Final
Cash		9,808			—			9,808
Accounts receivable		750			(327	)		423
Prepaid expenses and deposits		853			—			853
Inventory		2,733			2,011			4,744
Right of use assets		—			5,730			5,730
Property, plant and equipment		12,108			(5,730	)		6,378
Intangible assets		—			46,000			46,000
Net investment in subleases		23,751			50			23,801
Goodwill		114,537			(42,041	)		72,496
Accounts payable and accrued liabilities		(2,678	)		—			(2,678	)
Convertible debentures		(12,025	)		—			(12,025	)
Lease liabilities		(29,481	)		(50	)		(29,531	)
Financial guarantee liability		(407	)		—			(407	)
Deferred tax liability		—			(5,643	)		(5,643	)
		119,949			—			119,949

On August 4, 2021, the Company settled the convertible debenture liability through the issuance of 2.5 million common shares valued at $2.7 million and a cash payment of $9.3 million. Due to the change of control from the Inner Spirit Transaction, debenture holders were entitled to receive SNDL common shares and a cash payment based on a prescribed formula.

F-21

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The fair value of the Inner Spirit warrants has been estimated as $1.2 million and is made up of the following components: (i) equity component of $1.8 million (note 23(c)), (ii) liability component of $0.3 million and (iii) asset component of $0.9 million.

The consolidated financial statements incorporate the operations of Inner Spirit commencing July 20, 2021. During the period July 20, 2021, to December 31, 2021, the Company recorded revenues of $16.1 million and net earnings of $1.1 million. Had the acquisition closed on January 1, 2021, management estimates that for the period January 1, 2021, to July 19, 2021, revenue would have increased by $20.4 million and net earnings would have been reduced by $7.4 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2021.

The Company incurred acquisition-related costs of $1.9 million which have been included in transaction costs.

The Company recorded adjustments to the fair value in the third quarter of 2022 to reflect additional information and greater certainty with respect to management estimates pertaining to facts and circumstances that were either unknown or uncertain at the date of acquisition. These adjustments related to changes in preliminary valuation assumptions, including refinement of accounts receivable, inventory, net investment in subleases, lease liabilities and amounts allocated to intangible assets and deferred tax liability. All measurement period adjustments were offset to goodwill.

The Company made retrospective adjustments to provisional amounts in the comparative period as follows:

•The carrying amount of intangible assets as at December 31, 2021 was increased by $45.4 million, representing the increase in fair value of $46.0 million less additional amortization from the acquisition date to December 31, 2021 of $0.6 million.

•The deferred tax liability of $5.6 million was adjusted to nil with a corresponding adjustment recorded to income tax recovery, on the basis that the Company and Inner Spirit are subject to income tax under the same taxation authority.

•Amortization expense for 2021 was increased by $0.6 million (Q3 2021 — $0.3 million and Q4 2021 — $0.3 million).

•Cost of sales for 2021 was increased by $2.0 million, representing the increase in fair value of acquired inventory that was sold during 2021.

•General and administrative expenses was decreased by $0.3 million, representing the decrease in fair value of acquired accounts receivable.

•Goodwill was decreased by $42.0 million.

Inner Spirit goodwill and intangible asset impairment

For the purpose of impairment testing at September 30, 2022, intangible assets with indefinite lives consisting of the Inner Spirit brands and trademarks were allocated to the Company’s CGUs as follows: i) $17.7 million to the cannabis retail CGU and ii) $18.3 million to the cannabis franchise CGU. The impairment test for the Company’s cannabis retail and cannabis franchise CGUs used a value in use approach based on internal cash flow estimates at September 30, 2022, and a discount rate of 19.5%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s retail cannabis CGU of $16.4 million as at September 30, 2022 as the estimated recoverable amount for this CGU of $1.9 million was lower than the respective carrying amount. The impairment loss was fully allocated to intangible assets with indefinite lives and included in asset impairment. The impairment was recognized in the Company’s cannabis retail reportable segment.

For the purpose of impairment testing at September 30, 2022, goodwill of $72.5 million from the Inner Spirit acquisition was allocated to the group CGU containing the cannabis retail and cannabis franchise CGUs. The impairment test for the Company’s group CGU used a value in use approach based on internal cash flow estimates at September 30, 2022, and a discount rate of 19.5%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model

F-22

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s group CGU of $67.9 million as at September 30, 2022 as the estimated recoverable amount for this group CGU of $40.0 million was lower than the respective carrying amount. The impairment loss was fully allocated to goodwill and included in asset impairment. The estimated value in use for the Company’s group CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1% would increase the impairment by approximately $1.1 million. The impairment was recognized in the Company’s cannabis retail reportable segment.

c)Zenabis

On November 1, 2022, the Company announced that, in the context of proceedings pursuant to the Zenabis Group’s (as defined below) filing under the Companies’ Creditors Arrangement Act (“CCAA”), it had successfully acquired all of the assets of the business of the Zenabis Group, subject to certain exclusions, (the “Zenabis Business”), pursuant to an approval order of the Québec Superior Court (the “Court”).

The order of the Court approved the acquisition by a wholly owned subsidiary of SNDL of all issued and outstanding shares of Zenabis Ltd., a corporation resulting from the amalgamation of select Zenabis entities (collectively, the “Zenabis Group”), as part of the consideration for the senior secured debt of the Zenabis Group due to the SNDL subsidiary. Zenabis Ltd. owns all of the Zenabis Business, free and clear of any encumbrances except certain permitted encumbrances (namely the security of the wholly owned subsidiary of SNDL, which was preserved).

The Zenabis acquisition consideration was comprised of (i) the extinguishment of the Company’s senior loan.

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts, if any.

The fair value of consideration paid was as follows:

	Final
Extinguishment of senior loan		18,215
		18,215

The fair value of the assets and liabilities acquired was as follows:

	Final
Cash		2,509
Accounts receivable		888
Biological assets		909
Prepaid expenses and deposits		1,856
Inventory		4,512
Assets held for sale		6,375
Right of use assets		32
Property, plant and equipment		4,658
Accounts payable and accrued liabilities		(3,437	)
Lease liabilities		(87	)
		18,215

Assets held for sale are comprised of a processing facility in Stellarton, Nova Scotia, whose primary purpose was the packaging and processing of value added and derivative products for the adult-use cannabis market.

These consolidated financial statements incorporate the operations of Zenabis commencing November 1, 2022. During the period November 1, 2022 to December 31, 2022, the Company recorded revenues of $0.4 million and net loss of $1.8 million from the Zenabis operations. Had the acquisition closed on January 1, 2022, management estimates that for the period January 1, 2022, to October 31, 2022, revenue would have increased by $2.0 million and net loss would have increased by $9.0 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2022.

F-23

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The Company incurred costs related to the Zenabis acquisition of $0.8 million which have been included in transaction costs.

6.Segment information

The Company’s reportable segments are organized by business line, and with the acquisition of Alcanna, are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.

Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as “Corporate”.

	Liquor Retail (1)		Cannabis Retail (1)			Cannabis Operations (2)			Investments (3)			Corporate			Total
As at December 31, 2022
Total assets		351,338		200,393			163,130			825,151			19,338			1,559,350
Year ended December 31, 2022
Net revenue		462,180		205,610			44,407			—			—			712,197
Gross margin		106,307		47,334			(13,266	)		—			—			140,375
Interest and fee revenue		—		—			—			16,739			—			16,739
Investment (loss) income		—		—			—			(65,164	)		—			(65,164	)
Share of loss of equity-accounted investees		—		—			—			(43,002	)		—			(43,002	)
Depreciation and amortization		17,025		9,920			199			—			13,801			40,945
Income (loss) before income tax		17,726		(183,055	)		(29,618	)		(127,362	)		(57,461	)		(379,770	)

(1)Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (note 5(a)).

(2)Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (note 5(c)).

(3)Total assets include cash and cash equivalents.

	Liquor Retail		Cannabis Retail (1)			Cannabis Operations			Investments (2)			Corporate			Total
As at December 31, 2021
Total assets (3)		—		157,022			147,887			1,093,596			29,155			1,427,660
Year ended December 31, 2021
Net revenue		—		16,091			40,037			—			—			56,128
Gross margin (3)		—		6,498			(15,499	)		—			—			(9,001	)
Interest and fee revenue		—		—			—			13,149			—			13,149
Investment loss		—		—			—			(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—		—			—			32,913			—			32,913
Depreciation and amortization (3)		—		1,282			3,108			—			897			5,287
Income (loss) before income tax (3)		—		(410	)		(117,990	)		(5,837	)		(110,461	)		(234,698	)

(1)Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021.

(2)Total assets include cash and cash equivalents.

(3)Adjustments to provisional amounts — refer to note 5(b)

Geographical disclosure

As at December 31, 2022, the Company had non-current assets related to investment credit operations in the United States of $519.3 million (December 31, 2021 — $412.9 million). For the year ended December 31, 2022, share of profit of equity-accounted investees related to investment credit operations in the United States was a loss of $43.0 million (year ended December 31, 2021 — gain of $32.9 million).

F-24

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

7.Restricted cash

As at	December 31, 2022		December 31, 2021
Securities collateral		—		7,773
Captive insurance		19,044		19,240
Other		294		—
		19,338		27,013

Securities collateral is comprised of a cash balance to satisfy margin requirements on the Company’s option trading positions.

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures (note 3).

8.Marketable securities

As at	December 31, 2022			December 31, 2021
Balance, beginning of year		83,724			—
Additions		3,755			158,101
Dispositions		—			(9,663	)
Change in fair value recognized in profit or loss		(65,553	)		(64,714	)
Balance, end of year		21,926			83,724

During the year ended December 31, 2022, proceeds of nil (year ended December 31, 2021 — $29.9 million) were received for dispositions of marketable securities and a gain on disposition of nil (year ended December 31, 2021 — $20.2 million) was recognized (note 26).

Marketable securities have been designated as FVTPL (note 31).

Subsequent to December 31, 2022, the marketable securities held in Valens were converted to SNDL common shares and subsequently cancelled in relation to the Valens acquisition (note 36).

The components of marketable securities are as follows:

As at	December 31, 2022		December 31, 2021
Equity securities		21,926		83,802
Put and call options		—		(78	)
		21,926		83,724

9.Accounts receivable

As at	December 31, 2022		December 31, 2021
Trade receivables		17,558		10,865
Other receivables		5,078		—
		22,636		10,865

The Company has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. Refer to note 31 for credit risk disclosures.

F-25

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

10.Biological assets

The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:

As at	December 31, 2022			December 31, 2021
Balance, beginning of year		4,410			3,531
Increase in biological assets due to capitalized costs		27,749			25,880
Acquisition		909			—
Net change in fair value of biological assets		(1,309	)		4,708
Transferred to inventory upon harvest		(28,282	)		(29,709	)
Balance, end of year		3,477			4,410

Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.

The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.

Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:

Assumption	Input	Weighted average input				Effect of 10% change ($000s)
		December 31 2022		December 31 2021		December 31 2022		December 31 2021
Yield per square foot of growing space (1)	Grams		48		49		279		435
Average net selling price (2)	$/gram		4.66		4.49		687		1,014
After harvest cost to complete and sell	$/gram		1.27		1.06		187		249

(1)Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

(2)Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

These assumptions are estimates that are subject to volatility in market prices and several uncontrollable factors. The Company’s estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

The Company estimates the harvest yields for cannabis at various stages of growth. As at December 31, 2022, it is estimated that the Company’s biological assets will yield approximately 3,904 kilograms (December 31, 2021 – 5,672 kilograms) of dry cannabis when harvested. During the year ended December 31, 2022, the Company harvested 19,854 kilograms of dry cannabis (year ended December 31, 2021 – 22,784 kilograms).

F-26

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

11.Inventory

As at	December 31, 2022		December 31, 2021
Retail liquor		82,589		—
Harvested cannabis
Raw materials, packaging and components		4,577		4,354
Work-in-progress		19,927		19,751
Finished goods		7,040		2,966
Retail cannabis		13,373		2,397
Millwork		276		35
		127,782		29,503

During the year ended December 31, 2022, inventories of $558.1 million were recognized in cost of sales as an expense (year ended December 31, 2021 - $50.6 million).

During the year ended December 31, 2022, the Company recognized inventory write downs of $8.9 million (year ended December 31, 2021 - $17.5 million), of which $7.0 million (year ended December 31, 2021 - $17.0 million) was recognized as an impaired and obsolete inventory provision, and $1.9 million (year ended December 31, 2021 - $0.5 million) was included in the change in fair value realized through inventory as the fair value component of the impaired and obsolete inventory provision.

12.right of use assets

Cost
Balance at December 31, 2020	1,894
Acquisition (note 5(b))	5,730
Additions	579
Dispositions	(165	)
Balance at December 31, 2021	8,038
Acquisition (note 5(a), note5(c))	140,781
Additions	6,103
Tenant inducement allowances	(46	)
Dispositions and remeasurements	12,191
Balance at December 31, 2022	167,067
Accumulated depreciation and impairment
Balance at December 31, 2020	571
Depreciation	897
Dispositions	(147	)
Balance at December 31, 2021	1,321
Depreciation	25,227
Impairment	6,365
Balance at December 31, 2022	32,913
Net book value
Balance at December 31, 2021	6,717
Balance at December 31, 2022	134,154

As at December 31, 2022, the Company recorded impairment losses of right of use assets of $6.4 million with $3.9 million in the cannabis retail reporting segment and $2.5 million in the liquor retail reporting segment. Refer to note 13 for the significant assumptions applied in the impairment test.

F-27

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

13.Property, plant and equipment

	Land			Production facilities			Leasehold improvements			Equipment			Construction in progress (“CIP”)			Total
Cost
Balance at December 31, 2020		8,640			152,935			2			28,894			8,819			199,290
Acquisition (note 5(b))		—			—			4,169			2,209			—			6,378
Additions		—			467			126			1,975			1,209			3,777
Transfers from CIP		3,748			—			—			—			(3,748	)		—
Dispositions		—			(70	)		(398	)		(301	)		(177	)		(946	)
Balance at December 31, 2021		12,388			153,332			3,899			32,777			6,103			208,499
Acquisition (note 5(a), note5(c))		130			2,982			65,605			44,263			2,369			115,349
Additions		57			256			3,465			5,907			982			10,667
Dispositions		(611	)		(3,844	)		(647	)		(4,025	)		—			(9,127	)
Balance at December 31, 2022		11,964			152,726			72,322			78,922			9,454			325,388
Accumulated depreciation and impairment
Balance at December 31, 2020		—			69,364			—			8,500			5,821			83,685
Depreciation		—			2,503			411			5,438			—			8,352
Impairment		—			60,000			—			—			—			60,000
Dispositions		—			—			—			(10	)		—			(10	)
Balance at December 31, 2021		—			131,867			411			13,928			5,821			152,027
Depreciation		—			1,288			7,212			11,373			—			19,873
Impairment		—			—			7,794			7,415			—			15,209
Dispositions		—			(1,324	)		(610	)		(3,196	)		—			(5,130	)
Balance at December 31, 2022		—			131,831			14,807			29,520			5,821			181,979
Net book value
Balance at December 31, 2021		12,388			21,465			3,488			18,849			282			56,472
Balance at December 31, 2022		11,964			20,895			57,515			49,402			3,633			143,409

During the year ended December 31, 2022, depreciation expense of $6.4 million was capitalized to biological assets and inventory (year ended December 31, 2021 – $4.9 million).

During the year ended December 31, 2022, proceeds of $3.5 million were received for the disposition of the Company’s Merritt facility and a gain on disposal of $0.5 million was recognized. At December 31, 2021, the Merritt facility was classified as assets held for sale.

During the year ended December 31, 2022, proceeds of $3.9 million were received for the disposition of the Company’s Rocky View facility and no gain on disposal was recognized.

During the year ended December 31, 2022, the Company determined that indicators of impairment existed relating to idle machinery and equipment. The estimated recoverable amount of the assets was determined to be nil and an impairment of $2.4 million was recorded. The impairment was recognized in the Company’s cannabis operations reporting segment.

During the year ended December 31, 2022, the Company determined that indicators of impairment existed relating to its retail stores due to underperforming operating results of certain stores. For impairment testing of retail property, plant and equipment and right of use assets, the Company determined that a CGU was defined as each individual retail store. The Company completed impairment tests for each store location determined to have an indicator of potential impairment using a discounted cash flow methodology. The recoverable amounts for each CGU were based on the higher of its estimated value in use (“VIU”) and fair value less costs of disposal (“FVLCD”) using level 3 inputs (refer to note 31 for further discussion of each input level). The significant assumptions applied in the impairment test are described below:

F-28

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

•Cash flows: Estimated cash flows are based on forecasted EBITDA. The forecast is extended to a total of five years based on an analysis of the industry’s expected growth rates, historical and forecast volume changes, and inflation rates, except where a CGU has a defined life due to lease expiration. Management determined forecasted growth rates of sales based on past performance and its expectations of future performance for each location. Expenditures were based upon a combination of historical percentages of revenue, sales growth rates, and contractual lease payments.

•Discount rate: The weighted average cost of capital was estimated to be 12.0% and is based on market capital structure of debt, risk-free rate, equity risk premium, beta adjustment to the equity risk premium based on a review of betas of comparable publicly traded companies, the Company’s historical data, an unsystematic risk premium and after-tax cost of debt based on corporate bond yields.

•Long-term growth rate: Five years of cash flows have been included in the discounted cash flow models. Where a CGU’s lease terms do not define the forecast period, maintainable debt-free net cash flow beyond the forecast period is estimated to approximate the fifth-year cash flows increased by a terminal growth rate of 2.5% and is based on the industry’s expected growth rates, forecast inflation rates and management’s experience.

As at December 31, 2022, the Company recorded impairment losses of property, plant and equipment of $12.8 million with $5.3 million in the cannabis retail reporting segment and $7.5 million in the liquor retail reporting segment.

Due to curtailment in the utilization of a portion of the capacity in the Company’s Olds facility to align cannabis production with current demand estimates, the Company determined that indicators of impairment existed at June 30, 2021. The impairment test for the Company’s Olds CGU used a value in use approach based on internal cash flow estimates at June 30, 2021, and a discount rate of 25%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s Olds CGU of $60.0 million as at June 30, 2021, as the estimated recoverable amount for this CGU of $70.0 million was lower than the respective carrying amount. The estimated value in use for the Company’s Olds CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1% would increase the impairment by approximately $7.3 million. The impairment was recognized in the Company’s cannabis operations reporting segment.

14.Net investment in subleases

	December 31, 2022			December 31, 2021
Balance, beginning of year		26,562			—
Acquisition (note 5(b))		—			23,801
Additions		1,408			3,951
Finance income		833			573
Rents recovered (payments made directly to landlords)		(4,141	)		(1,713	)
Dispositions and remeasurements		(1,343	)		(50	)
Balance, end of year		23,319			26,562
Current portion		3,701			3,991
Long-term		19,618			22,571

Net investment in subleases represent leased retail stores that have been subleased to certain franchise partners. These subleases are classified as a finance lease as the sublease terms are for the remaining term of the head lease.

F-29

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

15.Intangible assets

	Brands and trademarks			Franchise agreements		Software		Retail Licenses		Total
Cost
Balance at December 31, 2020		5,445			—		—		—		5,445
Acquisition (note 5(b)) (1)		36,000			10,000		—		—		46,000
Balance at December 31, 2021		41,445			10,000		—		—		51,445
Acquisition (note 5(a))		38,950			—		5,400		750		45,100
Additions		55			—		142		—		197
Dispositions		(50	)		—		—		—		(50	)
Balance at December 31, 2022		80,400			10,000		5,542		750		96,692
Accumulated amortization and impairment
Balance at December 31, 2020		382			—		—		—		382
Amortization (1)		354			561		—		—		915
Balance at December 31, 2021		736			561		—		—		1,297
Amortization		293			1,250		679		—		2,222
Impairment		18,288			—		—		—		18,288
Balance at December 31, 2022		19,317			1,811		679		—		21,807
Net book value
Balance at December 31, 2021		40,709			9,439		—		—		50,148
Balance at December 31, 2022		61,083			8,189		4,863		750		74,885

(1)Adjustment to provisional amounts — refer to note 5(b).

Brands and trademarks are related to intellectual property purchased from Sun 8 Holdings Inc. (“Sun 8”) with a useful life of 15 years, other intellectual property with a useful life of 12 years, intellectual property acquired through the acquisition of Inner Spirit consisting of proprietary rights to brands and trademarks with an indefinite useful life, and intellectual property acquired through the acquisition of Alcanna with an indefinite useful life. The Inner Spirit and Alcanna brands and trademarks were determined to have an indefinite useful life due to the fact that there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows. Franchise agreements consist of intellectual property acquired through the acquisition of Inner Spirit consisting of franchise relationships with a useful life of 8 years. Software is comprised of licenses acquired through the acquisition of Alcanna and are amortized using the straight-line method over the life of the license. Retail licenses acquired through the acquisition of Alcanna have an indefinite life and are therefore not amortized. The retail licenses do not expire, but rather are subject to an administrative extension process each year indefinitely.

During the three months ended September 30, 2022, the Company determined that indicators of impairment existed regarding the Sun 8 intellectual property due to decreasing market competition. The estimated recoverable amount of the intangible asset was determined to be $2.5 million and an impairment of $1.9 million was recorded. The impairment was recognized in the Company’s cannabis operations reporting segment.

At September 30, 2022, the Company recorded impairments to intangible assets with indefinite useful lives of $16.4 million due to changes in circumstances since the date of the Inner Spirit acquisition, mainly caused by the continued oversaturation of the cannabis retail market (note 5(b)).

At December 31, 2022, the Company tested intangible assets with indefinite useful lives and goodwill for impairment based on changes in circumstances since the date of the Alcanna and Nova acquisition, mainly caused by the continued oversaturation of the cannabis retail market (note 5(a)).

F-30

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

16.Investments

As at	December 31, 2022		December 31, 2021
Investments at amortized cost		24,493		24,987
Investments at FVTPL		72,761		48,576
		97,254		73,563
Current portion		6,552		3,065
Long-term		90,702		70,498

Investments at fvtpl

Superette

On February 9, 2022, the Company closed an investment in a $5.0 million promissory note with a maturity date of February 9, 2025, and an interest rate of 15% per annum. On August 26, 2022, November 22, 2022 and December 31, 2022, the Company entered into an amended and restated promissory note whereby the Company would advance additional funds up to $8.1 million as part of pre-CCAA advances and debtor-in-possession advances and the maturity date was amended such that the full balance of the promissory note plus accrued interest and advances became due August 30, 2022. On August 31, 2022, the Company announced that, in the context of the initial order obtained by Superette Inc., Superette Ontario Inc. and certain of its subsidiaries (collectively, “Superette”) from the Ontario Superior Court of Justice on August 30, 2022 pursuant to the CCAA proceedings, it had entered into an agreement of purchase and sale with Superette, pursuant to which it proposed to acquire substantially all of the business and assets of Superette. As at December 31, 2022, the Company had advanced an additional $1.8 million under the amended and restated promissory note. Subsequent to December 31, 2022, the Company had advanced an additional $0.3 million under the amended and restated promissory note. The Company has adjusted the fair value of the promissory note downward by $3.7 million during the year ended December 31, 2022 (note 28) to management’s best estimate of the recoverable value of the collateral underlying the security of the promissory note. On February 7, 2023, the Company announced the acquisition of Superette (note 36).

Delta 9

On March 30, 2022, the Company closed an investment in a $10.0 million convertible debenture with Delta 9 Cannabis Inc. with a maturity date of March 30, 2025, and an interest rate of 10% per annum. On August 11, 2022, and again on September 9, 2022, the Company waived compliance under certain covenants in exchange for a requirement to meet additional conditions.

Zenabis

On June 17, 2022, Zenabis Global Inc. (“Zenabis Global”), as well as Zenabis Global’s direct and indirect wholly owned subsidiaries (collectively, the “Zenabis Global Group”), filed a petition with the Québec Superior Court for protection under CCAA. On June 16, 2022 (and amended on July 5, 2022), the Company entered into a purchase agreement pursuant to which the shares of Zenabis Global and all business and assets of the Zenabis Global Group (the “Zenabis Business”) would be acquired by SNDL. On November 1, 2022, the Company announced the acquisition of certain assets and permitted liabilities of Zenabis Global (note 5(c)). The Company has adjusted the fair value of the Zenabis Global senior loan downward by $33.7 million (note 28) to management’s best estimate of the fair value of the Zenabis Global senior loan at November 1, 2022, in accordance with the requirements of IFRS. The Zenabis Global senior loan was extinguished immediately preceding the business combination and forms the consideration transferred (note 5(c)).

Valens

On August 22, 2022, the Company and The Valens Company Inc. (“Valens”) announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) to combine their businesses. Pursuant to the terms of the Valens Arrangement Agreement, the Company will acquire, subject to Valens’ shareholder approval and

F-31

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). In connection with the Valens Arrangement Agreement, the Company and Valens closed a $60.0 million non-revolving term loan facility with a maturity date of December 15, 2023 and an interest rate of 10% per annum. The Valens Transaction closed on January 17, 2023 (note 36).

17.Equity-accounted investees

As at	December 31, 2022		December 31, 2021
Interest in joint venture (A)		519,255		412,858
Interest in associate (B)		—		—
		519,255		412,858

a)Interest in joint venture

SunStream is a joint venture in which the Company has a 50% ownership interest. SunStream is a private company, incorporated under the Business Corporations Act (Alberta), which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities.

SunStream is structured as a separate vehicle and the Company has a residual interest in the net assets of SunStream. Accordingly, the Company has classified its interest in SunStream as a joint venture, which is accounted for using the equity-method.

The current investment portfolio of SunStream is comprised of secured debt, hybrid debt and derivative instruments with United States based cannabis businesses. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss. SunStream actively monitors these investments for changes in credit risk, market risk and other risks specific to each investment.

As at December 31, 2022, the Company had funded $514.7 million out of the total $538.0 million that was originally committed to SunStream. Subsequent to December 31, 2022, the Company contributed $10.9 million to SunStream.

The following table summarizes the carrying amount of the Company’s interest in the joint venture:

	Carrying amount
Balance at December 31, 2020		—
Capital contributions		395,569
Share of net earnings		32,913
Share of other comprehensive income		9,878
Distributions		(25,502	)
Balance at December 31, 2021		412,858
Capital contributions		119,137
Share of net earnings (loss)		(43,002	)
Share of other comprehensive income		31,923
Distributions		(1,661	)
Balance at December 31, 2022		519,255

SunStream is a related party due to it being classified as a joint venture of the Company. Capital contributions to the joint venture and distributions received from the joint venture are classified as related party transactions.

F-32

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes the financial information of SunStream:

As at	December 31, 2022			December 31, 2021
Current assets (including cash and cash equivalents - 2022: $1.5 million, 2021: $0.2 million)		5,437			789
Non-current assets		509,418			407,860
Current liabilities		(1,146	)		(1,596	)
Net assets (liabilities) (100%)		513,709			407,053
Year ended December 31	2022			2021
Revenue (loss)		(35,046	)		36,203
Profit (loss) from operations		(42,627	)		32,841
Other comprehensive income		31,923			9,878
Total comprehensive income (loss)		(10,619	)		42,747

b)Interest in associate

The Company holds a 25% equity interest in its associate Pathway RX Inc. (“Pathway”). Pathway is a private company focused on developing cannabis-based pharmaceutical drugs to treat symptoms associated with a range of medical cannabis. The carrying amount of the Company’s interest in Pathway is nil.

18.Accounts payable and accrued liabilities

	December 31, 2022		December 31, 2021
Trade payables		9,774		4,172
Accrued and other liabilities		38,379		34,280
		48,153		38,452

19.Derivative warrants

	December 31, 2022			December 31, 2021
Balance, beginning of year		21,700			428
2021 Series A and B Warrants - fair value on issuance		—			62,680
2021 Additional Series A and B Warrants - fair value on issuance		—			38,576
New Warrants - fair value on issuance recognized in profit or loss		—			106,531
Change in fair value recognized in profit or loss		(10,783	)		(28,697	)
Converted to common shares		—			(157,818	)
Acquisition (note 5(a))		85			—
Balance, end of year		11,002			21,700

The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The derivative warrants are classified as a liability due to the Company’s share price being denominated in USD, which creates variability as to the value in CAD when they are exercised. The derivative warrants are recorded as a current liability, however, the Company has no cash obligation nor is there any cash loss with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

F-33

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes outstanding derivative warrants as at December 31, 2022:

	Exercise price (USD)		Number of warrants		Weighted average contractual life
2020 Series A Warrants (1)		1.77		50,000		2.6
Unsecured Convertible Notes Warrants (1)		1.77		50,000		1.0
New Warrants (2)		2.29		9,833,333		1.6
December 2018 Performance Warrants	CAD 5.51			118,067		1.0
				10,051,400		1.6

(1)The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

(2)The exercise price of the New Warrants was adjusted from USD $15.00 to $2.29 based on the July 26, 2022 Share Consolidation (as defined below) representing a share combination event (note 23(a)).

In connection with the Alcanna Transaction (note 5(a)), the Company acquired warrants previously issued by Nova (the “December 2018 Performance Warrants”) that are classified as a liability.

The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants. The Market Price condition has not been met. As such, the fair value of the December 2018 Performance Warrants was recognized as a warrant liability, inclusive of a probability weighting associated with the performance incentive being met. Under the terms of the warrant agreements, each performance warrant can be exercised for 0.05449 to 0.08174 of a Nova common share (depending on whether performance conditions are met) prior to the expiration date of December 18, 2023, at an exercise price of $5.51 per Nova common share. At December 31, 2022, there were 118,067 December 2018 Performance Warrants outstanding.

20.Lease LIABILITIES

	December 31, 2022			December 31, 2021
Balance, beginning of year		33,470			1,440
Acquisition (note 5(a), note5(c))		142,106			29,531
Additions		7,497			4,514
Lease payments		(31,834	)		(2,721	)
Dispositions and remeasurements		10,890			(70	)
Tenant inducement allowances received		1,799			—
Accretion expense		5,903			776
Balance, end of year		169,831			33,470
Current portion		30,206			5,701
Long-term		139,625			27,769

The following table presents the contractual undiscounted cash flows, excluding periods covered by lessee lease extension options that have been included in the determination of the lease term, related to the Company’s lease liabilities as at December 31, 2022:

F-34

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

	December 31, 2022
Less than one year		39,255
One to three years		64,892
Three to five years		48,955
Thereafter		47,468
Minimum lease payments		200,570

The Company has short-term leases with lease terms of 12 months or less as well as low-value leases. As these costs are incurred, they are recognized as general and administrative expense. These costs were immaterial in 2022 and 2021.

21.Other liabilities

	December 31, 2022		December 31, 2021
Financial guarantee liability (A)		407		466
Deferred share units liability (B)		2,302		4,039
		2,709		4,505

a)Financial guarantee liability

For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of ECLs in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs (note 28) in the consolidated statement of loss and comprehensive loss.

b)DSU liability

Deferred share units (“DSUs”) are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder, equal to the fair value of the Company’s common shares calculated at the date of such payment, when a director leaves the board. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. Changes in the fair value are recognized within share-based compensation expense (note 24(d)).

F-35

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

22.Income taxes

The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in profit and loss for the years ended December 31, 2022, December 31, 2021 and December 31, 2020:

	December 31, 2022			December 31, 2021			December 31, 2020
Loss before taxes		(379,770	)		(234,698	)		(206,317	)
Statutory income tax rates		23.0	%		23.0	%		24.0	%
Expected income tax recovery		(87,347	)		(53,981	)		(49,516	)
Non-deductible share-based compensation		2,508			2,308			1,970
Non-deductible finance expense		—			2			2,130
Revaluation of the fair value of warrant liabilities		(2,461	)		17,902			—
Non-controlling interest		8,167			—			—
Non-deductible portion of capital losses		7,458			5,118			—
Other non-deductible expenses		5,409			610			348
Goodwill impairment		35,919			—			—
Change in tax rates		—			—			1,528
Deferred tax benefits not recognized		23,005			20,127			43,540
Income tax (recovery) expense		(7,342	)		(7,914	)		—

Details of the deferred tax assets (liabilities) are as follows:

	December 31, 2022			December 31, 2021
Deferred tax assets (liabilities):
Inventory		23,329			20,472
Biological assets		(9,451	)		(9,509	)
Net investment in subleases		(5,363	)		(6,119	)
Intangible assets		(16,632	)		—
Lease liabilities		(5,488	)		(8,361	)
Marketable securities		14,981			7,442
Equity-accounted investee		(1,376	)		(3,925	)
Net deferred tax asset (liability)		—			—

Deferred tax assets have not been recognized for the following deductible temporary differences:

	December 31, 2022		December 31, 2021
Unrecognized deductible temporary differences:
Property, plant and equipment		7,413		81,583
Intangible assets		183		(45,256	)
Share issue costs		28,926		23,835
Investments		18,239		3,300
Lease liabilities		193,691		69,865
Financial obligations and other		2,300		4,100
Non-capital losses & scientific research and experimental development		490,326		220,596
Unrecognized deductible temporary differences		741,078		358,023

F-36

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The movement in deferred income tax liability is as follows:

	December 31, 2022			December 31, 2021
Balance, beginning of year		—			—
Recognized in profit and loss		(7,342	)		(7,914	)
Recognized in other comprehensive income		7,342			7,914
Balance, end of year		—			—

The Company has $490.3 million (December 31, 2021 - $218.5 million) of non-capital losses available for future periods that will expire prior to 2037-2042.

23.Share capital and warrants

a)Authorized

The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value.

On July 26, 2022, the Board approved a 1 to 10 share consolidation of the Company’s issued and outstanding common shares (the “Share Consolidation”). Each shareholder of record of the Company as of the close of business on the record date of July 25, 2022, received 1 common share for each 10 shares held on such date.

All references to common shares, warrants, derivative warrant liabilities, simple warrants, performance warrants, stock options, RSUs and DSUs (excluding the Nova RSUs and DSUs) have been fully retrospectively adjusted to reflect the Share Consolidation.

b)Issued and outstanding

		December 31, 2022						December 31, 2021
	Note	Number of Shares			Carrying Amount			Number of Shares		Carrying Amount
Balance, beginning of year			206,040,836			2,035,704			91,884,413		762,046
Share issuances			370,179			2,870			95,680,666		977,425
Share issuance costs			—			—			—		(16,371	)
Share repurchases			(4,252,489	)		(41,617	)		—		—
Acquisition	5		32,060,135			287,129			2,443,128		26,216
Convertible debenture settlement			—			—			248,875		2,671
Derivative warrants exercised			—			—			15,214,695		277,136
Warrants exercised			—			—			19,571		178
Employee awards exercised (1)			975,575			8,724			549,488		6,403
Balance, end of year			235,194,236			2,292,810			206,040,836		2,035,704

(1)Included in employee awards exercised are 87,500 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Included in employee awards exercised are 50,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

For the year ended December 31, 2022, the Company purchased and cancelled 4.3 million common shares at a weighted average price of $3.12 (US$2.33) per common share for a total cost of $13.3 million. Accumulated deficit was reduced by $28.3 million, representing the excess of the average carrying value of the common shares over their purchase price.

Subsequent to December 31, 2022, the Company purchased and cancelled 0.5 million common shares at a weighted average price of $2.78 (US$2.04) per common share for a total cost of $1.5 million.

F-37

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

(C)Common share purchase warrants

	Number of Warrants			Carrying Amount
Balance at December 31, 2020		102,400			6,138
Acquisition (note 5(b))		209,783			1,771
Warrants issued		64,000			361
Warrants exercised		(19,571	)		(178	)
Balance at December 31, 2021		356,612			8,092
Warrants expired		(48,000	)		(5,832	)
Balance at December 31, 2022		308,612			2,260

During the year ended December 31, 2022, the warrants issued in relation to the acquisition of a financial obligation expired.

During the year ended December 31, 2021, the Company issued 64,000 warrants to Sun 8 Holdings Inc. (“Sun 8”) with an exercise price of $9.40 per unit, in conjunction with achieving minimum thresholds of revenue derived from the brands or cultivars that the Company acquired from Sun 8 during the year ended December 31, 2019.

During the year ended December 31, 2021, 19,571 warrants that formed part of the contingent consideration from the Inner Spirit Transaction, were exercised resulting in a net payment of $0.2 million representing the difference between the exercise prices and the cash consideration (note 5(b)). The carrying value of the exercised warrants was adjusted from warrants to share capital.

The following table summarizes outstanding warrants as at December 31, 2022:

	Warrants outstanding and exercisable
Issued in relation to	Weighted average exercise price		Number of warrants		Weighted average contractual remaining life (years)
Financial services		45.98		54,400		6.6
Acquired from Inner Spirit (1)		3.37		190,212		1.2
Sun 8		9.40		64,000		3.0
	$	12.13		308,612		2.5

(1)Inner Spirit warrants are exchangeable for 0.00835 SNDL common shares in accordance with the Inner Spirit Transaction consideration (note 5(b)) and have been presented based on the number of SNDL common shares that are issuable.

24.Share-based compensation

The Company has a number of share-based compensation plans which include simple and performance warrants, stock options, RSUs and DSUs. Further detail on each of these plans is outlined below. Subsequent to the Company’s initial public offering, the Company established the stock option, RSU and DSU plans to replace the granting of simple warrants and performance warrants.

F-38

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The components of share-based compensation expense are as follows:

	Year ended December 31
	2022			2021			2020
Equity-settled expense
Simple warrants (A)		1,299			2,899			1,539
Performance warrants (A)		—			361			(42	)
Stock options (B)		78			(14	)		651
Restricted share units (1) (C)		9,423			6,789			4,069
Cash-settled expense
Deferred share units (1)(2) (D)		(1,129	)		2,272			2,349
		9,671			12,307			8,566

(1)For the year ended December 31, 2022, the Company recognized share-based compensation recovery under Nova’s RSU plan of $107 and share-based compensation expense under Nova’s DSU plan of $404.

(2)Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each reporting period. Fluctuations in the fair value are recognized during the period in which they occur.

Equity-settled plans

a)Simple and performance warrants

The Company issued simple warrants and performance warrants to employees, directors and others at the discretion of the Board. Simple and performance warrants granted generally vest annually over a three-year period, simple warrants expire five years after the grant date and performance warrants expire five years after vesting criteria met.

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2022 and the year ended December 31, 2021:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2020		342,460		$	44.13		167,200		$	41.89
Forfeited		(66,880	)		33.62		(20,480	)		54.80
Exercised		(12,000	)		9.38		(8,000	)		10.94
Expired		(4,160	)		34.51		—			0.00
Balance at December 31, 2021		259,420		$	48.60		138,720		$	41.77
Forfeited		(82,400	)		57.77		(15,520	)		37.86
Expired		(11,200	)		6.25		—			0.00
Balance at December 31, 2022		165,820		$	46.91		123,200		$	42.26

F-39

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

The following table summarizes outstanding simple and performance warrants as at December 31, 2022:

	Warrants outstanding						Warrants exercisable
Range of exercise prices	Number of warrants		Weighted average exercise price		Weighted average contractual life (years)		Number of warrants		Weighted average exercise price		Weighted average contractual life (years)
Simple warrants
$6.25 - $9.38		75,340		7.25		1.40		75,340		7.25		1.40
$29.69 - $45.31		27,120		31.26		1.61		26,320		31.02		1.54
$62.50 - $93.75		49,920		63.50		4.05		49,920		63.50		4.05
$125.00 - $375.00		13,440		239.15		4.62		7,040		205.18		3.70
		165,820	$	46.91		2.49		158,620	$	37.68		2.36
Performance warrants
$6.25 - $9.38		45,066		6.71	n/a			45,066		6.71		2.00
$12.50 - $18.75		17,334		15.15	n/a			17,334		15.15		0.93
$29.69 - $45.31		42,400		31.99	n/a			42,400		31.99		1.22
$62.50 - $93.75		9,334		77.68	n/a			1,334		93.75		1.10
$125.00 - $375.00		9,066		282.36	n/a			—		—	n/a
		123,200	$	42.26	n/a			106,134	$	19.28		1.91

b)Stock options

The Company issues stock options to employees and others at the discretion of the Board. Stock options granted generally vest annually in thirds over a three-year period and generally expire ten years after the grant date.

The following table summarizes changes in stock options during the year ended December 31, 2022 and the year ended December 31, 2021:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2020		72,060		$	18.18
Forfeited		(27,500	)		26.05
Expired		(100	)		31.50
Balance at December 31, 2021		44,460		$	13.28
Expired		(100	)		31.50
Balance at December 31, 2022		44,360		$	13.24

The following table summarizes outstanding stock options as at December 31, 2022:

	Stock options outstanding				Stock options exercisable
Exercise prices	Number of options		Weighted average contractual life (years)		Number of options		Weighted average contractual life (years)
$11.50		32,500		7.41		21,667		7.41
$11.90		8,160		7.49		8,160		7.49
$31.50		3,700		5.51		3,025		5.38
		44,360		7.27		32,852		7.24

F-40

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

c)Restricted share units

RSUs are granted to employees and the vesting requirements and maximum term are at the discretion of the Board. RSUs are exchangeable for an equal number of common shares.

The following table summarizes changes in RSUs during the year ended December 31, 2022 and the year ended December 31, 2021:

	RSUs outstanding
Balance at December 31, 2020		165,692
Granted		1,238,152
Forfeited		(158,263	)
Exercised		(491,988	)
Balance at December 31, 2021		753,593
Granted		1,728,557
Forfeited		(175,245	)
Exercised		(925,575	)
Balance at December 31, 2022		1,381,330

Subsequent to December 31, 2022, the Company granted 7.8 million RSUs to employees as part of its long-term incentive program.

Cash-settled plans

d)Deferred share units

DSUs are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end.

As at December 31, 2022, the Company recognized a liability of $2.3 million relating to the fair value of cash-settled DSUs (December 31, 2021 – $4.0 million). The liability is included as a non-current liability within other liabilities (note 21).

The following table summarizes changes in DSUs during the year ended December 31, 2022 and the year ended December 31, 2021:

	DSUs outstanding
Balance at December 31, 2020		332,331
Granted		248,919
Exercised		(30,000	)
Balance at December 31, 2021		551,250
Granted		1,216,076
Exercised		(58,943	)
Balance at December 31, 2022		1,708,383

As at December 31, 2022, nil (December 31, 2021 – 0.6 million) DSUs were exercisable.

25.Gross revenue

Liquor retail revenue is derived from the sale of wines, beers and spirits to customers. Cannabis retail revenue is derived from retail cannabis sales to customers, franchise revenue consists of royalty, advertising and franchise fee

F-41

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

revenue, and other revenue consists of millwork, supply and accessories revenue and proprietary licensing. Cannabis revenue is derived from contracts with customers and is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers.

	Year ended December 31
	2022		2021		2020
Liquor retail revenue		462,180		—		—
Cannabis retail revenue
Retail		192,710		10,207		—
Franchise		8,337		4,251		—
Other		4,563		1,633		—
Cannabis retail revenue		205,610		16,091		—
Cannabis revenue
Provincial boards		58,728		41,338		55,315
Medical		9		8		32
Wholesale		3,167		9,842		17,974
Cannabis revenue		61,904		51,188		73,321
Gross revenue		729,694		67,279		73,321

The Company has recognized the following receivables from contracts with customers:

	December 31, 2022		December 31, 2021		December 31, 2020
Receivables, included in 'trade receivables' (note 9)		17,558		10,865		15,786

Receivables from contracts with customers are typically settled within 30 days. As at December 31, 2022, an impairment of $0.6 million (December 31, 2021 – $0.2 million) has been recognized on receivables from contracts with customers (note 31).

26.Investment revenue (Loss)

	Year ended December 31
	2022		2021		2020
Interest and fee revenue
Interest revenue from investments at amortized cost		3,660		1,654		—
Interest and fee revenue from investments at FVTPL		6,036		8,514		—
Interest revenue from cash		7,043		2,981		—
		16,739		13,149		—

	Year ended December 31
	2022			2021			2020
Investment loss
Realized gains		389			20,213			—
Unrealized (losses) gains (note 8)		(65,553	)		(64,714	)		—
		(65,164	)		(44,501	)		—

F-42

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

27.Other operating expenses

a)General and administrative

	Year ended December 31
	2022		2021 (1)		2020
Salaries and wages		80,134		18,675		11,634
Consulting fees		1,934		1,112		2,193
Office and general		37,061		7,560		9,843
Professional fees		11,563		6,530		4,658
Merchant processing fees		4,748		—		—
Director fees		472		351		365
Other		4,256		3,815		3,336
		140,168		38,043		32,029

(1)Adjustment to provisional amounts — refer to note 5(b).

b)Sales and marketing

	Year ended December 31
	2022		2021		2020
Marketing		7,308		3,671		4,839
Events		102		191		393
Research		—		43		57
Media		1,007		1,138		448
		8,417		5,043		5,737

28.Finance costs

	Year ended December 31
	2022			2021			2020
Cash finance expense
Interest on long-term debt		—			—			7,482
Other finance costs		178			40			286
		178			40			7,768
Non-cash finance expense (income)
Change in fair value of investments at FVTPL		36,087			3,300			—
Accretion on lease liabilities		5,903			776			89
Financial guarantee liability (recovery) expense		(59	)		59			—
Accretion		—			—			1,622
Amortization of debt issue costs		—			—			1,782
Change in fair value of convertible notes		—			—			(7,141	)
Other		89			154			(86	)
		42,020			4,289			(3,734	)
Interest income		(884	)		(573	)		(215	)
		41,314			3,756			3,819

F-43

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

29.Supplemental cash flow disclosures

	Year ended December 31
	2022			2021			2020
Cash provided by (used in):
Accounts receivable		(5,815	)		9,339			(2,037	)
Biological assets		533			3,829			13,789
Inventory		4,243			(18,318	)		(12,315	)
Prepaid expenses and deposits		5,782			(3,922	)		2,280
Investments		918			(402	)		—
Right of use assets		(17,510	)		—			—
Property, plant and equipment		38			(305	)		—
Accounts payable and accrued liabilities		(27,864	)		9,665			(20,793	)
Lease liabilities		19,296			—			—
		(20,379	)		(114	)		(19,076	)
Changes in non-cash working capital relating to:
Operating		(22,073	)		150			(5,259	)
Investing		74			(612	)		(11,319	)
Financing		1,620			348			(2,498	)
		(20,379	)		(114	)		(19,076	)
Cash interest paid		—			—			6,094

30.Loss per share

	Year ended December 31
	2022			2021			2020
Weighted average shares outstanding (000s)
Basic and diluted (1)		229,871			186,038			21,865
Continuing operations
Net loss attributable to owners of the Company		(335,114	)		(226,984	)		(199,619	)
Per share - basic and diluted	$	(1.46	)	$	(1.22	)	$	(9.13	)
Discontinued operations
Net loss attributable to owners of the Company		—			—			(33,627	)
Per share - basic and diluted	$	—		$	—		$	(1.54	)
Net loss attributable to owners of the Company		(335,114	)		(226,984	)		(233,246	)
Per share - basic and diluted	$	(1.46	)	$	(1.22	)	$	(10.67	)

(1)For the year ended December 31, 2022, there were 0.3 million equity classified warrants, 10.1 million derivative warrants, 0.2 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 1.4 million RSUs that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2021 – 0.4 million equity classified warrants, 9.9 million derivative warrants, 0.3 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 0.8 million RSUs, year ended December 31, 2020 – 0.1 million equity classified warrants, 0.2 million derivative warrants, 0.3 million simple warrants, 0.2 million performance warrants, 0.07 million stock options and 0.2 million RSUs).

F-44

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

31.Financial instruments

The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, investments at amortized cost, investments at FVTPL, accounts payable and accrued liabilities and derivative warrants.

a)Fair value

The carrying value of cash and cash equivalents, restricted cash, accounts receivable and accounts payable and accrued liabilities approximate their fair value due to the short-term nature of the instruments. The carrying value of investments at amortized cost approximate their fair value as the fixed interest rates approximate market rates for comparable transactions.

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows:

			Fair value measurements using
December 31, 2022	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		21,926		21,926		—		—
Investments at FVTPL		72,761		—		—		72,761
Financial liabilities
Derivative warrants (1)		11,002		—		—		11,002
			Fair value measurements using
December 31, 2021	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		83,724		83,724		—		—
Investments at FVTPL		48,576		—		—		48,576
Financial liabilities
Derivative warrants (1)		21,700		—		—		21,700

(1)The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Marketable securities are designated as FVTPL. The fair value of marketable securities is re-measured each reporting period with changes in fair value recognized in profit and loss. The fair value of marketable securities is estimated by using current quoted prices in active markets for identical assets.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

As at December 31, 2022, the Company did not have any financial instruments measured at Level 2 fair value.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Investments designated as FVTPL are re-measured each reporting period with changes in the fair value recognized in profit and loss within finance costs. The fair values of the investments were estimated by using a discounted

F-45

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

cash flow analysis. The main assumptions used in the calculation were the determination of a credit-adjusted discount rate.

Derivative warrants are designated as FVTPL. The fair value of derivative warrants is re-measured each reporting period with changes in fair value recognized in profit and loss within finance costs. The fair value of derivative warrants is estimated by using a valuation model. Assumptions used in these calculations include volatility, discount rate and various probability factors.

At December 31, 2022, a 10% change in the material assumptions would change the estimated fair value of derivative warrant liabilities by approximately $1.3 million.

There were no transfers between Levels 1, 2 and 3 inputs during the year.

b)Credit risk management

Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company.

The Company applies the simplified approach under IFRS 9 to accounts receivable and has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions.

Impairment losses on accounts receivable recognized in profit or loss were as follows:

As at	December 31, 2022		December 31, 2021
Impairment loss (reversal) on trade receivables		642		214
Impairment loss (reversal) on other receivables		674		798
		1,316		1,012

The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2022 was as follows:

	December 31, 2022		December 31, 2021
Balance, beginning of year		1,132		120
Net remeasurement of impairment loss allowance		1,316		1,012
Balance, end of year		2,448		1,132

The Company applies the general approach under IFRS 9 to investments, which is an assessment of whether the credit risk of a financial instrument has increased significantly since initial recognition. The general approach compares the risk of a default occurring at the reporting date with the risk of a default occurring at the date of initial recognition. The Company has evaluated the credit risk of its investments, taking into consideration the risk of default, historical credit loss experience, financial factors specific to the debtors and general economic conditions and determined the expected credit loss to be $0.5 million for the year ended December 31, 2022.

The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable and investments. The Company attempts to mitigate such exposure to its cash by investing only in financial institutions with investment grade credit ratings or secured investments.

c)Market risk management

Market risk is the risk that changes in market prices will affect the Company’s income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations

F-46

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company’s marketable securities are shares held of publicly traded entities and put and call options.

At December 31, 2022, a 10% change in the market prices would change the fair value of marketable securities by approximately $2.1 million.

The Company had no risk management contracts relating to marketable securities outstanding as at December 31, 2022.

d)Liquidity risk management

Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

The timing of expected cash outflows relating to financial liabilities at December 31, 2022 is as follows:

	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		48,153		—		—		—		48,153
Financial guarantee liability (note 21)		—		407		—		—		407
Balance, end of year		48,153		407		—		—		48,560

32.Related party transactions

The Company entered into the following related party transactions during the periods noted, in addition to those disclosed in note 17 relating to the Company’s joint venture.

A member of key management personnel jointly controls a company that owns property leased to SNDL for one of its retail liquor stores. The lease term is from November 1, 2017 to October 31, 2027 and includes extension terms from November 1, 2027 to October 31, 2032 and November 1, 2032 to October 31, 2037. Monthly rent for the location includes base rent, common area costs and sign rent. The rent amounts are subject to increases in accordance with the executed lease agreement. Subsequent to the Alcanna Transaction and for the period March 31, 2022 to December 31, 2022, the Company paid $117.9 thousand in total rent with respect to this lease.

Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2022		2021		2020
Salaries and short-term benefits		4,505		2,348		1,944
Share-based compensation		5,871		8,275		7,629
		10,376		10,623		9,573

F-47

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

33.Capital management

The Company defines capital as shareholders’ equity and debt. Except as otherwise disclosed in these consolidated financial statements, there are no restrictions on the Company’s capital. The Company’s objectives with respect to the management of capital are to:

•Maintain financial flexibility in order to preserve the ability to meet financial obligations;

•Deploy capital to provide an appropriate investment return to shareholders; and

•Maintain a capital structure that allows various financing alternatives.

34.Non-controlling interests

The following tables provide summarized financial information for the Company’s subsidiary, Nova, that has a material non-controlling interest effective the date of closing of the Alcanna Transaction, before inter-company eliminations. The Company does have subsidiaries with non-material non-controlling interests that are not presented in the following financial information.

a)Nova summarized statement of financial position

	2022
Current assets		18,732
Current liabilities		19,892
Current net assets		(1,160	)
Non-current assets		94,419
Non-current liabilities		45,443
Non-current net assets		48,976
Net assets		47,816

b)Nova summarized statement of loss and comprehensive loss

	2022
Revenue		176,588
Loss and comprehensive loss		(7,672	)

c)Nova summarized statement of cash flows

	2022
Net cash provided by operating activities		5,848
Net cash used in investing activities		(5,549	)
Net cash used in financing activities		(183	)
Increase in cash		116

35.Commitments and contingencies

a)Commitments

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2022 of $2.5 million (December 31, 2021 - $2.5 million).

F-48

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

b)Contingencies

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include commercial litigation related to breach of contract claims brought by our customers, franchise partners, suppliers and contractors, as well as litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently pending and threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgements or settlement terms could have an adverse impact on our business and results of operations.

In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re SNDL Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re SNDL Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions asserted claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally alleged that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also included allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021. On October 5, 2022, the court entered an order and final judgement approving the settlement.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. SNDL Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserted claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act and Section 10(b) the Exchange Act, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleged that the Company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

36.Subsequent events

Valens Acquisition

On August 22, 2022, the Company and The Valens Company Inc. (“Valens”) announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) pursuant to which the Company would acquire, subject to Valens’ shareholder approval and customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). Concurrently with the execution of the Valens Arrangement Agreement, the Company assumed Valens’ non-revolving term loan facility from its then-existing lender, and amended and restated the related credit agreement to provide for a $60.0 million non-revolving term loan facility with a maturity date of December 15,

F-49

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

2023 and an interest rate of 10% per annum (the “Valens Facility”). As Valens is now a wholly-owned subsidiary of the Company, the Valens Facility became inter-company debt following the closing of the Valens Transaction. The Valens Transaction closed on January 17, 2023.

The Valens Transaction consideration was comprised of (i) the assumption of Valens’ $60 million non-revolving term loan facility from its then existing lender, as described above, and (ii) an aggregate 27.6 million SNDL common shares valued at $84.0 million based on the fair value of each common share of the Company on the closing date (0.3334 of a SNDL common share for each Valens common share).

Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and recreational consumer segments. Valens also distributes medicinal cannabis products to Australia through its subsidiary Valens Australia Pty Ltd. (“Valens Australia”). Additionally, Valens manufactured, distributed, and sold a wide range of CBD products in the United States through its subsidiary Green Roads, Inc. (“Green Roads”), prior to the Valens Transaction. Green Roads filed for bankruptcy in the United States on March 6, 2023. The Company has provided a superpriority secured debtor-in-possession line of credit to Green Roads in the amount of USD $1.75 million.

Due to the proximity of the closing of the Valens Transaction and the date of issuance of the consolidated financial statements, the Company has not yet prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

Superette Acquisition

On February 7, 2023, the Company announced that, in the context of the Superette Group’s (as defined below) proceedings under the CCAA, it had successfully closed the Superette Transaction (as defined below) contemplated by the agreement of purchase and sale dated August 29, 2022 (as amended and restated on December 12, 2022) (the “APS”) and the approval and vesting order issued by the Ontario Superior Court of Justice (Commercial List) on December 20, 2022.

The Superette Group sells cannabis and non-cannabis branded merchandise and has furthered its market exposure and brand awareness through private-label cannabis offerings. Pursuant to the APS, certain of the Superette entities, including Superette Inc. and Superette Ontario Inc. (“Superette Ontario”) (collectively, the “Superette Group”), have sold their right, title and interest in (i) the five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand (the “Superette IP”); and (iii) the shares of Superette Ontario (collectively, the “Superette Transaction”).

Pursuant to applicable laws and regulatory considerations, SNDL directed that the shares of Superette Ontario be transferred to Spirit Leaf Ontario Inc. (“SLO”). SNDL has entered into an option agreement with SLO to purchase all of the issued and outstanding shares of Superette Ontario if certain conditions are met, including compliance with regulatory considerations. The retail location s and intellectual property were transferred to Superette Ontario to assist in operating the retail locations and the Superette IP was transferred to SNDL directly. Certain of the Superette IP will be licensed by SNDL to SLO to allow it to use the Superette brand in the retail locations.

Due to the proximity of the closing of the Superette Transaction and the date of issuance of the consolidated financial statements, the Company has not yet prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

LIGHTBOX Acquisition

On March 28, 2023, the Company announced that it had entered into an agreement (the “Lightbox Agreement”) with Lightbox Enterprises Ltd. (“Lightbox”) to acquire four cannabis retail stores operating under the Dutch Love Cannabis banner (“Dutch Love”). Under the Lightbox Agreement, SNDL will acquire from Lightbox the rights to four Dutch Love stores and the rights to use certain Dutch Love related intellectual property for total consideration of $7.8 million. The

F-50

SNDL Inc.

Notes to the Consolidated Financial Statements

For the year ended December 31, 2022

(Expressed in thousands of Canadian dollars, except where otherwise noted)

consideration is comprised of i) $1.5 million cash; ii) the cancellation of the $3.0 million debt owed by Lightbox to SNDL; and iii) $3.3 million payable in common shares of SNDL.

The transaction is expected to be completed in the context of Lightbox's proceedings under the CCAA from the Supreme Court of British Columbia (the “BC Court”). On December 2, 2022, the BC Court granted an order that approved a sale and investment solicitation process (“SISP”) in respect of the assets, undertakings and properties of Lightbox, and the Agreement is the result of the SISP process.

The transaction is anticipated to close by the end of May 2023.

F-51

EX-1

CORPORATE ACCESS NUMBER: 2024820637

 

BUSINESS CORPORATIONS ACT

CERTIFICATE OF

AMALGAMATION

SNDL INC.

IS THE RESULT OF AN AMALGAMATION FILED ON 2023/01/01.

 

Articles of Amalgamation For

SNDL INC.

Share Structure: Share Transfers Restrictions: Number of Directors: Min Number of Directors: Max Number of Directors: Business Restricted To: Business Restricted From: Other Provisions: SEE SCHEDULE "A" ATTACHED NONE 1 15 NONE NONE SEE SCHEDULE "C" ATTACHED

Registration Authorized By: JIM KEOUGH OFFICER

SCHEDULE "A"

THE CLASSES OF SHARES AND ANY MAXIMUM NUMBER OF SHARES THAT THE CORPORATION IS AUTHORIZED TO ISSUE ARE:

1.An unlimited number of Common shares, the holders of which are entitled:

(a)to receive notice of and to attend and vote at all meetings of shareholders, except meetings at which only holders of a specified class of shares are entitled to vote;

(b)to receive any dividend declared by the Corporation on this class of shares; provided that the Corporation shall be entitled to declare dividends on the Preferred shares, or on any other classes of shares without being obliged to declare any dividends on the Common shares of the Corporation;

(c)subject to the rights, privileges, restrictions and conditions attaching to any other class of shares of the Corporation, to receive the rema1n1ng property of the Corporation upon dissolution in equal rank with the holders of all other Common shares of the Corporation.

2.An unlimited number of Preferred shares, which as a class, have attached thereto the following rights, privileges, restrictions and conditions:

(a)the Preferred shares may from time to time be issued in one or more series, and the Directors may fix from time to time before such issue the number of Preferred shares which is to comprise each series and the designation, rights, privileges, restrictions and conditions attaching to each series of Preferred shares including, without limiting the generality of the foregoing, any voting rights, the rate or amount of dividends or the method of calculating dividends, the dates of payment thereof, the terms and conditions of redemption, purchase and conversion if any, and any sinking fund or other provisions;

(b)the Preferred shares of each series shall, with respect to the payment of dividends and the distribution of assets or return of capital in the event of liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, or any other return of capital or distribution of the assets of the Corporation amongst its shareholders for the purpose of winding up its affairs, be entitled to preference over the Common shares and over any other shares of the Corporation ranking by their terms junior to the Preferred shares of that series. The Preferred shares of any series may also be given such other preferences, not inconsistent with these Articles, over the Common shares and any other such Preferred shares as may be fixed in accordance with clause (2)(a); and

(c)if any cumulative dividends or amounts payable on the return of capital in respect of a series of Preferred shares are not paid in full, all series of Preferred shares shall participate rateably in respect of accumulated dividends and return of capital.

SCHEDULE "C"

OTHER RULES OR PROVISIONS:

1. The directors may, between annual meetings, appoint one or more additional directors of the Corporation to serve until the next annual meeting, but the number of additional directors shall not at any time exceed one-third (1/3) of the number of directors who held office at the expiration of the last annual meeting of the Corporation.

Amalgamate Alberta Corporation - Registration Statement

Alberta Registration Date: 2023/01/01

Corporate Access Number: 2024820637

Business Number:

Service Request Number: Alberta Corporation Type: Legal Entity Name: Business Number: French Equivalent Name: Nuans Number: Nuans Date: French Nuans Number: French Nuans Date: REGISTERED ADDRESS Street: Legal Description: City: Province: Postal Code: RECORDS ADDRESS Street: Legal Description: City: Province: Postal Code: ADDRESS FOR SERVICE BY MAIL Post Office Box: City: Province: Postal Code: Email Address: Share Structure: Share Transfers Restrictions: Number of Directors: Min Number Of Directors: Max Number Of Directors: Business Restricted To: Business Restricted From: Other Provisions: 38878702 Named Alberta Corporation SNDL INC. 4000-421 7 AVE SW CALGARY ALBERTA T2P4K9 4000-421 7 AVE SW CALGARY ALBERTA T2P4K9 CAL-ANNUAL-DOCS@MCCARTHY.CA SEE SCHEDULE "A" ATTACHED NONE 1 15 NONE NONE SEE SCHEDULE "C" ATTACHED

Professional Endorsement Provided: Future Dating Required: Registration Date: 2023/01/01

Agent for Service

Agent for Service Type: Last Name: First Name: Middle Name: Firm Name: Street: City: Province: Postal Code: Email Address: Primary BROWN JESSICA M. MCCARTHY TETRAULT LLP 4000, 421 - 7 AVENUE SW CALGARY ALBERTA T2P4K9 CAL-ANNUAL-DOCS@MCCARTHY.CA

Director

Last Name: First Name: Middle Name: Street/Box Number: City: Province: Postal Code: Country: Named On Stat Dec: PINNEY BRYAN 4000, 421 - 7 AVENUE SW CALGARY ALBETA T2P4K9

Last Name: First Name: Middle Name: Street/Box Number: City: Province: Postal Code: Country: Named On Stat Dec: GEORGE ZACHARY 4000, 421 - 7 AVENUE SW CALGARY ALBETA T2P4K9 Y

Last Name: First Name: Middle Name: Street/Box Number: TURNBULL GREGORY G. 4000, 421 - 7 AVENUE SW

City: Province: Postal Code: Country: Named On Stat Dec: CALGARY ALBETA T2P4K9

Last Name: First Name: Middle Name: Street/Box Number: City: Province: Postal Code: Country: Named On Stat Dec: MILLS J. GREGORY 4000, 421 - 7 AVENUE SW CALGARY ALBETA T2P4K9

Last Name: First Name: Middle Name: Street/Box Number: City: Province: Postal Code: Country: Named On Stat Dec: ELL LORI 4000, 421 - 7 AVENUE SW CALGARY ALBETA T2P4K9

Amalgamating Corporation

Corporate Access Number	Business Number	Legal Entity Name
2012627127	840747166	SNDL INC.
2024817625	843430919	ALCANNA INC.

Attachment

Attachment Type	Microfilm Bar Code	Date Recorded
Statutory Declaration	10000607142504094	2023/01/01
Other Rules or Provisions	ELECTRONIC	2023/01/01
Share Structure	ELECTRONIC	2023/01/01

Registration Authorized By: JIM KEOUGH OFFICER

The Registrar of Corporations certifies that the information contained in this statement is an accurate reproduction of the data contained in the specified service request in the official public records of Corporate Registry.

EX-8

Exhibit 8.1

SNDL Inc.

Subsidiaries of the Registrant

Subsidiaries	Jurisdiction of incorporation
KamCan Products Inc.	British Columbia, Canada
Sundial Deutschland GmbH	Germany
2657408 Ontario Inc.	Ontario, Canada
NGBA-BC Holdings Ltd.	British Columbia, Canada
Sundial Insurance (Bermuda) Ltd.	Bermuda
Inner Spirit Holdings Ltd.	Alberta, Canada
Spirit Leaf Inc.	Alberta, Canada
Spirit Leaf Corporate Inc.	Alberta, Canada
Spirit Leaf Ontario Inc.	Ontario, Canada
Zenabis Ltd.	Alberta, Canada
Alcanna Inc.	Canada
Liquor Stores GP Inc.	Alberta, Canada
Liquor Stores Limited Partnership	Alberta, Canada
Canadian Liquor Retailers Alliance GP Inc.	Alberta, Canada
Nova Cannabis Inc.	Alberta, Canada
Nova Cannabis Stores GP Inc.	Alberta, Canada
Nova Cannabis Stores Limited Partnership	Alberta, Canada
Nova Cannabis Analytics GP Inc.	Alberta, Canada
Nova Cannabis Analytics Limited Partnership	Alberta, Canada
Alcanna Cannabis Stores Finance Ltd.	Alberta, Canada
YSS SK Cannabis Inc.	Alberta, Canada
2472573 Alberta Inc.	Alberta, Canada
Sweet Tree Modern Apothecary Ltd.	Alberta, Canada
YSS Cannabis Corp.	Alberta, Canada
2102012 Alberta Ltd.	Alberta, Canada

EX-12

EXHIBIT 12.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

I, Zachary George, certify that:

1.I have reviewed this annual report on Form 20-F of SNDL Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of SNDL Inc. as of, and for, the periods presented in this report;

4.The other certifying officer of SNDL Inc. and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for SNDL Inc. and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to SNDL Inc., including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of disclosure controls and procedures of SNDL Inc. and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in internal control over financial reporting of SNDL Inc. that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect internal control over financial reporting of SNDL Inc.; and

5.The other certifying officer of SNDL Inc. and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the auditors of SNDL Inc. and the audit committee of the board of directors of SNDL Inc. (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the ability of SNDL Inc. to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the internal control over financial reporting of SNDL Inc.

Date: April 24, 2023

/s/ Zachary George

Chief Executive Officer

EX-12

EXHIBIT 12.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

I, James Keough, certify that:

1.I have reviewed this annual report on Form 20-F of SNDL Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of SNDL Inc. as of, and for, the periods presented in this report;

4.The other certifying officer of SNDL Inc. and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for SNDL Inc. and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to SNDL Inc., including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of disclosure controls and procedures of SNDL Inc. and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in internal control over financial reporting of SNDL Inc. that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect internal control over financial reporting of SNDL Inc.; and

5.The other certifying officer of SNDL Inc. and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the auditors of SNDL Inc. and the audit committee of the board of directors of SNDL Inc. (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the ability of SNDL Inc. to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the internal control over financial reporting of SNDL Inc.

Date: April 24, 2023

/s/ James Keough

Chief Financial Officer

EX-13

EXHIBIT 13.1

PRINCIPAL EXECUTIVE OFFICER CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Zachary George, Chief Executive Officer of SNDL Inc., certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.The Annual Report on Form 20-F of SNDL Inc. for the period ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of SNDL Inc.

Date: April 24, 2023

/s/ Zachary George

Chief Executive Officer

EX-13

EXHIBIT 13.2

PRINCIPAL FINANCIAL OFFICER CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James Keough, Chief Financial Officer of SNDL Inc., hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1.The Annual Report on Form 20-F of SNDL Inc. for the period ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of SNDL Inc.

Date: April 24, 2023

/s/ James Keough

Chief Financial Officer

EX-15

EXHIBIT 15.1

 

SNDL Inc.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For the year ended December 31, 2022

Management’s Discussion and Analysis

This Management’s Discussion and Analysis (“MD&A”) of the financial condition and performance of SNDL Inc. (“SNDL” or the “Company”) for the year ended December 31, 2022 is dated April 24, 2023. This MD&A should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022 and the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 (collectively, the “Audited Financial Statements”) and the risks identified in the Company’s Annual Report on Form 20-F for the year ended December 31, 2022 (the “Annual Report”) and elsewhere in this MD&A. This MD&A has been prepared in accordance with National Instrument 51-102 – Continuous Disclosure Obligations and is presented in thousands of Canadian dollars, except where otherwise indicated. All share amounts in this MD&A have been adjusted retrospectively to reflect the Share Consolidation (as defined herein) unless otherwise noted. See “Liquidity and Capital Resources – Equity”.

MD&A – Table of Contents

COMPANY OVERVIEW	1
RECENT DEVELOPMENTS	2
OTHER DEVELOPMENTS	3
OPERATIONAL AND FINANCIAL HIGHLIGHTS	4
CONSOLIDATED RESULTS	5
OPERATING SEGMENTS	7
LIQUOR RETAIL SEGMENT RESULTS	8
CANNABIS RETAIL SEGMENT RESULTS	9
CANNABIS OPERATIONS SEGMENT RESULTS	10
INVESTMENTS SEGMENT RESULTS	13
FOURTH QUARTER 2022	14
SELECTED QUARTERLY INFORMATION	17
SELECTED ANNUAL INFORMATION	17
LIQUIDITY AND CAPITAL RESOURCES	19
CONTRACTUAL COMMITMENTS AND CONTINGENCIES	22
SPECIFIED FINANCIAL MEASURES	23
RELATED PARTIES	24
OFF BALANCE SHEET ARRANGEMENTS	24
CRITICAL ACCOUNTING POLICIES AND ESTIMATES	25
NEW ACCOUNTING PRONOUNCEMENTS	25
RISK FACTORS	25
DISCLOSURE CONTROLS AND PROCEDURES	25
INTERNAL CONTROL OVER FINANCIAL REPORTING	26
REMEDIATION	27
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING	27
ABBREVIATIONS	27
FORWARD-LOOKING INFORMATION	27
ADDITIONAL INFORMATION	28

COMPANY OVERVIEW

SNDL Inc., formerly Sundial Growers Inc., operates under four reportable segments:

•Liquor retail sales of wines, beers and spirits,

•Cannabis retail sales of cannabis products and accessories through corporate-owned and franchised cannabis retail operations,

•Cannabis operations as a licensed producer that grows cannabis using indoor facilities, and

•Investments targeting the global cannabis industry.

The principal activities of the Company are the retailing of wines, beers and spirits under the Wine and Beyond, Liquor Depot and Ace Liquor retail banners; the operation and support of corporate-owned and franchise retail cannabis stores in certain Canadian jurisdictions where the private sale of recreational cannabis is permitted, under the Value Buds, Sweet Tree and Spiritleaf retail banners; the production, distribution and sale of cannabis in domestically and for export pursuant to the Cannabis Act (Canada) (the “Cannabis Act”) through a cannabis brand portfolio that includes Top Leaf, Sundial Cannabis, Palmetto, Spiritleaf Selects, Value Buds, Namaste, Re-up and Grasslands; and, the deployment of capital to direct and indirect investments and partnerships throughout the global cannabis industry.

The Company produces and markets cannabis products for the Canadian adult-use market and recently expanded to include export for the international medicinal market. SNDL’s purpose-built indoor modular grow rooms create consistent, highly controlled cultivation environments and are the foundation of the Company’s production of high-quality, strain-specific cannabis products. SNDL’s operations cultivate cannabis using an individualized “room” approach, in approximately 448,000 square feet of total space in Olds and approximately 380,000 square feet of total space in Atholville. The Company has established supply agreements with ten Canadian provinces and has a distribution network that covers 98% of the national adult-use cannabis industry.

As of December 31, 2022, SNDL and its subsidiaries currently operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. (“SunStream”), the Company provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.

The Company also owns approximately 63% of Nova Cannabis Inc. (“Nova”), whose principal activities are related to the retail sale of cannabis.

SNDL was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. The Company’s common shares are listed under the symbol “SNDL” on the NASDAQ Capital Market (“Nasdaq”).

On July 25, 2022, the Company’s shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from “Sundial Growers Inc.” to “SNDL Inc.” and the change became effective on the same day. In light of the evolution of SNDL’s business over the past two years, the new name more appropriately reflects the operating model and strategy across liquor and cannabis retail, cannabis cultivation and investments. The rebrand underscores SNDL’s differentiated vertical integration model and reorients to its position as Canada’s largest private sector regulated cannabis and liquor product platform.

SNDL is headquartered in Calgary, Alberta, with operations in Olds, Alberta, and Atholville, New Brunswick, and corporate-owned and franchised retail liquor and cannabis stores in five provinces across Canada.

SNDL’s overall strategy is to build sustainable, long-term shareholder value by improving liquidity and cost of capital while optimizing the capacity and capabilities of its production facilities in the creation of a consumer-centric brand and product portfolio. SNDL’s retail operations will continue to build a Canadian retail liquor brand and a network of retail cannabis stores across Canadian jurisdictions where the private distribution of cannabis is legal. SNDL’s investment operations seek to deploy capital through direct and indirect investments and partnerships throughout the global cannabis industry.

1

RECENT DEVELOPMENTS

Valens Acquisition

On August 22, 2022, the Company and The Valens Company Inc. (“Valens”) announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) pursuant to which the Company would acquire, subject to Valens’ shareholder approval and customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). Concurrently with the execution of the Valens Arrangement Agreement, the Company assumed Valens’ non-revolving term loan facility from its then-existing lender, and amended and restated the related credit agreement to provide for a $60.0 million non-revolving term loan facility with a maturity date of December 15, 2023 and an interest rate of 10% per annum (the “Valens Facility”). As Valens is now a wholly-owned subsidiary of the Company, the Valens Facility became inter-company debt following the closing of the Valens Transaction. The Valens Transaction closed on January 17, 2023.

The Valens Transaction consideration was comprised of (i) the assumption of Valens’ $60 million non-revolving term loan facility from its then-existing lender, as described above, and (ii) an aggregate 27.6 million SNDL common shares valued at $84.0 million based on the fair value of each common share of the Company on the closing date (0.3334 of a SNDL common share for each Valens common share).

Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and recreational consumer segments. Valens distributes medicinal cannabis products to Australia through its subsidiary Valens Australia Pty Ltd. (“Valens Australia”). Additionally, Valens manufactured, distributed, and sold a wide range of CBD products in the United States through its subsidiary Green Roads, Inc (“Green Roads”), prior to the Valens Transaction. Green Roads filed for bankruptcy in the United States on March 6, 2023.

Due to the proximity of the closing of the Valens Transaction and the date of issuance of the consolidated financial statements, the Company has not prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

Superette Acquisition

On February 7, 2023, the Company announced that, in the context of the Superette Group’s (as defined below) proceedings under the Companies’ Creditors Arrangement Act (Canada) (“CCAA”), it has successfully closed the Superette Transaction (as defined below) contemplated by the agreement of purchase and sale dated August 29, 2022 (as amended and restated on December 12, 2022) (the “APS”) and the approval and vesting order issued by the Ontario Superior Court of Justice (Commercial List) on December 20, 2022.

The Superette Group sells cannabis and non-cannabis branded merchandise and has furthered its market exposure and brand awareness through private-label cannabis offerings. Pursuant to the APS, certain of the Superette entities, including Superette Inc. and Superette Ontario Inc. (“Superette Ontario”) (collectively, the “Superette Group”), have sold their right, title and interest in (i) the five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand (the “Superette IP”); and (iii) the shares of Superette Ontario (collectively, the “Superette Transaction”).

Pursuant to applicable laws and regulatory considerations, SNDL directed that the shares of Superette Ontario be transferred to Spirit Leaf Ontario Inc. (“SLO”). SNDL has entered into an option agreement with SLO to purchase all of the issued and outstanding shares of Superette Ontario if certain conditions are met, including compliance with regulatory considerations. The retail locations and intellectual property were transferred to Superette Ontario to assist in operating the retail locations and the Superette IP was transferred to SNDL directly. Certain of the Superette IP will be licensed by SNDL to SLO to allow it to use the Superette brand in the retail locations.

Due to the proximity of the closing of the Superette Transaction and the date of issuance of the consolidated financial statements, the Company has not prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

2

Cost-saving measures and rightsizing cannabis operations at alberta facility

On February 13, 2023, the Company announced changes to its operations through a rightsizing of cannabis cultivation in Olds, Alberta, in an effort to focus the facility on premium products and brands. The Valens Transaction has accelerated the need to optimize and rationalize SNDL's manufacturing and operational footprint to better address market saturation and oversupply. SNDL has initiated a headcount reduction of approximately 85 employees at the Olds facility as a part of a larger phased cost savings program that is expected to deliver close to $9 million in savings across labour and operational costs for the remainder of 2023. SNDL expects to complete most of this transition within the first quarter of 2023.

Through its integration and rationalization efforts, the Company is assessing all assets and will continue to make decisions based on sustainable profitability.

LIGHTBOX Acquisition

On March 28, 2023, the Company announced that it had entered into an agreement (the “Lightbox Agreement”) with Lightbox Enterprises Ltd. (“Lightbox”) to acquire four cannabis retail stores operating under the Dutch Love Cannabis banner (“Dutch Love”). Under the Lightbox Agreement, SNDL will acquire from Lightbox the rights to four Dutch Love stores and the rights to use certain Dutch Love related intellectual property for total consideration of $7.8 million. The consideration is comprised of i) $1.5 million cash; ii) the cancellation of the $3.0 million debt owed by Lightbox to SNDL; and iii) $3.3 million payable in common shares of SNDL.

The transaction is expected to be completed in the context of Lightbox's proceedings under the CCAA from the Supreme Court of British Columbia (the “BC Court”). On December 2, 2022, the BC Court granted an order that approved a sale and investment solicitation process (“SISP”) in respect of the assets, undertakings and properties of Lightbox, and the Agreement is the result of the SISP process.

The transaction is anticipated to close by the end of May 2023.

OTHER DEVELOPMENTS

acquisition of zenabis business

On November 1, 2022, the Company announced that, in the context of proceedings pursuant to the Zenabis Group’s (as defined below) filing under the CCAA, it had successfully acquired all assets of the business of the Zenabis Group, subject to certain exclusions (the “Zenabis Business”), pursuant to an approval order of the Québec Superior Court (the “Court”).

The Zenabis Business’ core asset is the 380,000 square foot indoor growing facility in Atholville, New Brunswick, which has an annual production capacity of approximately 46,000 kilograms of dried cannabis and 15,000 kilograms of extraction capacity. The facility previously received EU GMP certification and has exported cannabis shipments to Malta, Israel and Australia.

The Company acquired more than 22 million grams of cannabis inventory, which will reduce near-term cultivation requirements and is expected to be monetized through wholesale transactions, international export, and branded product sales, partially through SNDL’s network of 185 retail stores. The Zenabis Business’ non-core assets include a 255,000-square foot industrial facility in Stellarton, Nova Scotia, which is under non-binding discussions for sale by SNDL. Certain intellectual property rights for the Zenabis brands and cannabis strains were also acquired.

The order of the Court approved the acquisition by a wholly owned subsidiary of SNDL of all issued and outstanding shares of Zenabis Ltd., a corporation resulting from the amalgamation of select Zenabis entities (collectively, the “Zenabis Group”), as part of the consideration for the senior secured debt of the Zenabis Group due to the SNDL subsidiary. Zenabis Ltd. owns all of the Zenabis Business, free and clear of any encumbrances except certain permitted encumbrances (namely the security of the wholly owned subsidiary of SNDL, which was preserved).

Initiation of share repurchase program

On November 11, 2021, the Company announced that the board of directors of SNDL (the “Board”) approved a share repurchase program which authorized the Company to repurchase, from time to time, up to an aggregate of $100 million of its outstanding common shares through open market purchases at prevailing market prices. SNDL may only purchase

3

a maximum of 10.3 million common shares under the share repurchase program, representing approximately 5% of the issued and outstanding common shares as at the date of announcement.

Subject to the foregoing limitations, the share repurchase program commenced on November 19, 2021 and expired on November 19, 2022.

On November 16, 2022, the Company announced that the Board approved a renewal of the share repurchase program upon its expiry on November 19, 2022. The renewed share repurchase program authorizes the Company to repurchase up to $100 million of its outstanding common shares through open market purchases at prevailing market prices. SNDL may only purchase a maximum of 11.8 million common shares under the share repurchase program, representing approximately 5% of the issued and outstanding common shares as at the date of announcement, and will expire on November 30, 2023. The renewed share repurchase program does not require the Company to purchase any minimum number of common shares and repurchases may be suspended or terminated at any time at the Company's discretion. The actual number of common shares which may be purchased pursuant to the renewed share repurchase program and the timing of any purchases will be determined by SNDL’s management and the Board. All common shares purchased pursuant to the renewed share repurchase program will be returned to treasury for cancellation.

Refer to “Liquidity and Capital Resources – Equity” below and “Item 16E – Purchases of Equity Securities by the Issuer and Affiliated Purchasers” in the Annual Report to which this MD&A is attached as an exhibit for further details regarding common shares purchased and cancelled during the year.

OPERATIONAL AND FINANCIAL HIGHLIGHTS

The following table summarizes selected financial information of the Company for the periods noted.

($000s, except as indicated)	YTD 2022			YTD 2021 (3)			Change			% Change
Financial
Gross revenue		729,694			67,279			662,415			985	%
Net revenue		712,197			56,128			656,069			1169	%
Cost of sales (3)		558,089			50,612			507,477			1003	%
Gross margin (3)		140,375			(9,001	)		149,376			1660	%
Gross margin % (3)		20	%		-16	%					36	%
Gross margin before fair value adjustments (1)(2)(3)		147,096			(11,462	)		158,558			1383	%
Gross margin before fair value adjustments % (2)(3)		21	%		-20	%					201	%
Interest and fee revenue		16,739			13,149			3,590			27	%
Investment loss		(65,164	)		(44,501	)		(20,663	)		-46	%
Loss from operations (3)		(347,774	)		(134,376	)		(213,398	)		-159	%
Net loss attributable to owners of the Company (3)		(335,114	)		(226,984	)		(108,130	)		-48	%
Per share, basic and diluted (3)		(1.46	)		(1.22	)		(0.24	)		-20	%
Adjusted EBITDA (2)(3)		(15,831	)		30,402			(46,233	)		152	%
Statement of Financial Position
Cash and cash equivalents		279,586			558,251			(278,665	)		-50	%
Inventory		127,782			29,503			98,279			333	%
Property, plant and equipment		143,409			56,472			86,937			154	%
Total assets		1,559,350			1,427,660			131,690			9	%

(1)Includes inventory obsolescence and impairment of $7.0 million for the year ended December 31, 2022, and $17.0 million for year ended December 31, 2021.

(2)Adjusted EBITDA, gross margin before fair value adjustments and gross margin before fair value adjustments percentage are specified financial measures that do not have standardized meanings prescribed by International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

(3)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

4

CONSOLIDATED RESULTS

General and administrative

	Year ended December 31
($000s)	2022		2021 (1)
Salaries and wages		80,134		18,675
Consulting fees		1,934		1,112
Office and general		37,061		7,560
Professional fees		11,563		6,530
Merchant processing fees		4,748		—
Director fees		472		351
Other		4,256		3,815
		140,168		38,043

(1)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

General and administrative expenses for the year ended December 31, 2022 were $140.2 million compared to $38.0 million for the year ended December 31, 2021. The increase of $102.2 million was mainly due to increases in salaries and wages, office and general expenses, professional fees and merchant processing fees as a result of the Alcanna and Inner Spirit acquisitions.

Share-based compensation

	Year ended December 31
($000s)	2022			2021
Equity-settled expense
Simple warrants		1,299			2,899
Performance warrants		—			361
Stock options		78			(14	)
Restricted share units		9,423			6,789
Cash-settled expense
Deferred share units		(1,129	)		2,272
		9,671			12,307

Share-based compensation expense includes the expense related to the Company’s issuance of simple and performance warrants, stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees, directors, and others at the discretion of the Board. Share-based compensation also includes the expense related to Nova’s issuance of RSUs and DSUs.

The fair value of the Company’s common shares is based on public trading data. The estimated fair value of the Company’s common shares at the time of grant is used to determine the associated share-based compensation expense. The Company determines the amount of share-based compensation expense for equity settled awards by utilizing the Black-Scholes pricing model with inputs based on the terms of the award, including the strike price, and other estimates and assumptions, including the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of the awards granted.

Share-based compensation expense for the year ended December 31, 2022 was $9.7 million compared to $12.3 million for the year ended December 31, 2021. The decrease of $2.6 million was primarily due to a decrease in DSU expense and simple warrant expense, partially offset by an increase in RSU expense. The current period DSU recovery was caused by a decrease in fair value of the DSUs resulting from a decrease in the Company’s share price. In the prior year there was a change in the DSUs from being equity-settled to cash-settled, thereby requiring the DSUs to be accounted for as a liability instrument measured at fair value. The decrease in simple warrant expense was caused by the vesting of awards issued in prior years. The increase in RSU expense was due to the issuance of new RSUs during the year, partially offset by the vesting of RSUs granted in prior years.

5

Transaction costs

	Year ended December 31
($000s)	2022		2021
Transaction costs		1,352		17,566

Transaction costs for the year ended December 31, 2022 were $1.4 million compared to $17.6 million for the year ended December 31, 2021. Transaction costs relate to various acquisitions, partially offset by a recovery related to the reversal of a provision for costs associated with securities class action lawsuits. The provision was recorded at the full amount payable upon settlement and has now been reduced by the amount covered by the Company’s directors and officers’ insurance policy. Transaction costs in the comparative year include costs associated with registered securities offerings, the Inner Spirit acquisition, the Alcanna acquisition, legal costs and various financing initiatives.

Finance costs

	Year ended December 31
($000s)	2022			2021
Cash finance expense
Other finance costs		178			40
		178			40
Non-cash finance expense
Change in fair value of investments at fair value through profit or loss		36,087			3,300
Accretion on lease liabilities		5,903			776
Financial guarantee liability (recovery) expense		(59	)		59
Other		89			154
		42,020			4,289
Interest income		(884	)		(573	)
		41,314			3,756

Finance costs include accretion expense related to lease liabilities, finance income related to net investment in subleases, change in fair value of investments at Fair Value Through Profit or Loss (“FVTPL”) and certain other expenses.

Finance costs for the year ended December 31, 2022 were $41.3 million compared to $3.8 million for the year ended December 31, 2021. The increase of $37.5 million was due to the change in fair value of investments at FVTPL and an increase in accretion on lease liabilities. The decrease in the fair value of investments at FVTPL was mainly due to an adjustment to the Zenabis senior loan (refer to note 16 in the Audited Financial Statements). The Company's lease liabilities have increased significantly due to both the Inner Spirit and Alcanna acquisitions as the Company acquired leases of retail space for corporate-owned stores.

Change in estimate of fair value of derivative warrants

	Year ended December 31
($000s)	2022			2021
Change in estimate of fair value of derivative warrants		(10,783	)		77,834

Change in estimate of fair value of derivative warrants for the year ended December 31, 2022 was a recovery of $10.8 million compared to an expense of $77.8 million for year ended December 31, 2021. The recovery in the current period relates to a decrease in the fair value, mainly due to a decrease in the Company’s share price from US$5.78 on December 31, 2021, to US$2.09 on December 31, 2022. The expense in the comparative period related to the granting of 25.0 million derivative warrants, partially offset by a decrease in fair value.

The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability, pursuant to IFRS requirements due to the warrant exercise prices being denominated in United States dollars. Refer to note 31 in the Audited Financial Statements for valuation methodology. The Company has no cash obligation with respect to the derivative warrants, and its only obligation is to deliver common shares if, and when, warrants are exercised.

6

Net loss

	Year ended December 31
($000s)	2022			2021 (1)
Net loss		(372,428	)		(226,784	)

(1)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

Net loss for the year ended December 31, 2022 was $372.4 million compared to a net loss of $226.8 million for year ended December 31, 2021. The increased loss of $145.6 million was mostly due to increases in investment losses ($20.7 million), share of loss of equity-accounted investees ($75.9 million), general and administrative expenses ($102.1 million), depreciation and amortization ($35.7 million), asset impairment ($136.0 million) and finance costs ($37.6 million), partially offset by an increase in gross margin ($149.4 million), lower transaction costs ($16.2 million) and change in fair value of derivative warrant liabilities ($88.6 million).

Adjusted EBITDA

	Year ended December 31
($000s)	2022			2021
Adjusted EBITDA (1)(2)		(15,831	)		30,402

(1)Adjusted EBITDA from continuing operations is a specified financial measure that does not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

(2)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

Adjusted EBITDA was a loss of $15.8 million for the year ended December 31, 2022 compared to $30.4 million for the year ended December 31, 2021. The increased loss was due to the following:

•Increase in general and administrative expenses due to the acquisition of Alcanna, Nova and Inner Spirit;

•Decrease in realized gain on marketable securities; and

•Decrease in share of profit of equity-accounted investees related to fair value accounting adjustments to the Company’s SunStream joint venture investments.

The increase was partially offset by an:

•Increase in gross margin, including from the acquisition of Alcanna, Nova and Inner Spirit.

OPERATING SEGMENTS

The Company’s reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.

Liquor retail includes the sale of wines, beers and spirits through wholly owned liquor stores. Cannabis retail includes the private sale of recreational cannabis through wholly owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as “Corporate”.

7

($000s)	Liquor Retail (1)		Cannabis Retail (1)			Cannabis Operations (2)			Investments (3)			Corporate			Total
As at December 31, 2022
Total assets		351,338		200,393			163,130			825,151			19,338			1,559,350
Year ended December 31, 2022
Net revenue		462,180		205,610			44,407			—			—			712,197
Gross margin		106,307		47,334			(13,266	)		—			—			140,375
Interest and fee revenue		—		—			—			16,739			—			16,739
Investment (loss) income		—		—			—			(65,164	)		—			(65,164	)
Share of loss of equity-accounted investees		—		—			—			(43,002	)		—			(43,002	)
Depreciation and amortization		17,025		9,920			199			—			13,801			40,945
Income (loss) before income tax		17,726		(183,055	)		(29,618	)		(127,362	)		(57,461	)		(379,770	)

(1)Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (refer to note 5(a) in the Company’s Audited Financial Statements).

(2)Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (refer to note 5(c) in the Company’s Audited Financial Statements).

(3)Total assets include cash and cash equivalents.

($000s)	Liquor Retail		Cannabis Retail (1)			Cannabis Operations			Investments (2)			Corporate			Total
As at December 31, 2021
Total assets (3)		—		157,022			147,887			1,093,596			29,155			1,427,660
Year ended December 31, 2021
Net revenue		—		16,091			40,037			—			—			56,128
Gross margin (3)		—		6,498			(15,499	)		—			—			(9,001	)
Interest and fee revenue		—		—			—			13,149			—			13,149
Investment loss		—		—			—			(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—		—			—			32,913			—			32,913
Depreciation and amortization (3)		—		1,282			3,108			—			897			5,287
Income (loss) before income tax (3)		—		(410	)		(117,990	)		(5,837	)		(110,461	)		(234,698	)

(1)Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021.

(2)Total assets include cash and cash equivalents.

(3)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

LIQUOR RETAIL SEGMENT RESULTS

GROSS MARGIN

	Year ended December 31
($000s)	2022 (1)		2021
Gross revenue		462,180		—
Cost of sales		355,873		—
Gross margin		106,307		—

(1)Liquor retail results are for the period from March 31, 2022 to December 31, 2022.

The liquor retail segment results are comprised of operations for the period from March 31, 2022, to December 31, 2022. Gross margin for the year ended December 31, 2022 was $106.3 million (23%). Cost of sales for liquor retail operations is comprised of the cost of wine, beer and spirits.

Asset impairment

	Year ended December 31
($000s)	2022		2021
Asset impairment		10,079		—

8

During the year ended December 31, 2022, the Company recorded impairments to right of use assets of $2.5 million and property, plant and equipment of $7.5 million, due to underperforming operating results of certain stores.

CANNABIS RETAIL SEGMENT RESULTS

GROSS revenue

	Year ended December 31
($000s)	2022 (1)		2021 (2)
Retail		192,710		10,207
Franchise		8,337		4,251
Other		4,563		1,633
Gross revenue		205,610		16,091

(1)Cannabis retail results include the operations of Nova for the period from March 31, 2022 to December 31, 2022.

(2)Cannabis retail results include the operations of Inner Spirit for the period July 20, 2021 to December 31, 2021.

Gross revenue for the year ended December 31, 2022 was $205.6 million compared to $16.1 million for the year ended December 31, 2021. The increase is attributable to the Alcanna Transaction. Retail revenue is comprised of retail cannabis sales to private customers from corporate-owned stores. Franchise revenue is comprised of royalty revenue, advertising revenue and franchise fees. Other revenue consists of millwork, supply and accessories revenue and proprietary licensing. Prior to opening, Spiritleaf franchised retail cannabis stores purchase millwork (store fixtures) from the Company. Once a franchise Spiritleaf retail cannabis store is open and operating, it purchases supplies and Spiritleaf accessories from the Company to sell to customers.

GROSS MARGIN

	Year ended December 31
($000s)	2022 (1)		2021 (2)(3)
Gross revenue		205,610		16,091
Cost of sales		158,276		9,593
Gross margin		47,334		6,498

(1)Cannabis retail results include the operations of Nova for the period from March 31, 2022 to December 31, 2022.

(2)Cannabis retail results include the operations of Inner Spirit for the period July 20, 2021 to December 31, 2021.

(3)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

Gross margin for the year ended December 31, 2022 was $47.3 million (23%) compared to $6.5 million (40%) for the year ended December 31, 2021. Cost of sales for cannabis retail operations is comprised of the cost of pre-packaged cannabis and related accessories. Gross margin percentage in the prior year is higher due to the proportion of franchise revenue compared to gross revenue. Franchise revenue does not have a corresponding cost of sales.

Asset impairment

	Year ended December 31
($000s)	2022		2021
Asset impairment		181,665		—

During the three months ended September 30, 2022, the Company recorded impairments to goodwill of $67.9 million and intangible assets with indefinite useful lives of $16.4 million, both from the Inner Spirit acquisition, due to changes in circumstances since the date of the acquisition, mainly caused by the continued oversaturation of the cannabis retail market. During the three months ended December 31, 2022, the Company recorded impairments to goodwill of $88.0 million from the Alcanna and Nova acquisition, due to changes in circumstances since the date of the acquisition, mainly caused by the continued oversaturation of the cannabis retail market.

9

During the year ended December 31, 2022, the Company recorded impairments to right of use assets of $3.9 million and property, plant and equipment of $5.3 million, due to underperforming operating results of certain stores.

CANNABIS OPERATIONS SEGMENT RESULTS

Cannabis operations segment results include the operations of Zenabis from the period November 1, 2022 to December 31, 2022.

Kilogram equivalents sold

	Year ended December 31
	2022		2021
Provincial boards		15,840		12,583
Medical		4		4
Wholesale		7,371		5,432
Total kilogram equivalents sold		23,215		18,019

For the year ended December 31, 2022, the Company sold 23,215 kilogram equivalents of cannabis compared to 18,019 kilogram equivalents for the year ended December 31, 2021. The increase of 5,196 kilogram equivalents sold was due to increases in kilogram equivalents sold to provincial boards and wholesale kilogram equivalents sold. The Company’s sales growth strategy is to continue targeting branded sales to provincial boards.

The Company’s calculation of kilogram equivalents (or other measurement equivalents stated in this MD&A, such as gram equivalents) is based upon internal estimates and may not be comparable to similar measures used by other companies.

Selling price

	Year ended December 31
($/gram equivalent)	2022			2021
Provincial boards		3.71			3.29
Medical		2.25			9.80
Wholesale		0.43			1.81
Average gross selling price		2.67			2.84
Excise taxes		(0.75	)		(0.62	)
Average net selling price		1.91			2.22

For the year ended December 31, 2022, the average net selling price was $1.91 per gram equivalent compared to $2.22 per gram equivalent for the year ended December 31, 2021. The decrease of $0.31 per gram equivalent was mainly due to lower wholesale prices, partially offset by higher prices for provincial board sales. The decrease in wholesale prices was due to several large bulk sales as part of the Company's inventory optimization strategy. The bulk sales included shake and trim which lowered the price per gram average. Provincial board sales prices have increased due to the shift from value products to core products and lower price discounts and concessions compared to the prior year.

The principal drivers of the Company’s realized prices are the formats of the products sold (currently both bulk and packaged flower, inhalables and accessories, trim, bulk extracted oil, edibles and concentrates) and the channels in which products are sold (principally Canadian provincial boards, Canadian licensed producers (“LPs”) and international exports).

Excise taxes are the federal excise duties and additional provincial or territorial duties payable on adult-use cannabis products. Excise taxes for the year ended December 31, 2022 and 2021 are based solely on adult-use end-consumer packaged cannabis sales.

10

Revenue

Revenue by form

	Year ended December 31
($000s)	2022		2021
Revenue from dried flower		35,481		31,975
Revenue from pre-rolls		15,677		7,597
Revenue from vapes		5,718		4,743
Revenue from oil		118		1,665
Revenue from edibles and concentrates		4,156		2,555
Revenue from services		754		2,653
Gross revenue		61,904		51,188

Revenue by channel

	Year ended December 31
($000s, except as indicated)	2022			2021
Provincial boards		58,728			41,338
Medical		9			8
Wholesale		3,167			9,842
Gross revenue		61,904			51,188
Excise taxes		(17,497	)		(11,151	)
Net revenue		44,407			40,037
Gross revenue per gram sold	$	2.67		$	2.84
Net revenue per gram sold	$	1.91		$	2.22

The Company’s revenue comprises bulk and packaged sales under the Cannabis Act pursuant to its supply agreements with Canadian provincial boards, other LPs and international exports. The Company’s sales growth strategy is to continue targeting branded sales to provincial boards.

The Company had entered into a concentrates licensing agreement with a third party based out of the Rocky View facility, which was previously owned by the Company. Administrative fees and facility fees charged under the licensing agreement were recorded as revenue from services. This agreement ended with the sale of the Rocky View facility on June 30, 2022.

Gross revenue for the year ended December 31, 2022 was $61.9 million compared to $51.2 million for the year ended December 31, 2021. The increase of $10.7 million was due to an increase in kilogram equivalents sold, partially offset by a decrease in selling prices. Provincial board revenue increased by $17.4 million due to increases in kilogram equivalents sold and selling prices. Wholesale revenue decreased by $6.6 million due to a decrease in selling prices, partially offset by an increase in kilogram equivalents sold.

Excise taxes are the federal excise duties and additional provincial or territorial duties payable on adult-use cannabis products at the time such product is shipped from the production facility in its final packaging. Federal duties on adult-use cannabis products are calculated as the greater of (i) $0.25 per gram of flowering material, (ii) $0.75 per gram of non-flowering material or $0.25 per viable seed or seedling and (iii) 2.5% of the dutiable amount as calculated in accordance with the Excise Act, 2001. The rates of provincial or territorial duties vary by jurisdiction.

Excise taxes for the year ended December 31, 2022 were $17.5 million compared to $11.2 million for the year ended December 31, 2021. The increase of $6.3 million was due to expanded sales in provinces with higher provincial duties than the comparable year.

11

Cost of sales

	Year ended December 31
($000s, except as indicated)	2022		2021
Cost of sales		43,940		41,019
Cost of sales per gram sold	$	1.89	$	2.28

Cost of sales includes three main categories: pre-harvest, post-harvest and shipment and fulfillment costs. These costs are incurred in respect of cultivating, harvesting, processing and packaging cannabis products. Pre-harvest costs include all direct and indirect costs incurred between initial recognition and the point of harvest, including labour-related costs, grow consumables, materials, utilities, facilities costs and depreciation related to production facilities. Post-harvest costs include all direct and indirect costs incurred subsequent to the point of harvest, including labour-related costs, consumables, materials, utilities and facilities costs. Shipment and fulfillment costs include packaging, transportation, quality control and testing costs.

Cost of sales for the year ended December 31, 2022 were $43.9 million compared to $41.0 million for the year ended December 31, 2021. The increase of $2.9 million was due to an increase in kilogram equivalents sold compared to the prior year, partially offset by a decrease in the cost of sales per gram sold compared to the prior year.

Gross margin

	Year ended December 31
($000s)	2022			2021
Net revenue		44,407			40,037
Cost of sales		43,940			41,019
Inventory impairment and obsolescence		7,012			16,978
Gross margin before fair value adjustments (1)		(6,545	)		(17,960	)
Change in fair value of biological assets		(1,309	)		4,708
Change in fair value realized through inventory		(5,412	)		(2,247	)
Gross margin		(13,266	)		(15,499	)

(1)Gross margin before fair value adjustments is a specified financial measure that does not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

Gross margin before fair value adjustments

Gross margin before fair value adjustments is defined as net revenue less cost of sales and inventory obsolescence and impairment before adjusting for the non-cash changes in the fair value adjustments on the sale of inventory and the growth of biological assets.

Gross margin before fair value adjustments for the year ended December 31, 2022 was negative $6.5 million compared to negative $18.0 million for the year ended December 31, 2021. The increase of $11.5 million was due to higher net revenue and a lower inventory obsolescence provision compared to the prior year, partially offset by higher cost of sales. The inventory obsolescence provision was applied across all product formats. The inventory obsolescence provision in the comparative period was applied to vapes, oil, concentrates, bulk flower and shake due to price compression in the market, as well as certain packaging inventory.

The total inventory obsolescence and impairment recognized during the year ended December 31, 2022 was $8.9 million, with $7.0 million relating to cost of sales and $1.9 million relating to the change in fair value realized through inventory. The total inventory obsolescence and impairment recognized during the year ended December 31, 2021 was $17.5 million, with $17.0 million relating to cost of sales and $0.5 million relating to the change in fair value realized through inventory.

Change in fair value of biological assets

Biological assets consist of cannabis plants in various stages of vegetation, including clones, which have not yet been harvested. Net unrealized changes in fair value of biological assets less cost to sell during the period are included in the results of operations for the related period. Biological assets are presented at their fair values less costs to sell up to the

12

point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusted for the amount for the expected selling price less costs to sell per gram.

Change in fair value realized through inventory

Change in fair value realized through inventory comprises fair value adjustments associated with the cost of inventory when such inventory is sold. Inventories are carried at the lower of cost and net realizable value. When sold, the cost of inventory is recorded as cost of sales, while fair value adjustments are recorded as change in fair value realized through inventory.

Asset impairment

	Year ended December 31
($000s)	2022		2021
Asset impairment		4,289		60,000

The Company determined that indicators of impairment existed during the year ended December 31, 2022, regarding the Sun 8 intellectual property due to decreasing market demand. The estimated recoverable amount of the intangible assets was determined to be $2.5 million and an impairment of $1.9 million was recorded.

The Company determined that indicators of impairment existed during the year ended December 31, 2022, relating to certain machinery and equipment due to their discontinued use. The estimated recoverable amount of the assets was determined to be nil and an impairment of $2.4 million was recorded.

At December 31, 2022, the Company determined that no further indicators of impairment existed or indicators that a previous impairment should be reversed, and no impairment test was required.

The Company determined that indicators of impairment existed during the second quarter in the year ended December 31, 2021, with respect to the Company’s Olds cash generating unit (“CGU”) as a result of curtailment in the utilization of the capacity in the Company’s Olds facility to align cannabis production with current demand estimates. A test for impairment was performed at June 30, 2021, at the CGU level, by comparing the estimated recoverable amount to the carrying values of the assets. The estimated recoverable amount of the assets was determined to be their value in use and an impairment of $60.0 million was recorded to write down the assets to their estimated recoverable amount.

INVESTMENTS SEGMENT RESULTS

Interest and fee revenue

	Year ended December 31
($000s)	2022		2021
Interest and fee revenue
Interest revenue from investments at amortized cost		3,660		1,654
Interest and fee revenue from investments at FVTPL		6,036		8,514
Interest revenue from cash		7,043		2,981
		16,739		13,149

Interest and fee revenue for the year ended December 31, 2022, was $16.7 million compared to $13.1 million for the year ended December 31, 2021. The increase of $3.6 million was due to an increase in interest revenue from cash and investments at amortized cost, partially offset by a decrease in interest and fee revenue from investments at FVTPL. Interest revenue from cash increased due to increases in the prime interest rate. Interest revenue from investments at amortized cost increased due to increases in the number and dollar amount of investments compared to the prior period. Interest and fee revenue from investments at FVTPL decreased due to the suspension of interest payments on the Zenabis senior loan (refer to note 16 in Audited Financial Statements).

13

Investment revenue

	Year ended December 31
($000s)	2022			2021
Investment revenue
Realized gains		389			20,213
Unrealized losses		(65,553	)		(64,714	)
		(65,164	)		(44,501	)

Investment revenue is comprised of realized and unrealized gains and losses on marketable securities.

Investment revenue for the year ended December 31, 2022, was negative $65.2 million compared to negative $44.5 million for the year ended December 31, 2021. The Company realized a gain on disposition in the comparative period from the disposition of all its shares held in another Canadian LP. The Company continues to strategically deploy capital with a focus on maximizing risk-adjusted cash flows and shareholder value.

Share of profit of equity-accounted investees

	Year ended December 31
($000s)	2022			2021
Net profit (loss)		(43,002	)		32,913

Share of profit of equity-accounted investees is comprised of the Company’s share of the net profit generated from its investments in SunStream. The current investment portfolio of SunStream is comprised of secured debt and hybrid debt and derivative instruments with United States based cannabis businesses.

Share of profit of equity-accounted investees for the year ended December 31, 2022 was a loss of $43.0 million compared to a gain of $32.9 million for the year ended December 31, 2021. The decrease of $75.9 million was due to fair value adjustments to the investments related to increased assessed credit risk in the US cannabis industry.

FOURTH QUARTER 2022

($000s, except as indicated)	Q4 2022			Q4 2021 (3)			Change			% Change
Financial
Gross revenue		246,866			25,630			221,236			863	%
Net revenue		240,405			22,719			217,686			958	%
Cost of sales (3)		190,379			17,929			172,450			962	%
Gross margin (3)		43,568			(4,510	)		48,078			1066	%
Gross margin % (3)		18	%		-20	%					38	%
Gross margin before fair value adjustments (1)(2)(3)		46,559			(4,912	)		51,471			1048	%
Gross margin before fair value adjustments % (2)(3)		19	%		-22	%					41	%
Interest and fee revenue		5,989			3,647			2,342			64	%
Investment loss		(6,868	)		(41,755	)		34,887			84	%
Loss from operations (3)		(154,646	)		(45,999	)		(108,647	)		-236	%
Net loss attributable to owners of the Company (3)		(125,801	)		(56,989	)		(68,812	)		-121	%
Per share, basic and diluted (3)		(0.53	)		(0.28	)		(0.25	)		-91	%
Adjusted EBITDA (2)(3)		(7,549	)		16,741			(24,290	)		145	%

(1)Includes inventory obsolescence and impairment of $3.5 million for the three months ended December 31, 2022, and $9.7 million for three months ended December 31, 2021.

(2)Adjusted EBITDA, gross margin before fair value adjustments and gross margin before fair value adjustments percentage are specified financial measures that do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

(3)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

14

CONSOLIDATED results

General and administrative expenses for the three months ended December 31, 2022 were $44.2 million compared to $11.3 million for the three months ended December 31, 2021. The increase of $32.9 million was mainly due to increases in salaries and wages and office and general expenses as a result of the Alcanna acquisition on March 31, 2022 and the Inner Spirit acquisition on July 20, 2021.

Share-based compensation expense for the three months ended December 31, 2022 was $3.0 million compared to $2.4 million for the three months ended December 31, 2021. The increase of $0.6 million was due to an increase in RSU expense and DSU expense, partially offset by a decrease in simple warrant expense. RSU expense increased due to the increased number of RSUs granted during the year. DSU expense increased due to a smaller decline in fair value than the comparative period. The decrease in simple warrant expense was caused by the vesting of awards issued in prior years, lowering the expense in the current period.

Transaction costs for the three months ended December 31, 2022, were $2.4 million compared to $7.8 million for the three months ended December 31, 2021. Transaction costs in the current period relate to the Zenabis, Valens and Superette acquisition. Transaction costs in the comparative period related to the Inner Spirit and Alcanna acquisitions and legal costs.

Finance costs for the three months ended December 31, 2022 were $6.5 million compared to $3.5 million for the three months ended December 31, 2021. The increase of $3.0 million was mainly due to an increase in accretion on lease liabilities and change in fair value of investments at FVTPL. The Company’s lease liabilities have increased significantly due to both the Inner Spirit and Alcanna acquisitions as the Company acquired leases of retail space for corporate-owned stores.

Change in estimate of fair value of derivative warrants for the three months ended December 31, 2022 was a recovery of $3.9 million compared to a recovery of $8.2 million for the three months ended December 31, 2021. The current period recovery was due to a decrease in fair value, mainly caused by a decrease in the Company's share price from US$2.18 on September 30, 2022 to US$2.09 on December 31, 2022. The recovery in the comparative period was caused by a decrease in the fair value, mainly caused by a decrease in the Company’s share price from US$6.78 on September 30, 2021 to US$5.78 on December 31, 2021.

Net loss for the three months ended December 31, 2022 was $161.6 million compared to a net loss of $56.8 million for three months ended December 31, 2021. The increased loss of $104.8 million was largely due to increased share of loss of equity-accounted investees ($37.6 million), general and administrative expenses ($32.9 million), depreciation and amortization ($21.0 million), asset impairment ($107.7 million) and change in fair value of derivative warrants ($4.3 million), partially offset by an increase in gross margin ($47.9 million), lower investment losses ($34.9 million), loss on cancellation of contracts ($5.4 million) that were recorded in the prior period, transaction costs ($5.4 million) and income tax recovery ($6.4 million).

Adjusted EBITDA was a loss of $7.5 million for the three months ended December 31, 2022 compared to $16.7 million for the three months ended December 31, 2021. The increased loss was due to the following:

•Increase in general and administrative expenses due to the acquisitions of Alcanna, Nova and Inner Spirit;

•Decrease in share of profit of equity-accounted investees related to fair value accounting adjustments to the Company’s SunStream joint venture investments;

The increase was partially offset by an:

•Increase in gross margin including from the acquisition of Alcanna, Nova and Inner Spirit.

Liquor retail segment results

Gross margin for the three months ended December 31, 2022 was $36.9 million (23%). Cost of sales for liquor retail operations is comprised of the cost of wine, beer and spirits.

During the three months ended December 31, 2022, the Company recorded impairments to right of use assets of $2.5 million and property, plant and equipment of $7.5 million, due to underperforming operating results of certain stores.

15

cannabis retail segment results

Gross revenue for the three months ended December 31, 2022 was $68.4 million compared to $10.0 million for the three months ended December 31, 2021. The increase of $58.4 million was due to the Alcanna Transaction.

Gross margin for the three months ended December 31, 2022 was $15.7 million (23%) compared to $2.8 million (29%) for the three months ended December 31, 2021. Cost of sales for cannabis retail operations is comprised of the cost of pre-packaged cannabis and related accessories.

During the three months ended December 31, 2022, the Company recorded impairments to goodwill of $88.0 million from the Alcanna and Nova acquisition, due to changes in circumstances since the date of the acquisition, mainly caused by the continued oversaturation of the cannabis retail market. During the three months ended December 31, 2022, the Company recorded impairments to right of use assets of $3.9 million and property, plant and equipment of $5.3 million, due to underperforming operating results of certain stores.

CANNABIS operations segment results

For the three months ended December 31, 2022, the Company sold 10,955 kilogram equivalents of cannabis compared to 5,202 kilogram equivalents for the three months ended December 31, 2021. The increase of 5,753 kilogram equivalents sold was due to increases in kilogram equivalents sold to provincial boards and wholesale kilogram equivalents sold. The Company’s sales growth strategy is to continue targeting branded sales to provincial boards.

For the three months ended December 31, 2022, the average net selling price was $1.12 per gram equivalent compared to $2.45 per gram equivalent for the three months ended December 31, 2021. The decrease of $1.33 per gram equivalent was largely due to a decrease in wholesale prices. The decrease in wholesale prices was due to several large bulk sales as part of the Company's inventory optimization strategy. The bulk sales included shake and trim which lowered the average price per gram.

Gross revenue for the three months ended December 31, 2022 was $18.7 million compared to $15.7 million for the three months ended December 31, 2021. The increase of $3.0 million was due to an increase in kilogram equivalents sold, partially offset by a decrease in selling prices. Provincial board revenue increased by $6.8 million due to an increase in kilogram equivalents sold, partially offset by a decrease in selling prices. Wholesale revenue decreased by $3.8 million due to a decrease in selling prices, partially offset by an increase in kilogram equivalents sold.

Cost of sales for the three months ended December 31, 2022 were $14.8 million compared to $10.8 million for the three months ended December 31, 2021. The increase of $4.0 million was due to an increase in kilogram equivalents sold compared to the prior period, partially offset by a decrease in the cost of sales per gram sold compared to the prior period.

Gross margin before fair value adjustments for the three months ended December 31, 2022 was negative $6.0 million compared to negative $7.8 million for the three months ended December 31, 2021. The increase of $1.8 million was due to a lower inventory obsolescence provision compared to the prior period, partially offset by lower net revenue and higher cost of sales. The inventory obsolescence provision was applied across all product formats. The inventory obsolescence provision in the comparative period was applied primarily to vapes, oil, bulk flower and shake due to price compression in the market.

INVESTMENTS segment results

Interest and fee revenue for the three months ended December 31, 2022, was $6.0 million compared to $3.6 million for the three months ended December 31, 2021. The increase of $2.4 million was mainly due to an increase in interest revenue from cash, due to increases in the prime interest rate.

Investment revenue for the three months ended December 31, 2022, was negative $6.9 million compared to negative $41.8 million for the three months ended December 31, 2021. The change was primarily due to a decrease in unrealized losses. The comparative period had larger decreases in share prices of the Company's investments in Indiva Limited, Village Farms International Inc., and Valens.

Share of profit of equity-accounted investees for the three months ended December 31, 2022 was a loss of $18.3 million, compared to income of $19.3 million for the three months ended December 31, 2021. The decrease of $37.6 million was due to fair value adjustments to the investments related to increased assessed credit risk in the US cannabis industry.

16

SELECTED QUARTERLY INFORMATION

The following table summarizes selected consolidated operating and financial information of the Company for the preceding eight quarters.

	2022												2021
($000s, except as indicated)	Q4			Q3			Q2			Q1			Q4 (1)			Q3 (1)			Q2			Q1
Gross revenue		246,866			235,144			227,557			20,127			25,630			17,162			12,739			11,748
Gross investment (loss) income		(879	)		(1,201	)		(32,496	)		(13,849	)		(38,108	)		(14,699	)		5,706			15,749
Gross margin (1)		43,568			50,309			43,079			3,419			(4,510	)		1,782			(2,821	)		(3,452	)
Net (loss) income attributable to owners of the Company (1)		(125,801	)		(98,108	)		(73,301	)		(37,904	)		(56,989	)		16,708			(52,287	)		(134,416	)
Per share, basic and diluted (1)		(0.53	)		(0.41	)		(0.31	)		(0.18	)		(0.28	)		0.08			(0.28	)		(0.93	)
Adjusted EBITDA (1)(2)		(7,549	)		18,320			(25,927	)		(675	)		16,741			10,539			(205	)		3,327

(1)Adjustments to provisional amounts have been made in the comparative period (Q3 2021 and Q4 2021) due the consummation of the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

(2)Adjusted EBITDA is a specified financial measure that does not have standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures used by other companies. Refer to the “Specified Financial Measures” section of this MD&A for further information.

During the eight most recent quarters the following items have had a significant impact on the Company’s financial results and results of operations:

•Implementing several streamlining and efficiency initiatives which included workforce optimizations;

•Issuance of equity securities in several registered offerings;

•Issuance of common shares under several at-the-market programs;

•Entering into and acquiring several cannabis-related investments;

•Investing and disposing of marketable securities;

•Shift to include investment strategy as part of the Company’s operations;

•Price discounts and provisions for product returns;

•Impairment of property, plant and equipment;

•Provisions for inventory obsolescence and impairment;

•Investments in SunStream; and

•Acquisitions of Inner Spirit and Alcanna, inclusive of its subsidiary, Nova.

SELECTED ANNUAL INFORMATION

The following table summarizes selected financial information of the Company for the three most recently completed financial years.

	Year ended December 31			Year ended December 31			Year ended December 31
($000s, except as indicated)	2022			2021			2020
Gross revenue		729,694			67,279			73,321
Net loss (1)(2)		(335,114	)		(226,984	)		(199,619	)
Per share, basic and diluted (1)	$	(1.46	)	$	(1.22	)	$	(9.13	)
Total assets (2)		1,559,350			1,427,660			294,871
Total non-current liabilities		142,334			32,274			1,031

(1)Net loss and net loss per share areattributable to owners of the Company.

(2)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

GROSS REVENUE

During the year ended December 31, 2022, gross revenue increased by $662.4 million due to the acquisition of Alcanna and its subsidiary Nova ($639.5 million), the inclusion of a full year of revenue from Inner Spirit ($12.2 million) and an increase in cannabis revenue ($10.7 million) due to an increase in kilogram equivalents sold, partially offset by a decrease in selling prices.

17

During the year ended December 31, 2021, gross revenue decreased by $6.0 million due to a decrease in kilogram equivalents sold and a decrease in average selling prices, partially offset by the post Inner Spirit acquisition cannabis retail revenue.

During the year ended December 31, 2020, gross revenue increased by $6.4 million due to an increase in provincial board sales, partially offset by a decrease in sales to other LPs.

Net loss

During the year ended December 31, 2022, net loss increased by $108.1 million due to increases in investment losses, share of loss of equity-accounted investees, general and administrative expenses, depreciation and amortization, asset impairment and finance costs, partially offset by an increase in gross margin, lower transaction costs and change in fair value of derivative warrant liabilities. Gross margin, general and administrative expenses, depreciation and amortization and finance costs all increased due to the Alcanna and Inner Spirit acquisitions. Transaction costs related to various acquisitions, partially offset by a recovery related to the reversal of a provision for costs associated with securities class action lawsuits. Change in fair value of derivative warrant liabilities related to a decrease in the fair value. Investment losses increased due to the Company realizing a gain on disposition in the comparative period. Share of loss of equity-accounted investees increased due to fair value adjustments to the investments related to increased assessed credit risk in the US cannabis industry. The asset impairment related to cannabis retail goodwill and intangible assets from the Inner Spirit acquisition and Alcanna and Nova acquisition.

During the year ended December 31, 2021, net loss increased by $27.4 million due to lower net revenue, investment losses, higher general and administrative expenses, transaction costs and change in fair value of derivative warrant liabilities, partially offset by lower cost of sales, lower inventory obsolescence provision, change in fair value through inventory, lower asset impairment and income tax recovery. The lower net revenue and cost of sales was due to a decrease in kilogram equivalents sold. Investment losses were due to unrealized losses caused by decreasing market prices of the related investments. The increase in general and administrative expenses was due to higher salaries and wages and professional fees, partially offset by lower office and general expenses. Transaction costs related to acquisitions and legal costs. The change in fair value of derivative warrant liabilities was due to an increase in warrants granted and exercised during the period.

During the year ended December 31, 2020, net loss increased by $57.1 million due to a lower gross margin and higher asset impairment, partially offset by lower share-based compensation, finance costs and a loss on financial obligation in the prior year. The lower gross margin was due to an inventory obsolescence provision and changes in fair value of biological assets and fair value realized through inventory. Asset impairments were recorded for property, plant and equipment and intangible assets. Share-based compensation decreased due to the accelerated vesting in the prior year and a decrease in the value of awards granted. The Company incurred a loss on financial obligation in the prior year in connection with the termination of an investment and royalty agreement with an entity controlled by the Company’s former executive chairman and director, which had no current year impact.

Total assets

During the year ended December 31, 2022, total assets increased by $131.7 million due to increases in inventory, right-of-use assets, property, plant and equipment, investments, equity-accounted investees and goodwill, partially offset by decreases in cash and cash equivalents and marketable securities. Inventory, right-of-use assets, property, plant and equipment and goodwill increased due to the acquisition of Alcanna and Nova. Investments increased mainly due to the Company's loan to Valens. Equity-accounted investees increased due to capital contributions made during the year, partially offset by decreases in fair value. Cash and cash equivalents decreased mainly due to investments made during the year, capital contributions to the Company's equity accounted investee and the Alcanna and Nova acquisition. Marketable securities decreased due to an increase in unrealized losses.

During the year ended December 31, 2021, total assets increased by $1,132.8 million due to increases in cash and cash equivalents, marketable securities, net investments in subleases, equity accounted investees and goodwill. Cash and cash equivalents increased mainly due to proceeds from the issuance of shares and registered offerings and proceeds from the exercise of derivative warrants. Marketable securities increased due to the Company investing in cannabis-related equity instruments. Net investments in subleases and goodwill increased due to the acquisition of Inner Spirit. Equity accounted investees increased due to investment in SunStream.

18

During the year ended December 31, 2020, total assets decreased by $215.2 million. The decrease was due to decreases in accounts receivable, biological assets, inventory, property, plant and equipment, intangible assets and goodwill, partially offset by an increase in investments. Accounts receivable, biological assets and inventory decreased due to the disposition of Bridge Farm and recording an inventory obsolescence provision. Property, plant and equipment and intangible assets decreased due to the disposition of Bridge Farm and asset impairments. Goodwill decreased due to the disposition of Bridge Farm. Investments increased due to acquiring an investment in a cannabis company.

Total non-current liabilities

During the year ended December 31, 2022, total non-current liabilities increased by $110.1 million due to an increase in lease liabilities from the Alcanna and Nova acquisition.

During the year ended December 31, 2021, total non-current liabilities increased by $31.2 million. The increase was due to an increase in lease liabilities from the Inner Spirit acquisition and the recognition of a DSU liability.

During the year ended December 31, 2020, total non-current liabilities decreased by $18.6 million. The decrease was due to decreases in lease liabilities and deferred tax liability due to the Bridge Farm disposition.

LIQUIDITY AND CAPITAL RESOURCES

($000s)	December 31, 2022		December 31, 2021
Cash and cash equivalents		279,586		558,251

Capital resources are financing resources available to the Company and are defined as the Company’s debt and equity. The Company manages its capital resources with the objective of maximizing shareholder value and sustaining future development of the business. The Company manages its capital structure and adjusts it, based on the funds available to the Company, in order to support the Company’s activities. The Company may adjust capital spending, issue new equity or issue new debt, subject to the availability of such debt or equity financing on commercial terms.

The Company’s primary need for liquidity is to fund investment opportunities, capital expenditures, working capital requirements and for general corporate purposes. The Company’s lease liabilities have increased significantly due to both the Inner Spirit and Alcanna acquisitions as corporate stores occupy leased retail space. Refer to “Contractual Commitments and Contingencies – Commitments” for an estimate of the contractual maturities of the Company’s lease liabilities. The Company’s primary source of liquidity historically has been from funds received from the proceeds of common share issuances and debt financing. The Company’s ability to fund operations and investments and make planned capital expenditures depends on future operating performance and cash flows, as well as the availability of future financing–all of which is subject to prevailing economic conditions and financial, business and other factors.

Management believes its current capital resources will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses and future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

Debt

As at December 31, 2022, the Company had no outstanding bank debt or other debt.

Equity

On July 25, 2022, the Company’s shareholders approved a special resolution for the consolidation of all of the issued and outstanding common shares (the “Share Consolidation”) on the basis of not more than one post-consolidation common share for every ten pre-consolidation common shares and not less than one post-consolidation common share for every twenty-five pre-consolidation common shares, to be determined by the Board in its sole discretion, to become effective at such time as the Board considers it to be in the best interests of the Company, but in any event not later than July 25, 2023.

Immediately following the shareholder approval, the Board determined to effect the Share Consolidation on the basis of one post-consolidation common share for every ten pre-consolidation common shares. The Share Consolidation took

19

effect on July 25, 2022, and the common shares began trading on Nasdaq on a post-consolidation basis beginning on July 26, 2022.

All references to common shares, warrants, simple warrants, performance warrants, stock options, RSUs and DSUs (excluding the Nova RSUs and DSUs), including exercise prices where applicable, have been fully retrospectively adjusted to reflect the Share Consolidation.

As at December 31, 2022, the Company had the following share capital instruments outstanding:

(000s)	December 31, 2022		December 31, 2021
Common shares		235,194		206,041
Common share purchase warrants (1)		309		357
Simple warrants (2)		166		259
Performance warrants (3)		123		139
Stock options (4)		44		45
Restricted share units		1,381		754

(1)0.3 million warrants were exercisable as at December 31, 2022.

(2)0.2 million simple warrants were exercisable as at December 31, 2022.

(3)0.1 million performance warrants were exercisable as at December 31, 2022.

(4)32.9 thousand stock options were exercisable as at December 31, 2022.

As atDecember 31, 2022, the Company had 235.2 million shares outstanding (December 31, 2021 – 206.0 million shares).

Common shares were issued during the year ended December 31, 2022 in connection with the vesting of RSUs under the long term incentive plan and the following transactions:

•The Company issued 0.4 million common shares related to the termination of the service and sale agreement with Sun 8 Holdings Inc.;

•The Company issued 32.1 million common shares as consideration for the Alcanna acquisition; and

•The Company also purchased and cancelled 4.3 million common shares at a weighted average price of $3.12 (US$2.33) per common share for a total cost of $13.3 million.

From January 1, 2023, to April 24, 2023:

•The Company purchased and cancelled 0.5 million common shares at a weighted average price of $2.78 (US$2.04) per common share for a total cost of $1.5 million; and

•The Company issued 25.4 million net common shares as consideration for the Valens acquisition.

As at April 24, 2023, a total of 260.1 million common shares were outstanding.

Cash Flow Summary

	Year ended December 31
($000s)	2022			2021
Cash provided by (used in):
Operating activities		(6,711	)		(155,752	)
Investing activities		(230,164	)		(496,280	)
Financing activities		(41,790	)		1,149,916
Effect of exchange rate changes		—			(9	)
Change in cash and cash equivalents		(278,665	)		497,875

Cash Flow – Operating Activities

Net cash used in operating activities was $6.7 million for the year ended December 31, 2022 compared to $155.8 million used in operating activities for the year ended December 31, 2021. The decrease of $149.1 million was due to a decrease in net loss adjusted for non-cash items, a decrease in additions to marketable securities and an increase in interest received, partially offset by lower proceeds from disposal of marketable securities, a decrease in income distributions from equity-accounted investees and non-cash working capital. The change in non-cash working capital is comprised of changes in inventory, accounts receivable, prepaid expenses and deposits and accounts payable.

20

Cash Flow – Investing Activities

Net cash used in investing activities was $230.2 million for the year ended December 31, 2022 compared to $496.3 million used in investing activities for the year ended December 31, 2021. The decrease of $266.1 million was primarily due to a decrease in additions to equity-accounted investees and a decrease in acquisitions, partially offset by an increase in additions to investments and a decrease in capital distributions from equity-accounted investees.

Cash Flow – Financing Activities

Net cash used in financing activities was $41.8 million for the year ended December 31, 2022 compared to $1.1 billion provided by financing activities for the year ended December 31, 2021. The decrease of $1.2 billion was largely due to proceeds from the issuance of shares, proceeds from registered offerings and proceeds from the exercise of derivative warrants in 2021.

Liquidity risks associated with financial instruments

Credit risk

Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable, and investments. The Company attempts to mitigate such exposure to its cash and cash equivalents by investing only in financial institutions with investment grade credit ratings or secured investments. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company.

The Company applies the simplified approach under IFRS 9 and has calculated expected credit losses based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions.

The Company has evaluated the credit risk of its investments, taking into consideration historical credit loss experience, financial factors specific to the debtors and general economic conditions, and determined the expected credit loss to be $0.5 million for the year ended December 31, 2022.

Liquidity risk

Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. The Company prepares forecasts to ensure sufficient liquidity to fulfil obligations and operating plans. Management believes its current capital resources will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses and future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

Market risk

Market risk is the risk that changes in market prices will affect the Company’s income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company’s marketable securities are shares of publicly traded entities. An unrealized loss of $65.6 million was recognized during the year ended December 31, 2022, due to the continued decline in market prices of the Company’s marketable securities (Refer to “Investments Segment Results – Investment Revenue”

21

CONTRACTUAL COMMITMENTS AND CONTINGENCIES

a)Commitments

The information presented in the table below reflects management’s estimate of the contractual maturities of the Company’s obligations at December 31, 2022.

($000s)	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		48,153		—		—		—		48,153
Lease liabilities		39,255		64,892		48,955		47,468		200,570
Financial guarantee liability		—		407		—		—		407
Total		87,408		65,299		48,955		47,468		249,130

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2022 of $2.5 million (December 31, 2021 – $2.5 million).

b)Contingencies

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include commercial litigation related to breach of contract claims brought by our customers, suppliers and contractors, as well as litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently pending and threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgments or settlement terms could have an adverse impact on our business and results of operations.

In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re SNDL Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re SNDL Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions asserted claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally alleged that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also included allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021. On October 5, 2022, the court entered an order and final judgement approving the settlement.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. SNDL Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserted claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act and Section 10(b) the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleged that the Company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as

22

regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

SPECIFIED FINANCIAL MEASURES

Certain specified financial measures in this MD&A including adjusted EBITDA, gross margin before fair value adjustments and gross margin before fair value adjustments percentage are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for measures of performance prepared in accordance with IFRS.

Non-IFRS Financial Measures

Adjusted EBITDA

Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results in a similar manner to its management team. Adjusted EBITDA is defined as net income (loss) before finance costs, change in estimate of fair value of derivative warrants, depreciation and amortization, income tax recovery and excluding change in fair value of biological assets, change in fair value realized through inventory, unrealized foreign exchange gains or losses, unrealized gains or losses on marketable securities, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment, cost of sales non-cash component, restructuring costs, transaction costs and certain one-time non-operating expenses, as determined by management.

The following table reconciles adjusted EBITDA to net loss for the periods noted.

	Three months ended December 31						Year ended December 31
($000s)	2022			2021			2022			2021
Net (loss) income (1)		(161,571	)		(56,760	)		(372,428	)		(226,784	)
Adjustments:
Finance costs		6,461			3,530			41,314			3,756
Change in estimate of fair value of derivative warrants		(3,927	)		(8,200	)		(10,783	)		77,834
Loss (gain) on cancellation of contracts		(290	)		5,116			(290	)		5,116
Depreciation and amortization (1)		21,623			667			40,945			5,287
Income tax (recovery) expense (1)		1,376			7,787			(7,342	)		(7,914	)
Change in fair value of biological assets		2,712			(2,158	)		1,309			(4,708	)
Change in fair value realized through inventory		279			1,756			5,412			2,247
Unrealized foreign exchange (gain) loss		24			(1	)		(16	)		(63	)
Unrealized loss on marketable securities		6,868			43,750			65,553			64,714
Share-based compensation		2,960			2,443			9,671			12,307
Asset impairment		107,661			—			196,033			60,000
Loss (gain) on disposition of PP&E		502			(374	)		94			(235	)
Cost of sales non-cash component (2)		1,702			772			7,003			3,675
Inventory impairment and obsolescence		3,467			9,702			7,012			16,978
Restructuring costs (recoveries)		212			874			(670	)		874
Transaction costs		2,392			7,837			1,352			17,566
Government subsidies		—			—			—			(2,180	)
Other expenses		—			—			—			1,932
Adjusted EBITDA (1)		(7,549	)		16,741			(15,831	)		30,402

(1)Adjustments to provisional amounts have been made in the comparative period due to the finalization of the business combination accounting for the Inner Spirit acquisition, refer to note 5(b) in the Company’s Audited Financial Statements.

(2)Cost of sales non-cash component is comprised of depreciation expense.

23

Gross margin before fair value adjustments

Gross margin before fair value adjustments is a non-IFRS financial measure which the Company uses to evaluate its operating performance in the Company’s cannabis operations segment. Gross margin before fair value adjustments provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company’s operating results as it removes non-cash fair value metrics. Gross margin before fair value adjustments is defined as gross margin less the non-cash changes in the fair value adjustments on the sale of inventory and the growth of biological assets. Gross margin before fair value adjustments is comprised of net revenue less cost of sales and inventory obsolescence and impairment.

The following table reconciles gross margin before fair value adjustments to gross margin for the periods noted.

	Three months ended December 31						Year ended December 31
($000s)	2022			2021			2022			2021
Gross margin		(9,009	)		(7,350	)		(13,266	)		(15,499	)
Change in fair value of biological assets		(2,712	)		2,158			(1,309	)		4,708
Change in fair value realized through inventory		(279	)		(1,756	)		(5,412	)		(2,247	)
Gross margin before fair value adjustments		(6,018	)		(7,752	)		(6,545	)		(17,960	)

Non-IFRS Financial Ratios

Gross margin before fair value adjustments percentage

Gross margin before fair value adjustments percentage is a non-IFRS financial ratio which the Company uses to evaluate its operating performance in the Company’s cannabis operations segment. Gross margin before fair value adjustments percentage is defined as gross margin before fair value adjustments divided by net revenue.

RELATED PARTIES

The Company entered into the following related party transactions during the periods noted, in addition to those disclosed in note 17 of the Audited Financial Statements relating to the Company’s SunStream joint venture.

A member of key management personnel jointly controls a company that owns property leased to SNDL for one of its retail liquor stores. The lease term is from November 1, 2017 to October 31, 2027 and includes extension terms from November 1, 2027 to October 31, 2032 and November 1, 2032 to October 31, 2037. Monthly rent for the location includes base rent, common area costs and sign rent. The rent amounts are subject to increases in accordance with the executed lease agreement. Subsequent to the Alcanna Transaction and for the period March 31, 2022 to December 31, 2022, the Company paid $117.9 thousand in total rent with respect to this lease.

Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2022		2021
Salaries and short-term benefits		4,505		2,348
Share-based compensation		5,871		8,275
		10,376		10,623

OFF BALANCE SHEET ARRANGEMENTS

As at December 31, 2022, the Company did not have any off-balance sheet arrangements.

24

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company makes assumptions in applying critical accounting estimates that are uncertain at the time the accounting estimate is made and may have a significant effect on the consolidated financial statements. Critical accounting estimates include the classification and recoverable amounts of CGUs, value of biological assets and inventory, estimating potential future returns on revenue, convertible instruments, value of investments, value of equity-accounted investees, value of leases, acquisitions and fair value of assets acquired and liabilities assumed in a business combination. Critical accounting estimates are based on variable inputs including but not limited to:

•Demand for cannabis for recreational and medical purposes;

•Price of cannabis;

•Expected sales volumes;

•Changes in market interest and discount rates;

•Future development and operating costs;

•Costs to convert harvested cannabis to finished goods;

•Expected yields from cannabis plants;

•Potential returns and pricing adjustments;

•Facts and circumstances supporting the likelihood and amount of contingent liabilities;

•Assumptions and methodologies for the valuation of derivative financial instruments;

•Discount rates used to value investments; and

•Market prices, volatility and discount rates used to determine fair value of equity-accounted investees.

Changes in critical accounting estimates can have a significant effect on net income as a result of their impact on revenue, costs of sales, provisions and impairments. Changes in critical accounting estimates can have a significant effect on the valuation of biological assets, inventory, property, plant and equipment, provisions and derivative financial instruments.

For a detailed discussion regarding the Company’s critical accounting policies and estimates, refer to the notes to the Audited Financial Statements.

NEW ACCOUNTING PRONOUNCEMENTS

The International Accounting Standards Board (IASB) and the IFRS Interpretations Committee regularly issue new and revised accounting pronouncements which have future effective dates and therefore are not reflected in the Company’s consolidated financial statements. Once adopted, these new and amended pronouncements may have an impact on the Company’s consolidated financial statements. The Company’s analysis of recent accounting pronouncements is included in the notes to the Audited Financial Statements.

RISK FACTORS

In addition to the other risks described elsewhere in this document, for a detailed discussion regarding the Company’s risk factors, refer to the “Risk Factors” section of the Annual Report.

DISCLOSURE CONTROLS AND PROCEDURES

The Company has designed disclosure controls and procedures to provide reasonable assurance that: (i) material information relating to the Company is made known to the Company’s Chief Executive Officer and Chief Financial Officer by others, particularly during the period in which the annual and interim filings are being prepared; and (ii) information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time period specified in securities legislation. Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange, as of December 31, 2022. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer

25

have concluded that our disclosure controls and procedures were not effective as of December 31, 2022, due to a material weakness in the Company’s internal control over financial reporting further described below.

During 2022, the Company's operations continued to expand rapidly and significantly in scale and scope particularly through the Alcanna Transaction and the resulting addition of the liquor retail segment and significant expansion of the cannabis retail segment.

However, giving full consideration to the material weakness discussed below, the Company has concluded that the consolidated financial statements included in the Annual Report on Form 20-F present fairly, in all material respects, the Company’s financial position, the results of its operations and its cash flows for each of the periods presented in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”).

INTERNAL CONTROL OVER FINANCIAL REPORTING

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in NI 52-109 and Rule 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS and includes those policies and procedures that:

(1)pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and the dispositions of our assets;

(2)provide reasonable assurance that our transactions are recorded as necessary to permit preparation of financial statements in accordance with applicable accounting principles and that our receipts and expenditures are being made only in accordance with appropriate authorizations of our management and directors; and

(3)provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness for future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision of and with the participation of our Chief Executive Officer and Chief Financial Officer, management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework (2013). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

As at December 31, 2022, the Company’s management determined that it did not maintain effective internal control over financial reporting due to the existence of the following material weakness:

•Information technology general controls (“ITGCs”) were not designed and operating effectively to ensure (i) that access to applications and data, and the ability to make program and job changes, were adequately restricted to appropriate personnel and (ii) that the activities of individuals with access to modify data and make program and job changes were appropriately monitored. Business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted.

This material weakness did not result in material misstatements of the consolidated financial statements as of and for the year ended December 31, 2022. This material weakness creates a reasonable possibility that a material misstatement to the consolidated financial statements would not be prevented or detected on a timely basis.

In accordance with guidance issued by the Canadian Securities Administrators and the SEC, companies are permitted to exclude acquisitions from their final assessment of internal control over financial reporting for the first fiscal year in which the acquisition occurred. Our management, with the participation of our Chief Executive Officer and Chief Financial

26

Officer, did not limit the evaluation of our internal control over financial reporting to exclude controls, policies and procedures and internal control over financial reporting over any acquired operations including the operations acquired through the Alcanna Transaction.

The Company’s independent auditors, Marcum LLP, have issued an unqualified opinion on our financial statements and an adverse opinion on the effectiveness of internal control over financial reporting as of December 31, 2022. These audit reports are included in the annual report on Form 20-F.

REMEDIATION

Management has implemented and continues to implement measures designed to ensure that control deficiencies are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:

•continuing to strengthen procedures and controls related to the provision of and periodic review of user access to IT systems;

•continuing to strengthen the logging and monitoring of software updates and changes to systems supporting our financial reporting processes;

•enhancing the timeliness of executing user access reviews and the subsequent actions as required; and

•working with our advisors to continue to assist with process improvements and strengthening of controls over financial systems.

At April 24, 2023 the above remediation measures are in progress but will not be considered remediated, until the updated controls operate for a sufficient period of time, and management has concluded through testing, that these controls are operating effectively.

The Company is pursuing remediation of the above material weakness during the 2023 fiscal year.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

Except for the remediation activities described above, as of December 31, 2022, there have been no other changes in our internal control over financial reporting (as defined in NI 52-109 and Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the year ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

ABBREVIATIONS

The following provides a summary of common abbreviations used in this document:

Financial and Business Environment
$ or C$	Canadian dollars
IFRS	International Financial Reporting Standards, as issued by the International Accounting Standards Board
MD&A	Management’s Discussion and Analysis
U.S.	United States
US$	United States dollars

FORWARD-LOOKING INFORMATION

This document may contain forward-looking information concerning the Company’s business, operations and financial performance and condition, as well as its plans, objectives and expectations for its business operations and financial

27

performance and condition, such as the expectation for cost savings to be generated by the Company’s continued cost savings initiatives. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable technology.

These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. As a result, any or all of the forward-looking information in this document may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” in the Annual Report and otherwise described in this MD&A. Although management believes that its underlying assessments and assumptions are reasonable based on currently available information, given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. All forward-looking statements in this MD&A are qualified by these cautionary statements. These statements are made as of the date of this MD&A and, except as required by applicable law, the Company assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. Additionally, the Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, its financial or operating results or its securities.

This document contains estimates, projections and other information concerning the Company’s industry, business and the markets for its products. Information that is based on estimates, forecasts, projections, market research of similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from its own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

In addition, assumptions and estimates of the Company’s and industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section “Risk Factors” in the Annual Report and elsewhere in this MD&A. These and other factors could cause the Company’s future performance to differ materially from the Company’s assumptions and estimates.

Further information regarding the assumptions and risks inherent in the making of forward-looking statements can be found in the Annual Report, along with the Company’s other public disclosure documents. Copies of the Annual Report and other public disclosure documents are available under the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com and on the EDGAR section of the U.S. Securities and Exchange Commission’s (the “SEC”) website at www.sec.gov.

Certain information in this MD&A is “financial outlook” within the meaning of applicable Canadian securities laws. The purpose of the financial outlook is to provide readers with disclosure of the Company’s reasonable expectations of its anticipated results. The financial outlook is provided as of the date of this MD&A. Readers are cautioned that the financial outlook may not be appropriate for other purposes.

ADDITIONAL INFORMATION

Additional information relating to the Company can be viewed under the Company’s profile on SEDAR at www.sedar.com, on the EDGAR section of the SEC’s website at www.sec.gov, or on the Company’s website at www.sndlgroup.com. The information on or accessible through our website is not part of and is not incorporated by reference into this MD&A, and the inclusion of our website address in this MD&A is only for reference.

28

EX-15

Independent Registered Public Accounting Firm’s Consent

We consent to the incorporation by reference in the Registration Statement of SNDL Inc. on Form S-8 [FILE NO. 333-262233] and Form F-3 [FILE NO. 333-253169] and [FILE NO. 333-253813] of our report on the consolidated financial statements which refers to an emphasis of matter for the retrospective adjustment to provisional amounts dated April 24, 2023, with respect to our audits of the consolidated financial statements of SNDL Inc. as of December 31, 2022 and for the year ended December 31, 2022 and our report dated April 24, 2023 with respect to our audit of internal control over financial reporting of SNDL Inc. as of December 31, 2022, which reports are included in this Annual Report on Form 20-F of SNDL Inc. for the year ended December 31, 2022.

Our report on the effectiveness of internal control over financial reporting expressed an adverse opinion because of the existence of a material weakness.

/s/ Marcum llp

Marcum llp

New York, NY

April 24, 2023

EX-15

 

KPMG LLP

205 5th Avenue SW

Suite 3100

Calgary AB T2P 4B9

Tel (403) 691-8000

Fax (403) 691-8008

www.kpmg.ca

Consent of Independent Registered Public Accounting Firm

The Board of Directors

SNDL Inc. (formerly Sundial Growers Inc.)

We consent to the use of our report, dated April 27, 2022, on the consolidated financial statements of Sundial Growers Inc.(the “Entity”) which comprise the consolidated statements of financial position as at December 31, 2021, the related consolidated statements of loss and comprehensive loss, changes in shareholders’ equity and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively the “consolidated financial statements”), which is included in the Annual Report on Form 20-F of the Entity for the fiscal year ended December 31, 2022.

We also consent to the incorporation by reference of such reports in the Registration Statement on Form F-3 (No. 333-253169 and No. 333-253813) and Form S-8 (No. 333-233156, No. 333-262233, No. 333-267510 and No. 333-269242) of the Entity.

/s/ KPMG LLP

April 24, 2023

Calgary, Canada

XML

Document and Entity Information - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	SNDL Inc.
Entity Central Index Key	0001766600
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Incorporation, State or Country Code	A0
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	235,194,236
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Shares
Trading Symbol	SNDL
Security Exchange Name	NASDAQ
Entity File Number	001-39005
Entity Address, State or Province	AB
Entity Address, Address Line One	#300, 919
Entity Address, Address Line Two	11 Avenue SW
Entity Address, City or Town	Calgary
Entity Address, Postal Zip Code	T2R 1P3
Entity Address, Country	CA
Document Annual Report	true
Document Transition Report	false
Document Registration Statement	false
Document Shell Company Report	false
ICFR Auditor Attestation Flag	true
Document Accounting Standard	International Financial Reporting Standards
Auditor Name	Marcum	KPMG
Auditor Location	New York, New York, United States	Calgary, Alberta, Canada
Auditor Firm ID	688	85
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	300, 919
Entity Address, Address Line Two	11 Avenue SW
Entity Address, City or Town	Calgary
Entity Address, Postal Zip Code	T2R 1P3
City Area Code	403
Local Phone Number	948-5227
Entity Address, Country	CA
Contact Personnel Name	James Keough
Contact Personnel Email Address	investors@sndl.com

XML

Consolidated Statements of Financial Position $ in Thousands, $ in Millions		Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($)
Current assets
Cash and cash equivalents		$ 279,586	$ 558,251	[1]
Restricted cash		19,338	27,013	[1]
Marketable securities		21,926	83,724	[1]
Accounts receivable		22,636	10,865	[1]
Biological assets		3,477	4,410	[1]
Inventory		127,782	29,503	[1]
Prepaid expenses and deposits		10,110	4,355	[1]
Investments		6,552	3,065	[1]
Assets held for sale		6,375	2,998	[1]
Net investment in subleases		3,701	3,991	[1]
Current assets		501,483	728,175	[1]
Non-current assets
Long-term deposits		8,584	7,725	[1]
Right of use assets		134,154	6,717	[1]
Property, plant and equipment		143,409	56,472	[1]
Net investment in subleases		19,618	22,571	[1]
Intangible assets	[1]	74,885	50,148
Investments		90,702	70,498	[1]
Equity-accounted investees		519,255	412,858	[1]
Goodwill	[1]	67,260	72,496
Total assets		1,559,350	1,427,660	[1],[2]
Current liabilities
Accounts payable and accrued liabilities		48,153	38,452	[1]
Current lease liabilities		30,206	5,701	[1]
Derivative warrants		11,002	21,700	[1]
Current liabilities		89,361	65,853	[1]
Non-current liabilities
Lease liabilities		139,625	27,769	[1]
Other liabilities		2,709	4,505	[1]
Total liabilities		231,695	98,127	[1]
Shareholders’ equity
Share capital		2,292,810	2,035,704	[1]
Warrants		2,260	8,092	[1]
Contributed surplus		68,961	60,734	[1]
Contingent consideration		2,279	2,279	[1]
Accumulated deficit	[1]	(1,091,999)	(785,112)
Accumulated other comprehensive income		32,188	7,607	[1]
Total shareholders’ equity		1,306,499	1,329,304	[1]
Non-controlling interest		21,156	229	[1]
Total liabilities and shareholders’ equity		$ 1,559,350	$ 1,427,660	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustments to provisional amounts — refer to note 5(b)

XML

Consolidated Statements of Loss and Comprehensive Loss - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Statement of comprehensive income [abstract]
Gross revenue		$ 729,694		$ 67,279	[1]	$ 73,321
Excise taxes		17,497		11,151	[1]	12,403
Net revenue		712,197		56,128	[1]	60,918
Cost of sales	[1]	558,089		50,612		51,740
Inventory impairment and obsolescence		7,012		16,978	[1]	45,913
Gross margin before fair value adjustments		147,096		(11,462)	[1]	(36,735)
Change in fair value of biological assets		(1,309)		4,708	[1]	5,432
Change in fair value realized through inventory		(5,412)		(2,247)	[1]	(18,566)
Gross margin		140,375		(9,001)	[1],[2]	(49,869)
Interest and fee revenue		16,739		13,149	[1]	0
Investment loss		(65,164)		(44,501)	[1]
Share of profit (loss) of equity-accounted investees		(43,002)		32,913	[1]	0
General and administrative	[1]	140,168		38,043		32,029
Sales and marketing		8,417		5,043	[1]	5,737
Research and development		2,448		2,446	[1]	488
Depreciation and amortization	[1]	40,945		5,287	[2]	4,711
Share-based compensation		9,671		12,307	[1]	8,566
Restructuring costs		(670)		874	[1]	6,470
Asset impairment		196,033		60,000	[1]	79,191
Government subsidies				(2,180)	[1]	(4,128)
Loss (gain) on cancellation of contracts		(290)		5,116	[1]	2,471
Loss from operations		(347,774)		(134,376)	[1]	(185,404)
Transaction costs		(1,352)		(17,566)	[1]	(3,587)
Finance costs, net		(41,314)		(3,756)	[1]	(3,819)
Change in estimate of fair value of derivative warrants		10,783		(77,834)	[1]	(12,995)
Foreign exchange gain (loss)		(19)		531	[1]	(1,000)
Gain (loss) on disposition of assets		(94)		235	[1]	488
Other expenses	[1]			(1,932)
Loss before income tax		(379,770)		(234,698)	[1],[2]	(206,317)
Income tax recovery	[1]	7,342		7,914
Net loss from continuing operations		(372,428)	[3]	(226,784)	[1]	(206,317)	[3]
Net loss from discontinued operations						(33,627)
Net loss		(372,428)		(226,784)	[1]	(239,944)
Equity-accounted investees - share of other comprehensive income, net of tax		24,581		7,607	[1]
Gain on translation of foreign operations						600
Comprehensive loss		(347,847)		(219,177)	[1]	(239,344)
Net loss from continuing operations attributable to:
Owners of the company	[1]	(335,114)		(226,984)		(199,619)
Non-controlling interest		(37,314)		200	[1]	(6,698)
Net loss from continuing operations		(372,428)	[3]	(226,784)	[1]	(206,317)	[3]
Net income (loss) attributable to:
Owners of the company	[1]	(335,114)		(226,984)		(233,246)
Non-controlling interest		(37,314)		200	[1]	(6,698)
Net loss		(372,428)		(226,784)	[1]	(239,944)
Comprehensive income (loss) attributable to:
Owners of the company	[1]	(310,533)		(219,377)		(232,646)
Non-controlling interest		(37,314)		200	[1]	(6,698)
Comprehensive loss		$ (347,847)		$ (219,177)	[1]	$ (239,344)
Net loss per common share attributable to owners of the company
Basic and diluted		$ (1.46)		$ (1.22)	[1]	$ (10.67)

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustments to provisional amounts — refer to note 5(b)

[3] Adjustment to provisional amounts — refer to note 5(b).

XML

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Total		Share Capital	Warrants	Contributed Surplus	Contingent Consideration	Accumulated Deficit	[1]	Accumulated Other Comprehensive income	Non-controlling interests [member]
Beginning balance at Dec. 31, 2019	$ 221,198		$ 509,654	$ 27,831	$ 30,192	$ 2,279	$ (360,338)		$ 6,866	$ 4,714
Net loss	(239,944)						(233,246)			(6,698)
Other comprehensive income	600								600
Share issuances	176,931		176,931
Share issuance costs	(5,593)		(5,593)
Derivative warrants exercised	55,912		55,912
Convertible debt - conversions	63,002		63,002
Warrants issued	306			306
Warrants expired				(21,999)	21,999
Dispositions	(10,457)		(38,447)				35,456		(7,466)
Share-based compensation	7,740		52		7,688
Employee awards exercised			535		(535)
Ending balance at Dec. 31, 2020	269,695		762,046	6,138	59,344	2,279	(558,128)			(1,984)
Net loss	(226,784)	[2]					(226,984)			200	[1]
Other comprehensive income	7,607								7,607
Loss of control of subsidiary	2,013									2,013
Share issuances	977,425		977,425
Share issuance costs	(16,371)		(16,371)
Derivative warrants exercised	277,136		277,136
Acquisition	27,987		26,216	1,771
Convertible debenture settlement	2,671		2,671
Convertible debt - conversions			2,671
Warrants issued	361			361
Warrants exercised			178	(178)
Share-based compensation	12,723		8		12,715
Employee awards exercised	201		6,395		(6,194)
Modification of equity-settled plan	(5,131)				(5,131)
Ending balance at Dec. 31, 2021	1,329,533		2,035,704	8,092	60,734	2,279	(785,112)		7,607	229
Net loss	(372,428)						(335,114)			(37,314)
Other comprehensive income	24,581								24,581
Share issuances	2,870		2,870
Share repurchases	(13,390)		(41,617)				28,227
Share issuances by subsidiaries	115				72					43
Share issuance costs			0
Derivative warrants exercised			0
Acquisition	345,351		287,129							58,222
Convertible debt - conversions			0
Warrants exercised			0
Warrants expired				(5,832)	5,832
Share-based compensation	11,047				11,047
Employee awards exercised			8,724		(8,724)
Distribution declared by subsidiaries	(24)									(24)
Ending balance at Dec. 31, 2022	$ 1,327,655		$ 2,292,810	$ 2,260	$ 68,961	$ 2,279	$ (1,091,999)		$ 32,188	$ 21,156

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

XML

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Operating activities
Net loss from continuing operations for the period		$ (372,428)	[1]	$ (226,784)	[2]	$ (206,317)	[1]
Items not involving cash:
Income tax recovery	[1]	(7,342)		(7,914)		0
Interest and fee revenue		(16,739)		(13,149)	[2]	0
Change in fair value of biological assets		1,309		(4,708)	[1]	(5,432)
Share-based compensation		9,671		12,307	[1]	8,566
Depreciation and amortization	[1]	47,322		10,164		11,582
Loss (gain) on disposition of assets		94		(235)	[1]	(488)
Inventory obsolescence		7,012		16,978	[1]	45,913
Finance costs		41,314		3,716	[1]	(3,734)
Change in estimate of fair value of derivative warrants		(10,783)		77,834	[2]	12,995
Loss on cancellation of contracts		0		2,870	[1]	671
Unrealized foreign exchange (gain) loss		(16)		(63)	[1]	(757)
Restructuring costs		0		0	[1]	448
Warrants issued for services		0		0	[1]	306
Asset impairment		196,033		60,000	[2]	79,191
Share of (profit) loss of equity-accounted investees		43,002		(32,913)	[2]	0
Other expenses		0		1,864	[1]	0
Gain on disposition of marketable securities		0		(20,213)	[1]	0
Unrealized loss on marketable securities		65,553		64,714	[1]	0
Additions to marketable securities		(3,500)		(158,101)	[1]	0
Proceeds from disposal of marketable securities		0		29,876	[1]	0
Income distributions from equity-accounted investees		1,661		15,021	[1]	0
Interest received		13,403		0	[1]	0
Exercise of cash-settled deferred share units		(204)		(315)	[1]	0
Change in non-cash working capital		(22,073)		150	[1]	(5,259)
Net cash used in operating activities from continuing operations		(6,711)		(155,752)	[1]	(62,315)
Net cash provided by operating activities from discontinued operations		0		0	[1]	4,820
Net cash used in operating activities		(6,711)		(155,752)	[1]	(57,495)
Investing activities
Additions to property, plant and equipment		(10,666)		(3,793)	[1]	(3,024)
Additions to intangible assets		(197)		0	[1]	(150)
Additions to investments		(75,598)		(24,206)	[1]	(51,876)
Additions to equity-accounted investees		(119,137)		(395,569)	[1]	0
Capital distributions from equity-accounted investees		0		10,481	[1]	0
Proceeds from disposal of property, plant and equipment		4,000		194	[1]	2,109
Acquisition, net of cash acquired		(28,640)		(82,775)	[1]	0
Change in non-cash working capital		74		(612)	[1]	(11,319)
Net cash used in investing activities from continuing operations		(230,164)		(496,280)	[1]	(64,260)
Net cash used in investing activities from discontinued operations		0		0	[1]	(6,617)
Net cash used in investing activities		(230,164)		(496,280)	[1]	(70,877)
Financing activities
Proceeds from convertible notes, net of costs		0		0	[1]	18,070
Change in restricted cash		7,675		(21,680)	[1]	10,494
Payments on lease liabilities, net		(27,693)		(1,008)	[1]	(420)
Repurchase of common shares, net of costs		(13,390)		0	[1]	0
Proceeds from issuance of shares and registered offerings, net of costs		22		1,062,310	[1]	181,841
Distributions declared by subsidiaries		(24)		0	[1]	0
Proceeds from exercise of derivative warrants		0		119,318	[1]	20,391
Proceeds from exercise of employee warrants		0		201	[1]	0
Repayment of long-term debt		(10,000)		0	[1]	(84,493)
Convertible debenture settlement		0		(9,354)	[1]	0
Payment on exercise of contingent consideration warrants		0		(219)	[1]	0
Change in non-cash working capital		1,620		348	[1]	(2,498)
Net cash (used in) provided by financing activities from continuing operations		(41,790)		1,149,916	[1]	143,385
Net cash used in financing activities from discontinued operations		0		0	[1]	(639)
Net cash (used in) provided by financing activities		(41,790)		1,149,916	[1]	142,746
Effect of exchange rate changes on cash held in foreign currency		0		(9)	[1]	665
Change in cash and cash equivalents		(278,665)		497,875	[1]	15,039
Cash and cash equivalents, beginning of year		558,251	[3]	60,376	[1]	45,337
Cash and cash equivalents, end of year		$ 279,586		$ 558,251	[3]	$ 60,376	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

[3] Adjustment to provisional amounts — refer to note 5(b).

XML

Description of Business

12 Months Ended

Dec. 31, 2022

Description Of Business [Abstract]

Description of Business

1.Description of business

SNDL Inc. (“SNDL” or the “Company”) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company’s shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from “Sundial Growers Inc.” to “SNDL Inc.”.

The Company’s head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada.

The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted, the production, distribution and sale of cannabis domestically and for export pursuant to the Cannabis Act (Canada) (the “Cannabis Act”), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company also owns approximately 63% of Nova Cannabis Inc. (“Nova”) (TSX: NOVC), whose principal activities are the retail sale of cannabis.

SNDL and its subsidiaries currently operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. (“SunStream”) (note 17), the Company provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.

The Company’s common shares trade on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “SNDL”.

XML

Basis of Presentation

12 Months Ended

Dec. 31, 2022

Disclosure Of Basis Of Presentation [Abstract]

Basis of Presentation

2.Basis of presentation

a)Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) in effect as of December 31, 2022.

These consolidated financial statements were approved and authorized for issue by the board of directors of SNDL (the “Board”) on April 24, 2023.

b)Basis of measurement

These consolidated financial statements have been prepared on a historical cost basis, except for biological assets, deferred share units (“DSUs”) and certain financial instruments (note 31(a)) which are measured at fair value with changes in fair value recorded in earnings.

c)Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company and its Canadian-based subsidiaries. Sundial Deutschland GmbH uses the European Euro as its functional currency. The Company’s equity-accounted joint venture uses the United States dollar as its functional currency. Transactions in currencies other than the functional currency are translated at the rate prevailing at the date of transaction. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rate prevailing at each reporting date. Income and expense amounts are translated at the dates of the transactions.

In preparing the Company’s consolidated financial statements, the financial statements of foreign subsidiaries and the foreign equity-accounted joint venture are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of foreign operations that do not have a functional currency of Canadian dollars, are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of foreign operations are translated into Canadian dollars using foreign exchange rates that approximate those

on the date of the underlying transactions. Foreign exchange differences from the translation of foreign subsidiaries and the foreign equity-accounted joint venture into Canadian dollars are recognized in other comprehensive income (“OCI”). The Company’s consolidated financial statements include its share of the Canadian dollar profit or loss and OCI of the equity-accounted joint venture.

d)Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. All intercompany balances, income and expenses and unrealized gains and losses resulting from intercompany transactions are eliminated upon consolidation.

XML

Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Disclosure Of Significant Accounting Policies [Abstract]

Significant Accounting Policies

3.Significant accounting policies

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.

RESTRICTED CASH

Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading positions, if any, and (ii) minimum funding requirements for two separate captive insurance structures.

BIOLOGICAL ASSETS

The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour-related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with International Accounting Standard 41 – Agriculture (“IAS 41”) and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

INVENTORY

Harvested cannabis

Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour-related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory.

Retail inventory

Retail inventory at Company-owned stores is valued at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined using the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels.

PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized.

Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates.

Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in profit and loss.

PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained, if required for operation. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

•Production facilities — 20 years

•Equipment — 1 to 10 years

•Right of use assets and leasehold improvements — Shorter of estimated useful life or lease term

INTANGIBLE ASSETS

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available

for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with International Accounting Standard 38 – Intangible Assets (“IAS 38”).

The Company’s intangible assets are comprised of the following:

•Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years.

•Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years.

•Intellectual property acquired through the acquisition of Inner Spirit (as defined below) consisting of a trade name with an indefinite life and franchise agreements with useful lives of 8 years.

•Intangible assets acquired through the acquisition of Alcanna consisting of brands, licenses, permits and software.

Joint arrangements

Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets.

For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases.

Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid.

Interests in equity-accounted investees

The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture.

Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities.

Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.

IMPAIRMENT OF ASSETS

Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining and maintaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates.

(i)Financial assets

The Company applies an expected credit loss (“ECL”) model to all financial assets not held at fair value through profit and loss (“FVTPL”) where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under International Financial Reporting Standard 9 – Financial Instruments (“IFRS 9”) and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECLs are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and has calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information.

(ii)Non-financial assets

The carrying amounts of the Company’s PP&E, right of use assets and intangible assets, including goodwill, are assessed for impairment indicators and impairment reversal indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment or impairment reversal. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss or impairment reversal, if any.

An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of asset’s estimated fair value less costs of disposal and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit (“CGU”)).

Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset or CGU is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized previously. A reversal of an impairment loss, net of any depreciation that would have been recorded, is recognized immediately in the statements of loss and comprehensive loss. Impairments of goodwill are not reversed.

FINANCIAL INSTRUMENTS

The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance.

(i)Financial assets

At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or fair value through other comprehensive income (“FVOCI”) depending on the business model and contractual cash flows of the instrument.

Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss.

The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at FVOCI.

(ii)Financial liabilities

Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method.

Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss.

Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt.

The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition.

Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of

the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2022 and 2021.

NON-MONETARY TRANSACTIONS

All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.

COMPOUND FINANCIAL INSTRUMENTS

The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition.

Interest and losses and gains relating to the financial liability are recognized in profit and loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.

REVENUE

Under International Financial Reporting Standard 15 – Revenue from Contracts with Customers (“IFRS 15”), to determine the amount and timing of revenue to be recognized, the Company follows a five-step model:

1.Identifying the contract with a customer

2.Identifying the performance obligations

3.Determining the transaction price

4.Allocating the transaction price to the performance obligations

5.Recognizing revenue when/as performance obligations are satisfied

Cannabis revenue

Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods.

For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory

less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly.

Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing.

Retail revenue

Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives.

It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift card.

The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price.

Franchise revenue

Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits.

Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and stewarding the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they utilize the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements.

Other revenue

Proprietary licensing revenue is generated from proprietary licensing services provided to customers. Revenue is recognized when the services are delivered to the customer at a point in time as outlined by the contract. The Company does not operate or manage these services separately from its primary retail sales or operations.

Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner.

Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped.

RESEARCH AND DEVELOPMENT

Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38. Research and development costs comprise consulting fees, costs to cultivate and test cultivar batches to the point of commercialization and licence acquisition fees. No development costs have been capitalized as at December 31, 2022, or December 31, 2021.

SHARE-BASED COMPENSATION

The Company’s share-based compensation plans include equity-settled awards and cash-settled awards.

The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted.

Equity-settled

Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted from time to time to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital.

Cash-settled

DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment.

Nova DSUs are granted to Nova directors and represent a right for the holder to receive a cash payment equal to the fair value of Nova’s common shares calculated at the date of such payment, or Nova common shares, at the discretion of Nova.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur.

INCOME TAXES

Income taxes are recognized in profit and loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity.

Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and include any adjustment to income tax payable or recoverable in respect of previous periods.

Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable.

Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted at the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income

(loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized.

Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected.

BUSINESS COMBINATIONS

Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net earnings. Transaction costs associated with business combinations are expensed as incurred.

FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED IN A BUSINESS COMBINATION

The fair value of assets acquired and liabilities assumed in a business combination, including contingent consideration and goodwill, is estimated based on information available at the date of acquisition. Various valuation techniques are applied for measuring fair value including market comparables and discounted cash flows which rely on assumptions such as future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in these variables could significantly impact the carrying value of the net assets. Specific judgement is required in the identification of intangible assets.

GOODWILL

Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in profit and loss. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.

NON-CONTROLLING INTERESTS

The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.

Loss of control

When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

LEASES

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost and any direct costs of obtaining the lease, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease liability. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease liability is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payments made. Lease payments are allocated between the liability and accretion expense. Accretion expense is recognized on the lease liability using the effective interest rate method and payments are applied against the lease liability.

The carrying amounts of the right of use assets, lease liability, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgements including economic environment, term, and the underlying risk inherent to the asset.

As a lessor

When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. Under a finance lease, the Company recognizes a receivable at an amount equal to the net investment in the lease which is the present value of the aggregate of lease payments receivable by the lessor. Under an operating lease, the Company recognizes lease payments received as income on a straight-line basis over the lease term. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right of use asset arising from the head lease, not with reference to the underlying asset.

GOVERNMENT GRANTS

Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.

Captive Insurance

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures.

The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate cell account (“Cell Captive”). The Company applies International Financial Reporting Standard 10 – Consolidated Financial Statements (“IFRS 10”) in its assessment of

control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. The Cell Captive funds are held as cash and may be invested according to the Company’s treasury policy. The funds are disclosed as restricted cash as the Cell Captive must be fully funded at all times. The Company will recognize any gains or losses from fair market value adjustments, interest and/or foreign exchange in the statements of income (loss) and comprehensive income (loss).

The second structure is a wholly owned subsidiary, Sundial Insurance (Bermuda) Ltd. (“SIBL”), incorporated to provide separate and additional coverage. The Company applies IFRS 10 in its assessment of control as it relates to SIBL. The Company’s accounting policy is to consolidate SIBL. The funds are disclosed as restricted cash as the funds were required for initial capitalization of the entity and there is a requirement to maintain minimum capital and surplus in accordance with industry regulations.

NEW ACCOUNTING STANDARDS

The following accounting standards were effective for annual periods beginning on or after January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements:

•Onerous Contracts — Cost of Fulfilling a Contract — Amendments to IAS 37

•Property, Plant and Equipment: Proceeds before Intended Use — Amendments to IAS 16

There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2023, that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2022. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include:

•Classification of Liabilities as Current or Non-current — Amendment to IAS 1

•IFRS 17 Insurance Contracts

•Definition of Accounting Estimate — Amendments to IAS 8

•Deferred Tax related to Assets and Liabilities arising from a Single Transaction — Amendments to IAS 12

XML

Significant Accounting Estimates, Assumptions and Judgements

12 Months Ended

Dec. 31, 2022

Disclosure of initial application of standards or interpretations [abstract]

Significant accounting estimates, assumptions and judgements

4.Significant accounting estimates, assumptions and judgements

The preparation of these consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Judgement is used mainly in determining whether a balance or transaction should be recognized in the consolidated financial statements. Estimates and assumptions are mostly used in determining the measurement of recognized transactions and balances. However, judgements and estimates are often interrelated.

Judgements, estimates and assumptions are continually evaluated and are based on factors including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected.

Judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment include the following:

IMPAIRMENTS

CGU’s are defined as the lowest grouping of integrated assets that generate identifiable cash inflows that are largely independent of the cash inflows of other assets or groups of assets. The classification of assets into CGU’s requires significant judgement and interpretations with respect to the integration between assets, the existence of active markets, external users, shared infrastructure and the way in which management monitors the Company’s operations.

The recoverable amounts of CGU’s and individual assets have been determined as the higher of the CGU’s or the asset’s fair value less costs of disposal and its value in use. These calculations require the use of estimates and assumptions and are subject to changes as new information becomes available including information on the likelihood of obtaining future licences from Health Canada, total addressable market, market share escalation factor, gross margin escalation factor, terminal multiple and discount rates. Changes in assumptions used in determining the recoverable amount could affect the carrying value of the related assets and CGU’s.

BIOLOGICAL ASSETS AND INVENTORY

Biological assets, comprising cannabis plants and agricultural product consisting of cannabis, are measured at fair value less costs to produce and sell up to the point of harvest.

Determination of the fair values of the biological assets and the agricultural product requires the Company to make assumptions about how market participants assign fair values to these assets. These assumptions primarily relate to the level of effort required to bring the cannabis up to the point of harvest, costs to convert the harvested cannabis to finished goods, sales price, risk of loss, expected future yields from the cannabis plants and estimating values during the growth cycle.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and thus any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. The Company must also determine if the carrying value of any inventory exceeds its net realizable value, such as cases where prices have decreased, or inventory has spoiled or has otherwise been damaged.

Revenue

Government customers typically have a right of product return, and in some cases, the right to pricing adjustments for products that are subsequently discounted or sold for a lower price in another jurisdiction. Licensed Producers can, in some cases, have a right of product return or warranty period. The estimate of potential future returns includes the use of estimates and assumptions and are subject to change as new information becomes available.

CONVERTIBLE INSTRUMENTS

The derivative warrant liabilities are financial liabilities measured at FVTPL. The determination of the fair value of the liabilities are estimated based on various assumptions, including future share price, volatility, discount rate and various probability factors.

ACQUISITIONS

The Company assesses whether an acquisition should be accounted for as an asset acquisition or a business combination under International Financial Reporting Standard 3 – Business Combinations (“IFRS 3”). This assessment requires management to make judgements on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business inputs and processes.

Investments

The Company’s investments at FVTPL are financial assets measured at fair value each reporting period. The determination of the fair value of each investment requires judgement from management and the primary assumption is the discount rate.

equity-accounted investees

The Company’s interest in a joint venture is accounted for using the equity-method. The current investment portfolio of the joint venture is comprised of secured debt and hybrid instruments which include options and warrants. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss.

The determination of the fair value of the underlying investments is based on a discounted cash flow methodology and requires judgement from management. The discounted cash flows are based on various assumptions, including an estimation of market prices, volatility and discount rates.

XML

Business Acquisitions

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about business combination [abstract]

Business Acquisitions

5.Business acquisitions

a)Alcanna

On October 7, 2021, the Company announced that it had entered into an arrangement agreement with Alcanna Inc. (“Alcanna”) pursuant to which the Company would acquire all of the issued and outstanding common shares of Alcanna by way of a statutory plan of arrangement (the “Alcanna Transaction”). The Company and Alcanna amended the arrangement agreement in respect of the Alcanna Transaction on January 6, 2022, and the Alcanna Transaction closed on March 31, 2022. Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”. Alcanna holds an approximate 63% equity interest in Nova, a Canadian cannabis retailer operating stores across Alberta, Saskatchewan and Ontario, under its “Value Buds” and “Sweet Tree” retail brands. The Company is deemed to control Nova through its equity interest and Nova’s results are included in the consolidated financial statements of the Company with the minority interest shown as non-controlling interest through equity.

Alcanna was acquired to diversify and stabilize cash flows and advance the Company’s vertical integration strategy.

The Alcanna Transaction consideration was comprised of (i) an aggregate $54.3 million cash ($1.50 in cash for each Alcanna common share), and (ii) an aggregate 32.1 million SNDL common shares valued at $287.1 million based on the fair value of each common share of the Company on the closing date (0.885 of a SNDL common share for each Alcanna common share).

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts, if any.

The fair value of consideration paid was as follows:

	Provisional		Adjustments		Final
Cash		54,339		—		54,339
Issuance of common shares		287,129		—		287,129
		341,468		—		341,468

The fair value of the assets and liabilities acquired was as follows:

	Provisional			Adjustments			Final
Cash		23,190			—			23,190
Accounts receivable		1,868			—			1,868
Prepaid expenses and deposits		10,986			—			10,986
Inventory		105,022			—			105,022
Right of use assets		171,866			(31,117	)		140,749
Property, plant and equipment		86,059			24,632			110,691
Intangible assets		—			45,100			45,100
Goodwill		280,243			(129,308	)		150,935
Accounts payable and accrued liabilities		(36,703	)		(44	)		(36,747	)
Long-term debt		(10,000	)		—			(10,000	)
Lease liabilities		(232,755	)		90,736			(142,019	)
Derivative warrants		(58	)		(27	)		(85	)
Non-controlling interest		(58,250	)		28			(58,222	)
		341,468			—			341,468

Non-controlling interest has been measured as the fair value of the non-controlling interest in Nova, which at the time was 37%, and was measured by applying a market approach with reference to Nova’s closing share price on the day of the Alcanna Transaction of $2.66.

On March 31, 2022, the Company repaid in full the acquired long-term debt balance of $10.0 million.

These consolidated financial statements incorporate the operations of Alcanna commencing March 31, 2022. During the period March 31, 2022 to December 31, 2022, the Company recorded revenues of $639.5 million and net loss of $101.0 million from the Alcanna operations. Had the Alcanna Transaction closed on January 1, 2022, management estimates that for the period January 1, 2022, to March 30, 2022, revenue would have increased by $162.5 million and net loss would have increased by $25.5 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2022.

The Company incurred costs related to the Alcanna Transaction of $7.0 million which have been included in transaction costs.

The Company recorded adjustments to the fair value in the fourth quarter of 2022 to reflect additional information and greater certainty with respect to management estimates pertaining to facts and circumstances that were either unknown or uncertain at the date of acquisition. These adjustments related to changes in preliminary valuation assumptions, including refinement of right of use assets, property, plant and equipment, intangible assets, accounts payable and accrued liabilities, lease liabilities, derivative warrants and non-controlling interest. All measurement period adjustments were offset to goodwill.

goodwill impairment

For the purpose of impairment testing at December 31, 2022, intangible assets with indefinite lives were allocated to the Company’s CGUs as follows: i) $2.7 million to the cannabis retail CGU, ii) $18.3 million to the cannabis franchise CGU and iii) $43.1 million to the liquor retail CGU. Goodwill from the Alcanna acquisition was allocated as follows: i) $126.6 million to the cannabis retail CGU and ii) $24.3 million to the liquor retail CGU. The remaining goodwill from the Inner Spirit acquisition of $4.6 million was allocated to the group CGU containing the cannabis retail and cannabis franchise CGUs. The impairment test for the Company’s cannabis retail CGU used its fair value less costs of disposal and the fair value measurement was categorized as a Level 1 fair value based on the inputs in the valuation technique used. The impairment test for the Company’s cannabis franchise and liquor retail CGUs used a value in use approach based on internal cash flow estimates at December 31, 2022, and a discount rate of 12.0%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis and

liquor industry market sizes and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s retail cannabis CGU of $88.0 million as at December 31, 2022 as the estimated recoverable amount for this CGU of $84.8 million was lower than the respective carrying amount. The impairment loss was fully allocated to goodwill and included in asset impairment. The impairment was recognized in the Company’s cannabis retail reportable segment.

b)Inner Spirit

On May 5, 2021, the Company and Inner Spirit Holdings Ltd. (“Inner Spirit”) announced that they had entered into an arrangement agreement pursuant to which the Company acquired all of the issued and outstanding common shares of Inner Spirit (the “Inner Spirit Transaction”). The Inner Spirit Transaction closed on July 20, 2021. Inner Spirit is a retailer and franchisor of Spiritleaf adult-use cannabis stores across Canada, with a network that included more than 100 franchised and corporate-owned locations at the acquisition date.

The Inner Spirit Transaction consideration was comprised of (i) an aggregate $92.6 million cash ($0.30 in cash for each Inner Spirit common share), (ii) an aggregate 2.4 million SNDL common shares valued at $26.2 million based on the fair value of each common share of the Company on the closing date (0.00835 of a SNDL common share for each Inner Spirit common share) and (iii) contingent consideration valued at $1.2 million representing the fair value of Inner Spirit warrants.

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts.

The fair value of consideration paid was as follows:

	Provisional		Adjustments		Final
Cash		92,583		—		92,583
Issuance of common shares		26,216		—		26,216
Contingent consideration		1,150		—		1,150
		119,949		—		119,949

The fair value of the assets and liabilities acquired was as follows:

	Provisional			Adjustments			Final
Cash		9,808			—			9,808
Accounts receivable		750			(327	)		423
Prepaid expenses and deposits		853			—			853
Inventory		2,733			2,011			4,744
Right of use assets		—			5,730			5,730
Property, plant and equipment		12,108			(5,730	)		6,378
Intangible assets		—			46,000			46,000
Net investment in subleases		23,751			50			23,801
Goodwill		114,537			(42,041	)		72,496
Accounts payable and accrued liabilities		(2,678	)		—			(2,678	)
Convertible debentures		(12,025	)		—			(12,025	)
Lease liabilities		(29,481	)		(50	)		(29,531	)
Financial guarantee liability		(407	)		—			(407	)
Deferred tax liability		—			(5,643	)		(5,643	)
		119,949			—			119,949

On August 4, 2021, the Company settled the convertible debenture liability through the issuance of 2.5 million common shares valued at $2.7 million and a cash payment of $9.3 million. Due to the change of control from the Inner Spirit Transaction, debenture holders were entitled to receive SNDL common shares and a cash payment based on a prescribed formula.

The fair value of the Inner Spirit warrants has been estimated as $1.2 million and is made up of the following components: (i) equity component of $1.8 million (note 23(c)), (ii) liability component of $0.3 million and (iii) asset component of $0.9 million.

The consolidated financial statements incorporate the operations of Inner Spirit commencing July 20, 2021. During the period July 20, 2021, to December 31, 2021, the Company recorded revenues of $16.1 million and net earnings of $1.1 million. Had the acquisition closed on January 1, 2021, management estimates that for the period January 1, 2021, to July 19, 2021, revenue would have increased by $20.4 million and net earnings would have been reduced by $7.4 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2021.

The Company incurred acquisition-related costs of $1.9 million which have been included in transaction costs.

The Company recorded adjustments to the fair value in the third quarter of 2022 to reflect additional information and greater certainty with respect to management estimates pertaining to facts and circumstances that were either unknown or uncertain at the date of acquisition. These adjustments related to changes in preliminary valuation assumptions, including refinement of accounts receivable, inventory, net investment in subleases, lease liabilities and amounts allocated to intangible assets and deferred tax liability. All measurement period adjustments were offset to goodwill.

The Company made retrospective adjustments to provisional amounts in the comparative period as follows:

•The carrying amount of intangible assets as at December 31, 2021 was increased by $45.4 million, representing the increase in fair value of $46.0 million less additional amortization from the acquisition date to December 31, 2021 of $0.6 million.

•The deferred tax liability of $5.6 million was adjusted to nil with a corresponding adjustment recorded to income tax recovery, on the basis that the Company and Inner Spirit are subject to income tax under the same taxation authority.

•Amortization expense for 2021 was increased by $0.6 million (Q3 2021 — $0.3 million and Q4 2021 — $0.3 million).

•Cost of sales for 2021 was increased by $2.0 million, representing the increase in fair value of acquired inventory that was sold during 2021.

•General and administrative expenses was decreased by $0.3 million, representing the decrease in fair value of acquired accounts receivable.

•Goodwill was decreased by $42.0 million.

Inner Spirit goodwill and intangible asset impairment

For the purpose of impairment testing at September 30, 2022, intangible assets with indefinite lives consisting of the Inner Spirit brands and trademarks were allocated to the Company’s CGUs as follows: i) $17.7 million to the cannabis retail CGU and ii) $18.3 million to the cannabis franchise CGU. The impairment test for the Company’s cannabis retail and cannabis franchise CGUs used a value in use approach based on internal cash flow estimates at September 30, 2022, and a discount rate of 19.5%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s retail cannabis CGU of $16.4 million as at September 30, 2022 as the estimated recoverable amount for this CGU of $1.9 million was lower than the respective carrying amount. The impairment loss was fully allocated to intangible assets with indefinite lives and included in asset impairment. The impairment was recognized in the Company’s cannabis retail reportable segment.

For the purpose of impairment testing at September 30, 2022, goodwill of $72.5 million from the Inner Spirit acquisition was allocated to the group CGU containing the cannabis retail and cannabis franchise CGUs. The impairment test for the Company’s group CGU used a value in use approach based on internal cash flow estimates at September 30, 2022, and a discount rate of 19.5%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGUs. The estimated cash flows were based on a 5-year model

taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s group CGU of $67.9 million as at September 30, 2022 as the estimated recoverable amount for this group CGU of $40.0 million was lower than the respective carrying amount. The impairment loss was fully allocated to goodwill and included in asset impairment. The estimated value in use for the Company’s group CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1% would increase the impairment by approximately $1.1 million. The impairment was recognized in the Company’s cannabis retail reportable segment.

c)Zenabis

On November 1, 2022, the Company announced that, in the context of proceedings pursuant to the Zenabis Group’s (as defined below) filing under the Companies’ Creditors Arrangement Act (“CCAA”), it had successfully acquired all of the assets of the business of the Zenabis Group, subject to certain exclusions, (the “Zenabis Business”), pursuant to an approval order of the Québec Superior Court (the “Court”).

The order of the Court approved the acquisition by a wholly owned subsidiary of SNDL of all issued and outstanding shares of Zenabis Ltd., a corporation resulting from the amalgamation of select Zenabis entities (collectively, the “Zenabis Group”), as part of the consideration for the senior secured debt of the Zenabis Group due to the SNDL subsidiary. Zenabis Ltd. owns all of the Zenabis Business, free and clear of any encumbrances except certain permitted encumbrances (namely the security of the wholly owned subsidiary of SNDL, which was preserved).

The Zenabis acquisition consideration was comprised of (i) the extinguishment of the Company’s senior loan.

The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts, if any.

The fair value of consideration paid was as follows:

	Final
Extinguishment of senior loan		18,215
		18,215

The fair value of the assets and liabilities acquired was as follows:

	Final
Cash		2,509
Accounts receivable		888
Biological assets		909
Prepaid expenses and deposits		1,856
Inventory		4,512
Assets held for sale		6,375
Right of use assets		32
Property, plant and equipment		4,658
Accounts payable and accrued liabilities		(3,437	)
Lease liabilities		(87	)
		18,215

Assets held for sale are comprised of a processing facility in Stellarton, Nova Scotia, whose primary purpose was the packaging and processing of value added and derivative products for the adult-use cannabis market.

These consolidated financial statements incorporate the operations of Zenabis commencing November 1, 2022. During the period November 1, 2022 to December 31, 2022, the Company recorded revenues of $0.4 million and net loss of $1.8 million from the Zenabis operations. Had the acquisition closed on January 1, 2022, management estimates that for the period January 1, 2022, to October 31, 2022, revenue would have increased by $2.0 million and net loss would have increased by $9.0 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2022.

The Company incurred costs related to the Zenabis acquisition of $0.8 million which have been included in transaction costs.

XML

Segment Information

12 Months Ended

Dec. 31, 2022

Disclosure of operating segments [abstract]

Segment Information

6.Segment information

The Company’s reportable segments are organized by business line, and with the acquisition of Alcanna, are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.

Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as “Corporate”.

	Liquor Retail (1)		Cannabis Retail (1)			Cannabis Operations (2)			Investments (3)			Corporate			Total
As at December 31, 2022
Total assets		351,338		200,393			163,130			825,151			19,338			1,559,350
Year ended December 31, 2022
Net revenue		462,180		205,610			44,407			—			—			712,197
Gross margin		106,307		47,334			(13,266	)		—			—			140,375
Interest and fee revenue		—		—			—			16,739			—			16,739
Investment (loss) income		—		—			—			(65,164	)		—			(65,164	)
Share of loss of equity-accounted investees		—		—			—			(43,002	)		—			(43,002	)
Depreciation and amortization		17,025		9,920			199			—			13,801			40,945
Income (loss) before income tax		17,726		(183,055	)		(29,618	)		(127,362	)		(57,461	)		(379,770	)

(1)Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (note 5(a)).

(2)Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (note 5(c)).

(3)Total assets include cash and cash equivalents.

	Liquor Retail		Cannabis Retail (1)			Cannabis Operations			Investments (2)			Corporate			Total
As at December 31, 2021
Total assets (3)		—		157,022			147,887			1,093,596			29,155			1,427,660
Year ended December 31, 2021
Net revenue		—		16,091			40,037			—			—			56,128
Gross margin (3)		—		6,498			(15,499	)		—			—			(9,001	)
Interest and fee revenue		—		—			—			13,149			—			13,149
Investment loss		—		—			—			(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—		—			—			32,913			—			32,913
Depreciation and amortization (3)		—		1,282			3,108			—			897			5,287
Income (loss) before income tax (3)		—		(410	)		(117,990	)		(5,837	)		(110,461	)		(234,698	)

(1)Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021.

(2)Total assets include cash and cash equivalents.

(3)Adjustments to provisional amounts — refer to note 5(b)

Geographical disclosure

As at December 31, 2022, the Company had non-current assets related to investment credit operations in the United States of $519.3 million (December 31, 2021 — $412.9 million). For the year ended December 31, 2022, share of profit of equity-accounted investees related to investment credit operations in the United States was a loss of $43.0 million (year ended December 31, 2021 — gain of $32.9 million).

XML

Restricted Cash

12 Months Ended

Dec. 31, 2022

Restricted Cash [Abstract]

Restricted Cash

7.Restricted cash

As at	December 31, 2022		December 31, 2021
Securities collateral		—		7,773
Captive insurance		19,044		19,240
Other		294		—
		19,338		27,013

Securities collateral is comprised of a cash balance to satisfy margin requirements on the Company’s option trading positions.

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures (note 3).

XML

Marketable Securities

12 Months Ended

Dec. 31, 2022

Marketable Securities Disclosure [Abstract]

Marketable Securities

8.Marketable securities

As at	December 31, 2022			December 31, 2021
Balance, beginning of year		83,724			—
Additions		3,755			158,101
Dispositions		—			(9,663	)
Change in fair value recognized in profit or loss		(65,553	)		(64,714	)
Balance, end of year		21,926			83,724

During the year ended December 31, 2022, proceeds of nil (year ended December 31, 2021 — $29.9 million) were received for dispositions of marketable securities and a gain on disposition of nil (year ended December 31, 2021 — $20.2 million) was recognized (note 26).

Marketable securities have been designated as FVTPL (note 31).

Subsequent to December 31, 2022, the marketable securities held in Valens were converted to SNDL common shares and subsequently cancelled in relation to the Valens acquisition (note 36).

The components of marketable securities are as follows:

As at	December 31, 2022		December 31, 2021
Equity securities		21,926		83,802
Put and call options		—		(78	)
		21,926		83,724

XML

Accounts Receivable

12 Months Ended

Dec. 31, 2022

Subclassifications of assets, liabilities and equities [abstract]

Accounts Receivable

9.Accounts receivable

As at	December 31, 2022		December 31, 2021
Trade receivables		17,558		10,865
Other receivables		5,078		—
		22,636		10,865

The Company has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. Refer to note 31 for credit risk disclosures.

XML

Biological Assets

12 Months Ended

Dec. 31, 2022

Disclosure of reconciliation of changes in biological assets [abstract]

Biological Assets

10.Biological assets

The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:

As at	December 31, 2022			December 31, 2021
Balance, beginning of year		4,410			3,531
Increase in biological assets due to capitalized costs		27,749			25,880
Acquisition		909			—
Net change in fair value of biological assets		(1,309	)		4,708
Transferred to inventory upon harvest		(28,282	)		(29,709	)
Balance, end of year		3,477			4,410

Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.

The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.

Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:

Assumption	Input	Weighted average input				Effect of 10% change ($000s)
		December 31 2022		December 31 2021		December 31 2022		December 31 2021
Yield per square foot of growing space (1)	Grams		48		49		279		435
Average net selling price (2)	$/gram		4.66		4.49		687		1,014
After harvest cost to complete and sell	$/gram		1.27		1.06		187		249

(1)Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

(2)Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

These assumptions are estimates that are subject to volatility in market prices and several uncontrollable factors. The Company’s estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

The Company estimates the harvest yields for cannabis at various stages of growth. As at December 31, 2022, it is estimated that the Company’s biological assets will yield approximately 3,904 kilograms (December 31, 2021 – 5,672 kilograms) of dry cannabis when harvested. During the year ended December 31, 2022, the Company harvested 19,854 kilograms of dry cannabis (year ended December 31, 2021 – 22,784 kilograms).

XML

Inventory

12 Months Ended

Dec. 31, 2022

Classes of current inventories [abstract]

Inventory

11.Inventory

As at	December 31, 2022		December 31, 2021
Retail liquor		82,589		—
Harvested cannabis
Raw materials, packaging and components		4,577		4,354
Work-in-progress		19,927		19,751
Finished goods		7,040		2,966
Retail cannabis		13,373		2,397
Millwork		276		35
		127,782		29,503

During the year ended December 31, 2022, inventories of $558.1 million were recognized in cost of sales as an expense (year ended December 31, 2021 - $50.6 million).

During the year ended December 31, 2022, the Company recognized inventory write downs of $8.9 million (year ended December 31, 2021 - $17.5 million), of which $7.0 million (year ended December 31, 2021 - $17.0 million) was recognized as an impaired and obsolete inventory provision, and $1.9 million (year ended December 31, 2021 - $0.5 million) was included in the change in fair value realized through inventory as the fair value component of the impaired and obsolete inventory provision.

XML

Right Of Use Assets

12 Months Ended

Dec. 31, 2022

Disclosure of quantitative information about right-of-use assets [abstract]

Right Of Use Assets

12.right of use assets

Cost
Balance at December 31, 2020	1,894
Acquisition (note 5(b))	5,730
Additions	579
Dispositions	(165	)
Balance at December 31, 2021	8,038
Acquisition (note 5(a), note5(c))	140,781
Additions	6,103
Tenant inducement allowances	(46	)
Dispositions and remeasurements	12,191
Balance at December 31, 2022	167,067
Accumulated depreciation and impairment
Balance at December 31, 2020	571
Depreciation	897
Dispositions	(147	)
Balance at December 31, 2021	1,321
Depreciation	25,227
Impairment	6,365
Balance at December 31, 2022	32,913
Net book value
Balance at December 31, 2021	6,717
Balance at December 31, 2022	134,154

As at December 31, 2022, the Company recorded impairment losses of right of use assets of $6.4 million with $3.9 million in the cannabis retail reporting segment and $2.5 million in the liquor retail reporting segment. Refer to note 13 for the significant assumptions applied in the impairment test.

XML

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2022

Property, plant and equipment [abstract]

Property, Plant and Equipment

13.Property, plant and equipment

	Land			Production facilities			Leasehold improvements			Equipment			Construction in progress (“CIP”)			Total
Cost
Balance at December 31, 2020		8,640			152,935			2			28,894			8,819			199,290
Acquisition (note 5(b))		—			—			4,169			2,209			—			6,378
Additions		—			467			126			1,975			1,209			3,777
Transfers from CIP		3,748			—			—			—			(3,748	)		—
Dispositions		—			(70	)		(398	)		(301	)		(177	)		(946	)
Balance at December 31, 2021		12,388			153,332			3,899			32,777			6,103			208,499
Acquisition (note 5(a), note5(c))		130			2,982			65,605			44,263			2,369			115,349
Additions		57			256			3,465			5,907			982			10,667
Dispositions		(611	)		(3,844	)		(647	)		(4,025	)		—			(9,127	)
Balance at December 31, 2022		11,964			152,726			72,322			78,922			9,454			325,388
Accumulated depreciation and impairment
Balance at December 31, 2020		—			69,364			—			8,500			5,821			83,685
Depreciation		—			2,503			411			5,438			—			8,352
Impairment		—			60,000			—			—			—			60,000
Dispositions		—			—			—			(10	)		—			(10	)
Balance at December 31, 2021		—			131,867			411			13,928			5,821			152,027
Depreciation		—			1,288			7,212			11,373			—			19,873
Impairment		—			—			7,794			7,415			—			15,209
Dispositions		—			(1,324	)		(610	)		(3,196	)		—			(5,130	)
Balance at December 31, 2022		—			131,831			14,807			29,520			5,821			181,979
Net book value
Balance at December 31, 2021		12,388			21,465			3,488			18,849			282			56,472
Balance at December 31, 2022		11,964			20,895			57,515			49,402			3,633			143,409

During the year ended December 31, 2022, depreciation expense of $6.4 million was capitalized to biological assets and inventory (year ended December 31, 2021 – $4.9 million).

During the year ended December 31, 2022, proceeds of $3.5 million were received for the disposition of the Company’s Merritt facility and a gain on disposal of $0.5 million was recognized. At December 31, 2021, the Merritt facility was classified as assets held for sale.

During the year ended December 31, 2022, proceeds of $3.9 million were received for the disposition of the Company’s Rocky View facility and no gain on disposal was recognized.

During the year ended December 31, 2022, the Company determined that indicators of impairment existed relating to idle machinery and equipment. The estimated recoverable amount of the assets was determined to be nil and an impairment of $2.4 million was recorded. The impairment was recognized in the Company’s cannabis operations reporting segment.

During the year ended December 31, 2022, the Company determined that indicators of impairment existed relating to its retail stores due to underperforming operating results of certain stores. For impairment testing of retail property, plant and equipment and right of use assets, the Company determined that a CGU was defined as each individual retail store. The Company completed impairment tests for each store location determined to have an indicator of potential impairment using a discounted cash flow methodology. The recoverable amounts for each CGU were based on the higher of its estimated value in use (“VIU”) and fair value less costs of disposal (“FVLCD”) using level 3 inputs (refer to note 31 for further discussion of each input level). The significant assumptions applied in the impairment test are described below:

•Cash flows: Estimated cash flows are based on forecasted EBITDA. The forecast is extended to a total of five years based on an analysis of the industry’s expected growth rates, historical and forecast volume changes, and inflation rates, except where a CGU has a defined life due to lease expiration. Management determined forecasted growth rates of sales based on past performance and its expectations of future performance for each location. Expenditures were based upon a combination of historical percentages of revenue, sales growth rates, and contractual lease payments.

•Discount rate: The weighted average cost of capital was estimated to be 12.0% and is based on market capital structure of debt, risk-free rate, equity risk premium, beta adjustment to the equity risk premium based on a review of betas of comparable publicly traded companies, the Company’s historical data, an unsystematic risk premium and after-tax cost of debt based on corporate bond yields.

•Long-term growth rate: Five years of cash flows have been included in the discounted cash flow models. Where a CGU’s lease terms do not define the forecast period, maintainable debt-free net cash flow beyond the forecast period is estimated to approximate the fifth-year cash flows increased by a terminal growth rate of 2.5% and is based on the industry’s expected growth rates, forecast inflation rates and management’s experience.

As at December 31, 2022, the Company recorded impairment losses of property, plant and equipment of $12.8 million with $5.3 million in the cannabis retail reporting segment and $7.5 million in the liquor retail reporting segment.

Due to curtailment in the utilization of a portion of the capacity in the Company’s Olds facility to align cannabis production with current demand estimates, the Company determined that indicators of impairment existed at June 30, 2021. The impairment test for the Company’s Olds CGU used a value in use approach based on internal cash flow estimates at June 30, 2021, and a discount rate of 25%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5-year model taking into account the overall forecasted Canadian cannabis industry market size and the Company’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, there was an impairment of the Company’s Olds CGU of $60.0 million as at June 30, 2021, as the estimated recoverable amount for this CGU of $70.0 million was lower than the respective carrying amount. The estimated value in use for the Company’s Olds CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1% would increase the impairment by approximately $7.3 million. The impairment was recognized in the Company’s cannabis operations reporting segment.

XML

Net Investment In Subleases

12 Months Ended

Dec. 31, 2022

Disclosure Of Net Investment In Subleases [Abstract]

Disclosure of Net Investment in Subleases Explanatory

14.Net investment in subleases

	December 31, 2022			December 31, 2021
Balance, beginning of year		26,562			—
Acquisition (note 5(b))		—			23,801
Additions		1,408			3,951
Finance income		833			573
Rents recovered (payments made directly to landlords)		(4,141	)		(1,713	)
Dispositions and remeasurements		(1,343	)		(50	)
Balance, end of year		23,319			26,562
Current portion		3,701			3,991
Long-term		19,618			22,571

Net investment in subleases represent leased retail stores that have been subleased to certain franchise partners. These subleases are classified as a finance lease as the sublease terms are for the remaining term of the head lease.

XML

Intangible assets

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about intangible assets [abstract]

Intangible Assets

15.Intangible assets

	Brands and trademarks			Franchise agreements		Software		Retail Licenses		Total
Cost
Balance at December 31, 2020		5,445			—		—		—		5,445
Acquisition (note 5(b)) (1)		36,000			10,000		—		—		46,000
Balance at December 31, 2021		41,445			10,000		—		—		51,445
Acquisition (note 5(a))		38,950			—		5,400		750		45,100
Additions		55			—		142		—		197
Dispositions		(50	)		—		—		—		(50	)
Balance at December 31, 2022		80,400			10,000		5,542		750		96,692
Accumulated amortization and impairment
Balance at December 31, 2020		382			—		—		—		382
Amortization (1)		354			561		—		—		915
Balance at December 31, 2021		736			561		—		—		1,297
Amortization		293			1,250		679		—		2,222
Impairment		18,288			—		—		—		18,288
Balance at December 31, 2022		19,317			1,811		679		—		21,807
Net book value
Balance at December 31, 2021		40,709			9,439		—		—		50,148
Balance at December 31, 2022		61,083			8,189		4,863		750		74,885

(1)Adjustment to provisional amounts — refer to note 5(b).

Brands and trademarks are related to intellectual property purchased from Sun 8 Holdings Inc. (“Sun 8”) with a useful life of 15 years, other intellectual property with a useful life of 12 years, intellectual property acquired through the acquisition of Inner Spirit consisting of proprietary rights to brands and trademarks with an indefinite useful life, and intellectual property acquired through the acquisition of Alcanna with an indefinite useful life. The Inner Spirit and Alcanna brands and trademarks were determined to have an indefinite useful life due to the fact that there is no foreseeable limit to the period over which the asset is expected to generate net cash inflows. Franchise agreements consist of intellectual property acquired through the acquisition of Inner Spirit consisting of franchise relationships with a useful life of 8 years. Software is comprised of licenses acquired through the acquisition of Alcanna and are amortized using the straight-line method over the life of the license. Retail licenses acquired through the acquisition of Alcanna have an indefinite life and are therefore not amortized. The retail licenses do not expire, but rather are subject to an administrative extension process each year indefinitely.

During the three months ended September 30, 2022, the Company determined that indicators of impairment existed regarding the Sun 8 intellectual property due to decreasing market competition. The estimated recoverable amount of the intangible asset was determined to be $2.5 million and an impairment of $1.9 million was recorded. The impairment was recognized in the Company’s cannabis operations reporting segment.

At September 30, 2022, the Company recorded impairments to intangible assets with indefinite useful lives of $16.4 million due to changes in circumstances since the date of the Inner Spirit acquisition, mainly caused by the continued oversaturation of the cannabis retail market (note 5(b)).

At December 31, 2022, the Company tested intangible assets with indefinite useful lives and goodwill for impairment based on changes in circumstances since the date of the Alcanna and Nova acquisition, mainly caused by the continued oversaturation of the cannabis retail market (note 5(a)).

XML

Investments

12 Months Ended

Dec. 31, 2022

Disclosure Of Investments [Abstract]

Investments

16.Investments

As at	December 31, 2022		December 31, 2021
Investments at amortized cost		24,493		24,987
Investments at FVTPL		72,761		48,576
		97,254		73,563
Current portion		6,552		3,065
Long-term		90,702		70,498

Investments at fvtpl

Superette

On February 9, 2022, the Company closed an investment in a $5.0 million promissory note with a maturity date of February 9, 2025, and an interest rate of 15% per annum. On August 26, 2022, November 22, 2022 and December 31, 2022, the Company entered into an amended and restated promissory note whereby the Company would advance additional funds up to $8.1 million as part of pre-CCAA advances and debtor-in-possession advances and the maturity date was amended such that the full balance of the promissory note plus accrued interest and advances became due August 30, 2022. On August 31, 2022, the Company announced that, in the context of the initial order obtained by Superette Inc., Superette Ontario Inc. and certain of its subsidiaries (collectively, “Superette”) from the Ontario Superior Court of Justice on August 30, 2022 pursuant to the CCAA proceedings, it had entered into an agreement of purchase and sale with Superette, pursuant to which it proposed to acquire substantially all of the business and assets of Superette. As at December 31, 2022, the Company had advanced an additional $1.8 million under the amended and restated promissory note. Subsequent to December 31, 2022, the Company had advanced an additional $0.3 million under the amended and restated promissory note. The Company has adjusted the fair value of the promissory note downward by $3.7 million during the year ended December 31, 2022 (note 28) to management’s best estimate of the recoverable value of the collateral underlying the security of the promissory note. On February 7, 2023, the Company announced the acquisition of Superette (note 36).

Delta 9

On March 30, 2022, the Company closed an investment in a $10.0 million convertible debenture with Delta 9 Cannabis Inc. with a maturity date of March 30, 2025, and an interest rate of 10% per annum. On August 11, 2022, and again on September 9, 2022, the Company waived compliance under certain covenants in exchange for a requirement to meet additional conditions.

Zenabis

On June 17, 2022, Zenabis Global Inc. (“Zenabis Global”), as well as Zenabis Global’s direct and indirect wholly owned subsidiaries (collectively, the “Zenabis Global Group”), filed a petition with the Québec Superior Court for protection under CCAA. On June 16, 2022 (and amended on July 5, 2022), the Company entered into a purchase agreement pursuant to which the shares of Zenabis Global and all business and assets of the Zenabis Global Group (the “Zenabis Business”) would be acquired by SNDL. On November 1, 2022, the Company announced the acquisition of certain assets and permitted liabilities of Zenabis Global (note 5(c)). The Company has adjusted the fair value of the Zenabis Global senior loan downward by $33.7 million (note 28) to management’s best estimate of the fair value of the Zenabis Global senior loan at November 1, 2022, in accordance with the requirements of IFRS. The Zenabis Global senior loan was extinguished immediately preceding the business combination and forms the consideration transferred (note 5(c)).

Valens

On August 22, 2022, the Company and The Valens Company Inc. (“Valens”) announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) to combine their businesses. Pursuant to the terms of the Valens Arrangement Agreement, the Company will acquire, subject to Valens’ shareholder approval and

customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). In connection with the Valens Arrangement Agreement, the Company and Valens closed a $60.0 million non-revolving term loan facility with a maturity date of December 15, 2023 and an interest rate of 10% per annum. The Valens Transaction closed on January 17, 2023 (note 36).

XML

Equity-Accounted Investees

12 Months Ended

Dec. 31, 2022

Disclosure Of Interests In Other Entities [Abstract]

Equity-Accounted Investees

17.Equity-accounted investees

As at	December 31, 2022		December 31, 2021
Interest in joint venture (A)		519,255		412,858
Interest in associate (B)		—		—
		519,255		412,858

a)Interest in joint venture

SunStream is a joint venture in which the Company has a 50% ownership interest. SunStream is a private company, incorporated under the Business Corporations Act (Alberta), which provides growth capital that pursues indirect investment and financial services opportunities in the global cannabis sector, as well as other investment opportunities.

SunStream is structured as a separate vehicle and the Company has a residual interest in the net assets of SunStream. Accordingly, the Company has classified its interest in SunStream as a joint venture, which is accounted for using the equity-method.

The current investment portfolio of SunStream is comprised of secured debt, hybrid debt and derivative instruments with United States based cannabis businesses. These investments are recorded at fair value each reporting period with any changes in fair value recorded through profit or loss. SunStream actively monitors these investments for changes in credit risk, market risk and other risks specific to each investment.

As at December 31, 2022, the Company had funded $514.7 million out of the total $538.0 million that was originally committed to SunStream. Subsequent to December 31, 2022, the Company contributed $10.9 million to SunStream.

The following table summarizes the carrying amount of the Company’s interest in the joint venture:

	Carrying amount
Balance at December 31, 2020		—
Capital contributions		395,569
Share of net earnings		32,913
Share of other comprehensive income		9,878
Distributions		(25,502	)
Balance at December 31, 2021		412,858
Capital contributions		119,137
Share of net earnings (loss)		(43,002	)
Share of other comprehensive income		31,923
Distributions		(1,661	)
Balance at December 31, 2022		519,255

SunStream is a related party due to it being classified as a joint venture of the Company. Capital contributions to the joint venture and distributions received from the joint venture are classified as related party transactions.

The following table summarizes the financial information of SunStream:

As at	December 31, 2022			December 31, 2021
Current assets (including cash and cash equivalents - 2022: $1.5 million, 2021: $0.2 million)		5,437			789
Non-current assets		509,418			407,860
Current liabilities		(1,146	)		(1,596	)
Net assets (liabilities) (100%)		513,709			407,053
Year ended December 31	2022			2021
Revenue (loss)		(35,046	)		36,203
Profit (loss) from operations		(42,627	)		32,841
Other comprehensive income		31,923			9,878
Total comprehensive income (loss)		(10,619	)		42,747

b)Interest in associate

The Company holds a 25% equity interest in its associate Pathway RX Inc. (“Pathway”). Pathway is a private company focused on developing cannabis-based pharmaceutical drugs to treat symptoms associated with a range of medical cannabis. The carrying amount of the Company’s interest in Pathway is nil.

XML

Accounts Payable and Accrued Liabilities

12 Months Ended

Dec. 31, 2022

Subclassifications of assets, liabilities and equities [abstract]

Accounts Payable and Accrued Liabilities

18.Accounts payable and accrued liabilities

	December 31, 2022		December 31, 2021
Trade payables		9,774		4,172
Accrued and other liabilities		38,379		34,280
		48,153		38,452

XML

Derivative Warrants

12 Months Ended

Dec. 31, 2022

Derivative Warrant Liabilities [Abstract]

Derivative Warrants

19.Derivative warrants

	December 31, 2022			December 31, 2021
Balance, beginning of year		21,700			428
2021 Series A and B Warrants - fair value on issuance		—			62,680
2021 Additional Series A and B Warrants - fair value on issuance		—			38,576
New Warrants - fair value on issuance recognized in profit or loss		—			106,531
Change in fair value recognized in profit or loss		(10,783	)		(28,697	)
Converted to common shares		—			(157,818	)
Acquisition (note 5(a))		85			—
Balance, end of year		11,002			21,700

The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The derivative warrants are classified as a liability due to the Company’s share price being denominated in USD, which creates variability as to the value in CAD when they are exercised. The derivative warrants are recorded as a current liability, however, the Company has no cash obligation nor is there any cash loss with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

The following table summarizes outstanding derivative warrants as at December 31, 2022:

	Exercise price (USD)		Number of warrants		Weighted average contractual life
2020 Series A Warrants (1)		1.77		50,000		2.6
Unsecured Convertible Notes Warrants (1)		1.77		50,000		1.0
New Warrants (2)		2.29		9,833,333		1.6
December 2018 Performance Warrants	CAD 5.51			118,067		1.0
				10,051,400		1.6

(1)The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

(2)The exercise price of the New Warrants was adjusted from USD $15.00 to $2.29 based on the July 26, 2022 Share Consolidation (as defined below) representing a share combination event (note 23(a)).

In connection with the Alcanna Transaction (note 5(a)), the Company acquired warrants previously issued by Nova (the “December 2018 Performance Warrants”) that are classified as a liability.

The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants. The Market Price condition has not been met. As such, the fair value of the December 2018 Performance Warrants was recognized as a warrant liability, inclusive of a probability weighting associated with the performance incentive being met. Under the terms of the warrant agreements, each performance warrant can be exercised for 0.05449 to 0.08174 of a Nova common share (depending on whether performance conditions are met) prior to the expiration date of December 18, 2023, at an exercise price of $5.51 per Nova common share. At December 31, 2022, there were 118,067 December 2018 Performance Warrants outstanding.

XML

Lease Liabilities

12 Months Ended

Dec. 31, 2022

Lease liabilities [abstract]

Lease Liabilities

20.Lease LIABILITIES

	December 31, 2022			December 31, 2021
Balance, beginning of year		33,470			1,440
Acquisition (note 5(a), note5(c))		142,106			29,531
Additions		7,497			4,514
Lease payments		(31,834	)		(2,721	)
Dispositions and remeasurements		10,890			(70	)
Tenant inducement allowances received		1,799			—
Accretion expense		5,903			776
Balance, end of year		169,831			33,470
Current portion		30,206			5,701
Long-term		139,625			27,769

The following table presents the contractual undiscounted cash flows, excluding periods covered by lessee lease extension options that have been included in the determination of the lease term, related to the Company’s lease liabilities as at December 31, 2022:

	December 31, 2022
Less than one year		39,255
One to three years		64,892
Three to five years		48,955
Thereafter		47,468
Minimum lease payments		200,570

The Company has short-term leases with lease terms of 12 months or less as well as low-value leases. As these costs are incurred, they are recognized as general and administrative expense. These costs were immaterial in 2022 and 2021.

XML

Other Liabilities

12 Months Ended

Dec. 31, 2022

Disclosure Of Other Liabilities [Abstract]

Other Liabilities

21.Other liabilities

	December 31, 2022		December 31, 2021
Financial guarantee liability (A)		407		466
Deferred share units liability (B)		2,302		4,039
		2,709		4,505

a)Financial guarantee liability

For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of ECLs in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs (note 28) in the consolidated statement of loss and comprehensive loss.

b)DSU liability

Deferred share units (“DSUs”) are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder, equal to the fair value of the Company’s common shares calculated at the date of such payment, when a director leaves the board. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. Changes in the fair value are recognized within share-based compensation expense (note 24(d)).

XML

Income Taxes

12 Months Ended

Dec. 31, 2022

Major components of tax expense (income) [abstract]

Income Taxes

22.Income taxes

The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in profit and loss for the years ended December 31, 2022, December 31, 2021 and December 31, 2020:

	December 31, 2022			December 31, 2021			December 31, 2020
Loss before taxes		(379,770	)		(234,698	)		(206,317	)
Statutory income tax rates		23.0	%		23.0	%		24.0	%
Expected income tax recovery		(87,347	)		(53,981	)		(49,516	)
Non-deductible share-based compensation		2,508			2,308			1,970
Non-deductible finance expense		—			2			2,130
Revaluation of the fair value of warrant liabilities		(2,461	)		17,902			—
Non-controlling interest		8,167			—			—
Non-deductible portion of capital losses		7,458			5,118			—
Other non-deductible expenses		5,409			610			348
Goodwill impairment		35,919			—			—
Change in tax rates		—			—			1,528
Deferred tax benefits not recognized		23,005			20,127			43,540
Income tax (recovery) expense		(7,342	)		(7,914	)		—

Details of the deferred tax assets (liabilities) are as follows:

	December 31, 2022			December 31, 2021
Deferred tax assets (liabilities):
Inventory		23,329			20,472
Biological assets		(9,451	)		(9,509	)
Net investment in subleases		(5,363	)		(6,119	)
Intangible assets		(16,632	)		—
Lease liabilities		(5,488	)		(8,361	)
Marketable securities		14,981			7,442
Equity-accounted investee		(1,376	)		(3,925	)
Net deferred tax asset (liability)		—			—

Deferred tax assets have not been recognized for the following deductible temporary differences:

	December 31, 2022		December 31, 2021
Unrecognized deductible temporary differences:
Property, plant and equipment		7,413		81,583
Intangible assets		183		(45,256	)
Share issue costs		28,926		23,835
Investments		18,239		3,300
Lease liabilities		193,691		69,865
Financial obligations and other		2,300		4,100
Non-capital losses & scientific research and experimental development		490,326		220,596
Unrecognized deductible temporary differences		741,078		358,023

The movement in deferred income tax liability is as follows:

	December 31, 2022			December 31, 2021
Balance, beginning of year		—			—
Recognized in profit and loss		(7,342	)		(7,914	)
Recognized in other comprehensive income		7,342			7,914
Balance, end of year		—			—

The Company has $490.3 million (December 31, 2021 - $218.5 million) of non-capital losses available for future periods that will expire prior to 2037-2042.

XML

Share Capital and Warrants

12 Months Ended

Dec. 31, 2022

Share Capital And Warrants [Abstract]

Share Capital and Warrants

23.Share capital and warrants

a)Authorized

The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value.

On July 26, 2022, the Board approved a 1 to 10 share consolidation of the Company’s issued and outstanding common shares (the “Share Consolidation”). Each shareholder of record of the Company as of the close of business on the record date of July 25, 2022, received 1 common share for each 10 shares held on such date.

All references to common shares, warrants, derivative warrant liabilities, simple warrants, performance warrants, stock options, RSUs and DSUs (excluding the Nova RSUs and DSUs) have been fully retrospectively adjusted to reflect the Share Consolidation.

b)Issued and outstanding

		December 31, 2022						December 31, 2021
	Note	Number of Shares			Carrying Amount			Number of Shares		Carrying Amount
Balance, beginning of year			206,040,836			2,035,704			91,884,413		762,046
Share issuances			370,179			2,870			95,680,666		977,425
Share issuance costs			—			—			—		(16,371	)
Share repurchases			(4,252,489	)		(41,617	)		—		—
Acquisition	5		32,060,135			287,129			2,443,128		26,216
Convertible debenture settlement			—			—			248,875		2,671
Derivative warrants exercised			—			—			15,214,695		277,136
Warrants exercised			—			—			19,571		178
Employee awards exercised (1)			975,575			8,724			549,488		6,403
Balance, end of year			235,194,236			2,292,810			206,040,836		2,035,704

(1)Included in employee awards exercised are 87,500 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Included in employee awards exercised are 50,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

For the year ended December 31, 2022, the Company purchased and cancelled 4.3 million common shares at a weighted average price of $3.12 (US$2.33) per common share for a total cost of $13.3 million. Accumulated deficit was reduced by $28.3 million, representing the excess of the average carrying value of the common shares over their purchase price.

Subsequent to December 31, 2022, the Company purchased and cancelled 0.5 million common shares at a weighted average price of $2.78 (US$2.04) per common share for a total cost of $1.5 million.

(C)Common share purchase warrants

	Number of Warrants			Carrying Amount
Balance at December 31, 2020		102,400			6,138
Acquisition (note 5(b))		209,783			1,771
Warrants issued		64,000			361
Warrants exercised		(19,571	)		(178	)
Balance at December 31, 2021		356,612			8,092
Warrants expired		(48,000	)		(5,832	)
Balance at December 31, 2022		308,612			2,260

During the year ended December 31, 2022, the warrants issued in relation to the acquisition of a financial obligation expired.

During the year ended December 31, 2021, the Company issued 64,000 warrants to Sun 8 Holdings Inc. (“Sun 8”) with an exercise price of $9.40 per unit, in conjunction with achieving minimum thresholds of revenue derived from the brands or cultivars that the Company acquired from Sun 8 during the year ended December 31, 2019.

During the year ended December 31, 2021, 19,571 warrants that formed part of the contingent consideration from the Inner Spirit Transaction, were exercised resulting in a net payment of $0.2 million representing the difference between the exercise prices and the cash consideration (note 5(b)). The carrying value of the exercised warrants was adjusted from warrants to share capital.

The following table summarizes outstanding warrants as at December 31, 2022:

	Warrants outstanding and exercisable
Issued in relation to	Weighted average exercise price		Number of warrants		Weighted average contractual remaining life (years)
Financial services		45.98		54,400		6.6
Acquired from Inner Spirit (1)		3.37		190,212		1.2
Sun 8		9.40		64,000		3.0
	$	12.13		308,612		2.5

(1)Inner Spirit warrants are exchangeable for 0.00835 SNDL common shares in accordance with the Inner Spirit Transaction consideration (note 5(b)) and have been presented based on the number of SNDL common shares that are issuable.

XML

Share-based Compensation

12 Months Ended

Dec. 31, 2022

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Share-based Compensation

24.Share-based compensation

The Company has a number of share-based compensation plans which include simple and performance warrants, stock options, RSUs and DSUs. Further detail on each of these plans is outlined below. Subsequent to the Company’s initial public offering, the Company established the stock option, RSU and DSU plans to replace the granting of simple warrants and performance warrants.

The components of share-based compensation expense are as follows:

	Year ended December 31
	2022			2021			2020
Equity-settled expense
Simple warrants (A)		1,299			2,899			1,539
Performance warrants (A)		—			361			(42	)
Stock options (B)		78			(14	)		651
Restricted share units (1) (C)		9,423			6,789			4,069
Cash-settled expense
Deferred share units (1)(2) (D)		(1,129	)		2,272			2,349
		9,671			12,307			8,566

(1)For the year ended December 31, 2022, the Company recognized share-based compensation recovery under Nova’s RSU plan of $107 and share-based compensation expense under Nova’s DSU plan of $404.

(2)Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each reporting period. Fluctuations in the fair value are recognized during the period in which they occur.

Equity-settled plans

a)Simple and performance warrants

The Company issued simple warrants and performance warrants to employees, directors and others at the discretion of the Board. Simple and performance warrants granted generally vest annually over a three-year period, simple warrants expire five years after the grant date and performance warrants expire five years after vesting criteria met.

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2022 and the year ended December 31, 2021:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2020		342,460		$	44.13		167,200		$	41.89
Forfeited		(66,880	)		33.62		(20,480	)		54.80
Exercised		(12,000	)		9.38		(8,000	)		10.94
Expired		(4,160	)		34.51		—			0.00
Balance at December 31, 2021		259,420		$	48.60		138,720		$	41.77
Forfeited		(82,400	)		57.77		(15,520	)		37.86
Expired		(11,200	)		6.25		—			0.00
Balance at December 31, 2022		165,820		$	46.91		123,200		$	42.26

The following table summarizes outstanding simple and performance warrants as at December 31, 2022:

	Warrants outstanding						Warrants exercisable
Range of exercise prices	Number of warrants		Weighted average exercise price		Weighted average contractual life (years)		Number of warrants		Weighted average exercise price		Weighted average contractual life (years)
Simple warrants
$6.25 - $9.38		75,340		7.25		1.40		75,340		7.25		1.40
$29.69 - $45.31		27,120		31.26		1.61		26,320		31.02		1.54
$62.50 - $93.75		49,920		63.50		4.05		49,920		63.50		4.05
$125.00 - $375.00		13,440		239.15		4.62		7,040		205.18		3.70
		165,820	$	46.91		2.49		158,620	$	37.68		2.36
Performance warrants
$6.25 - $9.38		45,066		6.71	n/a			45,066		6.71		2.00
$12.50 - $18.75		17,334		15.15	n/a			17,334		15.15		0.93
$29.69 - $45.31		42,400		31.99	n/a			42,400		31.99		1.22
$62.50 - $93.75		9,334		77.68	n/a			1,334		93.75		1.10
$125.00 - $375.00		9,066		282.36	n/a			—		—	n/a
		123,200	$	42.26	n/a			106,134	$	19.28		1.91

b)Stock options

The Company issues stock options to employees and others at the discretion of the Board. Stock options granted generally vest annually in thirds over a three-year period and generally expire ten years after the grant date.

The following table summarizes changes in stock options during the year ended December 31, 2022 and the year ended December 31, 2021:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2020		72,060		$	18.18
Forfeited		(27,500	)		26.05
Expired		(100	)		31.50
Balance at December 31, 2021		44,460		$	13.28
Expired		(100	)		31.50
Balance at December 31, 2022		44,360		$	13.24

The following table summarizes outstanding stock options as at December 31, 2022:

	Stock options outstanding				Stock options exercisable
Exercise prices	Number of options		Weighted average contractual life (years)		Number of options		Weighted average contractual life (years)
$11.50		32,500		7.41		21,667		7.41
$11.90		8,160		7.49		8,160		7.49
$31.50		3,700		5.51		3,025		5.38
		44,360		7.27		32,852		7.24

c)Restricted share units

RSUs are granted to employees and the vesting requirements and maximum term are at the discretion of the Board. RSUs are exchangeable for an equal number of common shares.

The following table summarizes changes in RSUs during the year ended December 31, 2022 and the year ended December 31, 2021:

	RSUs outstanding
Balance at December 31, 2020		165,692
Granted		1,238,152
Forfeited		(158,263	)
Exercised		(491,988	)
Balance at December 31, 2021		753,593
Granted		1,728,557
Forfeited		(175,245	)
Exercised		(925,575	)
Balance at December 31, 2022		1,381,330

Subsequent to December 31, 2022, the Company granted 7.8 million RSUs to employees as part of its long-term incentive program.

Cash-settled plans

d)Deferred share units

DSUs are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder equal to the fair value of the Company’s common shares calculated at the date of such payment. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end.

As at December 31, 2022, the Company recognized a liability of $2.3 million relating to the fair value of cash-settled DSUs (December 31, 2021 – $4.0 million). The liability is included as a non-current liability within other liabilities (note 21).

The following table summarizes changes in DSUs during the year ended December 31, 2022 and the year ended December 31, 2021:

	DSUs outstanding
Balance at December 31, 2020		332,331
Granted		248,919
Exercised		(30,000	)
Balance at December 31, 2021		551,250
Granted		1,216,076
Exercised		(58,943	)
Balance at December 31, 2022		1,708,383

As at December 31, 2022, nil (December 31, 2021 – 0.6 million) DSUs were exercisable.

XML

Gross Revenue

12 Months Ended

Dec. 31, 2022

Revenue [abstract]

Gross Revenue

25.Gross revenue

Liquor retail revenue is derived from the sale of wines, beers and spirits to customers. Cannabis retail revenue is derived from retail cannabis sales to customers, franchise revenue consists of royalty, advertising and franchise fee

revenue, and other revenue consists of millwork, supply and accessories revenue and proprietary licensing. Cannabis revenue is derived from contracts with customers and is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers.

	Year ended December 31
	2022		2021		2020
Liquor retail revenue		462,180		—		—
Cannabis retail revenue
Retail		192,710		10,207		—
Franchise		8,337		4,251		—
Other		4,563		1,633		—
Cannabis retail revenue		205,610		16,091		—
Cannabis revenue
Provincial boards		58,728		41,338		55,315
Medical		9		8		32
Wholesale		3,167		9,842		17,974
Cannabis revenue		61,904		51,188		73,321
Gross revenue		729,694		67,279		73,321

The Company has recognized the following receivables from contracts with customers:

	December 31, 2022		December 31, 2021		December 31, 2020
Receivables, included in 'trade receivables' (note 9)		17,558		10,865		15,786

Receivables from contracts with customers are typically settled within 30 days. As at December 31, 2022, an impairment of $0.6 million (December 31, 2021 – $0.2 million) has been recognized on receivables from contracts with customers (note 31).

XML

Investment Revenue (Loss)

12 Months Ended

Dec. 31, 2022

Investment Revenue (Loss) [Abstract]

Investment Revenue (Loss)

26.Investment revenue (Loss)

	Year ended December 31
	2022		2021		2020
Interest and fee revenue
Interest revenue from investments at amortized cost		3,660		1,654		—
Interest and fee revenue from investments at FVTPL		6,036		8,514		—
Interest revenue from cash		7,043		2,981		—
		16,739		13,149		—

	Year ended December 31
	2022			2021			2020
Investment loss
Realized gains		389			20,213			—
Unrealized (losses) gains (note 8)		(65,553	)		(64,714	)		—
		(65,164	)		(44,501	)		—

XML

Other Operating Expenses

12 Months Ended

Dec. 31, 2022

Expenses by nature [abstract]

Other Operating Expenses

27.Other operating expenses

a)General and administrative

	Year ended December 31
	2022		2021 (1)		2020
Salaries and wages		80,134		18,675		11,634
Consulting fees		1,934		1,112		2,193
Office and general		37,061		7,560		9,843
Professional fees		11,563		6,530		4,658
Merchant processing fees		4,748		—		—
Director fees		472		351		365
Other		4,256		3,815		3,336
		140,168		38,043		32,029

(1)Adjustment to provisional amounts — refer to note 5(b).

b)Sales and marketing

	Year ended December 31
	2022		2021		2020
Marketing		7,308		3,671		4,839
Events		102		191		393
Research		—		43		57
Media		1,007		1,138		448
		8,417		5,043		5,737

XML

Finance Costs

12 Months Ended

Dec. 31, 2022

Disclosure Of Finance Cost [Abstract]

Finance Costs

28.Finance costs

	Year ended December 31
	2022			2021			2020
Cash finance expense
Interest on long-term debt		—			—			7,482
Other finance costs		178			40			286
		178			40			7,768
Non-cash finance expense (income)
Change in fair value of investments at FVTPL		36,087			3,300			—
Accretion on lease liabilities		5,903			776			89
Financial guarantee liability (recovery) expense		(59	)		59			—
Accretion		—			—			1,622
Amortization of debt issue costs		—			—			1,782
Change in fair value of convertible notes		—			—			(7,141	)
Other		89			154			(86	)
		42,020			4,289			(3,734	)
Interest income		(884	)		(573	)		(215	)
		41,314			3,756			3,819

XML

Supplemental Cash Flow Disclosures

12 Months Ended

Dec. 31, 2022

Supplemental Cash Flow Disclosure [Abstract]

Supplemental Cash Flow Disclosures

29.Supplemental cash flow disclosures

	Year ended December 31
	2022			2021			2020
Cash provided by (used in):
Accounts receivable		(5,815	)		9,339			(2,037	)
Biological assets		533			3,829			13,789
Inventory		4,243			(18,318	)		(12,315	)
Prepaid expenses and deposits		5,782			(3,922	)		2,280
Investments		918			(402	)		—
Right of use assets		(17,510	)		—			—
Property, plant and equipment		38			(305	)		—
Accounts payable and accrued liabilities		(27,864	)		9,665			(20,793	)
Lease liabilities		19,296			—			—
		(20,379	)		(114	)		(19,076	)
Changes in non-cash working capital relating to:
Operating		(22,073	)		150			(5,259	)
Investing		74			(612	)		(11,319	)
Financing		1,620			348			(2,498	)
		(20,379	)		(114	)		(19,076	)
Cash interest paid		—			—			6,094

XML

Loss Per Share

12 Months Ended

Dec. 31, 2022

Earnings per share [abstract]

Loss Per Share

30.Loss per share

	Year ended December 31
	2022			2021			2020
Weighted average shares outstanding (000s)
Basic and diluted (1)		229,871			186,038			21,865
Continuing operations
Net loss attributable to owners of the Company		(335,114	)		(226,984	)		(199,619	)
Per share - basic and diluted	$	(1.46	)	$	(1.22	)	$	(9.13	)
Discontinued operations
Net loss attributable to owners of the Company		—			—			(33,627	)
Per share - basic and diluted	$	—		$	—		$	(1.54	)
Net loss attributable to owners of the Company		(335,114	)		(226,984	)		(233,246	)
Per share - basic and diluted	$	(1.46	)	$	(1.22	)	$	(10.67	)

(1)For the year ended December 31, 2022, there were 0.3 million equity classified warrants, 10.1 million derivative warrants, 0.2 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 1.4 million RSUs that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2021 – 0.4 million equity classified warrants, 9.9 million derivative warrants, 0.3 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 0.8 million RSUs, year ended December 31, 2020 – 0.1 million equity classified warrants, 0.2 million derivative warrants, 0.3 million simple warrants, 0.2 million performance warrants, 0.07 million stock options and 0.2 million RSUs).

XML

Financial Instruments

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about financial instruments [abstract]

Financial Instruments

31.Financial instruments

The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, investments at amortized cost, investments at FVTPL, accounts payable and accrued liabilities and derivative warrants.

a)Fair value

The carrying value of cash and cash equivalents, restricted cash, accounts receivable and accounts payable and accrued liabilities approximate their fair value due to the short-term nature of the instruments. The carrying value of investments at amortized cost approximate their fair value as the fixed interest rates approximate market rates for comparable transactions.

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows:

			Fair value measurements using
December 31, 2022	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		21,926		21,926		—		—
Investments at FVTPL		72,761		—		—		72,761
Financial liabilities
Derivative warrants (1)		11,002		—		—		11,002
			Fair value measurements using
December 31, 2021	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		83,724		83,724		—		—
Investments at FVTPL		48,576		—		—		48,576
Financial liabilities
Derivative warrants (1)		21,700		—		—		21,700

(1)The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Marketable securities are designated as FVTPL. The fair value of marketable securities is re-measured each reporting period with changes in fair value recognized in profit and loss. The fair value of marketable securities is estimated by using current quoted prices in active markets for identical assets.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

As at December 31, 2022, the Company did not have any financial instruments measured at Level 2 fair value.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Investments designated as FVTPL are re-measured each reporting period with changes in the fair value recognized in profit and loss within finance costs. The fair values of the investments were estimated by using a discounted

cash flow analysis. The main assumptions used in the calculation were the determination of a credit-adjusted discount rate.

Derivative warrants are designated as FVTPL. The fair value of derivative warrants is re-measured each reporting period with changes in fair value recognized in profit and loss within finance costs. The fair value of derivative warrants is estimated by using a valuation model. Assumptions used in these calculations include volatility, discount rate and various probability factors.

At December 31, 2022, a 10% change in the material assumptions would change the estimated fair value of derivative warrant liabilities by approximately $1.3 million.

There were no transfers between Levels 1, 2 and 3 inputs during the year.

b)Credit risk management

Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its investments by ensuring the agreements governing the investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company.

The Company applies the simplified approach under IFRS 9 to accounts receivable and has calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions.

Impairment losses on accounts receivable recognized in profit or loss were as follows:

As at	December 31, 2022		December 31, 2021
Impairment loss (reversal) on trade receivables		642		214
Impairment loss (reversal) on other receivables		674		798
		1,316		1,012

The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2022 was as follows:

	December 31, 2022		December 31, 2021
Balance, beginning of year		1,132		120
Net remeasurement of impairment loss allowance		1,316		1,012
Balance, end of year		2,448		1,132

The Company applies the general approach under IFRS 9 to investments, which is an assessment of whether the credit risk of a financial instrument has increased significantly since initial recognition. The general approach compares the risk of a default occurring at the reporting date with the risk of a default occurring at the date of initial recognition. The Company has evaluated the credit risk of its investments, taking into consideration the risk of default, historical credit loss experience, financial factors specific to the debtors and general economic conditions and determined the expected credit loss to be $0.5 million for the year ended December 31, 2022.

The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable and investments. The Company attempts to mitigate such exposure to its cash by investing only in financial institutions with investment grade credit ratings or secured investments.

c)Market risk management

Market risk is the risk that changes in market prices will affect the Company’s income or value of its holdings of financial instruments. The Company is exposed to market risk in that changes in market prices will cause fluctuations

in the fair value of its marketable securities. The fair value of marketable securities is based on quoted market prices as the Company’s marketable securities are shares held of publicly traded entities and put and call options.

At December 31, 2022, a 10% change in the market prices would change the fair value of marketable securities by approximately $2.1 million.

The Company had no risk management contracts relating to marketable securities outstanding as at December 31, 2022.

d)Liquidity risk management

Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary.

The timing of expected cash outflows relating to financial liabilities at December 31, 2022 is as follows:

	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		48,153		—		—		—		48,153
Financial guarantee liability (note 21)		—		407		—		—		407
Balance, end of year		48,153		407		—		—		48,560

XML

Related Party Transactions

12 Months Ended

Dec. 31, 2022

Related party transactions [abstract]

Related Party Transactions

32.Related party transactions

The Company entered into the following related party transactions during the periods noted, in addition to those disclosed in note 17 relating to the Company’s joint venture.

A member of key management personnel jointly controls a company that owns property leased to SNDL for one of its retail liquor stores. The lease term is from November 1, 2017 to October 31, 2027 and includes extension terms from November 1, 2027 to October 31, 2032 and November 1, 2032 to October 31, 2037. Monthly rent for the location includes base rent, common area costs and sign rent. The rent amounts are subject to increases in accordance with the executed lease agreement. Subsequent to the Alcanna Transaction and for the period March 31, 2022 to December 31, 2022, the Company paid $117.9 thousand in total rent with respect to this lease.

Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2022		2021		2020
Salaries and short-term benefits		4,505		2,348		1,944
Share-based compensation		5,871		8,275		7,629
		10,376		10,623		9,573

XML

Capital Management

12 Months Ended

Dec. 31, 2022

Disclosure of objectives, policies and processes for managing capital [abstract]

Capital Management

33.Capital management

The Company defines capital as shareholders’ equity and debt. Except as otherwise disclosed in these consolidated financial statements, there are no restrictions on the Company’s capital. The Company’s objectives with respect to the management of capital are to:

•Maintain financial flexibility in order to preserve the ability to meet financial obligations;

•Deploy capital to provide an appropriate investment return to shareholders; and

•Maintain a capital structure that allows various financing alternatives.

XML

Non-Controlling Interests

12 Months Ended

Dec. 31, 2022

Disclosure of Non Controlling Interests [Abstract]

Non-Controlling Interests

34.Non-controlling interests

The following tables provide summarized financial information for the Company’s subsidiary, Nova, that has a material non-controlling interest effective the date of closing of the Alcanna Transaction, before inter-company eliminations. The Company does have subsidiaries with non-material non-controlling interests that are not presented in the following financial information.

a)Nova summarized statement of financial position

	2022
Current assets		18,732
Current liabilities		19,892
Current net assets		(1,160	)
Non-current assets		94,419
Non-current liabilities		45,443
Non-current net assets		48,976
Net assets		47,816

b)Nova summarized statement of loss and comprehensive loss

	2022
Revenue		176,588
Loss and comprehensive loss		(7,672	)

c)Nova summarized statement of cash flows

	2022
Net cash provided by operating activities		5,848
Net cash used in investing activities		(5,549	)
Net cash used in financing activities		(183	)
Increase in cash		116

XML

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Disclosure Of Commitments And Contingencies [Abstract]

Commitments and contingencies

35.Commitments and contingencies

a)Commitments

The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2022 of $2.5 million (December 31, 2021 - $2.5 million).

b)Contingencies

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of our business. Such proceedings, certain of which have been threatened against us, could include commercial litigation related to breach of contract claims brought by our customers, franchise partners, suppliers and contractors, as well as litigation related to termination of certain of our employees. The outcome of any litigation is inherently uncertain. Although we believe we have meritorious defenses against all currently pending and threatened proceedings and intend to vigorously defend all claims if they are brought, unfavorable rulings, judgements or settlement terms could have an adverse impact on our business and results of operations.

In connection with our initial public offering (“IPO”), we and certain of our current and former officers and directors, as well as the underwriters of our IPO, were named as defendants in several putative shareholder class action lawsuits filed between September 9, 2019 and November 1, 2019. The cases were consolidated in two separate actions depending on the court in which they were first filed, one in the Supreme Court of New York, New York County, captioned In re SNDL Inc. Securities Litigation, Index No. 655178/2019 (the “New York IPO Action”), and the other in the United States District Court for the Southern District of New York, captioned In re SNDL Inc. Securities Litigation, Master Case No. 1:19-cv-08913-ALC (the “Federal IPO Action”). The complaints in each of the two consolidated actions asserted claims under Sections 11, 12(a)(2), and 15 of the U.S. Securities Act of 1933, as amended (the “Securities Act”). They generally alleged that we made material misstatements and omissions in the prospectus and registration statement in connection with the IPO with respect to, among other things, the failure to disclose systemic quality control issues as well as the return of cannabis and termination of the supply agreement by one of the Company’s customers. The complaint in the Federal IPO Action also included allegations that we made misstatements as to revenue. The New York IPO Action was dismissed on May 15, 2020 and the dismissal was affirmed on February 16, 2021, by the Appellate Division, First Judicial Department, of the Supreme Court of New York.

In the Federal IPO Action, the court denied defendants’ motion to dismiss on March 30, 2021. On August 27, 2021, following a mediation, the parties notified the court that they had reached an agreement in principle to settle the Federal IPO Action. On December 2, 2021, the parties executed a settlement agreement, which was submitted to the court for approval on December 3, 2021. On October 5, 2022, the court entered an order and final judgement approving the settlement.

In addition, on May 7, 2020, the Company and certain of its current and former directors and officers were named as defendants in a lawsuit, captioned SUN, a Series of E Squared Investment Fund, LLC et al. v. SNDL Inc. et al., Case No. 1:20-cv-03579-ALC, in the United States District Court for the Southern District of New York. The complaint asserted claims for alleged violations of U.S. federal securities laws, including Sections 12(a)(2) and 15 of the Securities Act and Section 10(b) the Exchange Act, as well as claims for breach of contract, fraud in the inducement and negligent misrepresentation. Among other things, the complaint alleged that the Company made misrepresentations regarding the licensing and ability of Bridge Farm to export hemp and CBD to Europe, as well as regarding the quality of the Company’s cannabis. On September 30, 2021, the court granted defendants’ motion to dismiss and dismissed the case, dismissing the claims under the U.S. federal securities laws with prejudice and the remaining claims without prejudice.

XML

Subsequent Events

12 Months Ended

Dec. 31, 2022

Disclosure of non-adjusting events after reporting period [abstract]

Subsequent events

36.Subsequent events

Valens Acquisition

On August 22, 2022, the Company and The Valens Company Inc. (“Valens”) announced that they had entered into an arrangement agreement (the “Valens Arrangement Agreement”) pursuant to which the Company would acquire, subject to Valens’ shareholder approval and customary closing conditions, all of the issued and outstanding common shares of Valens, other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the “Valens Transaction”). Concurrently with the execution of the Valens Arrangement Agreement, the Company assumed Valens’ non-revolving term loan facility from its then-existing lender, and amended and restated the related credit agreement to provide for a $60.0 million non-revolving term loan facility with a maturity date of December 15,

2023 and an interest rate of 10% per annum (the “Valens Facility”). As Valens is now a wholly-owned subsidiary of the Company, the Valens Facility became inter-company debt following the closing of the Valens Transaction. The Valens Transaction closed on January 17, 2023.

The Valens Transaction consideration was comprised of (i) the assumption of Valens’ $60 million non-revolving term loan facility from its then existing lender, as described above, and (ii) an aggregate 27.6 million SNDL common shares valued at $84.0 million based on the fair value of each common share of the Company on the closing date (0.3334 of a SNDL common share for each Valens common share).

Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and recreational consumer segments. Valens also distributes medicinal cannabis products to Australia through its subsidiary Valens Australia Pty Ltd. (“Valens Australia”). Additionally, Valens manufactured, distributed, and sold a wide range of CBD products in the United States through its subsidiary Green Roads, Inc. (“Green Roads”), prior to the Valens Transaction. Green Roads filed for bankruptcy in the United States on March 6, 2023. The Company has provided a superpriority secured debtor-in-possession line of credit to Green Roads in the amount of USD $1.75 million.

Due to the proximity of the closing of the Valens Transaction and the date of issuance of the consolidated financial statements, the Company has not yet prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

Superette Acquisition

On February 7, 2023, the Company announced that, in the context of the Superette Group’s (as defined below) proceedings under the CCAA, it had successfully closed the Superette Transaction (as defined below) contemplated by the agreement of purchase and sale dated August 29, 2022 (as amended and restated on December 12, 2022) (the “APS”) and the approval and vesting order issued by the Ontario Superior Court of Justice (Commercial List) on December 20, 2022.

The Superette Group sells cannabis and non-cannabis branded merchandise and has furthered its market exposure and brand awareness through private-label cannabis offerings. Pursuant to the APS, certain of the Superette entities, including Superette Inc. and Superette Ontario Inc. (“Superette Ontario”) (collectively, the “Superette Group”), have sold their right, title and interest in (i) the five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand (the “Superette IP”); and (iii) the shares of Superette Ontario (collectively, the “Superette Transaction”).

Pursuant to applicable laws and regulatory considerations, SNDL directed that the shares of Superette Ontario be transferred to Spirit Leaf Ontario Inc. (“SLO”). SNDL has entered into an option agreement with SLO to purchase all of the issued and outstanding shares of Superette Ontario if certain conditions are met, including compliance with regulatory considerations. The retail location s and intellectual property were transferred to Superette Ontario to assist in operating the retail locations and the Superette IP was transferred to SNDL directly. Certain of the Superette IP will be licensed by SNDL to SLO to allow it to use the Superette brand in the retail locations.

Due to the proximity of the closing of the Superette Transaction and the date of issuance of the consolidated financial statements, the Company has not yet prepared the acquisition date fair value of the total consideration transferred or the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed.

LIGHTBOX Acquisition

On March 28, 2023, the Company announced that it had entered into an agreement (the “Lightbox Agreement”) with Lightbox Enterprises Ltd. (“Lightbox”) to acquire four cannabis retail stores operating under the Dutch Love Cannabis banner (“Dutch Love”). Under the Lightbox Agreement, SNDL will acquire from Lightbox the rights to four Dutch Love stores and the rights to use certain Dutch Love related intellectual property for total consideration of $7.8 million. The

consideration is comprised of i) $1.5 million cash; ii) the cancellation of the $3.0 million debt owed by Lightbox to SNDL; and iii) $3.3 million payable in common shares of SNDL.

The transaction is expected to be completed in the context of Lightbox's proceedings under the CCAA from the Supreme Court of British Columbia (the “BC Court”). On December 2, 2022, the BC Court granted an order that approved a sale and investment solicitation process (“SISP”) in respect of the assets, undertakings and properties of Lightbox, and the Agreement is the result of the SISP process.

The transaction is anticipated to close by the end of May 2023.

XML

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Disclosure Of Significant Accounting Policies [Abstract]

Cash and cash equivalents

CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.

Restricted cash

RESTRICTED CASH

Restricted cash is recorded as current assets representing (i) a cash balance to satisfy margin requirements on the Company’s option trading positions, if any, and (ii) minimum funding requirements for two separate captive insurance structures.

Biological assets

BIOLOGICAL ASSETS

The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour-related costs, consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less costs to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with International Accounting Standard 41 – Agriculture (“IAS 41”) and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices, market conditions, yields and costs, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

Inventory

INVENTORY

Harvested cannabis

Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less costs to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labour-related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value.

The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory.

Retail inventory

Retail inventory at Company-owned stores is valued at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of selling the final product. Cost is determined using the weighted average method and comprises direct purchase costs. Inventory is written down to its net realizable value when the cost of inventory is estimated to be unrecoverable due to obsolescence, damage or declining selling prices. The Company makes estimates related to obsolescence, future selling prices, seasonality, customer behavior and fluctuations in inventory levels.

Property, plant, and equipment

PROPERTY, PLANT, AND EQUIPMENT

Property, plant and equipment (“PP&E”) are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of PP&E with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of PP&E is capitalized, the carrying amount of the replaced component is derecognized.

Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s licence is granted. The assets’ residual values and useful lives are reviewed, and adjusted as appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates.

Any gain or loss arising on the disposal or retirement of a component of PP&E is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in profit and loss.

PP&E are depreciated as they become available for use. Buildings are not depreciated until a producer’s licence is obtained, if required for operation. For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

•Production facilities — 20 years

•Equipment — 1 to 10 years

•Right of use assets and leasehold improvements — Shorter of estimated useful life or lease term

Intangible assets

INTANGIBLE ASSETS

Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available

for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with International Accounting Standard 38 – Intangible Assets (“IAS 38”).

The Company’s intangible assets are comprised of the following:

•Intellectual property purchased from Sun 8 Holdings Inc. in 2019 consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years.

•Intellectual property purchased from a private company consisting of world-wide proprietary rights to certain cannabis strains with a useful life of 12 years.

•Intellectual property acquired through the acquisition of Inner Spirit (as defined below) consisting of a trade name with an indefinite life and franchise agreements with useful lives of 8 years.

•Intangible assets acquired through the acquisition of Alcanna consisting of brands, licenses, permits and software.

Joint arrangements

Joint arrangements

Joint arrangements represent activities where the Company has joint control established by a contractual agreement. Joint control requires unanimous consent for the relevant financial and operational decisions. A joint arrangement is either a joint operation, whereby the parties have rights to the assets and obligations for the liabilities, or a joint venture, whereby the parties have rights to the net assets.

For a joint operation, the parties consolidate their proportionate share of the assets, liabilities, revenues, expenses and cash flows of the arrangement with items of a similar nature on a line-by-line basis, from the date that joint control commences until the date that joint control ceases.

Joint ventures are accounted for using the equity method of accounting and are initially recognized at cost, or fair value if acquired as part of a business combination. Joint ventures are adjusted thereafter for the post-acquisition change in the Company's share of the equity accounted investment's net assets. The Company’s consolidated financial statements include its share of the equity accounted investment's profit or loss and other comprehensive income, until the date that joint control ceases. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest, including any long-term investments, is reduced to nil, and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. Distributions from and contributions to investments in equity accounted investees are recognized when received or paid.

Interests in equity-accounted investees

Interests in equity-accounted investees

The Company’s interest in equity-accounted investees comprise interests in an associate and a joint venture.

Associates are those entities in which the Company has significant influence, but not control or joint control, over the financial and operating policies. A joint venture is an arrangement in which the Company has joint control, whereby the Company has rights to the net assets of the arrangement, rather than rights to assets and obligations for its liabilities.

Interests in associates and joint ventures are accounted for using the equity method. They are initially recognized at cost, which includes transaction costs. Subsequent to initial recognition, the consolidated financial statements include the Company’s share of the profit or loss and OCI of equity-accounted investees, until the date on which significant influence or joint control ceases.

Impairment of assets

IMPAIRMENT OF ASSETS

Management assesses and continually monitors internal and external indicators of impairment relating to the Company’s assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining and maintaining future licences from Health Canada, the demand for cannabis for recreational purposes, the price of cannabis, and changes in market discount rates.

(i)Financial assets

The Company applies an expected credit loss (“ECL”) model to all financial assets not held at fair value through profit and loss (“FVTPL”) where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, the Company has applied the simplified approach under International Financial Reporting Standard 9 – Financial Instruments (“IFRS 9”) and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECLs are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow the Company expects to receive. ECLs are discounted at the effective interest rate of the financial asset. For financial assets measured at amortized cost, the Company has applied the general approach under IFRS 9 and has calculated ECLs based on lifetime expected credit losses, taking into consideration whether the credit risk of a financial asset has increased significantly since initial recognition. When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers quantitative and qualitative information and analysis, based on the Company’s historical experience and informed credit assessment, that includes forward-looking information.

(ii)Non-financial assets

The carrying amounts of the Company’s PP&E, right of use assets and intangible assets, including goodwill, are assessed for impairment indicators and impairment reversal indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment or impairment reversal. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss or impairment reversal, if any.

An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of asset’s estimated fair value less costs of disposal and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit (“CGU”)).

Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset or CGU is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized previously. A reversal of an impairment loss, net of any depreciation that would have been recorded, is recognized immediately in the statements of loss and comprehensive loss. Impairments of goodwill are not reversed.

Financial instruments

FINANCIAL INSTRUMENTS

The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments:

Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance.

(i)Financial assets

At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or fair value through other comprehensive income (“FVOCI”) depending on the business model and contractual cash flows of the instrument.

Financial assets at amortized cost are subsequently measured at amortized cost using the effective interest rate method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in profit or loss.

The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s marketable securities are measured at FVTPL. The Company’s long-term investments are measured at amortized cost and FVTPL. The Company has no financial assets measured at FVOCI.

(ii)Financial liabilities

Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method.

Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense and foreign exchange gains and losses, are recognized in profit or loss.

Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in profit or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt.

The Company’s accounts payable and accrued liabilities and financial guarantee liability are measured at amortized cost. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition.

Provisions

Provisions

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. The amount of a provision is the best estimate of the consideration at the end of

the reporting period. Provisions measured using estimated cash flows required to settle the obligation are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The Company has no onerous contracts during the years ended and as at December 31, 2022 and 2021.

Non-monetary transactions

NON-MONETARY TRANSACTIONS

All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.

Compound financial instruments

COMPOUND FINANCIAL INSTRUMENTS

The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition.

Interest and losses and gains relating to the financial liability are recognized in profit and loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.

Revenue

REVENUE

Under International Financial Reporting Standard 15 – Revenue from Contracts with Customers (“IFRS 15”), to determine the amount and timing of revenue to be recognized, the Company follows a five-step model:

1.Identifying the contract with a customer

2.Identifying the performance obligations

3.Determining the transaction price

4.Allocating the transaction price to the performance obligations

5.Recognizing revenue when/as performance obligations are satisfied

Cannabis revenue

Gross revenue from the direct sale of cannabis for a fixed price is recognized when the Company transfers control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods.

For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory

less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly.

Gross revenue earned in Canada includes excise taxes, which the Company pays as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing.

Retail revenue

Retail revenue consists of sales through corporate stores and e-commerce operations. Revenue at corporate stores is recognized at the point of sale when the customer takes control of the goods or service and is measured at the amount of consideration to which the Company expects to be entitled to, net of estimated returns, and sales incentives. The Company considers its performance obligations to be satisfied at the point of sale. The Company’s goods and services are generally capable of being distinct and are accounted for as a separate performance obligation. Sales through e-commerce operations are recognized when the customer takes control of the goods or services upon delivery and is measured at the amount of consideration to which the Company expects to be entitled, net of estimated returns, and sales incentives.

It is the Company’s policy to sell merchandise with a limited right to return. Returns are only provided through exchanges or the issuance of a gift card.

The Company sells gift cards. The sale of a gift card creates a future performance obligation. When (or as) the performance obligation is satisfied, the Company recognizes revenue as the amount of the transaction price.

Franchise revenue

Franchise fees are recognized at a point in time when the Company satisfies its performance obligations which is determined to be when the franchise begins operations. Performance obligations include site selection, lease assistance and training. Initial franchise fees are allocated to the performance obligations based on the estimated standalone selling prices. Funds received in advance of a franchise starting operations are recorded as franchise fee deposits.

Ongoing royalty and advertisement fees, which are determined on a formula basis in accordance with the terms of the relevant franchise agreement, based on monthly revenues of the franchisees, are recognized as revenue when the contractual performance obligations have been achieved or other service-related performance obligations have been completed. The performance obligations relate to providing support to the franchise partners and stewarding the Spiritleaf brand. While the franchisees are operating under the name Spiritleaf, they utilize the Spiritleaf trademark, thereby, the Company has performed its obligations to recognize the revenue, as per the franchise agreements.

Other revenue

Proprietary licensing revenue is generated from proprietary licensing services provided to customers. Revenue is recognized when the services are delivered to the customer at a point in time as outlined by the contract. The Company does not operate or manage these services separately from its primary retail sales or operations.

Millwork revenue is defined as the proceeds and receivables related to the sale of millwork, which includes store fixtures. Millwork revenue is recognized at a point in time when a contractual exchange agreement has been entered into, and the performance obligation is considered to have been met when the millwork has been delivered to the franchise partner.

Supply revenue represents revenues earned from the sales of custom Spiritleaf accessories to franchise locations. The Spiritleaf accessory revenue is earned when the goods are shipped.

Research and development

RESEARCH AND DEVELOPMENT

Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization per IAS 38. Research and development costs comprise consulting fees, costs to cultivate and test cultivar batches to the point of commercialization and licence acquisition fees. No development costs have been capitalized as at December 31, 2022, or December 31, 2021.

Share-based compensation

SHARE-BASED COMPENSATION

The Company’s share-based compensation plans include equity-settled awards and cash-settled awards.

The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted.

Equity-settled

Simple and performance warrants, stock options and restricted share units (“RSUs”) are granted from time to time to employees, directors, and others at the discretion of the Board. The grant date fair value of simple warrants, performance warrants, stock options and RSUs is recognized as share-based compensation expense, with a corresponding increase in contributed surplus, over the vesting period of the awards. On exercise of simple warrants, performance warrants and stock options, the cash consideration received is credited to share capital and the associated amount in contributed surplus is reclassified to share capital. On exercise of RSUs, the associated amount in contributed surplus is reclassified to share capital.

Cash-settled

DSUs are granted to directors and represent a right for the holder to receive a cash payment equal to the fair value of the Company’s common shares calculated at the date of such payment.

Nova DSUs are granted to Nova directors and represent a right for the holder to receive a cash payment equal to the fair value of Nova’s common shares calculated at the date of such payment, or Nova common shares, at the discretion of Nova.

DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. The fair value is recognized as share-based compensation over the vesting period. Fluctuations in the fair value are recognized within share-based compensation in the period in which they occur.

Income taxes

INCOME TAXES

Income taxes are recognized in profit and loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity.

Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and include any adjustment to income tax payable or recoverable in respect of previous periods.

Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable.

Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted at the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income

(loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized.

Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected.

Business combinations

BUSINESS COMBINATIONS

Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as the fair value of consideration transferred to the sellers, including cash paid and the fair value of assets given, equity instruments issued, and liabilities of the seller assumed at the acquisition date. Any excess of the fair value of the consideration paid over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net earnings. Transaction costs associated with business combinations are expensed as incurred.

Fair value of assets acquired and liabilities assumed in a business combination

FAIR VALUE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED IN A BUSINESS COMBINATION

The fair value of assets acquired and liabilities assumed in a business combination, including contingent consideration and goodwill, is estimated based on information available at the date of acquisition. Various valuation techniques are applied for measuring fair value including market comparables and discounted cash flows which rely on assumptions such as future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in these variables could significantly impact the carrying value of the net assets. Specific judgement is required in the identification of intangible assets.

Goodwill

GOODWILL

Goodwill is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in profit and loss. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.

Non-controlling Interests

NON-CONTROLLING INTERESTS

The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.

Loss of control

Loss of control

When the Company loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

Leases

LEASES

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

The Company recognizes a right of use asset and a lease liability at the lease commencement date. The right of use asset is initially measured at cost and any direct costs of obtaining the lease, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease liability. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease liability is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payments made. Lease payments are allocated between the liability and accretion expense. Accretion expense is recognized on the lease liability using the effective interest rate method and payments are applied against the lease liability.

The carrying amounts of the right of use assets, lease liability, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgements including economic environment, term, and the underlying risk inherent to the asset.

As a lessor

When the Company acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers substantially all of the risks and rewards incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease. Under a finance lease, the Company recognizes a receivable at an amount equal to the net investment in the lease which is the present value of the aggregate of lease payments receivable by the lessor. Under an operating lease, the Company recognizes lease payments received as income on a straight-line basis over the lease term. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right of use asset arising from the head lease, not with reference to the underlying asset.

Government grants

GOVERNMENT GRANTS

Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.

Captive insurance

Captive Insurance

The Company has secured insurance coverage for its directors and officers through two separate captive insurance structures.

The first structure is a captive cell program entered into with a registered insurer for the purpose of holding and managing the Company’s coverage funds through a separate cell account (“Cell Captive”). The Company applies International Financial Reporting Standard 10 – Consolidated Financial Statements (“IFRS 10”) in its assessment of

control as it relates to the Cell Captive. The Company’s accounting policy is to consolidate the Cell Captive. The Cell Captive funds are held as cash and may be invested according to the Company’s treasury policy. The funds are disclosed as restricted cash as the Cell Captive must be fully funded at all times. The Company will recognize any gains or losses from fair market value adjustments, interest and/or foreign exchange in the statements of income (loss) and comprehensive income (loss).

The second structure is a wholly owned subsidiary, Sundial Insurance (Bermuda) Ltd. (“SIBL”), incorporated to provide separate and additional coverage. The Company applies IFRS 10 in its assessment of control as it relates to SIBL. The Company’s accounting policy is to consolidate SIBL. The funds are disclosed as restricted cash as the funds were required for initial capitalization of the entity and there is a requirement to maintain minimum capital and surplus in accordance with industry regulations.

New accounting standards

NEW ACCOUNTING STANDARDS

The following accounting standards were effective for annual periods beginning on or after January 1, 2022 and did not have a material impact on the Company’s consolidated financial statements:

•Onerous Contracts — Cost of Fulfilling a Contract — Amendments to IAS 37

•Property, Plant and Equipment: Proceeds before Intended Use — Amendments to IAS 16

There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2023, that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2022. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include:

•Classification of Liabilities as Current or Non-current — Amendment to IAS 1

•IFRS 17 Insurance Contracts

•Definition of Accounting Estimate — Amendments to IAS 8

•Deferred Tax related to Assets and Liabilities arising from a Single Transaction — Amendments to IAS 12

XML

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Significant Accounting Policies [Abstract]

Estimated Use Full Life Of Asset Explanatory

For assets available for use, depreciation is computed using the straight-line method over the estimated useful lives of the assets, as described below:

•Production facilities — 20 years

•Equipment — 1 to 10 years

•Right of use assets and leasehold improvements — Shorter of estimated useful life or lease term

XML

Business Acquisitions (Tables)

12 Months Ended

Dec. 31, 2022

Alcanna

Disclosure of detailed information about business combination [line items]

Summary of Purchase Price Allocated

The fair value of consideration paid was as follows:

	Provisional		Adjustments		Final
Cash		54,339		—		54,339
Issuance of common shares		287,129		—		287,129
		341,468		—		341,468

Summary of Fair Value of Assets and Liabilities Acquired

The fair value of the assets and liabilities acquired was as follows:

	Provisional			Adjustments			Final
Cash		23,190			—			23,190
Accounts receivable		1,868			—			1,868
Prepaid expenses and deposits		10,986			—			10,986
Inventory		105,022			—			105,022
Right of use assets		171,866			(31,117	)		140,749
Property, plant and equipment		86,059			24,632			110,691
Intangible assets		—			45,100			45,100
Goodwill		280,243			(129,308	)		150,935
Accounts payable and accrued liabilities		(36,703	)		(44	)		(36,747	)
Long-term debt		(10,000	)		—			(10,000	)
Lease liabilities		(232,755	)		90,736			(142,019	)
Derivative warrants		(58	)		(27	)		(85	)
Non-controlling interest		(58,250	)		28			(58,222	)
		341,468			—			341,468

Inner Spirit

Disclosure of detailed information about business combination [line items]

Summary of Purchase Price Allocated

The fair value of consideration paid was as follows:

	Provisional		Adjustments		Final
Cash		92,583		—		92,583
Issuance of common shares		26,216		—		26,216
Contingent consideration		1,150		—		1,150
		119,949		—		119,949

Summary of Fair Value of Assets and Liabilities Acquired

The fair value of the assets and liabilities acquired was as follows:

	Provisional			Adjustments			Final
Cash		9,808			—			9,808
Accounts receivable		750			(327	)		423
Prepaid expenses and deposits		853			—			853
Inventory		2,733			2,011			4,744
Right of use assets		—			5,730			5,730
Property, plant and equipment		12,108			(5,730	)		6,378
Intangible assets		—			46,000			46,000
Net investment in subleases		23,751			50			23,801
Goodwill		114,537			(42,041	)		72,496
Accounts payable and accrued liabilities		(2,678	)		—			(2,678	)
Convertible debentures		(12,025	)		—			(12,025	)
Lease liabilities		(29,481	)		(50	)		(29,531	)
Financial guarantee liability		(407	)		—			(407	)
Deferred tax liability		—			(5,643	)		(5,643	)
		119,949			—			119,949

Zenabis

Disclosure of detailed information about business combination [line items]

Summary of Purchase Price Allocated

The fair value of consideration paid was as follows:

	Final
Extinguishment of senior loan		18,215
		18,215

Summary of Fair Value of Assets and Liabilities Acquired

The fair value of the assets and liabilities acquired was as follows:

	Final
Cash		2,509
Accounts receivable		888
Biological assets		909
Prepaid expenses and deposits		1,856
Inventory		4,512
Assets held for sale		6,375
Right of use assets		32
Property, plant and equipment		4,658
Accounts payable and accrued liabilities		(3,437	)
Lease liabilities		(87	)
		18,215

XML

Segment Information (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of operating segments [abstract]

Disclosure of Reportable Segments Explanatory

	Liquor Retail (1)		Cannabis Retail (1)			Cannabis Operations (2)			Investments (3)			Corporate			Total
As at December 31, 2022
Total assets		351,338		200,393			163,130			825,151			19,338			1,559,350
Year ended December 31, 2022
Net revenue		462,180		205,610			44,407			—			—			712,197
Gross margin		106,307		47,334			(13,266	)		—			—			140,375
Interest and fee revenue		—		—			—			16,739			—			16,739
Investment (loss) income		—		—			—			(65,164	)		—			(65,164	)
Share of loss of equity-accounted investees		—		—			—			(43,002	)		—			(43,002	)
Depreciation and amortization		17,025		9,920			199			—			13,801			40,945
Income (loss) before income tax		17,726		(183,055	)		(29,618	)		(127,362	)		(57,461	)		(379,770	)

(1)Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (note 5(a)).

(2)Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (note 5(c)).

(3)Total assets include cash and cash equivalents.

	Liquor Retail		Cannabis Retail (1)			Cannabis Operations			Investments (2)			Corporate			Total
As at December 31, 2021
Total assets (3)		—		157,022			147,887			1,093,596			29,155			1,427,660
Year ended December 31, 2021
Net revenue		—		16,091			40,037			—			—			56,128
Gross margin (3)		—		6,498			(15,499	)		—			—			(9,001	)
Interest and fee revenue		—		—			—			13,149			—			13,149
Investment loss		—		—			—			(44,501	)		—			(44,501	)
Share of profit of equity-accounted investees		—		—			—			32,913			—			32,913
Depreciation and amortization (3)		—		1,282			3,108			—			897			5,287
Income (loss) before income tax (3)		—		(410	)		(117,990	)		(5,837	)		(110,461	)		(234,698	)

(1)Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021.

(2)Total assets include cash and cash equivalents.

(3)Adjustments to provisional amounts — refer to note 5(b)

XML

Restricted Cash (Tables)

12 Months Ended

Dec. 31, 2022

Restricted Cash [Abstract]

Disclosure of Restricted Cash

As at	December 31, 2022		December 31, 2021
Securities collateral		—		7,773
Captive insurance		19,044		19,240
Other		294		—
		19,338		27,013

XML

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2022

Marketable Securities Disclosure [Abstract]

Disclosure of Marketable Securities

As at	December 31, 2022			December 31, 2021
Balance, beginning of year		83,724			—
Additions		3,755			158,101
Dispositions		—			(9,663	)
Change in fair value recognized in profit or loss		(65,553	)		(64,714	)
Balance, end of year		21,926			83,724

Schedule of Components of Marketable Securities

The components of marketable securities are as follows:

As at	December 31, 2022		December 31, 2021
Equity securities		21,926		83,802
Put and call options		—		(78	)
		21,926		83,724

XML

Accounts Receivable (Tables)

12 Months Ended

Dec. 31, 2022

Subclassifications of assets, liabilities and equities [abstract]

Summary of Accounts Receivable

As at	December 31, 2022		December 31, 2021
Trade receivables		17,558		10,865
Other receivables		5,078		—
		22,636		10,865

XML

Biological Assets (Tables)

12 Months Ended

Dec. 31, 2022

Changes in biological assets [abstract]

Summary of Change in Carrying Value of Biological Assets

The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:

As at	December 31, 2022			December 31, 2021
Balance, beginning of year		4,410			3,531
Increase in biological assets due to capitalized costs		27,749			25,880
Acquisition		909			—
Net change in fair value of biological assets		(1,309	)		4,708
Transferred to inventory upon harvest		(28,282	)		(29,709	)
Balance, end of year		3,477			4,410

Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets

Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:

Assumption	Input	Weighted average input				Effect of 10% change ($000s)
		December 31 2022		December 31 2021		December 31 2022		December 31 2021
Yield per square foot of growing space (1)	Grams		48		49		279		435
Average net selling price (2)	$/gram		4.66		4.49		687		1,014
After harvest cost to complete and sell	$/gram		1.27		1.06		187		249

(1)Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

(2)Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

XML

Inventory (Tables)

12 Months Ended

Dec. 31, 2022

Classes of current inventories [abstract]

Summary of Inventories

As at	December 31, 2022		December 31, 2021
Retail liquor		82,589		—
Harvested cannabis
Raw materials, packaging and components		4,577		4,354
Work-in-progress		19,927		19,751
Finished goods		7,040		2,966
Retail cannabis		13,373		2,397
Millwork		276		35
		127,782		29,503

XML

Right Of Use Assets (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of quantitative information about right-of-use assets [abstract]

Schedule of Right Of Use Assets

Cost
Balance at December 31, 2020	1,894
Acquisition (note 5(b))	5,730
Additions	579
Dispositions	(165	)
Balance at December 31, 2021	8,038
Acquisition (note 5(a), note5(c))	140,781
Additions	6,103
Tenant inducement allowances	(46	)
Dispositions and remeasurements	12,191
Balance at December 31, 2022	167,067
Accumulated depreciation and impairment
Balance at December 31, 2020	571
Depreciation	897
Dispositions	(147	)
Balance at December 31, 2021	1,321
Depreciation	25,227
Impairment	6,365
Balance at December 31, 2022	32,913
Net book value
Balance at December 31, 2021	6,717
Balance at December 31, 2022	134,154

XML

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2022

Property, plant and equipment [abstract]

Schedule of Property Plant and Equipment

	Land			Production facilities			Leasehold improvements			Equipment			Construction in progress (“CIP”)			Total
Cost
Balance at December 31, 2020		8,640			152,935			2			28,894			8,819			199,290
Acquisition (note 5(b))		—			—			4,169			2,209			—			6,378
Additions		—			467			126			1,975			1,209			3,777
Transfers from CIP		3,748			—			—			—			(3,748	)		—
Dispositions		—			(70	)		(398	)		(301	)		(177	)		(946	)
Balance at December 31, 2021		12,388			153,332			3,899			32,777			6,103			208,499
Acquisition (note 5(a), note5(c))		130			2,982			65,605			44,263			2,369			115,349
Additions		57			256			3,465			5,907			982			10,667
Dispositions		(611	)		(3,844	)		(647	)		(4,025	)		—			(9,127	)
Balance at December 31, 2022		11,964			152,726			72,322			78,922			9,454			325,388
Accumulated depreciation and impairment
Balance at December 31, 2020		—			69,364			—			8,500			5,821			83,685
Depreciation		—			2,503			411			5,438			—			8,352
Impairment		—			60,000			—			—			—			60,000
Dispositions		—			—			—			(10	)		—			(10	)
Balance at December 31, 2021		—			131,867			411			13,928			5,821			152,027
Depreciation		—			1,288			7,212			11,373			—			19,873
Impairment		—			—			7,794			7,415			—			15,209
Dispositions		—			(1,324	)		(610	)		(3,196	)		—			(5,130	)
Balance at December 31, 2022		—			131,831			14,807			29,520			5,821			181,979
Net book value
Balance at December 31, 2021		12,388			21,465			3,488			18,849			282			56,472
Balance at December 31, 2022		11,964			20,895			57,515			49,402			3,633			143,409

XML

Net Investment In Subleases (Table)

12 Months Ended

Dec. 31, 2022

Disclosure Of Net Investment In Subleases [Abstract]

Disclosure of Detailed Information Net Investment in Subleases Explanatory

	December 31, 2022			December 31, 2021
Balance, beginning of year		26,562			—
Acquisition (note 5(b))		—			23,801
Additions		1,408			3,951
Finance income		833			573
Rents recovered (payments made directly to landlords)		(4,141	)		(1,713	)
Dispositions and remeasurements		(1,343	)		(50	)
Balance, end of year		23,319			26,562
Current portion		3,701			3,991
Long-term		19,618			22,571

XML

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about intangible assets [abstract]

Summary of Reconciliation of Changes in Intangible Assets and Goodwill

	Brands and trademarks			Franchise agreements		Software		Retail Licenses		Total
Cost
Balance at December 31, 2020		5,445			—		—		—		5,445
Acquisition (note 5(b)) (1)		36,000			10,000		—		—		46,000
Balance at December 31, 2021		41,445			10,000		—		—		51,445
Acquisition (note 5(a))		38,950			—		5,400		750		45,100
Additions		55			—		142		—		197
Dispositions		(50	)		—		—		—		(50	)
Balance at December 31, 2022		80,400			10,000		5,542		750		96,692
Accumulated amortization and impairment
Balance at December 31, 2020		382			—		—		—		382
Amortization (1)		354			561		—		—		915
Balance at December 31, 2021		736			561		—		—		1,297
Amortization		293			1,250		679		—		2,222
Impairment		18,288			—		—		—		18,288
Balance at December 31, 2022		19,317			1,811		679		—		21,807
Net book value
Balance at December 31, 2021		40,709			9,439		—		—		50,148
Balance at December 31, 2022		61,083			8,189		4,863		750		74,885

(1)Adjustment to provisional amounts — refer to note 5(b).

XML

Investments (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Investments [Abstract]

Investments Other Than Investments Accounted for Using Equity Method

As at	December 31, 2022		December 31, 2021
Investments at amortized cost		24,493		24,987
Investments at FVTPL		72,761		48,576
		97,254		73,563
Current portion		6,552		3,065
Long-term		90,702		70,498

XML

Equity-Accounted Investees (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Interests In Other Entities [Abstract]

Schedule of Equity Method Investments Table

As at	December 31, 2022		December 31, 2021
Interest in joint venture (A)		519,255		412,858
Interest in associate (B)		—		—
		519,255		412,858

Disclosure of joint ventures

The following table summarizes the carrying amount of the Company’s interest in the joint venture:

	Carrying amount
Balance at December 31, 2020		—
Capital contributions		395,569
Share of net earnings		32,913
Share of other comprehensive income		9,878
Distributions		(25,502	)
Balance at December 31, 2021		412,858
Capital contributions		119,137
Share of net earnings (loss)		(43,002	)
Share of other comprehensive income		31,923
Distributions		(1,661	)
Balance at December 31, 2022		519,255

Summary of Financial Information of SunStream

The following table summarizes the financial information of SunStream:

As at	December 31, 2022			December 31, 2021
Current assets (including cash and cash equivalents - 2022: $1.5 million, 2021: $0.2 million)		5,437			789
Non-current assets		509,418			407,860
Current liabilities		(1,146	)		(1,596	)
Net assets (liabilities) (100%)		513,709			407,053
Year ended December 31	2022			2021
Revenue (loss)		(35,046	)		36,203
Profit (loss) from operations		(42,627	)		32,841
Other comprehensive income		31,923			9,878
Total comprehensive income (loss)		(10,619	)		42,747

XML

Accounts Payable and Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Subclassifications of assets, liabilities and equities [abstract]

Summary of Accounts Payable and Accrued Liabilities

	December 31, 2022		December 31, 2021
Trade payables		9,774		4,172
Accrued and other liabilities		38,379		34,280
		48,153		38,452

XML

Derivative Warrants (Tables)

12 Months Ended

Dec. 31, 2022

Derivative Warrant Liabilities [Abstract]

Summary of Derivative Warrants

	December 31, 2022			December 31, 2021
Balance, beginning of year		21,700			428
2021 Series A and B Warrants - fair value on issuance		—			62,680
2021 Additional Series A and B Warrants - fair value on issuance		—			38,576
New Warrants - fair value on issuance recognized in profit or loss		—			106,531
Change in fair value recognized in profit or loss		(10,783	)		(28,697	)
Converted to common shares		—			(157,818	)
Acquisition (note 5(a))		85			—
Balance, end of year		11,002			21,700

The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The derivative warrants are classified as a liability due to the Company’s share price being denominated in USD, which creates variability as to the value in CAD when they are exercised. The derivative warrants are recorded as a current liability, however, the Company has no cash obligation nor is there any cash loss with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Summary of Outstanding Derivative Warrants

The following table summarizes outstanding derivative warrants as at December 31, 2022:

	Exercise price (USD)		Number of warrants		Weighted average contractual life
2020 Series A Warrants (1)		1.77		50,000		2.6
Unsecured Convertible Notes Warrants (1)		1.77		50,000		1.0
New Warrants (2)		2.29		9,833,333		1.6
December 2018 Performance Warrants	CAD 5.51			118,067		1.0
				10,051,400		1.6

(1)The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

(2)The exercise price of the New Warrants was adjusted from USD $15.00 to $2.29 based on the July 26, 2022 Share Consolidation (as defined below) representing a share combination event (note 23(a)).

XML

Lease Liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Lease liabilities [abstract]

Summary of Lease Liabilities

	December 31, 2022			December 31, 2021
Balance, beginning of year		33,470			1,440
Acquisition (note 5(a), note5(c))		142,106			29,531
Additions		7,497			4,514
Lease payments		(31,834	)		(2,721	)
Dispositions and remeasurements		10,890			(70	)
Tenant inducement allowances received		1,799			—
Accretion expense		5,903			776
Balance, end of year		169,831			33,470
Current portion		30,206			5,701
Long-term		139,625			27,769

Summary of Minimum Lease Payments

The following table presents the contractual undiscounted cash flows, excluding periods covered by lessee lease extension options that have been included in the determination of the lease term, related to the Company’s lease liabilities as at December 31, 2022:

	December 31, 2022
Less than one year		39,255
One to three years		64,892
Three to five years		48,955
Thereafter		47,468
Minimum lease payments		200,570

XML

Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Other Liabilities [Abstract]

Schedule Of Other Liabilities

	December 31, 2022		December 31, 2021
Financial guarantee liability (A)		407		466
Deferred share units liability (B)		2,302		4,039
		2,709		4,505

a)Financial guarantee liability

For franchise operated locations where the Company provided an indemnity for its franchisees, lease payments are made directly to the landlord by the franchisee, and the obligation to make lease payments would only revert to the Company if a franchisee defaulted on their obligations under the terms of the sub-lease or lease. The Company has made an estimate of ECLs in the event of default by the franchisees in making lease payments. This amount is recognized as a financial guarantee liability in the consolidated statement of financial position, and changes in the estimated liability are recognized as a financial guarantee liability expense within finance costs (note 28) in the consolidated statement of loss and comprehensive loss.

b)DSU liability

Deferred share units (“DSUs”) are granted to directors and generally vest in equal instalments over one year. DSUs are settled by making a cash payment to the holder, equal to the fair value of the Company’s common shares calculated at the date of such payment, when a director leaves the board. DSUs are accounted for as a liability instrument and measured at fair value based on the market value of the Company’s common shares at each period end. Changes in the fair value are recognized within share-based compensation expense (note 24(d)).

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Major components of tax expense (income) [abstract]

Summary of Income Tax Expense (Recovery)

The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in profit and loss for the years ended December 31, 2022, December 31, 2021 and December 31, 2020:

	December 31, 2022			December 31, 2021			December 31, 2020
Loss before taxes		(379,770	)		(234,698	)		(206,317	)
Statutory income tax rates		23.0	%		23.0	%		24.0	%
Expected income tax recovery		(87,347	)		(53,981	)		(49,516	)
Non-deductible share-based compensation		2,508			2,308			1,970
Non-deductible finance expense		—			2			2,130
Revaluation of the fair value of warrant liabilities		(2,461	)		17,902			—
Non-controlling interest		8,167			—			—
Non-deductible portion of capital losses		7,458			5,118			—
Other non-deductible expenses		5,409			610			348
Goodwill impairment		35,919			—			—
Change in tax rates		—			—			1,528
Deferred tax benefits not recognized		23,005			20,127			43,540
Income tax (recovery) expense		(7,342	)		(7,914	)		—

Summary of Deferred Tax Assets (Liabilities)

Details of the deferred tax assets (liabilities) are as follows:

	December 31, 2022			December 31, 2021
Deferred tax assets (liabilities):
Inventory		23,329			20,472
Biological assets		(9,451	)		(9,509	)
Net investment in subleases		(5,363	)		(6,119	)
Intangible assets		(16,632	)		—
Lease liabilities		(5,488	)		(8,361	)
Marketable securities		14,981			7,442
Equity-accounted investee		(1,376	)		(3,925	)
Net deferred tax asset (liability)		—			—

Summary of Unrecognized Deductible Temporary Differences

Deferred tax assets have not been recognized for the following deductible temporary differences:

	December 31, 2022		December 31, 2021
Unrecognized deductible temporary differences:
Property, plant and equipment		7,413		81,583
Intangible assets		183		(45,256	)
Share issue costs		28,926		23,835
Investments		18,239		3,300
Lease liabilities		193,691		69,865
Financial obligations and other		2,300		4,100
Non-capital losses & scientific research and experimental development		490,326		220,596
Unrecognized deductible temporary differences		741,078		358,023

Summary of Movement in Deferred Income Tax Liability

The movement in deferred income tax liability is as follows:

	December 31, 2022			December 31, 2021
Balance, beginning of year		—			—
Recognized in profit and loss		(7,342	)		(7,914	)
Recognized in other comprehensive income		7,342			7,914
Balance, end of year		—			—

XML

Share Capital and Warrants (Tables)

12 Months Ended

Dec. 31, 2022

Share Capital And Warrants [Abstract]

Summary of Issued and Outstanding

b)Issued and outstanding

		December 31, 2022						December 31, 2021
	Note	Number of Shares			Carrying Amount			Number of Shares		Carrying Amount
Balance, beginning of year			206,040,836			2,035,704			91,884,413		762,046
Share issuances			370,179			2,870			95,680,666		977,425
Share issuance costs			—			—			—		(16,371	)
Share repurchases			(4,252,489	)		(41,617	)		—		—
Acquisition	5		32,060,135			287,129			2,443,128		26,216
Convertible debenture settlement			—			—			248,875		2,671
Derivative warrants exercised			—			—			15,214,695		277,136
Warrants exercised			—			—			19,571		178
Employee awards exercised (1)			975,575			8,724			549,488		6,403
Balance, end of year			235,194,236			2,292,810			206,040,836		2,035,704

(1)Included in employee awards exercised are 87,500 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Included in employee awards exercised are 50,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

Summary of Common Share Purchase Warrants

(C)Common share purchase warrants

	Number of Warrants			Carrying Amount
Balance at December 31, 2020		102,400			6,138
Acquisition (note 5(b))		209,783			1,771
Warrants issued		64,000			361
Warrants exercised		(19,571	)		(178	)
Balance at December 31, 2021		356,612			8,092
Warrants expired		(48,000	)		(5,832	)
Balance at December 31, 2022		308,612			2,260

Summary of Outstanding Warrants

The following table summarizes outstanding warrants as at December 31, 2022:

	Warrants outstanding and exercisable
Issued in relation to	Weighted average exercise price		Number of warrants		Weighted average contractual remaining life (years)
Financial services		45.98		54,400		6.6
Acquired from Inner Spirit (1)		3.37		190,212		1.2
Sun 8		9.40		64,000		3.0
	$	12.13		308,612		2.5

(1)Inner Spirit warrants are exchangeable for 0.00835 SNDL common shares in accordance with the Inner Spirit Transaction consideration (note 5(b)) and have been presented based on the number of SNDL common shares that are issuable.

XML

Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Components of Share-based Compensation Expense

The components of share-based compensation expense are as follows:

	Year ended December 31
	2022			2021			2020
Equity-settled expense
Simple warrants (A)		1,299			2,899			1,539
Performance warrants (A)		—			361			(42	)
Stock options (B)		78			(14	)		651
Restricted share units (1) (C)		9,423			6,789			4,069
Cash-settled expense
Deferred share units (1)(2) (D)		(1,129	)		2,272			2,349
		9,671			12,307			8,566

(1)For the year ended December 31, 2022, the Company recognized share-based compensation recovery under Nova’s RSU plan of $107 and share-based compensation expense under Nova’s DSU plan of $404.

(2)Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each reporting period. Fluctuations in the fair value are recognized during the period in which they occur.

Summary of Changes in Simple and Performance Warrants

The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2022 and the year ended December 31, 2021:

	Simple warrants outstanding			Weighted average exercise price		Performance warrants outstanding			Weighted average exercise price
Balance at December 31, 2020		342,460		$	44.13		167,200		$	41.89
Forfeited		(66,880	)		33.62		(20,480	)		54.80
Exercised		(12,000	)		9.38		(8,000	)		10.94
Expired		(4,160	)		34.51		—			0.00
Balance at December 31, 2021		259,420		$	48.60		138,720		$	41.77
Forfeited		(82,400	)		57.77		(15,520	)		37.86
Expired		(11,200	)		6.25		—			0.00
Balance at December 31, 2022		165,820		$	46.91		123,200		$	42.26

Summarizes Outstanding Simple and Performance Warrants

The following table summarizes outstanding simple and performance warrants as at December 31, 2022:

	Warrants outstanding						Warrants exercisable
Range of exercise prices	Number of warrants		Weighted average exercise price		Weighted average contractual life (years)		Number of warrants		Weighted average exercise price		Weighted average contractual life (years)
Simple warrants
$6.25 - $9.38		75,340		7.25		1.40		75,340		7.25		1.40
$29.69 - $45.31		27,120		31.26		1.61		26,320		31.02		1.54
$62.50 - $93.75		49,920		63.50		4.05		49,920		63.50		4.05
$125.00 - $375.00		13,440		239.15		4.62		7,040		205.18		3.70
		165,820	$	46.91		2.49		158,620	$	37.68		2.36
Performance warrants
$6.25 - $9.38		45,066		6.71	n/a			45,066		6.71		2.00
$12.50 - $18.75		17,334		15.15	n/a			17,334		15.15		0.93
$29.69 - $45.31		42,400		31.99	n/a			42,400		31.99		1.22
$62.50 - $93.75		9,334		77.68	n/a			1,334		93.75		1.10
$125.00 - $375.00		9,066		282.36	n/a			—		—	n/a
		123,200	$	42.26	n/a			106,134	$	19.28		1.91

Summary of Changes in Stock Options

The following table summarizes changes in stock options during the year ended December 31, 2022 and the year ended December 31, 2021:

	Stock options outstanding			Weighted average exercise price
Balance at December 31, 2020		72,060		$	18.18
Forfeited		(27,500	)		26.05
Expired		(100	)		31.50
Balance at December 31, 2021		44,460		$	13.28
Expired		(100	)		31.50
Balance at December 31, 2022		44,360		$	13.24

Summary of Outstanding Stock Options

The following table summarizes outstanding stock options as at December 31, 2022:

	Stock options outstanding				Stock options exercisable
Exercise prices	Number of options		Weighted average contractual life (years)		Number of options		Weighted average contractual life (years)
$11.50		32,500		7.41		21,667		7.41
$11.90		8,160		7.49		8,160		7.49
$31.50		3,700		5.51		3,025		5.38
		44,360		7.27		32,852		7.24

Summary of Changes in Restricted Share Units

The following table summarizes changes in RSUs during the year ended December 31, 2022 and the year ended December 31, 2021:

	RSUs outstanding
Balance at December 31, 2020		165,692
Granted		1,238,152
Forfeited		(158,263	)
Exercised		(491,988	)
Balance at December 31, 2021		753,593
Granted		1,728,557
Forfeited		(175,245	)
Exercised		(925,575	)
Balance at December 31, 2022		1,381,330

Summary of Changes in Deferred Share Units

The following table summarizes changes in DSUs during the year ended December 31, 2022 and the year ended December 31, 2021:

	DSUs outstanding
Balance at December 31, 2020		332,331
Granted		248,919
Exercised		(30,000	)
Balance at December 31, 2021		551,250
Granted		1,216,076
Exercised		(58,943	)
Balance at December 31, 2022		1,708,383

As at December 31, 2022, nil (December 31, 2021 – 0.6 million) DSUs were exercisable.

XML

Gross Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Revenue [abstract]

Disaggregation of Revenue from Contracts with Customers

Liquor retail revenue is derived from the sale of wines, beers and spirits to customers. Cannabis retail revenue is derived from retail cannabis sales to customers, franchise revenue consists of royalty, advertising and franchise fee

revenue, and other revenue consists of millwork, supply and accessories revenue and proprietary licensing. Cannabis revenue is derived from contracts with customers and is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers.

	Year ended December 31
	2022		2021		2020
Liquor retail revenue		462,180		—		—
Cannabis retail revenue
Retail		192,710		10,207		—
Franchise		8,337		4,251		—
Other		4,563		1,633		—
Cannabis retail revenue		205,610		16,091		—
Cannabis revenue
Provincial boards		58,728		41,338		55,315
Medical		9		8		32
Wholesale		3,167		9,842		17,974
Cannabis revenue		61,904		51,188		73,321
Gross revenue		729,694		67,279		73,321

Summary of Receivables from Contracts with Customers

The Company has recognized the following receivables from contracts with customers:

	December 31, 2022		December 31, 2021		December 31, 2020
Receivables, included in 'trade receivables' (note 9)		17,558		10,865		15,786

XML

Investment Revenue (Loss) (Tables)

12 Months Ended

Dec. 31, 2022

Investment Revenue [Abstract]

Summary of Interest and Fee Revenue

	Year ended December 31
	2022		2021		2020
Interest and fee revenue
Interest revenue from investments at amortized cost		3,660		1,654		—
Interest and fee revenue from investments at FVTPL		6,036		8,514		—
Interest revenue from cash		7,043		2,981		—
		16,739		13,149		—

Summary of Investment Loss

	Year ended December 31
	2022			2021			2020
Investment loss
Realized gains		389			20,213			—
Unrealized (losses) gains (note 8)		(65,553	)		(64,714	)		—
		(65,164	)		(44,501	)		—

XML

Other Operating Expenses (Tables)

12 Months Ended

Dec. 31, 2022

Expenses by nature [abstract]

Summary of General and Administrative Expense

a)General and administrative

	Year ended December 31
	2022		2021 (1)		2020
Salaries and wages		80,134		18,675		11,634
Consulting fees		1,934		1,112		2,193
Office and general		37,061		7,560		9,843
Professional fees		11,563		6,530		4,658
Merchant processing fees		4,748		—		—
Director fees		472		351		365
Other		4,256		3,815		3,336
		140,168		38,043		32,029

(1)Adjustment to provisional amounts — refer to note 5(b).

Summary of Sales and Marketing Expense

b)Sales and marketing

	Year ended December 31
	2022		2021		2020
Marketing		7,308		3,671		4,839
Events		102		191		393
Research		—		43		57
Media		1,007		1,138		448
		8,417		5,043		5,737

XML

Finance Costs (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure Of Finance Cost [Abstract]

Summary of Finance Costs

	Year ended December 31
	2022			2021			2020
Cash finance expense
Interest on long-term debt		—			—			7,482
Other finance costs		178			40			286
		178			40			7,768
Non-cash finance expense (income)
Change in fair value of investments at FVTPL		36,087			3,300			—
Accretion on lease liabilities		5,903			776			89
Financial guarantee liability (recovery) expense		(59	)		59			—
Accretion		—			—			1,622
Amortization of debt issue costs		—			—			1,782
Change in fair value of convertible notes		—			—			(7,141	)
Other		89			154			(86	)
		42,020			4,289			(3,734	)
Interest income		(884	)		(573	)		(215	)
		41,314			3,756			3,819

XML

Supplemental Cash Flow Disclosures (Tables)

12 Months Ended

Dec. 31, 2022

Supplemental Cash Flow Disclosure [Abstract]

Summary of Changes in Non-cash Working Capital

	Year ended December 31
	2022			2021			2020
Cash provided by (used in):
Accounts receivable		(5,815	)		9,339			(2,037	)
Biological assets		533			3,829			13,789
Inventory		4,243			(18,318	)		(12,315	)
Prepaid expenses and deposits		5,782			(3,922	)		2,280
Investments		918			(402	)		—
Right of use assets		(17,510	)		—			—
Property, plant and equipment		38			(305	)		—
Accounts payable and accrued liabilities		(27,864	)		9,665			(20,793	)
Lease liabilities		19,296			—			—
		(20,379	)		(114	)		(19,076	)
Changes in non-cash working capital relating to:
Operating		(22,073	)		150			(5,259	)
Investing		74			(612	)		(11,319	)
Financing		1,620			348			(2,498	)
		(20,379	)		(114	)		(19,076	)
Cash interest paid		—			—			6,094

XML

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings per share [abstract]

Summary of Loss Per Share

	Year ended December 31
	2022			2021			2020
Weighted average shares outstanding (000s)
Basic and diluted (1)		229,871			186,038			21,865
Continuing operations
Net loss attributable to owners of the Company		(335,114	)		(226,984	)		(199,619	)
Per share - basic and diluted	$	(1.46	)	$	(1.22	)	$	(9.13	)
Discontinued operations
Net loss attributable to owners of the Company		—			—			(33,627	)
Per share - basic and diluted	$	—		$	—		$	(1.54	)
Net loss attributable to owners of the Company		(335,114	)		(226,984	)		(233,246	)
Per share - basic and diluted	$	(1.46	)	$	(1.22	)	$	(10.67	)

(1)For the year ended December 31, 2022, there were 0.3 million equity classified warrants, 10.1 million derivative warrants, 0.2 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 1.4 million RSUs that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2021 – 0.4 million equity classified warrants, 9.9 million derivative warrants, 0.3 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 0.8 million RSUs, year ended December 31, 2020 – 0.1 million equity classified warrants, 0.2 million derivative warrants, 0.3 million simple warrants, 0.2 million performance warrants, 0.07 million stock options and 0.2 million RSUs).

XML

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of detailed information about financial instruments [abstract]

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants

Fair value measurements of marketable securities, investments at FVTPL and derivative warrants are as follows:

			Fair value measurements using
December 31, 2022	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		21,926		21,926		—		—
Investments at FVTPL		72,761		—		—		72,761
Financial liabilities
Derivative warrants (1)		11,002		—		—		11,002
			Fair value measurements using
December 31, 2021	Carrying amount		Level 1		Level 2		Level 3
Recurring measurements:
Financial assets
Marketable securities		83,724		83,724		—		—
Investments at FVTPL		48,576		—		—		48,576
Financial liabilities
Derivative warrants (1)		21,700		—		—		21,700

(1)The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss

Impairment losses on accounts receivable recognized in profit or loss were as follows:

As at	December 31, 2022		December 31, 2021
Impairment loss (reversal) on trade receivables		642		214
Impairment loss (reversal) on other receivables		674		798
		1,316		1,012

Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable

The movement in the allowance for impairment in respect of accounts receivable during the year ended December 31, 2022 was as follows:

	December 31, 2022		December 31, 2021
Balance, beginning of year		1,132		120
Net remeasurement of impairment loss allowance		1,316		1,012
Balance, end of year		2,448		1,132

Timing of Expected Cash Outflows Relating to Financial Liabilities

The timing of expected cash outflows relating to financial liabilities at December 31, 2022 is as follows:

	Less than one year		One to three years		Three to five years		Thereafter		Total
Accounts payable and accrued liabilities		48,153		—		—		—		48,153
Financial guarantee liability (note 21)		—		407		—		—		407
Balance, end of year		48,153		407		—		—		48,560

XML

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2022

Related party transactions [abstract]

Compensation of Key Management Personnel

Compensation of key management personnel

The Company considers directors and officers of the Company as key management personnel.

	Year ended December 31
	2022		2021		2020
Salaries and short-term benefits		4,505		2,348		1,944
Share-based compensation		5,871		8,275		7,629
		10,376		10,623		9,573

XML

Non-Controlling Interests (Tables)

12 Months Ended

Dec. 31, 2022

Disclosure of Non Controlling Interests [Abstract]

Summary of detailed information about non material non-controlling interests

The Company does have subsidiaries with non-material non-controlling interests that are not presented in the following financial information.

a)Nova summarized statement of financial position

	2022
Current assets		18,732
Current liabilities		19,892
Current net assets		(1,160	)
Non-current assets		94,419
Non-current liabilities		45,443
Non-current net assets		48,976
Net assets		47,816

b)Nova summarized statement of loss and comprehensive loss

	2022
Revenue		176,588
Loss and comprehensive loss		(7,672	)

c)Nova summarized statement of cash flows

	2022
Net cash provided by operating activities		5,848
Net cash used in investing activities		(5,549	)
Net cash used in financing activities		(183	)
Increase in cash		116

XML

Significant Accounting Policies - Additional Information (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Significant Accounting Policies [Line Items]
Depreciation method, property, plant and equipment	straight-line method
Onerous contracts provision	$ 0	$ 0
Gain loss on conversion of financial liability reclassified to equity	0
Development costs capitalized	$ 0	$ 0
Sun 8 Holdings Inc
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	15 years
World Wide Proprietary Rights
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	12 years
Inner Spirit
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	8 years
Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Cash and cash equivalents maturities period	90 days

XML

Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2022
Production Facilities
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	20 years
Equipment | Bottom of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	1 year
Equipment | Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	10 years
Right of Use Assets and Leasehold Improvements
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	Shorter of estimated useful life or lease term

XML

Business Acquisitions - Additional Information (Details)							2 Months Ended	3 Months Ended				5 Months Ended		7 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
		Sep. 30, 2022 CAD ($)	Mar. 31, 2022 CAD ($) shares $ / shares	Aug. 04, 2021 CAD ($) shares	Jul. 20, 2021 CAD ($) shares	Jun. 20, 2021	Dec. 31, 2022 CAD ($)	Mar. 30, 2022 CAD ($)	Dec. 31, 2021 CAD ($)		Sep. 30, 2021 CAD ($)	Dec. 31, 2021 CAD ($)		Jul. 19, 2021 CAD ($)	Dec. 31, 2022 CAD ($)	Oct. 31, 2022 CAD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($)		Dec. 31, 2020 CAD ($)	Dec. 31, 2019 CAD ($)
Disclosure Of Business Combinations [Line Items]
Convertible debenture settlement																	$ 0	$ 9,354,000	[1]	$ 0
Equity component							$ 1,327,655,000		$ 1,329,533,000			$ 1,329,533,000			$ 1,327,655,000		1,327,655,000	1,329,533,000		269,695,000	$ 221,198,000
Liabilities component							231,695,000		98,127,000	[2]		98,127,000	[2]		231,695,000		231,695,000	98,127,000	[2]
Assets component							1,559,350,000		1,427,660,000	[2],[3]		1,427,660,000	[2],[3]		1,559,350,000		1,559,350,000	1,427,660,000	[2],[3]
Intangible assets	[2]						74,885,000		50,148,000			50,148,000			74,885,000		74,885,000	50,148,000
Impairment loss																	$ 196,033,000	60,000,000	[4]	79,191,000
Estimated cash flow term																	5 years
Issued Capital
Disclosure Of Business Combinations [Line Items]
Number of shares issued to settle convertible instruments, Shares | shares				2,500,000
Number of shares issued to settle convertible instruments, Value				$ 2,700,000
Convertible debenture settlement				$ 9,300,000
Equity component							2,292,810,000		2,035,704,000			2,035,704,000			2,292,810,000		$ 2,292,810,000	2,035,704,000		$ 762,046,000	$ 509,654,000
Brands and Trademarks
Disclosure Of Business Combinations [Line Items]
Intangible assets							61,083,000		40,709,000			40,709,000			61,083,000		$ 61,083,000	40,709,000
Inner Spirit
Disclosure Of Business Combinations [Line Items]
Business combination, Transaction end date						Jul. 20, 2021
Description of acquiree																	Inner Spirit is a retailer and franchisor of Spiritleaf adult-use cannabis stores across Canada, with a network that included more than 100 franchised and corporate-owned locations at the acquisition date.
Cash consideration					$ 92,583,000
Cash transferred for each ordinary shares of acquire					$ 0.30
Issuance of common shares | shares					2,400,000
Issuance of common shares, value					$ 26,216,000
Number of instruments or interests issued or issuable for each ordinary shares of acquire | shares					0.00835
Contingent consideration					$ 1,150,000
Equity component									1,800,000			1,800,000						1,800,000
Liabilities component									300,000			300,000						300,000
Assets component									900,000			900,000						900,000
Revenue												16,100,000
Net earnings (loss)												1,100,000
Revenue increased amount														$ 20,400,000
Net income (loss)														$ (7,400,000)
Acquisition-related costs for business transaction																		1,900,000
Intangible assets									45,400,000			45,400,000						$ 45,400,000
Increase in fair value of intangible assets												46,000,000.0
Amortization of intangible assets												$ 600,000
Deferred tax liability					(5,643,000)
Goodwill					72,496,000
Inner Spirit | Adjustments
Disclosure Of Business Combinations [Line Items]
Deferred tax liability					(5,643,000)
Increase in amortization expense					600,000				$ 300,000		$ 300,000
Cost of sales					2,000,000.0
Decrease in general and administrative expenses					300,000
Goodwill					(42,041,000)
Inner Spirit | Group CGU
Disclosure Of Business Combinations [Line Items]
Goodwill		$ 72,500,000					$ 4,600,000								4,600,000		$ 4,600,000
Impairment loss		$ 67,900,000
Estimated cash flow term		5 years
Discount rate		19.50%
Goodwill, Estimated Recoverable Amount		$ 40,000,000.0
Increase impairment discount rate		1.00%
Increase of impairment on assets		$ 1,100,000
Inner Spirit | Inner Spirit Warrants
Disclosure Of Business Combinations [Line Items]
Contingent consideration					$ 1,200,000
Inner Spirit | Brands and Trademarks
Disclosure Of Business Combinations [Line Items]
Estimated cash flow term		5 years
Discount rate		19.50%
Inner Spirit | Brands and Trademarks | Cannabis Franchise CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life		$ 18,300,000
Inner Spirit | Brands and Trademarks | Cannabis Retail CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life		17,700,000
Impairment of intangible assets with indefinite useful lives		16,400,000
Intangible Assets With Indefinite, Estimated Recoverable Amount		$ 1,900,000
Alcanna
Disclosure Of Business Combinations [Line Items]
Business Combination Transaction Initiated Date																	Jan. 06, 2022
Business combination, Transaction end date			Mar. 31, 2022
Description of acquiree																	Alcanna is a Canadian liquor retailer, operating predominantly in Alberta under its three retail brands, “Wine and Beyond”, “Liquor Depot” and “Ace Liquor”.
Cash consideration			$ 54,339,000
Cash transferred for each ordinary shares of acquire			$ 1.50
Issuance of common shares | shares			32,100,000
Issuance of common shares, value			$ 287,129,000
Number of instruments or interests issued or issuable for each ordinary shares of acquire | shares			0.885
Revenue															639,500,000
Net earnings (loss)															$ 101,000,000.0
Revenue increased amount								$ 162,500,000
Net income (loss)								$ (25,500,000)
Acquisition-related costs for business transaction																	$ 7,000,000.0
Percentage of fair value of non-controlling			37.00%
Share price transaction | $ / shares			$ 2.66
Payment of acquired long-term debt			$ 10,000,000.0
Goodwill			150,935,000
Estimated cash flow term																	5 years
Discount rate							12.00%								12.00%		12.00%
Alcanna | Adjustments
Disclosure Of Business Combinations [Line Items]
Goodwill			$ (129,308,000)
Alcanna | Cannabis Franchise CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life							$ 18,300,000								$ 18,300,000		$ 18,300,000
Alcanna | Cannabis Retail CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life							2,700,000								2,700,000		2,700,000
Goodwill							126,600,000								126,600,000		126,600,000
Impairment loss																	88,000,000.0
Estimated recoverable amount							84,800,000								84,800,000		84,800,000
Alcanna | Liquor Retail CGU
Disclosure Of Business Combinations [Line Items]
Intangible assets with indefinite useful life							43,100,000								43,100,000		43,100,000
Goodwill							24,300,000								$ 24,300,000		24,300,000
Zenabis
Disclosure Of Business Combinations [Line Items]
Revenue							400,000
Net earnings (loss)							$ 1,800,000
Revenue increased amount																$ 2,000,000.0
Net income (loss)																$ 9,000,000.0
Acquisition-related costs for business transaction																	$ 800,000
Nova | Alcanna
Disclosure Of Business Combinations [Line Items]
Percentage of equity interest			63.00%

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

[3] Adjustments to provisional amounts — refer to note 5(b)

[4] Adjustment to provisional amounts — refer to note 5(b).

XML

Business Acquisitions - Summary of Purchase Price Allocated (Details) - CAD ($) $ in Thousands	Nov. 01, 2022	Mar. 31, 2022	Jul. 20, 2021
Alcanna
Disclosure of detailed information about business combination [line items]
Cash		$ 54,339
Issuance of common shares		287,129
Total Purchase Price		341,468
Inner Spirit
Disclosure of detailed information about business combination [line items]
Cash			$ 92,583
Issuance of common shares			26,216
Contingent consideration			1,150
Total Purchase Price			119,949
Zenabis
Disclosure of detailed information about business combination [line items]
Extinguishment of senior loan	$ 18,215
Total Purchase Price	$ 18,215
Previously Reported | Alcanna
Disclosure of detailed information about business combination [line items]
Cash		54,339
Issuance of common shares		287,129
Total Purchase Price		$ 341,468
Previously Reported | Inner Spirit
Disclosure of detailed information about business combination [line items]
Cash			92,583
Issuance of common shares			26,216
Contingent consideration			1,150
Total Purchase Price			$ 119,949

XML

Business Acquisitions - Summary of Fair Value of the Assets and Liabilities Acquired (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Nov. 01, 2022	Mar. 31, 2022	Dec. 31, 2021	Jul. 20, 2021	Dec. 31, 2020
Disclosure Of Business Combinations [Line Items]
Net investment in subleases	$ 23,319			$ 26,562		$ 0
Inner Spirit
Disclosure Of Business Combinations [Line Items]
Cash					$ 9,808
Accounts receivable					423
Prepaid expenses and deposits					853
Inventory					4,744
Right of use assets					5,730
Property, plant and equipment					6,378
Intangible assets					46,000
Net investment in subleases					23,801
Goodwill					72,496
Accounts payable and accrued liabilities					(2,678)
Convertible debentures					(12,025)
Lease liabilities					(29,531)
Financial guarantee liability					(407)
Deferred tax liability					(5,643)
Total Purchase Price					119,949
Inner Spirit | Previously Reported
Disclosure Of Business Combinations [Line Items]
Cash					9,808
Accounts receivable					750
Prepaid expenses and deposits					853
Inventory					2,733
Property, plant and equipment					12,108
Net investment in subleases					23,751
Goodwill					114,537
Accounts payable and accrued liabilities					(2,678)
Convertible debentures					(12,025)
Lease liabilities					(29,481)
Financial guarantee liability					(407)
Total Purchase Price					119,949
Inner Spirit | Adjustments
Disclosure Of Business Combinations [Line Items]
Accounts receivable					(327)
Inventory					2,011
Right of use assets					5,730
Property, plant and equipment					(5,730)
Intangible assets					46,000
Net investment in subleases					50
Goodwill					(42,041)
Lease liabilities					(50)
Deferred tax liability					$ (5,643)
Alcanna
Disclosure Of Business Combinations [Line Items]
Cash			$ 23,190
Accounts receivable			1,868
Prepaid expenses and deposits			10,986
Inventory			105,022
Right of use assets			140,749
Property, plant and equipment			110,691
Intangible assets			45,100
Goodwill			150,935
Accounts payable and accrued liabilities			(36,747)
Long-term debt			(10,000)
Lease liabilities			(142,019)
Derivative warrants			(85)
Non-controlling interest			(58,222)
Total Purchase Price			341,468
Alcanna | Previously Reported
Disclosure Of Business Combinations [Line Items]
Cash			23,190
Accounts receivable			1,868
Prepaid expenses and deposits			10,986
Inventory			105,022
Right of use assets			171,866
Property, plant and equipment			86,059
Goodwill			280,243
Accounts payable and accrued liabilities			(36,703)
Long-term debt			(10,000)
Lease liabilities			(232,755)
Derivative warrants			(58)
Non-controlling interest			(58,250)
Total Purchase Price			341,468
Alcanna | Adjustments
Disclosure Of Business Combinations [Line Items]
Right of use assets			(31,117)
Property, plant and equipment			24,632
Intangible assets			45,100
Goodwill			(129,308)
Accounts payable and accrued liabilities			(44)
Lease liabilities			90,736
Derivative warrants			(27)
Non-controlling interest			$ 28
Zenabis
Disclosure Of Business Combinations [Line Items]
Cash		$ 2,509
Accounts receivable		888
Biological assets		909
Prepaid expenses and deposits		1,856
Inventory		4,512
Assets held for sale		6,375
Right of use assets		32
Property, plant and equipment		4,658
Accounts payable and accrued liabilities		(3,437)
Lease liabilities		(87)
Total Purchase Price		$ 18,215

XML

Discontinued Operations - Summary Results of Discontinued Operations (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure of analysis of single amount of discontinued operations [line items]
Gross revenue		$ 729,694	$ 67,279	[1]	$ 73,321
Net revenue		712,197	56,128	[1]	60,918
Cost of sales	[1]	558,089	50,612		51,740
Gross margin before fair value adjustments		147,096	(11,462)	[1]	(36,735)
Change in fair value of biological assets		(1,309)	4,708	[1]	5,432
Gross margin		140,375	(9,001)	[1],[2]	(49,869)
General and administrative	[1]	140,168	38,043		32,029
Sales and marketing		8,417	5,043	[1]	5,737
Depreciation and amortization	[1]	40,945	5,287	[2]	4,711
Share-based compensation		9,671	12,307	[1]	8,566
Loss from operations		(347,774)	(134,376)	[1]	(185,404)
Transaction costs		(1,352)	(17,566)	[1]	(3,587)
Finance costs, net		(41,314)	(3,756)	[1]	(3,819)
Gain on disposition of PP&E		(94)	235	[1]	488
Loss on disposition of Bridge Farm					(33,627)
Loss before income tax		(379,770)	(234,698)	[1],[2]	(206,317)
Income tax recovery	[1]	7,342	7,914
Net loss		$ (372,428)	$ (226,784)	[1]	$ (239,944)

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustments to provisional amounts — refer to note 5(b)

XML

Discontinued Operations - Summary of Effect of Disposal on Financial Position (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2019
Disclosure of analysis of single amount of discontinued operations [line items]
Cash and cash equivalents		$ 60,376	[1]	$ 279,586	$ 558,251	[2]	$ 45,337
Accounts receivable				22,636	10,865	[2]
Biological assets		3,531		3,477	4,410	[2]
Inventory				127,782	29,503	[2]
Property, plant and equipment				143,409	56,472	[2]
Goodwill	[2]			67,260	72,496
Intangible assets	[2]			74,885	50,148
Accounts payable and accrued liabilities				(48,153)	(38,452)	[2]
Lease obligation				(139,625)	(27,769)	[2]
Accumulated other comprehensive income				$ (32,188)	$ (7,607)	[2]
Consideration received
Net loss from discontinued operations		$ (33,627)

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

XML

Segment Information - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 CAD ($) Segment		Dec. 31, 2021 CAD ($)		Dec. 31, 2020 CAD ($)
Disclosure Of Operating Segments [Line Items]
Number of reportable segments | Segment	4
Equity-accounted investees	$ 519,255		$ 412,858	[1]
Share of profit (loss) of equity-accounted investees	$ (43,002)		32,913	[2]	$ 0
Liquor Retail | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Liquor retail includes the sale of wines, beers and spirits through owned liquor stores.
Cannabis Retail | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores.
Cannabis Operations | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export.
Investments | Operating segments [member]
Disclosure Of Operating Segments [Line Items]
Description of types of products and services from which each reportable segment derives its revenues	Investments include the deployment of capital to investment opportunities.
Share of profit (loss) of equity-accounted investees	$ (43,002)	[3]	$ 32,913	[4]

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

[3] Total assets include cash and cash equivalents.

[4] Total assets include cash and cash equivalents.

XML

Segment Information - Disclosure of Reportable Segments Explanatory (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Operating Segments [Line Items]
Total assets		$ 1,559,350		$ 1,427,660	[1],[2]
Net revenue		712,197		56,128	[3]	$ 60,918
Gross margin		140,375		(9,001)	[2],[3]	(49,869)
Interest and fee revenue		16,739		13,149
Investment (loss) income		(65,164)		(44,501)
Share of profit (loss) of equity-accounted investees		(43,002)		32,913	[3]	0
Depreciation and amortization	[3]	40,945		5,287	[2]	4,711
Income (loss) before income tax		(379,770)		(234,698)	[2],[3]	$ (206,317)
Operating segments [member] | Liquor Retail
Disclosure Of Operating Segments [Line Items]
Total assets	[4]	351,338
Net revenue	[4]	462,180
Gross margin	[4]	106,307
Depreciation and amortization	[4]	17,025
Income (loss) before income tax	[4]	17,726
Operating segments [member] | Cannabis Retail
Disclosure Of Operating Segments [Line Items]
Total assets		200,393	[4]	157,022	[2],[5]
Net revenue		205,610	[4]	16,091	[5]
Gross margin		47,334	[4]	6,498	[2],[5]
Depreciation and amortization		9,920	[4]	1,282	[2],[5]
Income (loss) before income tax		(183,055)	[4]	(410)	[2],[5]
Operating segments [member] | Cannabis Operations
Disclosure Of Operating Segments [Line Items]
Total assets		163,130	[6]	147,887	[2]
Net revenue		44,407	[6]	40,037
Gross margin		(13,266)	[6]	(15,499)	[2]
Depreciation and amortization		199	[6]	3,108	[2]
Income (loss) before income tax		(29,618)	[6]	(117,990)	[2]
Operating segments [member] | Investments
Disclosure Of Operating Segments [Line Items]
Total assets		825,151	[7]	1,093,596	[2],[8]
Interest and fee revenue		16,739	[7]	13,149	[8]
Investment (loss) income		(65,164)	[7]	(44,501)	[8]
Share of profit (loss) of equity-accounted investees		(43,002)	[7]	32,913	[8]
Income (loss) before income tax		(127,362)	[7]	(5,837)	[2],[8]
Corporate
Disclosure Of Operating Segments [Line Items]
Total assets		19,338		29,155	[2]
Depreciation and amortization		13,801		897	[2]
Income (loss) before income tax		$ (57,461)		$ (110,461)	[2]

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustments to provisional amounts — refer to note 5(b)

[3] Adjustment to provisional amounts — refer to note 5(b).

[4] Liquor retail includes operations for the period March 31, 2022 to December 31, 2022 and cannabis retail includes the operations of Nova retail stores for the period March 31, 2022 to December 31, 2022 (note 5(a)).

[5] Cannabis retail includes the operations of Inner Spirit retail and franchise stores for the period July 20, 2021 to December 31, 2021.

[6] Cannabis operations includes the operations of Zenabis for the period November 1, 2022 to December 31, 2022 (note 5(c)).

[7] Total assets include cash and cash equivalents.

[8] Total assets include cash and cash equivalents.

XML

Restricted Cash - Summary of Disclosure of Restricted Cash (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Restricted Cash [Abstract]
Securities collateral	$ 0	$ 7,773
Captive insurance	19,044	19,240
Other	294	0
Restricted cash and cash equivalents	$ 19,338	$ 27,013	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Marketable Securities - Disclosure of Marketable Securities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021
Marketable Securities Disclosure [Abstract]
Balance, beginning of year	$ 83,724	[1]	$ 0
Additions	3,755		158,101
Dispositions	0		(9,663)
Change in fair value recognized in profit or loss	(65,553)		(64,714)
Balance, end of year	$ 21,926		$ 83,724	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Marketable Securities - Additional Information (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Marketable Securities Disclosure [Abstract]
Proceeds from disposition of marketable securities	$ 0	$ 29,900,000
Gain on disposition of marketable securities	$ 0	$ 20,200,000

XML

Marketable Securities - Schedule of Components of Marketable Securities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Components Of Marketable Securities [Abstract]
Equity securities	$ 21,926	$ 83,802
Put and call options	0	(78)
Financial Assets Marketable Securities Current	$ 21,926	$ 83,724	[1]	$ 0

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Accounts Receivable - Summary of Accounts Receivable (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables	$ 17,558	$ 10,865
Other receivables	5,078
Accounts receivable	$ 22,636	$ 10,865	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Biological Assets - Summary of Change in Carrying Value of Biological Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022		Dec. 31, 2021
Changes in biological assets [abstract]
Balance, beginning of year	$ 4,410	[1]	$ 3,531
Increase in biological assets due to capitalized costs	27,749		25,880
Acquisition	909
Net change in fair value of biological assets	(1,309)		4,708
Transferred to inventory upon harvest	(28,282)		(29,709)
Balance, end of year	$ 3,477		$ 4,410	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Details) $ in Thousands		12 Months Ended
		Dec. 31, 2022 CAD ($) Quantity	Dec. 31, 2021 CAD ($) Quantity
Yield per Square Foot of Growing Space
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $	[1]	$ 279	$ 435
Average Net Selling Price
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $	[2]	687	1,014
After Harvest Cost to Complete and Sell
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change | $		$ 187	$ 249
Weighted Average Input
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Yield per square foot of growing space | Quantity	[1]	48	49
Average net selling price | Quantity	[2]	4.66	4.49
After harvest cost to complete and sell | Quantity		1.27	1.06

[1] Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

[2] Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

XML

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2022
Changes in biological assets [abstract]
Percentage of assumption of effect change	10.00%

XML

Biological Assets - Additional Information (Details) - kg	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Changes in biological assets [abstract]
Estimated biological assets to be harvested	3,904	5,672
Harvested biological assets	19,854	22,784

XML

Inventory - Summary of Inventories (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Inventories [Line Items]
Inventory	$ 127,782	$ 29,503	[1]
Retail Liquor
Disclosure Of Inventories [Line Items]
Inventory	82,589	0
Harvested Cannabis
Disclosure Of Inventories [Line Items]
Raw materials, packaging and components	4,577	4,354
Work-in-progress	19,927	19,751
Finished goods	7,040	2,966
Retail Cannabis
Disclosure Of Inventories [Line Items]
Inventory	13,373	2,397
Millwork
Disclosure Of Inventories [Line Items]
Inventory	$ 276	$ 35

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Inventory - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Classes of current inventories [abstract]
Inventories recognized as expense	$ 558.1	$ 50.6
Inventory write downs	8.9	17.5
Excess and obsolete inventory provision	7.0	17.0
Fair value component of excess and obsolete inventory provision	$ 1.9	$ 0.5

XML

Right Of Use Assets - Schedule of Right Of Use Assets (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Disclosure of quantitative information about right-of-use assets [line items]
Net book value	[1]	$ 56,472
Impairment		12,800
Dispositions			$ 0
Net book value		143,409	56,472	[1]
Cost
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		208,499	199,290
Acquisition (note 5)		115,349	6,378
Additions		10,667	3,777
Dispositions		(9,127)	(946)
Net book value		325,388	208,499
Accumulated Depreciation and Impairment
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		152,027	83,685
Depreciation		19,873	8,352
Impairment		15,209	60,000
Dispositions		(5,130)	(10)
Net book value		181,979	152,027
Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		6,717
Impairment		6,400
Net book value		134,154	6,717
Right of Use Assets | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		8,038	1,894
Acquisition (note 5)		140,781	5,730
Additions		6,103	579
Dispositions			(165)
Tenant inducement allowances		(46)
Dispositions and remeasurements		12,191
Net book value		167,067	8,038
Right of Use Assets | Accumulated Depreciation and Impairment
Disclosure of quantitative information about right-of-use assets [line items]
Net book value		1,321	571
Depreciation		25,227	897
Impairment		6,365
Dispositions			(147)
Net book value		$ 32,913	$ 1,321

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Right Of Use Assets - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 CAD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	$ 12.8
Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	6.4
Cannabis Retail Reporting Segment
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	5.3
Cannabis Retail Reporting Segment | Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	3.9
Liquor Retail Reporting Segment
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	7.5
Liquor Retail Reporting Segment | Right of Use Assets
Disclosure of quantitative information about right-of-use assets [line items]
Impairment losses of right of use assets	$ 2.5

XML

Property Plant and Equipment - Schedule of Property Plant and Equipment (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	[1]	$ 56,472
Impairment		12,800
Dispositions			$ 0
Net book value		143,409	56,472	[1]
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		208,499	199,290
Acquisition (note 5)		115,349	6,378
Additions		10,667	3,777
Transfers from CIP			0
Dispositions		(9,127)	(946)
Net book value		325,388	208,499
Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		152,027	83,685
Depreciation		19,873	8,352
Impairment		15,209	60,000
Dispositions		(5,130)	(10)
Net book value		181,979	152,027
Land
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		12,388
Additions			0
Net book value		11,964	12,388
Land | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		12,388	8,640
Acquisition (note 5)		130	0
Additions		57
Transfers from CIP			3,748
Dispositions		(611)	0
Net book value		11,964	12,388
Land | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		0	0
Depreciation		0	0
Impairment		0	0
Dispositions		0	0
Net book value		0	0
Production Facilities
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		21,465
Net book value		20,895	21,465
Production Facilities | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		153,332	152,935
Acquisition (note 5)		2,982	0
Additions		256	467
Transfers from CIP			0
Dispositions		(3,844)	(70)
Net book value		152,726	153,332
Production Facilities | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		131,867	69,364
Depreciation		1,288	2,503
Impairment		0	60,000
Dispositions		(1,324)	0
Net book value		131,831	131,867
Leasehold Improvements
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		3,488
Net book value		57,515	3,488
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		3,899	2
Acquisition (note 5)		65,605	4,169
Additions		3,465	126
Transfers from CIP			0
Dispositions		(647)	(398)
Net book value		72,322	3,899
Leasehold Improvements | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		411	0
Depreciation		7,212	411
Impairment		7,794	0
Dispositions		(610)	0
Net book value		14,807	411
Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		18,849
Net book value		49,402	18,849
Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		32,777	28,894
Acquisition (note 5)		44,263	2,209
Additions		5,907	1,975
Transfers from CIP			0
Dispositions		(4,025)	(301)
Net book value		78,922	32,777
Equipment | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		13,928	8,500
Depreciation		11,373	5,438
Impairment		7,415	0
Dispositions		(3,196)	(10)
Net book value		29,520	13,928
Construction in Progress
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		282
Net book value		3,633	282
Construction in Progress | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		6,103	8,819
Acquisition (note 5)		2,369	0
Additions		982	1,209
Transfers from CIP			(3,748)
Dispositions		0	(177)
Net book value		9,454	6,103
Construction in Progress | Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value		5,821	5,821
Depreciation		0	0
Impairment			0
Dispositions			0
Net book value		$ 5,821	$ 5,821

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Property Plant and Equipment - Additional Information (Details)	3 Months Ended	12 Months Ended
	Jun. 30, 2021 CAD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($)		Dec. 31, 2020 CAD ($)
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, capitalized to biological assets and inventory		$ 6,400,000	$ 4,900,000
Estimated cash flow term		5 years
Asset impairment		$ 196,033,000	$ 60,000,000	[1]	$ 79,191,000
Impairment		$ 12,800,000
EBITDA forecast extension period		5 years
Cash flows increased by a terminal growth rate		2.50%
Cannabis Retail Reporting Segment
Disclosure of detailed information about property, plant and equipment [line items]
Impairment		$ 5,300,000
Liquor Retail Reporting Segment
Disclosure of detailed information about property, plant and equipment [line items]
Impairment		$ 7,500,000
Weighted Average Cost of Capital
Disclosure of detailed information about property, plant and equipment [line items]
Significant unobservable input		12.0
Idle Machinery and Equipment | Cannabis Retail Reporting Segment
Disclosure of detailed information about property, plant and equipment [line items]
Impairment		$ 2,400,000
Merritt Facility
Disclosure of detailed information about property, plant and equipment [line items]
Proceeds from disposition		3,500,000
Fair value less costs of disposal and impairment		500,000
Rocky View Facility
Disclosure of detailed information about property, plant and equipment [line items]
Proceeds from disposition		3,900,000
Fair value less costs of disposal and impairment		$ 0
Old Cash Generating Units
Disclosure of detailed information about property, plant and equipment [line items]
Impairment discount rate	25.00%
Estimated cash flow term	5 years
Asset impairment	$ 60,000,000.0
Increase impairment discount rate		1.00%
Increase of impairment on assets		$ 7,300,000
Alberta CGU
Disclosure of detailed information about property, plant and equipment [line items]
Estimated recoverable amount	$ 70,000,000.0

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Net Investment In Subleases - Summary of Net Investment in Subleases (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Net Investment In Subleases [Abstract]
Balance, beginning of year	$ 26,562	$ 0
Acquisition (note 5(b))	0	23,801
Additions	1,408	3,951
Finance income	833	573
Rents recovered (payments made directly to landlords)	(4,141)	(1,713)
Dispositions and remeasurement	(1,343)	(50)
Balance, end of year	23,319	26,562
Current portion	3,701	3,991	[1]
Long-term	$ 19,618	$ 22,571	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Intangible Assets - Summary of Reconciliation of Changes in Intangible Assets and Goodwill (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Intangible Assets [Line Items]
Beginning Balance	[1]	$ 50,148
Depreciation	[2]	40,945	$ 5,287	[3]	$ 4,711
Ending Balance	[1]	74,885	50,148
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		51,445	5,445
Acquisition		45,100	46,000	[4]
Additions		197
Dispositions		(50)
Ending Balance		96,692	51,445		5,445
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		1,297	382
Amortization		2,222	915	[4]
Impairment		18,288
Ending Balance		21,807	1,297		382
Brands and Trademarks
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		40,709
Ending Balance		61,083	40,709
Brands and Trademarks | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		41,445	5,445
Acquisition		38,950	36,000	[4]
Additions		55
Dispositions		(50)
Ending Balance		80,400	41,445		5,445
Brands and Trademarks | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		736	382
Amortization		293	354	[4]
Impairment		18,288
Ending Balance		19,317	736		382
Franchises Agreements
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		9,439
Ending Balance		8,189	9,439
Franchises Agreements | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		10,000	0
Acquisition		0	10,000	[4]
Additions		0
Dispositions		0
Ending Balance		10,000	10,000		0
Franchises Agreements | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		561	0
Amortization		1,250	561	[4]
Impairment		0
Ending Balance		1,811	561		0
Software
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0
Ending Balance		4,863	0
Software | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Acquisition		5,400	0	[4]
Additions		142
Dispositions		0
Ending Balance		5,542	0		0
Software | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Amortization		679	0	[4]
Impairment		0
Ending Balance		679	0		0
Retail Licenses
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0
Ending Balance		750	0
Retail Licenses | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Acquisition		750	0	[4]
Additions		0
Dispositions		0
Ending Balance		750	0		0
Retail Licenses | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		0	0
Amortization		0	0	[4]
Impairment		0
Ending Balance		$ 0	$ 0		$ 0

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

[3] Adjustments to provisional amounts — refer to note 5(b)

[4] Adjustment to provisional amounts — refer to note 5(b).

XML

Intangible Assets - Additional Information (Details) - CAD ($) $ in Millions		3 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2022
Cannabis Retail
Disclosure Of Intangible Assets [Line Items]
Impairment of intangible assets with indefinite useful lives	$ 16.4
Inner Spirit
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets			8 years
Other Intellectual Property
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets			12 years
Sun 8 Holdings Inc
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets			15 years
Impairment		$ 1.9
Estimated recoverable amount	$ 2.5	$ 2.5

XML

Investments - Investments Other Than Investments Accounted for Using Equity Method (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	$ 97,254	$ 73,563
Investments	6,552	3,065	[1]
Long-term	90,702	70,498	[1]
Financial assets at amortized cost, category | At cost
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	24,493	24,987
Financial assets at fair value through profit or loss, category | At fair value
Disclosure Of Investments Other Than Investments Accounted For Using Equity Method [Line Items]
Investments other than investments accounted for using equity method	$ 72,761	$ 48,576

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Investments - Additional Information (Details) - CAD ($) $ in Millions								12 Months Ended
	Jan. 02, 2023	Dec. 31, 2022	Nov. 01, 2022	Aug. 26, 2022	Aug. 22, 2022	Mar. 30, 2022	Feb. 09, 2022	Dec. 31, 2022
ZENABIS
Disclosure Of Transactions Between Related Parties [Line Items]
Adjusted fair value of senior loan			$ 33.7
SUPERETTE | Promissory Notes
Disclosure Of Transactions Between Related Parties [Line Items]
Cash outflow for investment In debt instrument							$ 5.0
Maturity date of investments							Feb. 09, 2025
Rate of interest on investments							15.00%
SUPERETTE | Promissory Notes | Significant Advances and Adjustments
Disclosure Of Transactions Between Related Parties [Line Items]
Adjusted fair value of debt instrument								$ (3.7)
SUPERETTE | Amended and Restated Promissory Note
Disclosure Of Transactions Between Related Parties [Line Items]
Cash outflow for investment In debt instrument		$ 1.8		$ 8.1
SUPERETTE | Amended and Restated Promissory Note | Significant Advances and Adjustments
Disclosure Of Transactions Between Related Parties [Line Items]
Cash outflow for investment In debt instrument	$ 0.3
Term Loan | VALENS
Disclosure Of Transactions Between Related Parties [Line Items]
Cash Out Flow For Non Revolving Loan Issuance					$ 60.0
Maturity date of investments					Dec. 15, 2023
Rate of interest on investments					10.00%
Convertible Debenture | DELTA 9
Disclosure Of Transactions Between Related Parties [Line Items]
Debt instruments held						$ 10.0
Maturity date of investments						Mar. 30, 2025
Rate of interest on investments						10.00%

XML

Equity-Accounted Investees - Summary of Interest (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Investments accounted for using equity method [abstract]
Interest in joint venture	$ 519,255	$ 412,858
Interest in associate	0	0
Investments accounted for using equity method	$ 519,255	$ 412,858	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Equity-Accounted Investees - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended		24 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Apr. 14, 2023
Statements [Line Items]
Capital funded			$ 514,700
Interest in associate	$ 0	$ 0	$ 0
Pathway Rx Inc [Member]
Statements [Line Items]
Proportion of ownership interest in associate	25.00%
SunStream [Member] | Events After Reporting Period
Statements [Line Items]
Interest in associate				$ 10,900
Sun Stream Bancorp Inc. [Member]
Statements [Line Items]
Proportion of ownership interest in joint venture	50.00%
Capital funded	$ 119,137	$ 395,569
Commitment To funded Capital Towards Joint Venture Monetary Instant Credit Definition	$ 538,000

XML

Equity-Accounted Investees - Summary of Interest in Joint Venture (Details) - CAD ($) $ in Thousands	12 Months Ended				24 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020	Dec. 31, 2022
Disclosure of joint ventures [line items]
Beging Balance	$ 412,858
Capital contributions					$ 514,700
Distributions	0	$ 10,481	[1]	$ 0
Ending Balance	519,255	412,858			519,255
Sun Stream Bancorp Inc. [Member]
Disclosure of joint ventures [line items]
Beging Balance	412,858	0			0
Capital contributions	119,137	395,569
Share of net earnings (loss)	(43,002)	32,913
Share of other comprehensive income	31,923	9,878
Distributions	(1,661)	(25,502)
Ending Balance	$ 519,255	$ 412,858		$ 0	$ 519,255

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Equity-Accounted Investees - Summary of Financial Information of SunStream (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure of joint ventures [line items]
Current assets (including cash and cash equivalents - 2022: $1.5 million, 2021: $0.2 million)	$ 501,483	$ 728,175	[1]
Current liabilities	(89,361)	(65,853)	[1]
Profit (loss) from operations	(372,428)	(226,784)	[2]	$ (239,944)
Other comprehensive income	24,581	7,607		$ 600
Sundial Growers Inc [Member]
Disclosure of joint ventures [line items]
Current assets (including cash and cash equivalents - 2022: $1.5 million, 2021: $0.2 million)	5,437	789
Non-current assets	509,418	407,860
Current liabilities	(1,146)	(1,596)
Net assets and liabilities	513,709	407,053
Revenue (loss)	(35,046)	36,203
Profit (loss) from operations	(42,627)	32,841
Other comprehensive income	31,923	9,878
Total comprehensive income (loss)	$ (10,619)	$ 42,747

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

XML

Equity-Accounted Investees - Summary of Financial Information of SunStream (Parenthetical) (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020	[2]	Dec. 31, 2019
Disclosure of joint ventures [line items]
Cash and cash equivalents	$ 279,586	$ 558,251	[1]	$ 60,376		$ 45,337
Percentage of net assets liabilities	100.00%	100.00%
Sundial Growers Inc [Member]
Disclosure of joint ventures [line items]
Cash and cash equivalents	$ 1,500	$ 200

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

XML

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade payables	$ 9,774	$ 4,172
Accrued and other liabilities	38,379	34,280
Accounts payable and accrued liabilities	$ 48,153	$ 38,452	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Derivative Warrants - Summary of Derivative Warrants (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Balance, beginning of year	$ 21,700	$ 428
Change in fair value recognized in profit or loss	(10,783)	(28,697)
Converted to common shares	0	(157,818)
Balance, end of year	11,002	21,700
2021 Series A and B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	62,680
2021 Additional Series A and B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	38,576
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	0	106,531
Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	$ 85	$ 0

XML

Derivative Warrants - Secured Convertible Note Warrants - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description	The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants.

XML

Derivative Warrants - Unsecured Convertible Note Warrants - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description	The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants.
Warrants outstanding	10,051,400
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	50,000	[1]

[1] The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

XML

Derivative Warrants - Series A and Series B Warrants - Additional Information (Details)	Dec. 31, 2022 shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	10,051,400
2020 Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	50,000	[1]

[1] The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

XML

Derivative Warrants - Summary of Outstanding Derivative Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares		Dec. 31, 2022 shares $ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	10,051,400		10,051,400
Weighted average contractual life	1 year 7 months 6 days
2020 Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 1.77	[1]
Warrants outstanding	50,000	[1]	50,000	[1]
Weighted average contractual life	2 years 7 months 6 days	[1]
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 1.77	[1]
Warrants outstanding	50,000	[1]	50,000	[1]
Weighted average contractual life	1 year	[1]
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 2.29	[2]
Warrants outstanding	9,833,333	[2]	9,833,333	[2]
Weighted average contractual life	1 year 7 months 6 days	[2]
December 2018 Performance Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares			$ 5.51
Warrants outstanding	118,067		118,067
Weighted average contractual life	1 year

[1] The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

[2] The exercise price of the New Warrants was adjusted from USD $15.00 to $2.29 based on the July 26, 2022 Share Consolidation (as defined below) representing a share combination event (note 23(a)).

XML

Derivative Warrants - Summary of Outstanding Derivative Warrants (Parenthetical) (Details) - $ / shares		12 Months Ended
	Jul. 26, 2022	Dec. 31, 2022
New Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Weighted average exercise price of warrant	$ 15.00	$ 2.29

XML

Derivative Warrants - December 2018 Performance Warrants - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding | shares	10,051,400
Warrants description	The December 2018 Performance Warrants became immediately exercisable upon issuance. Each performance warrant includes a performance incentive that entitles the warrant holders to additional common shares of Nova upon exercise provided that the 20-day volume weighted average trading price of Nova’s common shares (the “Market Price”) equals or exceeds $19.27 at any time prior to the expiration date of the warrants.
December 2018 Performance Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding | shares	118,067
December 2018 Performance Warrants | Nova
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Value of market price equals or exceeds prior to expiration date of warrants	$ 19.27
Warrant exercise price	5.51
December 2018 Performance Warrants | Nova | Bottom of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrant exercise price	0.05449
December 2018 Performance Warrants | Nova | Top of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrant exercise price	$ 0.08174

XML

Lease Liabilities - Summary of Lease Liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Lease Obligations [Line Items]
Acquisition (note 5(a), note5(c))	$ 345,351	$ 27,987
Lease payments	(27,693)	(1,008)	[1]	$ (420)
Current portion	30,206	5,701	[2]
Long-term	139,625	27,769	[2]
IFRS 16
Disclosure Of Lease Obligations [Line Items]
Balance, beginning of year	33,470	1,440
Acquisition (note 5(a), note5(c))	142,106	29,531
Additions	7,497	4,514
Lease payments	(31,834)	(2,721)
Dispositions and remeasurements	10,890	(70)
Tenant inducement allowances received	1,799
Accretion expense	5,903	776
Balance, end of year	169,831	33,470		$ 1,440
Current portion	30,206	5,701
Long-term	$ 139,625	$ 27,769

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

XML

Lease Liabilities - Summary of Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2022 CAD ($)
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 200,570
Less Than One Year
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	39,255
One to Three Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	64,892
Three to Five Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	48,955
Thereafter
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 47,468

XML

Other Liabilities - Schedule Of Other Liabilities (Detail) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Other Liabilities [Abstract]
Financial guarantee liability	$ 407	$ 466
Deferred share units liability	2,302	4,039
Total	$ 2,709	$ 4,505	[1]

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Income Taxes - Summary of Income Tax Expense (Recovery) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Major components of tax expense (income) [abstract]
Loss before income tax	$ (379,770)	$ (234,698)	[1],[2]	$ (206,317)
Statutory income tax rates	23.00%	23.00%		24.00%
Expected income tax recovery	$ (87,347)	$ (53,981)		$ (49,516)
Non-deductible share-based compensation	2,508	2,308		1,970
Non-deductible finance expense	0	2		2,130
Revaluation of the fair value of warrant liabilities	(2,461)	17,902		0
Non-controlling interest	8,167	0		0
Non-deductible portion of capital losses	7,458	5,118		0
Other non-deductible expenses	5,409	610		348
Goodwill impairment	35,919	0		0
Change in tax rates	0	0		1,528
Deferred tax benefits not recognized	23,005	20,127		43,540
Income tax (recovery) expense	$ (7,342)	$ (7,914)		$ 0

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustments to provisional amounts — refer to note 5(b)

XML

Income Taxes - Summary of Deferred Tax Assets (Liabilities) (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ 0	$ 0	$ 0
Inventory
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	23,329	20,472
Biological assets
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(9,451)	(9,509)
Net Investment in Subleases
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(5,363)	(6,119)
Intangible Assets
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(16,632)	0
Lease liabilities
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	(5,488)	(8,361)
Marketable Securities
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	14,981	7,442
Equity Accounted Investee
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ (1,376)	$ (3,925)

XML

Income Taxes - Summary of Unrecognized Deductible Temporary Differences (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]
Property, plant and equipment	$ 7,413	$ 81,583
Intangible assets	183	(45,256)
Share issue costs	28,926	23,835
Investments	18,239	3,300
Lease liabilities	193,691	69,865
Financial obligations and other	2,300	4,100
Non-capital losses & scientific research and experimental development	490,326	220,596
Unrecognized deductible temporary differences	$ 741,078	$ 358,023

XML

Income Taxes - Summary of Movement in Deferred Income Tax Liability (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets And Liabilities [Line Items]
Balance, beginning of year	$ 0	$ 0
Recognized in profit and loss	(7,342)	(7,914)
Recognized in other comprehensive income	7,342	7,914
Balance, end of year	$ 0	$ 0

XML

Income Taxes - Additional Information (Details) - CAD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Major components of tax expense (income) [abstract]
Non-capital losses available for future periods	$ 490.3	$ 218.5

XML

Share Capital and Warrants - Summary of Issued and Outstanding (Details) - CAD ($) $ in Thousands			12 Months Ended
		Jul. 25, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Share issuances, shares		10,000,000	13,300,000
Share repurchases, shares			4,300,000
Beginning balance			$ 1,329,533	$ 269,695	$ 221,198
Share issuance costs				(16,371)	(5,593)
Share repurchases			13,390
Business acquisitions			345,351	27,987
Convertible debt - conversions					63,002
Disposition of bridge farm					(10,457)
Derivative warrants exercised				277,136	55,912
Ending balance			$ 1,327,655	$ 1,329,533	$ 269,695
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Balance, beginning of year, shares			206,040,836	91,884,413
Share issuances, shares			370,179	95,680,666
Share issuance costs, shares			0	0
Share repurchases, shares			(4,252,489)
Business acquisitions, shares			32,060,135	2,443,128,000
Convertible debt - conversions, shares			0	248,875
Derivative warrants exercised, shares			0	15,214,695
Warrants exercised, shares			0	19,571,000
Employee awards exercised, shares	[1]		975,575	549,488
Balance, end of year, shares			235,194,236	206,040,836	91,884,413
Beginning balance			$ 2,035,704	$ 762,046	$ 509,654
Share issuances, carrying amount			2,870	977,425
Share issuance costs			0	(16,371)	(5,593)
Share repurchases			41,617
Business acquisitions			287,129	26,216
Convertible debt - conversions			0	2,671	63,002
Disposition of bridge farm					(38,447)
Derivative warrants exercised			0	277,136	55,912
Warrants exercised			0	178
Employee awards exercised	[1]		8,724	6,403
Ending balance			$ 2,292,810	$ 2,035,704	$ 762,046

[1] Included in employee awards exercised are 87,500 RSUs that vested and were exercised in December 2020; however, the common shares were not issued until January 2021. Included in employee awards exercised are 50,000 RSUs that vested and were exercised in December 2021; however, the common shares were not issued until January 2022.

XML

Share Capital and Warrants - Summary of Issued and Outstanding (Parentheticals) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restricted Share Units
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares vested	50,000	87,500

XML

Share Capital and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions				12 Months Ended
	Apr. 14, 2023 $ / shares shares	Apr. 14, 2023 $ / shares shares	Jul. 25, 2022 shares	Dec. 31, 2022 CAD ($) $ / shares shares		Dec. 31, 2022 CAD ($) $ / shares shares		Dec. 31, 2021 CAD ($) $ / shares shares		Dec. 31, 2022 USD ($)
Share Capital And Warrants [Line Items]
Number of shares issued			10,000,000	13,300,000		13,300,000
Number of shares issued upon conversion			1
Share repurchases, shares				4,300,000		4,300,000
Shares repurchased weighted average price per common share | (per share)				$ 3.12		$ 2.33
Accumulated deficit				$ (1,091,999)	[1]	$ (1,091,999)	[1]	$ (785,112)	[1]	$ 28.3
Events After Reporting Period
Share Capital And Warrants [Line Items]
Number of shares issued	1,500,000	1,500,000
Share repurchases, shares	500,000	500,000
Shares repurchased weighted average price per common share | (per share)	$ 2.78	$ 2.04
Inner Spirit Holdings Ltd
Share Capital And Warrants [Line Items]
Warrants Exercised								19,571
Net payment of warrants | $								$ 200
Sun 8 Holdings Inc
Share Capital And Warrants [Line Items]
Number of warrants issued								64,000
Warrant exercise price | $ / shares								$ 9.40

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Share Capital and Warrants - Summary of Common Share Purchase Warrants (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance	$ 1,329,533	$ 269,695
Ending balance	$ 1,327,655	$ 1,329,533
Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance, Number of Warrants	356,612	102,400
Acquisition (note 5)		209,783
Warrants issued, Number of Warrants		64,000
Warrants exercised, Number of Warrants		(19,571)
Warrants expired, Number of Warrants	(48,000)
Ending balance, Number of Warrants	308,612	356,612
Beginning balance	$ 8,092	$ 6,138
Acquisition (note 5), Carrying Amount		1,771
Warrants Issued, Carrying Amount		361
Warrants exercised, Carrying Amount		(178)
Warrants expired, Carrying Amount	(5,832)
Ending balance	$ 2,260	$ 8,092

XML

Share Capital And Warrants - Summary of Outstanding Warrants (Details) - Warrants	12 Months Ended
	Dec. 31, 2022 Warrant $ / shares
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 12.13
Warrants outstanding and exercisable, Number of warrants | Warrant	308,612
Warrants outstanding and exercisable, Weighted average contractual life (years)	2 years 6 months
Sun 8 Holdings Inc
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 9.40
Warrants outstanding and exercisable, Number of warrants | Warrant	64,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	3 years
Financial Services
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 45.98
Warrants outstanding and exercisable, Number of warrants | Warrant	54,400
Warrants outstanding and exercisable, Weighted average contractual life (years)	6 years 7 months 6 days
Acquired From Inner Spirit [Member]
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 3.37	[1]
Warrants outstanding and exercisable, Number of warrants | Warrant	190,212	[1]
Warrants outstanding and exercisable, Weighted average contractual life (years)	1 year 2 months 12 days	[1]

[1] Inner Spirit warrants are exchangeable for 0.00835 SNDL common shares in accordance with the Inner Spirit Transaction consideration (note 5(b)) and have been presented based on the number of SNDL common shares that are issuable.

XML

Share Capital And Warrants - Summary of Outstanding Warrants (Parentheticals) (Details)	12 Months Ended
	Dec. 31, 2022 shares
Inner Spirit
Statements [Line Items]
Warrants are Exchangeable For Number Of Common Shares Accordance With The Transaction Consideration	0.00835

XML

Share-based Compensation - Components of Share-based Compensation Expense (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		$ 9,671	$ 12,307	[1]	$ 8,566
Simple Warrants | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		1,299	2,899		1,539
Performance Warrants | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation			361		(42)
Stock Options | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		78	(14)		651
Restricted Share Units | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	[2]	9,423	6,789		4,069
Deferred Share Units | Cash Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	[2],[3]	$ (1,129)	$ 2,272		$ 2,349

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] For the year ended December 31, 2022, the Company recognized share-based compensation recovery under Nova’s RSU plan of $107 and share-based compensation expense under Nova’s DSU plan of $404.

[3] Cash-settled DSUs are accounted for as a liability and are measured at fair value based on the market value of the Company’s common shares at each reporting period. Fluctuations in the fair value are recognized during the period in which they occur.

XML

Share-based Compensation - Components of Share-based Compensation Expense (Parenthetical) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	$ 9,671	$ 12,307		$ 8,566
NOVA RSU PLAN | Equity Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation recovery	107
NOVA DSU PLAN | Cash Settled Expense
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	$ 404

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Share-based Compensation - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 CAD ($) shares	Dec. 31, 2021 CAD ($) shares	Dec. 31, 2020 shares
Cash Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Fair value of cash settled deferred share units | $	$ 2.3	$ 4.0
Simple and Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period	3 years
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Maturity period	5 years
Exercised		12,000
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Maturity period	5 years
Exercised		8,000
Stock Options | Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period	3 years
Maturity period	10 years
Restricted Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercised		50,000	87,500
Restricted Share Units | Long-term Incentive Program
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted	7,800,000
Restricted Share Units | Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted	1,728,557	1,238,152
Exercised	925,575	491,988
Deferred Share Units | Cash Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted	1,216,076	248,919
Exercised	58,943	30,000
Vesting term	DSUs are granted to directors and generally vest in equal instalments over one year
Vesting period	1 year
Stock options, Exercisable	0	600,000

XML

Share-based Compensation - Summary of Changes in Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	259,420	342,460
Forfeited | shares	(82,400)	(66,880)
Exercised | shares		(12,000)
Expired | shares	(11,200)	(4,160)
Ending balance | shares	165,820	259,420
Weighted average exercise price, beginning balance	$ 48.60	$ 44.13
Weighted average exercise price, Forfeited	57.77	33.62
Weighted average exercise price, Exercised		9.38
Weighted average exercise price, Expired	6.25	34.51
Weighted average exercise price, ending balance	$ 46.91	$ 48.60
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	138,720	167,200
Forfeited | shares	(15,520)	(20,480)
Exercised | shares		(8,000)
Ending balance | shares	123,200	138,720
Weighted average exercise price, beginning balance	$ 41.77	$ 41.89
Weighted average exercise price, Forfeited	37.86	54.80
Weighted average exercise price, Exercised		10.94
Weighted average exercise price, Expired	0.00	0.00
Weighted average exercise price, ending balance	$ 42.26	$ 41.77

XML

Share-based Compensation - Summarizes Outstanding Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	165,820	259,420	342,460
Weighted average exercise price, Warrants outstanding | $ / shares	$ 46.91	$ 48.60	$ 44.13
Weighted average contractual life, Warrants outstanding (years)	2 years 5 months 26 days
Number of warrants, Warrants exercisable | shares	158,620
Weighted average exercise price, Warrants exercisable | $ / shares	$ 37.68
Weighted average contractual life, Warrants exercisable (years)	2 years 4 months 9 days
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	123,200	138,720	167,200
Weighted average exercise price, Warrants outstanding | $ / shares	$ 42.26	$ 41.77	$ 41.89
Number of warrants, Warrants exercisable | shares	106,134
Weighted average exercise price, Warrants exercisable | $ / shares	$ 19.28
Weighted average contractual life, Warrants exercisable (years)	1 year 10 months 28 days
$6.25 - $9.38 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	75,340
Weighted average exercise price, Warrants outstanding | $ / shares	$ 7.25
Weighted average contractual life, Warrants outstanding (years)	1 year 4 months 24 days
Number of warrants, Warrants exercisable | shares	75,340
Weighted average exercise price, Warrants exercisable | $ / shares	$ 7.25
Weighted average contractual life, Warrants exercisable (years)	1 year 4 months 24 days
$6.25 - $9.38 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	45,066
Weighted average exercise price, Warrants outstanding | $ / shares	$ 6.71
Number of warrants, Warrants exercisable | shares	45,066
Weighted average exercise price, Warrants exercisable | $ / shares	$ 6.71
Weighted average contractual life, Warrants exercisable (years)	2 years
$12.50 - $18.75 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	17,334
Weighted average exercise price, Warrants outstanding | $ / shares	$ 15.15
Number of warrants, Warrants exercisable | shares	17,334
Weighted average exercise price, Warrants exercisable | $ / shares	$ 15.15
Weighted average contractual life, Warrants exercisable (years)	11 months 4 days
$29.69 - $45.31 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	27,120
Weighted average exercise price, Warrants outstanding | $ / shares	$ 31.26
Weighted average contractual life, Warrants outstanding (years)	1 year 7 months 9 days
Number of warrants, Warrants exercisable | shares	26,320
Weighted average exercise price, Warrants exercisable | $ / shares	$ 31.02
Weighted average contractual life, Warrants exercisable (years)	1 year 6 months 14 days
$29.69 - $45.31 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	42,400
Weighted average exercise price, Warrants outstanding | $ / shares	$ 31.99
Number of warrants, Warrants exercisable | shares	42,400
Weighted average exercise price, Warrants exercisable | $ / shares	$ 31.99
Weighted average contractual life, Warrants exercisable (years)	1 year 2 months 19 days
$62.50 - $93.75 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	49,920
Weighted average exercise price, Warrants outstanding | $ / shares	$ 63.50
Weighted average contractual life, Warrants outstanding (years)	4 years 18 days
Number of warrants, Warrants exercisable | shares	49,920
Weighted average exercise price, Warrants exercisable | $ / shares	$ 63.50
Weighted average contractual life, Warrants exercisable (years)	4 years 18 days
$62.50 - $93.75 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	9,334
Weighted average exercise price, Warrants outstanding | $ / shares	$ 77.68
Number of warrants, Warrants exercisable | shares	1,334
Weighted average exercise price, Warrants exercisable | $ / shares	$ 93.75
Weighted average contractual life, Warrants exercisable (years)	1 year 1 month 6 days
$125.00 - $375.00 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	13,440
Weighted average exercise price, Warrants outstanding | $ / shares	$ 239.15
Weighted average contractual life, Warrants outstanding (years)	4 years 7 months 13 days
Number of warrants, Warrants exercisable | shares	7,040
Weighted average exercise price, Warrants exercisable | $ / shares	$ 205.18
Weighted average contractual life, Warrants exercisable (years)	3 years 8 months 12 days
$125.00 - $375.00 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	9,066
Weighted average exercise price, Warrants outstanding | $ / shares	$ 282.36

XML

Share-based Compensation - Summary of Changes in Stock Options (Details) - Equity Settled Plan - Stock Options	12 Months Ended
	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning Balance | shares	44,460	72,060
Forfeited | shares		(27,500)
Expired | shares	(100)	(100)
Ending Balance | shares	44,360	44,460
Weighted average exercise price, beginning balance | $ / shares	$ 13.28	$ 18.18
Weighted average exercise price, Forfeited | $ / shares		26.05
Weighted average exercise price, Expired | $ / shares	31.50	31.50
Weighted average exercise price, ending balance | $ / shares	$ 13.24	$ 13.28

XML

Share-based Compensation - Summary of Outstanding Stock Options (Details) - Equity Settled Plan - Stock Options - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	44,360	44,460	72,060
Warrants outstanding and exercisable, Weighted average contractual life (years)	7 years 3 months 7 days
Number of options, Stock options exercisable	32,852
Weighted average contractual life, Stock options exercisable (years)	7 years 2 months 26 days
$11.50
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	32,500
Warrants outstanding and exercisable, Weighted average contractual life (years)	7 years 4 months 28 days
Number of options, Stock options exercisable	21,667
Weighted average contractual life, Stock options exercisable (years)	7 years 4 months 28 days
$11.90
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	8,160
Warrants outstanding and exercisable, Weighted average contractual life (years)	7 years 5 months 26 days
Number of options, Stock options exercisable	8,160
Weighted average contractual life, Stock options exercisable (years)	7 years 5 months 26 days
$31.50
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	3,700
Warrants outstanding and exercisable, Weighted average contractual life (years)	5 years 6 months 3 days
Number of options, Stock options exercisable	3,025
Weighted average contractual life, Stock options exercisable (years)	5 years 4 months 17 days

XML

Share-based Compensation - Summary of Changes in Restricted Share Units (Details) - Restricted Share Units - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercised		(50,000)	(87,500)
Equity Settled Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	753,593	165,692
Granted	1,728,557	1,238,152
Forfeited	(175,245)	(158,263)
Exercised	(925,575)	(491,988)
Ending balance	1,381,330	753,593	165,692

XML

Share-based Compensation - Summary of Changes in Deferred Share Units (Details) - Cash Settled Plan - Deferred Share Units - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	551,250	332,331
Granted	1,216,076	248,919
Exercised	(58,943)	(30,000)
Ending balance	1,708,383	551,250

XML

Gross Revenue - Disaggregation of Revenue from Contracts with Customers (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 729,694	$ 67,279	$ 73,321
Liquor retail revenue
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	462,180	0	0
Cannabis retail revenue
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	205,610	16,091	0
Cannabis retail revenue | Retail
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	192,710	10,207	0
Cannabis retail revenue | Franchise
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	8,337	4,251	0
Cannabis retail revenue | Other
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	4,563	1,633	0
Cannabis
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	61,904	51,188	73,321
Cannabis | Provincial Boards
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	58,728	41,338	55,315
Cannabis | Medical
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	9	8	32
Cannabis | Wholesale
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 3,167	$ 9,842	$ 17,974

XML

Gross Revenue - Summary of Receivables from Contracts with Customers (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue [abstract]
Receivables, included in 'trade receivables' (note 9)	$ 17,558	$ 10,865	$ 15,786

XML

Gross Revenue - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue [abstract]
Maximum period to settle receivables from contracts with customers	30 days
Impairment loss (reversal) on receivables from contracts with customers	$ 0.6	$ 0.2

XML

Investment Revenue (Loss) - Summary of Interest and Fee Revenue (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment Revenue (Loss) [Abstract]
Interest revenue from investments at amortized cost	$ 3,660	$ 1,654	$ 0
Interest and fee revenue from investments at FVTPL	6,036	8,514	0
Interest revenue from cash	7,043	2,981	0
Interest and fee revenue	$ 16,739	$ 13,149	$ 0

XML

Investment Revenue (Loss) - Summary of Investment Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment Loss [Abstract]
Realized gains	$ 389	$ 20,213	$ 0
Unrealized (losses) gains (note 8)	(65,553)	(64,714)	0
Investment loss	$ (65,164)	$ (44,501)	$ 0

XML

Other Operating Expenses - Summary of General and Administrative Expense (Details) - CAD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Expenses by nature [abstract]
Salaries and wages		$ 80,134	$ 18,675	[1]	$ 11,634
Consulting fees		1,934	1,112	[1]	2,193
Office and general		37,061	7,560	[1]	9,843
Professional fees		11,563	6,530	[1]	4,658
Merchant Processing Fees		4,748
Director fees		472	351	[1]	365
Other		4,256	3,815	[1]	3,336
General and administrative expense	[2]	$ 140,168	$ 38,043		$ 32,029

[1] Adjustment to provisional amounts — refer to note 5(b).

[2] Adjustment to provisional amounts — refer to note 5(b).

XML

Other Operating Expenses - Summary of Sales and Marketing Expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Expenses by nature [abstract]
Marketing	$ 7,308	$ 3,671		$ 4,839
Events	102	191		393
Research		43		57
Media	1,007	1,138		448
Sales and marketing expense	$ 8,417	$ 5,043	[1]	$ 5,737

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Government Subsidies - Additional Information (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020
Disclosure Of Government Subsidies [Line Items]
Income from government subsidy	$ 2,180	[1]	$ 4,128

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Finance Costs - Summary of Finance Costs (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Cash finance expense
Interest on long-term debt				$ 7,482
Other finance costs	$ 178	$ 40		286
Interest expense	178	40		7,768
Non-cash finance expense (income)
Change in fair value of investment at FVTPL	36,087	3,300
Accretion on lease liabilities	5,903	776		89
Financial guarantee liability (recovery) expense	(59)	59
Accretion				1,622
Amortization of debt issue costs				1,782
Change in fair value of convertible notes				(7,141)
Other	89	154		(86)
Non-cash finance expense (income)	42,020	4,289		(3,734)
Interest income	(884)	(573)		(215)
Finance costs	$ 41,314	$ 3,756	[1]	$ 3,819

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Supplemental Cash Flow Disclosures - Summary of Changes in Non-cash Working Capital (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Cash provided by (used in):
Accounts receivable	$ (5,815)	$ 9,339		$ (2,037)
Biological assets	533	3,829		13,789
Inventory	4,243	(18,318)		(12,315)
Prepaid expenses and deposits	5,782	(3,922)		2,280
Investments	918	(402)
Right of use assets	(17,510)
Property, plant and equipment	38	(305)
Accounts payable and accrued liabilities	(27,864)	9,665		(20,793)
Lease liabilities	19,296
Changes in non cash working capital	(20,379)	(114)		(19,076)
Changes in non-cash working capital relating to:
Operating	(22,073)	150	[1]	(5,259)
Investing	74	(612)	[1]	(11,319)
Financing	1,620	348	[1]	(2,498)
Changes in non cash working capital	$ (20,379)	$ (114)		(19,076)
Cash interest paid				$ 6,094

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Loss Per Share - Summary of Loss Per Share (Details) - CAD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Weighted average shares outstanding (000s)
Basic and dilutive	[1]	229,871	186,038		21,865
Continuing operations
Net loss attributable to owners of the Company	[2]	$ (335,114)	$ (226,984)		$ (199,619)
Per share - basic and diluted		$ (1.46)	$ (1.22)		$ (9.13)
Discontinued operations
Net loss attributable to owners of the Company					$ (33,627)
Per share - basic and diluted					$ (1.54)
Net loss attributable to owners of the Company	[2]	$ (335,114)	$ (226,984)		$ (233,246)
Per share - basic and diluted		$ (1.46)	$ (1.22)	[2]	$ (10.67)

[1] For the year ended December 31, 2022, there were 0.3 million equity classified warrants, 10.1 million derivative warrants, 0.2 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 1.4 million RSUs that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2021 – 0.4 million equity classified warrants, 9.9 million derivative warrants, 0.3 million simple warrants, 0.1 million performance warrants, 0.04 million stock options and 0.8 million RSUs, year ended December 31, 2020 – 0.1 million equity classified warrants, 0.2 million derivative warrants, 0.3 million simple warrants, 0.2 million performance warrants, 0.07 million stock options and 0.2 million RSUs).

[2] Adjustment to provisional amounts — refer to note 5(b).

XML

Loss Per Share - Summary of Loss Per Share (Parenthetical) (Details) - CAD ($) $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings per share [abstract]
Equity Classified warrants	0.3	0.4	0.1
Derivative warrants	10.1	9.9	0.2
Simple warrants	0.2	0.3	0.3
Performance warrants	0.1	0.1	0.2
Stock options	$ 40	$ 40	$ 70
RSUs Exercisable	$ 1,400	$ 800	$ 200

XML

Financial Instruments - Summary of Fair Value Measurements of Long-term Debt, Derivative Warrant Liabilities and Contingent Consideration (Details) - Recurring fair value measurement [member] - CAD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		$ 21,926	$ 83,724
Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		72,761	48,576
Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	11,002	21,700
Level 1 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		21,926	83,724
Level 1 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 1 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	0	0
Level 2 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 2 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 2 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	0	0
Level 3 | Marketable Securities
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		0	0
Level 3 | Investments at FVTPL
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial assets		72,761	48,576
Level 3 | Derivative Warrants
Disclosure Of Fair Value Measurement Of Assets [Line Items]
Financial liabilities	[1]	$ 11,002	$ 21,700

[1] The carrying amount is an estimate of the fair value of the derivative warrants and is presented as a current liability. The Company has no cash obligation with respect to the derivative warrants, rather it will deliver common shares if and when warrants are exercised.

XML

Financial Instruments - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 CAD ($)
Disclosure Of Financial Instruments [Line Items]
Percentage of change in material assumptions	10.00%
Financial instruments expected credit loss	$ 0.5
Marketable Securities
Disclosure Of Financial Instruments [Line Items]
Threshold Percentage of Change in Market Prices Would Effect Fair Value of Marketable Securities	10.00%
Change in Fair Value of Securities	$ 2.1
Derivative Warrant Liabilities
Disclosure Of Financial Instruments [Line Items]
Change in fair value liabilities	$ 1.3

XML

Financial Instruments - Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Impairment loss (reversal) on trade receivables	$ 642	$ 214
Impairment loss (reversal) on other receivables	674	798
Impairment loss (reversal) on accounts receivable	$ 1,316	$ 1,012

XML

Financial Instruments - Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Balance, beginning of year	$ 1,132	$ 120
Net remeasurement of impairment loss allowance	1,316	1,012
Balance, end of year	$ 2,448	$ 1,132

XML

Financial Instruments - Timing of Expected Cash Outflows Relating to Financial Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	[1]
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	$ 48,153	$ 38,452
Liquidity Risk Management
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	48,153
Financial guarantee liability	407
Balance, end of year	48,560
Liquidity Risk Management | Less Than One Year
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	48,153
Financial guarantee liability	0
Balance, end of year	48,153
Liquidity Risk Management | One to Three Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Financial guarantee liability	407
Balance, end of year	407
Liquidity Risk Management | Three to Five Years
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Financial guarantee liability	0
Balance, end of year	0
Liquidity Risk Management | Thereafter
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	0
Financial guarantee liability	0
Balance, end of year	$ 0

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Related Party Transactions - Additional Information (Details) - CAD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022
Related party transactions [abstract]
Related party transaction, terms		The lease term is from November 1, 2017 to October 31, 2027 and includes extension terms from November 1, 2027 to October 31, 2032 and November 1, 2032 to October 31, 2037.
Total rent	$ 117,900

XML

Related Party Transactions - Compensation of Key Management Personnel (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of transactions between related parties [abstract]
Salaries and short-term benefits	$ 4,505	$ 2,348	$ 1,944
Share-based compensation	5,871	8,275	7,629
Key management personnel compensation	$ 10,376	$ 10,623	$ 9,573

XML

Non-Controlling Interests - Summarized Statement of Financial Position (Details) - CAD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	[1]
Disclosure of subsidiaries [line items]
Current assets	$ 501,483	$ 728,175
Current liabilities	89,361	$ 65,853
Nova [Member]
Disclosure of subsidiaries [line items]
Current assets	18,732
Current liabilities	19,892
Current net assets	(1,160)
Non-current assets	94,419
Non-current liabilities	45,443
Non-current net assets	48,976
Net assets and liabilities	$ 47,816

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Non-Controlling Interests - Summarized Statement of Loss and Comprehensive Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]	Dec. 31, 2020
Disclosure of subsidiaries [line items]
Revenue	$ 712,197	$ 56,128		$ 60,918
Nova [Member]
Disclosure of subsidiaries [line items]
Revenue	176,588
Loss and comprehensive loss	$ (7,672)

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Non-Controlling Interests - Summarized Statement of Cash Flows (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]	Dec. 31, 2020
Disclosure of subsidiaries [line items]
Net cash provided by operating activities	$ (6,711)	$ (155,752)		$ (57,495)
Net cash used in investing activities	(230,164)	(496,280)		(70,877)
Net cash used in financing activities	(41,790)	1,149,916		142,746
Change in cash and cash equivalents	(278,665)	$ 497,875		$ 15,039
Nova [Member]
Disclosure of subsidiaries [line items]
Net cash provided by operating activities	5,848
Net cash used in investing activities	(5,549)
Net cash used in financing activities	(183)
Change in cash and cash equivalents	$ 116

[1] Adjustment to provisional amounts — refer to note 5(b).

XML

Commitments and Contingencies - Additional Information (Details) - CAD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Commitments And Contingencies [Abstract]
Accrued financial penalties payable	$ 2.5	$ 2.5

XML

Subsequent Events - Additional Information (Details) $ in Thousands, shares in Millions, $ in Millions	Mar. 28, 2023 CAD ($) Store	Aug. 22, 2022 CAD ($) shares	Mar. 06, 2023 USD ($)
Valens Arrangement Agreement [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Investments interest rate		10.00%
Investments maturity date		Dec. 15, 2023
non-revolving term loan facility		$ 60.0
Bankruptcy Transaction
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Superpriority secured debtor-in-possession line of credit			$ 1,750
Lightbox Enterprises Ltd. | Major Business Combination | Lightbox Agreement
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of retail stores | Store	4
Total consideration	$ 7.8
Cash consideration	1.5
Issuance of common shares	3.3
Cancellation of debt	$ 3.0
VALENS | Valens Arrangement Agreement [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
non-revolving term loan facility		$ 60.0
VALENS | Major Ordinary Share Transactions | Valens Arrangement Agreement [Member]
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Number of units issued | shares		27.6
Aggregate shares issued,value		$ 84.0
Common stock ,conversion price		0.3334